Heterocyclic compounds and their uses

ABSTRACT

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren&#39;s syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

This application is a continuation of application Ser. No. 12/079,406,filed Mar. 24, 2008, which claims the benefit of U.S. ProvisionalApplication No. 60/919,568, filed Mar. 23, 2007, which are herebyincorporated by reference.

This application claims the benefit of U.S. Provisional Application No.60/919,568, filed Mar. 23, 2007, which is hereby incorporated byreference.

The present invention relates generally to phosphatidylinositol 3-kinase(PI3K) enzymes, and more particularly to selective inhibitors of PI3Kactivity and to methods of using such materials.

BACKGROUND OF THE INVENTION

Cell signaling via 3′-phosphorylated phosphoinositides has beenimplicated in a variety of cellular processes, e.g., malignanttransformation, growth factor signaling, inflammation, and immunity (seeRameh et al., J. Biol Chem, 274:8347-8350 (1999) for a review). Theenzyme responsible for generating these phosphorylated signalingproducts, phosphatidylinositol 3-kinase (PI 3-kinase; PI3K), wasoriginally identified as an activity associated with viral oncoproteinsand growth factor receptor tyrosine kinases that phosphorylatesphosphatidylinositol (PI) and its phosphorylated derivatives at the3′-hydroxyl of the inositol ring (Panayotou et al., Trends Cell Biol2:358-60 (1992)).

The levels of phosphatidylinositol-3,4,5-triphosphate (PIP3), theprimary product of PI 3-kinase activation, increase upon treatment ofcells with a variety of stimuli. This includes signaling throughreceptors for the majority of growth factors and many inflammatorystimuli, hormones, neurotransmitters and antigens, and thus theactivation of PI3Ks represents one, if not the most prevalent, signaltransduction events associated with mammalian cell surface receptoractivation (Cantley, Science 296:1655-1657 (2002); Vanhaesebroeck et al.Annu. Rev. Biochem, 70: 535-602 (2001)). PI 3-kinase activation,therefore, is involved in a wide range of cellular responses includingcell growth, migration, differentiation, and apoptosis (Parker et al.,Current Biology, 5:577-99 (1995); Yao et al., Science, 267:2003-05(1995)). Though the downstream targets of phosphorylated lipidsgenerated following PI 3-kinase activation have not been fullycharacterized, it is known that pleckstrin-homology (PH) domain- andFYVE-finger domain-containing proteins are activated when binding tovarious phosphatidylinositol lipids (Sternmark et al., J Cell Sci,112:4175-83 (1999); Lemmon et al., Trends Cell Biol, 7:237-42 (1997)).Two groups of PH-domain containing PI3K effectors have been studied inthe context of immune cell signaling, members of the tyrosine kinase TECfamily and the serine/threonine kinases of to AGC family. Members of theTec family containing PH domains with apparent selectivity for PtdIns(3,4,5)P₃ include Tec, Btk, Itk and Etk. Binding of PH to PIP₃ iscritical for tyrosine kinase activity of the Tec family members(Schaeffer and Schwartzberg, Curr. Opin. Immunol. 12: 282-288 (2000))AGC family members that are regulated by PI3K include thephosphoinositide-dependent kinase (PDK1), AKT (also termed PKB) andcertain isoforms of protein kinase C(PKC) and S6 kinase. There are threeisoforms of AKT and activation of AKT is strongly associated withPI3K-dependent proliferation and survival signals. Activation of AKTdepends on phosphorylation by PDK1, which also has a3-phosphoinositide-selective PH domain to recruit it to the membranewhere it interacts with AKT. Other important PDK1 substrates are PKC andS6 kinase (Deane and Fruman, Annu. Rev. Immunol. 22_(—)563-598 (2004)).In vitro, some isoforms of protein kinase C(PKC) are directly activatedby PIP3. (Burgering et al., Nature, 376:599-602 (1995)).

Presently, the PI 3-kinase enzyme family has been divided into threeclasses based on their substrate specificities. Class I PI3Ks canphosphorylate phosphatidylinositol (PI),phosphatidylinositol-4-phosphate, andphosphatidyl-inositol-4,5-biphosphate (PIP2) to producephosphatidylinositol-3-phosphate (PIP),phosphatidylinositol-3,4-biphosphate, andphosphatidylinositol-3,4,5-triphosphate, respectively. Class II PI3Ksphosphorylate PI and phosphatidyl-inositol-4-phosphate, whereas ClassIII PI3Ks can only phosphorylate PI.

The initial purification and molecular cloning of PI 3-kinase revealedthat it was a heterodimer consisting of p85 and p110 subunits (Otsu etal., Cell, 65:91-104 (1991); Hiles et al., Cell, 70:419-29 (1992)).Since then, four distinct Class I PI3Ks have been identified, designatedPI3K α, β, δ, and γ, each consisting of a distinct 110 kDa catalyticsubunit and a regulatory subunit. More specifically, three of thecatalytic subunits, i.e., p110α, p110β and p110δ, each interact with thesame regulatory subunit, p85; whereas p110γ interacts with a distinctregulatory subunit, p101. As described below, the patterns of expressionof each of these PI3Ks in human cells and tissues are also distinct.Though a wealth of information has been accumulated in recent past onthe cellular functions of PI 3-kinases in general, the roles played bythe individual isoforms are not fully understood.

Cloning of bovine p110α has been described. This protein was identifiedas related to the Saccharomyces cerevisiae protein: Vps34p, a proteininvolved in vacuolar protein processing. The recombinant p110α productwas also shown to associate with p85α, to yield a PI3K activity intransfected COS-1 cells. See Hiles et al., Cell, 70, 419-29 (1992).

The cloning of a second human p110 isoform, designated p110β, isdescribed in Hu et al., Mol Cell Biol, 13:7677-88 (1993). This isoformis said to associate with p85 in cells, and to be ubiquitouslyexpressed, as p110β mRNA has been found in numerous human and mousetissues as well as in human umbilical vein endothelial cells, Jurkathuman leukemic T cells, 293 human embryonic kidney cells, mouse 3T3fibroblasts, HeLa cells, and NBT2 rat bladder carcinoma cells. Such wideexpression suggests that this isoform is broadly important in signalingpathways.

Identification of the p1108 isoform of PI 3-kinase is described inChantry et al., J Biol Chem, 272:19236-41 (1997). It was observed thatthe human p1108 isoform is expressed in a tissue-restricted fashion. Itis expressed at high levels in lymphocytes and lymphoid tissues and hasbeen shown to play a key role in PI 3-kinase-mediated signaling in theimmune system (Al-Alwan al. JI 178: 2328-2335 (2007); Okkenhaug et alJI, 177: 5122-5128 (2006); Lee et al. PNAS, 103: 1289-1294 (2006)).P1108 has also been shown to be expressed at lower levels in breastcells, melanocytes and endothelial cells (Vogt et al. Virology, 344:131-138 (2006) and has since been implicated in conferring selectivemigratory properties to breast cancer cells (Sawyer et al. Cancer Res.63:1667-1675 (2003)). Details concerning the P1108 isoform also can befound in U.S. Pat. Nos. 5,858,753; 5,822,910; and 5,985,589. See also,Vanhaesebroeck et al., Proc Nat. Acad Sci USA, 94:4330-5 (1997), andinternational publication WO 97/46688.

In each of the PI3Kα, β, and δ subtypes, the p85 subunit acts tolocalize PI 3-kinase to the plasma membrane by the interaction of itsSH2 domain with phosphorylated tyrosine residues (present in anappropriate sequence context) in target proteins (Rameh et al., Cell,83:821-30 (1995)). Five isoforms of p85 have been identified (p85α,p85β, p55γ, p55α and p50α) encoded by three genes. Alternativetranscripts of Pik3r1 gene encode the p85α, p55α and p50α proteins(Deane and Fruman, Annu. Rev. Immunol. 22: 563-598 (2004)). p85a isubiquitously expressed while p85β, is primarily found in the brain andlymphoid tissues (Volinia et al., Oncogene, 7:789-93 (1992)).Association of the p85 subunit to the PI 3-kinase p110α, β, or δcatalytic subunits appears to be required for the catalytic activity andstability of these enzymes. In addition, the binding of Ras proteinsalso upregulates PI 3-kinase activity.

The cloning of p110γ revealed still further complexity within the PI3Kfamily of enzymes (Stoyanov et al., Science, 269:690-93 (1995)). Thep110γ isoform is closely related to p110α and p110β (45-48% identity inthe catalytic domain), but as noted does not make use of p85 as atargeting subunit. Instead, p110γ binds a p101 regulatory subunit thatalso binds to the βγ subunits of heterotrimeric G proteins. The p101regulatory subunit for PI3 K gamma was originally cloned in swine, andthe human ortholog identified subsequently (Krugmann et al., J BiolChem, 274:17152-8 (1999)). Interaction between the N-terminal region ofp101 with the N-terminal region of p110γ is known to activate PI3Kγthrough Gβγ. Recently, a p101-homologue has been identified, p84 orp87^(PIKAP) (PI3Kγ adapter protein of 87 kDa) that binds p110γ (Voigt etal. JBC, 281: 9977-9986 (2006), Suire et al. Curr. Biol. 15: 566-570(2005)). p87^(PIKAP) is homologous to p101 in areas that bind p110γ andGβγ and also mediates activation of p110γ downstream ofG-protein-coupled receptors. Unlike p101, p87^(PIKAP) is highlyexpressed in the heart and may be crucial to PI3Kγ cardiac function.

A constitutively active PI3K polypeptide is described in internationalpublication WO 96/25488. This publication discloses preparation of achimeric fusion protein in which a 102-residue fragment of p85 known asthe inter-SH2 (iSH2) region is fused through a linker region to theN-terminus of murine p110. The p85 iSH2 domain apparently is able toactivate PI3K activity in a manner comparable to intact p85 (Klippel etal., Mol Cell Biol, 14:2675-85 (1994)).

Thus, PI 3-kinases can be defined by their amino acid identity or bytheir activity. Additional members of this growing gene family includemore distantly related lipid and protein kinases including Vps34 TOR1,and TOR2 of Saccharo-myces cerevisiae (and their mammalian homologs suchas FRAP and mTOR), the ataxia telangiectasia gene product (ATR) and thecatalytic subunit of DNA-dependent protein kinase (DNA-PK). Seegenerally, Hunter, Cell, 83:1-4 (1995).

PI 3-kinase is also involved in a number of aspects of leukocyteactivation. A p85-associated PI 3-kinase activity has been shown tophysically associate with the cytoplasmic domain of CD28, which is animportant costimulatory molecule for the activation of T-cells inresponse to antigen (Pages et al., Nature, 369:327-29 (1994); Rudd,Immunity, 4:527-34 (1996)). Activation of T cells through CD28 lowersthe threshold for activation by antigen and increases the magnitude andduration of the proliferative response. These effects are linked toincreases in the transcription of a number of genes includinginterleukin-2 (IL2), an important T cell growth factor (Fraser et al.,Science, 251:313-16 (1991)). Mutation of CD28 such that it can no longerinteract with PI 3-kinase leads to a failure to initiate IL2 production,suggesting a critical role for PI 3-kinase in T cell activation.

Specific inhibitors against individual members of a family of enzymesprovide invaluable tools for deciphering functions of each enzyme. Twocompounds, LY294002 and wortmannin, have been widely used as PI 3-kinaseinhibitors. These compounds, however, are nonspecific PI3K inhibitors,as they do not distinguish among the four members of Class I PI3-kinases. For example, the IC₅₀ values of wortmannin against each ofthe various Class I PI 3-kinases are in the range of 1-10 nM. Similarly,the IC₅₀ values for LY294002 against each of these PI 3-kinases is about1 μM (Fruman et al., Ann Rev Biochem, 67:481-507 (1998)). Hence, theutility of these compounds in studying the roles of individual Class IPI 3-kinases is limited.

Based on studies using wortmannin, there is evidence that PI 3-kinasefunction also is required for some aspects of leukocyte signalingthrough G-protein coupled receptors (Thelen et al., Proc Natl Acad SciUSA, 91:4960-64 (1994)). Moreover, it has been shown that wortmannin andLY294002 block neutrophil migration and superoxide release. However,inasmuch as these compounds do not distinguish among the variousisoforms of PI3K, it remains unclear from these studies which particularPI3K isoform or isoforms are involved in these phenomena and whatfunctions the different Class I PI3K enzymes perform in both normal anddiseased tissues in general. The co-expression of several PI3K isoformsin most tissues has confounded efforts to segregate the activities ofeach enzyme until recently.

The separation of the activities of the various PI3K isozymes has beenadvanced recently with the development of genetically manipulated micethat allowed the study of isoform-specific knock-out and kinase deadknock-in mice and the development of more selective inhibitors for someof the different isoforms. P110α and p110β knockout mice have beengenerated and are both embryonic lethal and little information can beobtained from these mice regarding the expression and function of p110alpha and beta (Bi et al. Mamm. Genome, 13:169-172 (2002); Bi et al. J.Biol. Chem. 274:10963-10968 (1999)). More recently, p110α kinase deadknock in mice were generated with a single point mutation in the DFGmotif of the ATP binding pocket (p110αD^(933A)) that impairs kinaseactivity but preserves mutant p110α kinase expression. In contrast toknock out mice, the knockin approach preserves signaling complexstoichiometry, scaffold functions and mimics small molecule approachesmore realistically than knock out mice. Similar to the p110α KO mice,p110αD^(933A) homozygous mice are embryonic lethal. However,heterozygous mice are viable and fertile but display severely bluntedsignaling via insulin-receptor substrate (IRS) proteins, key mediatorsof insulin, insulin-like growth factor-1 and leptin action. Defectiveresponsiveness to these hormones leads to hyperinsulinemia, glucoseintolerance, hyperphagia, increase adiposity and reduced overall growthin heterozygotes (Foukas, et al. Nature, 441: 366-370 (2006)). Thesestudies revealed a defined, non-redundant role for p110α as anintermediate in IGF-1, insulin and leptin signaling that is notsubstituted for by other isoforms. We will have to await the descriptionof the p110β kinase-dead knock in mice to further understand thefunction of this isoform (mice have been made but not yet published;Vanhaesebroeck).

P110γ knock out and kinase-dead knock in mice have both been generatedand overall show similar and mild phenotypes with primary defects inmigration of cells of the innate immune system and a defect in thymicdevelopment of T cells (Li et al. Science, 287: 1046-1049 (2000), Sasakiet al. Science, 287: 1040-1046 (2000), Patrucco et al. Cell, 118:375-387 (2004)).

Similar to p110γ, PI3K delta knock out and kinase-dead knock-in micehave been made and are viable with mild and like phenotypes. Thep110δ^(D910A) mutant knock in mice demonstrated an important role fordelta in B cell development and function, with marginal zone B cells andCD5+B1 cells nearly undetectable, and B- and T cell antigen receptorsignaling (Clayton et al. J. Exp. Med. 196:753-763 (2002); Okkenhaug etal. Science, 297: 1031-1034 (2002)). The p110δ^(D910A) mice have beenstudied extensively and have elucidated the diverse role that deltaplays in the immune system. T cell dependent and T cell independentimmune responses are severely attenuated in p110δ^(D910A) and secretionof TH1 (INF-γ) and TH2 cytokine (IL-4, IL-5) are impaired (Okkenhaug etal. J. Immunol. 177: 5122-5128 (2006)). A human patient with a mutationin p1106 has also recently been described. A taiwanese boy with aprimary B cell immunodeficiency and a gamma-hypoglobulinemia ofpreviously unknown aetiology presented with a single base-pairsubstitution, m.3256G to A in codon 1021 in exon 24 of p1108. Thismutation resulted in a mis-sense amino acid substitution (E to K) atcodon 1021, which is located in the highly conserved catalytic domain ofp110δ protein. The patient has no other identified mutations and hisphenotype is consistent with p110δ deficiency in mice as far as studied.(Jou et al. Int. J. Immunogenet. 33: 361-369 (2006)).

Isoform-selective small molecule compounds have been developed withvarying success to all Class I PI3 kinase isoforms (Ito et al. J. Pharm.Exp. Therapeut., 321:1-8 (2007)). Inhibitors to alpha are desirablebecause mutations in p110α have been identified in several solid tumors;for example, an amplification mutation of alpha is associated with 50%of ovarian, cervical, lung and breast cancer and an activation mutationhas been described in more than 50% of bowel and 25% of breast cancers(Hennessy et al. Nature Reviews, 4: 988-1004 (2005)). Yamanouchi hasdeveloped a compound YM-024 that inhibits alpha and delta equi-potentlyand is 8- and 28-fold selective over beta and gamma respectively (Ito etal. J. Pharm. Exp. Therapeut., 321:1-8 (2007)).

P110β is involved in thrombus formation (Jackson et al. Nature Med. 11:507-514 (2005)) and small molecule inhibitors specific for this isoformare thought after for indication involving clotting disorders (TGX-221:0.007 uM on beta; 14-fold selective over delta, and more than 500-foldselective over gamma and alpha) (Ito et al. J. Pharm. Exp. Therapeut.,321:1-8 (2007)).

Selective compounds to p110γ are being developed by several groups asimmunosuppressive agents for autoimmune disease (Rueckle et al. NatureReviews, 5: 903-918 (2006)). Of note, AS 605240 has been shown to beefficacious in a mouse model of rheumatoid arthritis (Camps et al.Nature Medicine, 11: 936-943 (2005)) and to delay onset of disease in amodel of systemic lupus erythematosis (Barber et al. Nature Medicine,11: 933-935 (205)).

Delta-selective inhibitors have also been described recently. The mostselective compounds include the quinazolinone purine inhibitors (PIK39and IC87114). IC87114 inhibits p110δ in the high nanomolar range (tripledigit) and has greater than 100-fold selectivity against p110α, is 52fold selective against p110β but lacks selectivity against p110γ(approx. 8-fold). It shows no activity against any protein kinasestested (Knight et al. Cell, 125: 733-747 (2006)). Using delta-selectivecompounds or genetically manipulated mice (p110δ_(D910A)) it was shownthat in addition to playing a key role in B and T cell activation, deltais also partially involved in neutrophil migration and primed neutrophilrespiratory burst and leads to a partial block of antigen-IgE mediatedmast cell degranulation (Condliffe et al. Blood, 106: 1432-1440 (2005);Ali et al. Nature, 431: 1007-1011 (2002)). Hence p1106 is emerging as animportant mediator of many key inflammatory responses that are alsoknown to participate in aberrant inflammatory conditions, including butnot limited to autoimmune disease and allergy. To support this notion,there is a growing body of p110δ target validation data derived fromstudies using both genetic tools and pharmacologic agents. Thus, usingthe delta-selective compound IC 87114 and the p110δ^(D910A) mice, Ali etal. (Nature, 431: 1007-1011 (2002)) have demonstrated that delta plays acritical role in a murine model of allergic disease. In the absence offunctional delta, passive cutaneous anaphylaxis (PCA) is significantlyreduced and can be attributed to a reduction in allergen-IgE inducedmast cell activation and degranulation. In addition, inhibition of deltawith IC 87114 has been shown to significantly ameliorate inflammationand disease in a murine model of asthma using ovalbumin-induced airwayinflammation (Lee et al. FASEB, 20: 455-465 (2006). These data utilizingcompound were corroborated in p110δ^(D910A) mutant mice using the samemodel of allergic airway inflammation by a different group (Nashed etal. Eur. J. Immunol. 37:416-424 (2007)).

There exists a need for further characterization of PI3Kδ function ininflammatory and auto-immune settings. Furthermore, our understanding ofPI3Kδ requires further elaboration of the structural interactions ofp110δ, both with its regulatory subunit and with other proteins in thecell. There also remains a need for more potent and selective orspecific inhibitors of PI3K delta, in order to avoid potentialtoxicology associated with activity on isozymes p110 alpha (insulinsignaling) and beta (platelet activation). In particular, selective orspecific inhibitors of PI3Kδ are desirable for exploring the role ofthis isozyme further and for development of superior pharmaceuticals tomodulate the activity of the isozyme.

SUMMARY

The present invention comprises a new class of compounds having thegeneral formula

which are useful to inhibit the biological activity of human PI3Kδ.Another aspect of the invention is to provide compounds that inhibitPI3Kδ selectively while having relatively low inhibitory potency againstthe other PI3K isoforms. Another aspect of the invention is to providemethods of characterizing the function of human PI3Kδ. Another aspect ofthe invention is to provide methods of selectively modulating humanPI3Kδ activity, and thereby promoting medical treatment of diseasesmediated by PI3Kδ dysfunction. Other aspects and advantages of theinvention will be readily apparent to the artisan having ordinary skillin the art.

DETAILED DESCRIPTION

One aspect of the invention relates to compounds having the structure:

or any pharmaceutically-acceptable salt thereof, wherein:

X¹ is C(R⁹) or N;

X² is C(R¹⁰) or N;

Y is N(R¹¹), O or S;

Z is CR⁸ or N;

n is 0, 1, 2 or 3;

R¹ is a direct-bonded or oxygen-linked saturated, partially-saturated orunsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3or 4 atoms selected from N, O and S, but containing no more than one Oor S, wherein the available carbon atoms of the ring are substituted by0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or1 R² substituents, and the ring is additionally substituted by 0, 1, 2or 3 substituents independently selected from halo, nitro, cyano,C₁₋₄alkyl, OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl and C₁₋₄haloalkyl;

R² is selected from halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a); or R² isselected from C₁₋₆alkyl, phenyl, benzyl, heteroaryl, heterocycle,—(C₁₋₃alkyl)heteroaryl, —(C₁₋₃alkyl)heterocycle,—O(C₁₋₃alkyl)heteroaryl, —O(C₁₋₃alkyl)heterocycle,—NR^(a)(C₁₋₃alkyl)heteroaryl, —NR^(a)(C₁₋₃alkyl)heterocycle,—(C₁₋₃alkyl)phenyl, —O(C₁₋₃alkyl)phenyl and —NR^(a)(C₁₋₃alkyl)phenyl allof which are substituted by 0, 1, 2 or 3 substituents selected fromC₁₋₄haloalkyl, OC₁₋₄alkyl, Br, Cl, F, I and C₁₋₄alkyl;

R³ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from C₁₋₆haloalkyl, OC₁₋₆alkyl, Br, Cl, F,I and C₁₋₆alkyl;

R⁴ is, independently, in each instance, halo, nitro, cyano, OC₁₋₄alkyl,OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl or C₁₋₄haloalkyl;

R⁵ is, independently, in each instance, H, halo, C₁₋₆alkyl,C₁₋₄haloalkyl, or C₁₋₆alkyl substituted by 1, 2 or 3 substituentsselected from halo, cyano, OH, OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl,OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl; or both R⁵ groupstogether form a C₃₋₆-spiroalkyl substituted by 0, 1, 2 or 3 substituentsselected from halo, cyano, OH, OC₁₋₄. alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl,OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl;

R⁶ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁷ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁸ is selected from H, C₁₋₆haloalkyl, Br, Cl, F, I, OR^(a), NR^(a)R^(a),C₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein theC₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle are additionallysubstituted by 0, 1, 2 or 3 substituents selected from C₁₋₆haloalkyl,OC₁₋₆alkyl, Br, Cl, F, I and C₁₋₆alkyl;

R⁹ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —R^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a); or R⁹ is asaturated, partially-saturated or unsaturated 5-, 6- or 7-memberedmonocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O andS, but containing no more than one O or S, wherein the available carbonatoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups,wherein the ring is substituted by 0, 1, 2, 3 or 4 substituents selectedfrom halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a), —C(═O)OR^(a),—C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a), —OC(═O)R^(a),—OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a), —OC₂₋₆alkylNR^(a)R^(a),—OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a), —S(═O)₂R^(a),—S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a);

R¹⁰ is H, C₁₋₃alkyl, C₁₋₃haloalkyl, cyano, nitro, CO₂R^(a),C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a), S(═O)R^(b),S(═O)₂R^(b) or S(═O)₂NR^(a)R^(a);

R¹¹ is H or C₁₋₄alkyl;

R^(a) is independently, at each instance, H or R^(b); and

R^(b) is independently, at each instance, phenyl, benzyl or C₁₋₆alkyl,the phenyl, benzyl and C₁₋₆alkyl being substituted by 0, 1, 2 or 3substituents selected from halo, C₁₋₄alkyl, C₁₋₃haloalkyl, —OC₁₋₄alkyl,—NH₂, —NHC₁₋₄alkyl, —N(C₁₋₄alkyl)C₁₋₄alkyl.

Another aspect of the invention relates to compounds having thestructure:

or any pharmaceutically-acceptable salt thereof, wherein:

X¹ is C(R⁹) or N;

X² is C(R¹⁰) or N;

Y is N(R¹¹), O or S;

Z is CR⁸ or N;

n is 0, 1, 2 or 3;

R′ is a direct-bonded or oxygen-linked saturated, partially-saturated orunsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3or 4 atoms selected from N, O and S, but containing no more than one Oor S, wherein the available carbon atoms of the ring are substituted by0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or1 R² substituents, and the ring is additionally substituted by 0, 1, 2or 3 substituents independently selected from halo, nitro, cyano,C₁₋₄alkyl, OC₁₋₄alkyl, OC₁₋₄haloalkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl and C₁₋₄haloalkyl;

R² is selected from halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a); or R² isselected from C₁₋₆alkyl, phenyl, benzyl, heteroaryl, heterocycle,—(C₁₋₃alkyl)heteroaryl, —(C₁₋₃alkyl)heterocycle,—O(C₁₋₃alkyl)heteroaryl, —O(C₁₋₃alkyl)heterocycle,—NR^(a)(C₁₋₃alkyl)heteroaryl, —NR^(a)(C₁₋₃alkyl)heterocycle,—(C₁₋₃alkyl)phenyl, —O(C₁₋₃alkyl)phenyl and —NR^(a)(C₁₋₃alkyl)phenyl allof which are substituted by 0, 1, 2 or 3 substituents selected fromC₁₋₄haloalkyl, OC₁₋₄alkyl, Br, CI, F, I and C₁₋₄alkyl;

R³ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from C₁₋₆haloalkyl, OC₁₋₆alkyl, Br, Cl, F,I and C₁₋₆alkyl;

R⁴ is, independently, in each instance, halo, nitro, cyano, OC₁₋₄alkyl,OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl or C₁₋₄haloalkyl;

R⁵ is, independently, in each instance, H, halo, C₁₋₆alkyl,C₁₋₄haloalkyl, or C₁₋₆alkyl substituted by 1, 2 or 3 substituentsselected from halo, cyano, OH, N(C₁₋₄alkyl)C₁₋₄alkyl; or both R⁵ groupstogether form a C₃₋₆-spiroalkyl substituted by 0, 1, 2 or 3 substituentsselected from halo, cyano, OH, C₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl,OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl;

R⁶ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁷ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁸ is selected from H, C₁₋₆haloalkyl, Br, Cl, F, I, OR^(a), NR^(a)R^(a),C₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein theC₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle are additionallysubstituted by 0, 1, 2 or 3 substituents selected from C₁₋₆haloalkyl,OC₁₋₆alkyl, Br, Cl, F, I and C₁₋₆alkyl;

R⁹ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆allyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylOR^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a); or R⁹ is asaturated, partially-saturated or unsaturated 5-, 6- or 7-memberedmonocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O andS, but containing no more than one O or S, wherein the available carbonatoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups,wherein the ring is substituted by 0, 1, 2, 3 or 4 substituents selectedfrom halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a), —C(═O)OR^(a),—C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a), —OC(═O)R^(a),—OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a), —OC₂₋₆alkylNR^(a)R^(a),—OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a), —S(═O)₂R^(a),—S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a);

R¹⁰ is H, C₁₋₃alkyl, C₁₋₃haloalkyl, cyano, nitro, CO₂R^(a),C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a),

R¹¹ is H or C₁₋₄alkyl;

R^(a) is independently, at each instance, H or R^(b); and

R^(b) is independently, at each instance, phenyl, benzyl or C₁₋₆alkyl,the phenyl, benzyl and C₁₋₆alkyl being substituted by 0, 1, 2 or 3substituents selected from halo, C₁₋₄alkyl, C₁₋₃haloalkyl, —OC₁₋₄alkyl,—NH₂, —NHC₁₋₄alkyl, —N(C₁₋₄alkyl)C₁₋₄alkyl.

Another aspect of the invention relates to compounds having thestructure:

or any pharmaceutically-acceptable salt thereof, wherein:

X¹ is C(R⁹) or N;

X² is C(R¹⁰) or N;

Y is N(R¹¹), O or S;

Z is CR⁸ or N;

n is 0, 1, 2 or 3;

R¹ is a direct-bonded or oxygen-linked saturated, partially-saturated orunsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3or 4 atoms selected from N, O and S, but containing no more than one Oor S, wherein the available carbon atoms of the ring are substituted by0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or1 R² substituents, and the ring is additionally substituted by 0, 1, 2or 3 substituents independently selected from halo, nitro, cyano,C₁₋₄alkyl, OC₁₋₄haloalkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl and C₁₋₄haloalkyl;

R² is selected from halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a); or R² isselected from C₁₋₆alkyl, phenyl, benzyl, heteroaryl, heterocycle,—(C₁₋₃alkyl)heteroaryl, —(C₁₋₃alkyl)heterocycle,—O(C₁₋₃alkyl)heteroaryl, —O(C₁₋₃alkyl)heterocycle,—NR^(a)(C₁₋₃alkyl)heteroaryl, —NR^(a)(C₁₋₃alkyl)heterocycle,—(C₁₋₃alkyl)phenyl, —O(C₁₋₃alkyl)phenyl and —NR^(a)(C₁₋₃alkyl)phenyl allof which are substituted by 0, 1, 2 or 3 substituents selected fromC₁₋₄haloalkyl, OC₁₋₄alkyl, Br, Cl, F, I and C₁₋₄alkyl;

R³ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from C₁₋₆haloalkyl, OC₁₋₆alkyl, Br, Cl, F,I and C₁₋₆allyl;

R⁴ is, independently, in each instance, halo, nitro, cyano, C₁₋₄alkyl,OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl orC₁₋₄haloalkyl;

R⁵ is, independently, in each instance, H, halo, C₁₋₆alkyl,C₁₋₄haloalkyl, or C₁₋₆alkyl substituted by 1, 2 or 3 substituentsselected from halo, cyano, OH, OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl,OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl; or both R⁵ groupstogether form a C₃₋₆spiroalkyl substituted by 0, 1, 2 or 3 substituentsselected from halo, cyano, OH, OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl,OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl;

R⁶ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁷ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁸ is selected from H, C₁₋₆haloalkyl, Br, Cl, F, I, OR^(a), NR^(a)R^(a),C₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein theC₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle are additionallysubstituted by 0, 1, 2 or 3 substituents selected from C₁₋₆haloalkyl,OC₁₋₆alkyl, Br, Cl, F, I and C₁₋₆allyl;

R⁹ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a); or R⁹ is asaturated, partially-saturated or unsaturated 5-, 6- or 7-memberedmonocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O andS, but containing no more than one O or S, wherein the available carbonatoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups,wherein the ring is substituted by 0, 1, 2, 3 or 4 substituents selectedfrom halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—OC(═O)N(R^(a))S(═O)₂R^(a), —OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a),—SR^(a), —S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a), —NR^(a)R^(a), —N(R^(a))C(═O)R^(a),—N(R^(a))C(═O)OR^(a), —N(R^(a))C(═O)NR^(a)R^(a),—N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(a),—N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkylNR^(a)R^(a) and—NR^(a)C₂₋₆alkylOR^(a);

R¹⁰ is H, C₁₋₃alkyl, C₁₋₃haloalkyl, cyano, nitro, CO₂R^(a),C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a), S(═O)R^(b),S(═O)₂R^(b) or S(═O)₂NR^(a)R^(a);

R¹¹ is H or C₁₋₄alkyl;

R^(a) is independently, at each instance, H or R^(b); and

R^(b) is independently, at each instance, phenyl, benzyl or C₁₋₆alkyl,the phenyl, benzyl and C₁₋₆alkyl being substituted by 0, 1, 2 or 3substituents selected from halo, C₁₋₄alkyl, C₁₋₃haloalkyl, —OC₁₋₄alkyl,—Nh₂, —NHC₁₋₄alkyl,

Another aspect of the invention relates to compounds having thestructure:

or any pharmaceutically-acceptable salt thereof, wherein:

X¹ is C(R⁹) or N;

X² is C(R¹⁰) or N;

Y is N(R¹¹), O or S;

Z is CR⁸ or N;

n is 0, 1, 2 or 3;

R¹ is a direct-bonded or oxygen-linked saturated, partially-saturated orunsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3or 4 atoms selected from N, O and S, but containing no more than one Oor S, wherein the available carbon atoms of the ring are substituted by0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or1 R² substituents, and the ring is additionally substituted by 0, 1, 2or 3 substituents independently selected from halo, nitro, cyano,C₁₋₄alkyl, OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl and C₁₋₄haloalkyl;

R² is selected from halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a); or R² isselected from C₁₋₆alkyl, phenyl, benzyl, heteroaryl, heterocycle,—(C₁₋₃alkyl)heteroaryl, —(C₁₋₃alkyl)heterocycle,—O(C₁₋₃alkyl)heteroaryl, —O(C₁₋₃alkyl)heterocycle,—NR^(a)(C₁₋₃alkyl)heteroaryl, —NR^(a)(C₁₋₃alkyl)heterocycle,—(C₁₋₃alkyl)phenyl, —O(C₁₋₃alkyl)phenyl and —NR^(a)(C₁₋₃alkyl)phenyl allof which are substituted by 0, 1, 2 or 3 substituents selected fromC₁₋₄haloalkyl, OC₁₋₄alkyl, Br, Cl, F, I and C₁₋₄allyl;

R³ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from C₁₋₆haloalkyl, OC₁₋₆alkyl, Br, Cl, F,I and C₁₋₆alkyl;

R⁴ is, independently, in each instance, halo, nitro, cyano, C₁₋₄alkyl,OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl orC₁₋₄haloalkyl;

R⁵ is, independently, in each instance, H, halo, C₁₋₆alkyl,C₁₋₄haloalkyl, or C₁₋₆alkyl substituted by 1, 2 or 3 substituentsselected from halo, cyano, OH, OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl,OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl; or both R⁵ groupstogether form a C₃₋₆spiroalkyl substituted by 0, 1, 2 or 3 substituentsselected from halo, cyano, OH, OC₁₋₄alkyl, C₁₋₄ alkyl, C₁₋₃haloalkyl,OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl;

R⁶ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁷ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁸ is selected from H, C₁₋₆haloalkyl, Br, Cl, F, I, OR^(a), NR^(a)R^(a),C₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein theC₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle are additionallysubstituted by 0, 1, 2 or 3 substituents selected from C₁₋₆haloalkyl,OC₁₋₆alkyl, Br, Cl, F, I and C₁₋₆alkyl;

R⁹ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆allyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), partially-saturated or unsaturated 5-, 6- or7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selectedfrom N, O and S, but containing no more than one O or S, wherein theavailable carbon atoms of the ring are substituted by 0, 1 or 2 oxo orthioxo groups, wherein the ring is substituted by 0, 1, 2, 3 or 4substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkylNR^(a)and —NR^(a)C₂₋₆alkylOR^(a);

R¹⁰ is H, C₁₋₃alkyl, C₁₋₃haloalkyl, cyano, nitro, CO₂R^(a),C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a), S(═O)R^(b),S(═O)₂R^(b) or S(═O)₂NR^(a)R^(a);

R¹¹ is H or C₁₋₄alkyl;

R^(a) is independently, at each instance, H or R^(b); and

R^(b) is independently, at each instance, phenyl, benzyl or C₁₋₆alkyl,the phenyl, benzyl and C₁₋₄alkyl being substituted by 0, 1, 2 or 3substituents selected from halo, C₁₋₄alkyl, C₁₋₃haloalkyl, —OC₁₋₄alkyl,—NH₂, —NHC₁₋₄alkyl, —N(C₁₋₄alkyl)C₁₋₄alkyl.

One aspect of the invention relates to compounds having the structure:

or any pharmaceutically-acceptable salt or hydrate thereof, wherein:

X¹ is C(R⁹) or N;

X² is C(R¹⁰) or N;

Y is N(R¹¹), O or S;

Z is CR⁸ or N;

n is 0, 1, 2 or 3;

R¹ is a saturated, partially-saturated or unsaturated 5-, 6- or7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selectedfrom N, O and S, but containing no more than one O or S, wherein theavailable carbon atoms of the ring are substituted by 0, 1 or 2 oxo orthioxo groups, wherein the ring is substituted by 0 or 1 R²substituents, and the ring is additionally substituted by 0, 1, 2 or 3substituents independently selected from halo, nitro, cyano, C₁₋₄allyl,OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl andC₁₋₄haloalkyl;

R² is selected from halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a); or R² isselected from C₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle, allof which are substituted by 0, 1, 2 or 3 substituents selected fromC₁₋₄haloalkyl, OC₁₋₄alkyl, Br, Cl, F, I and C₁₋₄alkyl;

R³ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from C₁₋₆haloalkyl, OC₁₋₆alkyl, Br, Cl, F,I and C₁₋₆alkyl;

R⁴ is, independently, in each instance, halo, nitro, cyano, OC₁₋₄alkyl,OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl or C₁₋₄haloalkyl;

R⁵ is, independently, in each instance, H, halo, C₁₋₆alkyl,C₁₋₄haloalkyl, or C₁₋₆alkyl substituted by 1, 2 or 3 substituentsselected from halo, cyano, OH, OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl,OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl; or both R⁵ groupstogether form a C₃₋₆-spiroalkyl substituted by 0, 1, 2 or 3 substituentsselected from halo, cyano, OH, OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl,OC₁₋₄allyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl;

R⁶ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁷ is selected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a);

R⁸ is selected from H, C₁₋₆haloalkyl, Br, Cl, F, I, OR^(a), NR^(a)R^(a),C₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein theC₁₋₆alkyl, phenyl, benzyl, heteroaryl and heterocycle are additionallysubstituted by 0, 1, 2 or 3 substituents selected from C₁₋₆haloalkyl,OC₁₋₆alkyl, Br, Cl, F, I and C₁₋₆alkyl;

R⁹ is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —N(R^(a))C(═O)NR^(a)R^(a),—N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(a),—N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkylNR^(a)R^(a),—NR^(a)C₂₋₆alkylOR^(a); or R⁹ is a saturated, partially-saturated orunsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3or 4 atoms selected from N, O and S, but containing no more than one Oor S, wherein the available carbon atoms of the ring are substituted by0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0, 1,2, 3 or 4 substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a);

R¹⁰ is H, C₁₋₃alkyl, C₁₋₃haloalkyl, cyano, nitro, CO₂R^(a),C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a), S(═O)R^(b),S(═O)₂R^(b) or S(═O)₂NR^(a)R^(a);

R¹¹ is H or C₁₋₄alkyl;

R^(a) is independently, at each instance, H or R^(b); and

R^(b) is independently, at each instance, phenyl, benzyl or C₁₋₆alkyl,the phenyl, benzyl and C₁₋₆alkyl being substituted by 0, 1, 2 or 3substituents selected from halo, C₁₋₄alkyl, C₁₋₃haloalkyl, —OC₁₋₄alkyl,—NH₂, —NHC₁₋₄alkyl, —N(C₁₋₄alkyl)C₁₋₄alkyl.

In another embodiment, in conjunction with any of the above or belowembodiments, X¹ is C(R⁹) and X² is N.

In another embodiment, in conjunction with any of the above or belowembodiments, X¹ is C(R⁹) and X² is C(R¹⁰).

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is phenyl substituted by 0 or 1 R² substituents, and thephenyl is additionally substituted by 0, 1, 2 or 3 substituentsindependently selected from halo, nitro, cyano, C₁₋₄alkyl,OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl and C₁₋₄haloalkyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is phenyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is phenyl substituted by R², and the phenyl isadditionally substituted by 0, 1, 2 or 3 substituents independentlyselected from halo, nitro, cyano, C₁₋₄alkyl, OC₁₋₄alkyl, OC₁₋₄haloalkyl,NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl and C₁₋₄haloalkyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is selected from 2-methylphenyl, 2-chlorophenyl,2-trifluoromethylphenyl, 2-fluorophenyl and 2-methoxyphenyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is phenoxy.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is a direct-bonded or oxygen-linked saturated,partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ringcontaining 1, 2, 3 or 4 atoms selected from N, O and S, but containingno more than one O or S, wherein the available carbon atoms of the ringare substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring issubstituted by 0 or 1 R² substituents, and the ring is additionallysubstituted by 0, 1, 2 or 3 substituents independently selected fromhalo, nitro, cyano, C₁₋₄alkyl, OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl and C₁₋₄haloalkyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is an unsaturated 5- or 6-membered monocyclic ringcontaining 1, 2, 3 or 4 atoms selected from N, O and S, but containingno more than one O or S, wherein the ring is substituted by 0 or 1 R²substituents, and the ring is additionally substituted by 0, 1, 2 or 3substituents independently selected from halo, nitro, cyano, C₁₋₄alkyl,OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl andC₁₋₄haloalkyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is an unsaturated 5- or 6-membered monocyclic ringcontaining 1, 2, 3 or 4 atoms selected from N, O and S, but containingno more than one O or S, wherein the ring is substituted by 0 or 1 R²substituents, and the ring is additionally substituted by 1, 2 or 3substituents independently selected from halo, nitro, cyano, C₁₋₄alkyl,OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl andC₁₋₄haloalkyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is an unsaturated 5- or 6-membered monocyclic ringcontaining 1, 2, 3 or 4 atoms selected from N, O and S.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹ is selected from pyridyl and pyrimidinyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R³ is selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from C₁₋₆haloalkyl, OC₁₋₆alkyl, Br, Cl, F,I and C₁₋₆alkyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R³ is H.

In another embodiment, in conjunction with any of the above or belowembodiments, R³ is selected from F, Cl, C₁₋₆alkyl, phenyl, benzyl,heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl, benzyl,heteroaryl and heterocycle are additionally substituted by 0, 1, 2 or 3substituents selected from C₁₋₆haloalkyl, OC₁₋₆alkyl, Br, Cl, F, I andC₁₋₆alkyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁵ is, independently, in each instance, H, halo, C₁₋₆alkyl,4haloalkyl, or C₁₋₆alkyl substituted by 1, 2 or 3 substituents selectedfrom halo, cyano, OH, OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl, OC₁₋₄alkyl,NH₂, NHC₁₋₄alkyl, N(C₁₋₄allyl)C₁₋₄alkyl; or both R⁵ groups together forma C₃₋₆spiroalkyl substituted by 0, 1, 2 or 3 substituents selected fromhalo, cyano, OH, OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl, OC₁₋₄alkyl, NH₂,NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄allyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁵ is H.

In another embodiment, in conjunction with any of the above or belowembodiments, one R⁵ is S-methyl, the other is H.

In another embodiment, in conjunction with any of the above or belowembodiments, at least one R⁵ is halo, C₁₋₆alkyl, C₁₋₄haloalkyl, orC₁₋₆alkyl substituted by 1, 2 or 3 substituents selected from halo,cyano, OH, OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl, OC₁₋₄alkyl, NH₂,NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁶ is H.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁶ is F, Cl, cyano or nitro.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁷ is H.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁷ is F, Cl, cyano or nitro.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁸ is selected from H, CF₃, C₁₋₃alkyl, Br, Cl and F.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁸ is selected from H.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁸ is selected from CF₃, C₁₋₃alkyl, Br, Cl and F.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁹ is H.

In another embodiment, in conjunction with any of the above or belowembodiments, R⁹ is selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)R^(a), C₁₋₆alkyl, phenyl, benzyl,heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl, benzyl,heteroaryl and heterocycle are additionally substituted by 0, 1, 2 or 3substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a).

In another embodiment, in conjunction with any of the above or belowembodiments, R⁹ is a saturated, partially-saturated or unsaturated 5-,6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atomsselected from N, O and S, but containing no more than one O or S,wherein the available carbon atoms of the ring are substituted by 0, 1or 2 oxo or thioxo groups, wherein the ring is substituted by 0, 1, 2, 3or 4 substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a).

In another embodiment, in conjunction with any of the above or belowembodiments, R¹⁰ is H.

In another embodiment, in conjunction with any of the above or belowembodiments, R¹⁰ is cyano, nitro, CO₂R^(a), C(═O)NR^(a)R^(a),—C(═NR^(a))NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a), S(═O)R^(b),S(═O)₂R^(b) or S(═O)₂NR^(a)R^(a).

In another embodiment, in conjunction with any of the above or belowembodiments, R¹¹ is H.

Another aspect of the invention relates to a method of treatingPI3K-mediated conditions or disorders.

In certain embodiments, the PI3K-mediated condition or disorder isselected from rheumatoid arthritis, ankylosing spondylitis,osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases,and autoimmune diseases. In other embodiments, the PI3K-mediatedcondition or disorder is selected from cardiovascular diseases,atherosclerosis, hypertension, deep venous thrombosis, stroke,myocardial infarction, unstable angina, thromboembolism, pulmonaryembolism, thrombolytic diseases, acute arterial ischemia, peripheralthrombotic occlusions, and coronary artery disease. In still otherembodiments, the PI3K-mediated condition or disorder is selected fromcancer, colon cancer, glioblastoma, endometrial carcinoma,hepatocellular cancer, lung cancer, melanoma, renal cell carcinoma,thyroid carcinoma, cell lymphoma, lymphoproliferative disorders, smallcell lung cancer, squamous cell lung carcinoma, glioma, breast cancer,prostate cancer, ovarian cancer, cervical cancer, and leukemia. In yetanother embodiment, the PI3K-mediated condition or disorder is selectedfrom type II diabetes. In still other embodiments, the PI3K-mediatedcondition or disorder is selected from respiratory diseases, bronchitis,asthma, and chronic obstructive pulmonary disease. In certainembodiments, the subject is a human.

Another aspect of the invention relates to the treatment of rheumatoidarthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis,psoriasis, inflammatory diseases or autoimmune diseases comprising thestep of administering a compound according to any of the aboveembodiments.

Another aspect of the invention relates to the treatment of rheumatoidarthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis,psoriasis, inflammatory diseases and autoimmune diseases, inflammatorybowel disorders, inflammatory eye disorders, inflammatory or unstablebladder disorders, skin complaints with inflammatory components, chronicinflammatory conditions, autoimmune diseases, systemic lupuserythematosis (SLE), myestenia gravis, rheumatoid arthritis, acutedisseminated encephalomyelitis, idiopathic thrombocytopenic purpura,multiples sclerosis, Sjoegren's syndrome and autoimmune hemolyticanemia, allergic conditions and hypersensitivity, comprising the step ofadministering a compound according to any of the above or belowembodiments.

Another aspect of the invention relates to the treatment of cancers thatare mediated, dependent on or associated with p110δ activity, comprisingthe step of administering a compound according to any of the above orbelow embodiments.

Another aspect of the invention relates to the treatment of cancers areselected from acute myeloid leukaemia, myelo-dysplastic syndrome,myelo-proliferative diseases, chronic myeloid leukaemia, T-cell acutelymphoblastic leukaemia, B-cell acute lymphoblastic leukaemia,non-hodgkins lymphoma, B-cell lymphoma, solid tumors and breast cancer,comprising the step of administering a compound according to any of theabove or below embodiments.

Another aspect of the invention relates to a pharmaceutical compositioncomprising a compound according to any of the above embodiments and apharmaceutically-acceptable diluent or carrier.

Another aspect of the invention relates to the use of a compoundaccording to any of the above embodiments as a medicament.

Another aspect of the invention relates to the use of a compoundaccording to any of the above embodiments in the manufacture of amedicament for the treatment of rheumatoid arthritis, ankylosingspondylitis, osteoarthritis, psoriatic arthritis, psoriasis,inflammatory diseases, and autoimmune diseases.

The compounds of this invention may have in general several asymmetriccenters and are typically depicted in the form of racemic mixtures. Thisinvention is intended to encompass racemic mixtures, partially racemicmixtures and separate enantiomers and diasteromers.

Unless otherwise specified, the following definitions apply to termsfound in the specification and claims:

“C_(α-β)alkyl” means an alkyl group comprising a minimum of α and amaximum of β carbon atoms in a branched, cyclical or linear relationshipor any combination of the three, wherein α and β represent integers. Thealkyl groups described in this section may also contain one or twodouble or triple bonds. Examples of C₁₋₆alkyl include, but are notlimited to the following:

“Benzo group”, alone or in combination, means the divalent radicalC₄H₄═, one representation of which is —CH═CH—CH═CH—, that when vicinallyattached to another ring forms a benzene-like ring—for exampletetrahydronaphthalene, indole and the like.

The terms “oxo” and “thioxo” represent the groups ═O (as in carbonyl)and ═S (as in thiocarbonyl), respectively.

“Halo” or “halogen” means a halogen atoms selected from F, Cl, Br and I.

“C_(V-W)haloalkyl” means an alkyl group, as described above, wherein anynumber—at least one—of the hydrogen atoms attached to the alkyl chainare replaced by F, Cl, Br or I.

“Heterocycle” means a ring comprising at least one carbon atom and atleast one other atom selected from N, O and S. Examples of heterocyclesthat may be found in the claims include, but are not limited to, thefollowing:

“Available nitrogen atoms” are those nitrogen atoms that are part of aheterocycle and are joined by two single bonds (e.g. piperidine),leaving an external bond available for substitution by, for example, Hor CH₃.

“Pharmaceutically-acceptable salt” means a salt prepared by conventionalmeans, and are well known by those skilled in the art. The“pharmacologically acceptable salts” include basic salts of inorganicand organic acids, including but not limited to hydrochloric acid,hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid,ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaricacid, citric acid, lactic acid, fumaric acid, succinic acid, maleicacid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid andthe like. When compounds of the invention include an acidic functionsuch as a carboxy group, then suitable pharmaceutically acceptablecation pairs for the carboxy group are well known to those skilled inthe art and include alkaline, alkaline earth, ammonium, quaternaryammonium cations and the like. For additional examples of“pharmacologically acceptable salts,” see infra and Berge et al., J.Pharm. Sci. 66:1 (1977).

“Saturated, partially saturated or unsaturated” includes substituentssaturated with hydrogens, substituents completely unsaturated withhydrogens and substituents partially saturated with hydrogens.

“Leaving group” generally refers to groups readily displaceable by anucleophile, such as an amine, a thiol or an alcohol nucleophile. Suchleaving groups are well known in the art. Examples of such leavinggroups include, but are not limited to, N-hydroxysuccinimide,N-hydroxybenzotriazole, halides, triflates, tosylates and the like.Preferred leaving groups are indicated herein where appropriate.

“Protecting group” generally refers to groups well known in the artwhich are used to prevent selected reactive groups, such as carboxy,amino, hydroxy, mercapto and the like, from undergoing undesiredreactions, such as nucleophilic, electrophilic, oxidation, reduction andthe like. Preferred protecting groups are indicated herein whereappropriate. Examples of amino protecting groups include, but are notlimited to, aralkyl, substituted aralkyl, cycloalkenylalkyl andsubstituted cycloalkenyl alkyl, allyl, substituted allyl, acyl,alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples ofaralkyl include, but are not limited to, benzyl, ortho-methylbenzyl,trityl and benzhydryl, which can be optionally substituted with halogen,alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts,such as phosphonium and ammonium salts. Examples of aryl groups includephenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl),phenanthrenyl, durenyl and the like. Examples of cycloalkenylalkyl orsubstituted cycloalkylenylalkyl radicals, preferably have 6-10 carbonatoms, include, but are not limited to, cyclohexenyl methyl and thelike. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups includebenzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl,substituted benzoyl, butyryl, acetyl, trifluoroacetyl, trichloro acetyl,phthaloyl and the like. A mixture of protecting groups can be used toprotect the same amino group, such as a primary amino group can beprotected by both an aralkyl group and an aralkoxycarbonyl group. Aminoprotecting groups can also form a heterocyclic ring with the nitrogen towhich they are attached, for example, 1,2-bis(methylene)benzene,phthalimidyl, succinimidyl, maleimidyl and the like and where theseheterocyclic groups can further include adjoining aryl and cycloalkylrings. In addition, the heterocyclic groups can be mono-, di- ortri-substituted, such as nitrophthalimidyl. Amino groups may also beprotected against undesired reactions, such as oxidation, through theformation of an addition salt, such as hydrochloride, toluenesulfonicacid, trifluoroacetic acid and the like. Many of the amino protectinggroups are also suitable for protecting carboxy, hydroxy and mercaptogroups. For example, aralkyl groups. Alkyl groups are also suitablegroups for protecting hydroxy and mercapto groups, such as tert-butyl.Silyl protecting groups are silicon atoms optionally substituted by oneor more alkyl, aryl and aralkyl groups. Suitable silyl protecting groupsinclude, but are not limited to, trimethylsilyl, triethylsilyl,triisopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl,1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane anddiphenylmethylsilyl. Silylation of an amino groups provide mono- ordi-silylamino groups. Silylation of aminoalcohol compounds can lead to aN,N,O-trisilyl derivative. Removal of the silyl function from a silylether function is readily accomplished by treatment with, for example, ametal hydroxide or ammonium fluoride reagent, either as a discretereaction step or in situ during a reaction with the alcohol group.Suitable silylating agents are, for example, trimethylsilyl chloride,tert-butyl-dimethylsilyl chloride, phenyldimethylsilyl chloride,diphenylmethyl silyl chloride or their combination products withimidazole or DMF. Methods for silylation of amines and removal of silylprotecting groups are well known to those skilled in the art. Methods ofpreparation of these amine derivatives from corresponding amino acids,amino acid amides or amino acid esters are also well known to thoseskilled in the art of organic chemistry including amino acid/amino acidester or aminoalcohol chemistry.

Protecting groups are removed under conditions which will not affect theremaining portion of the molecule. These methods are well known in theart and include acid hydrolysis, hydrogenolysis and the like. Apreferred method involves removal of a protecting group, such as removalof a benzyloxycarbonyl group by hydrogenolysis utilizing palladium oncarbon in a suitable solvent system such as an alcohol, acetic acid, andthe like or mixtures thereof. A t-butoxycarbonyl protecting group can beremoved utilizing an inorganic or organic acid, such as HCl ortrifluoroacetic acid, in a suitable solvent system, such as dioxane ormethylene chloride. The resulting amino salt can readily be neutralizedto yield the free amine. Carboxy protecting group, such as methyl,ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can beremoved under hydrolysis and hydrogenolysis conditions well known tothose skilled in the art.

It should be noted that compounds of the invention may contain groupsthat may exist in tautomeric forms, such as cyclic and acyclic amidineand guanidine groups, heteroatom substituted heteroaryl groups (Y′═O, S,NR), and the like, which are illustrated in the following examples:

and though one form is named, described, displayed and/or claimedherein, all the tautomeric forms are intended to be inherently includedin such name, description, display and/or claim.

Prodrugs of the compounds of this invention are also contemplated bythis invention. A prodrug is an active or inactive compound that ismodified chemically through in vivo physiological action, such ashydrolysis, metabolism and the like, into a compound of this inventionfollowing administration of the prodrug to a patient. The suitabilityand techniques involved in making and using prodrugs are well known bythose skilled in the art. For a general discussion of prodrugs involvingesters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) andBundgaard Design of Prodrugs, Elsevier (1985). Examples of a maskedcarboxylate anion include a variety of esters, such as alkyl (forexample, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl(for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (forexample, pivaloyloxymethyl). Amines have been masked asarylcarbonyloxymethyl substituted derivatives which are cleaved byesterases in vivo releasing the free drug and formaldehyde (Bungaard J.Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, suchas imidazole, imide, indole and the like, have been masked withN-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)).Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloanand Little, Apr. 11, 1981) discloses Mannich-base hydroxamic acidprodrugs, their preparation and use.

The specification and claims contain listing of species using thelanguage “selected from . . . and . . . .” and “is . . . or . . . .”(sometimes referred to as Markush groups). When this language is used inthis application, unless otherwise stated it is meant to include thegroup as a whole, or any single members thereof, or any subgroupsthereof. The use of this language is merely for shorthand purposes andis not meant in any way to limit the removal of individual elements orsubgroups as needed.

EXPERIMENTAL

The following abbreviations are used:

aq.—aqueousBINAP—2,2′-bis(diphenylphosphino)-1,1′-binaphthylcond—concentrated

DCM DCM DMF—DMF

Et₂O—diethyl etherEtOAc—ethyl acetateEtOH—ethyl alcoholh—hour(s)min—minutesMeOH—methyl alcoholrt room temperaturesatd—saturatedTHF—tetrahydrofuran

General

Reagents and solvents used below can be obtained from commercialsources. ¹H-NMR spectra were recorded on a Bruker 400 MHz and 500 MHzNMR spectrometer. Significant peaks are tabulated in the order:multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m,multiplet; br s, broad singlet), coupling constant(s) in Hertz (Hz) andnumber of protons. Mass spectrometry results are reported as the ratioof mass over charge, followed by the relative abundance of each ion (inparentheses Electrospray ionization (ESI) mass spectrometry analysis wasconducted on a Agilent 1100 series LC/MSD electrospray massspectrometer. All compounds could be analyzed in the positive ESI modeusing acetonitrile:water with 0.1% formic acid as the delivery solvent.Reverse phase analytical HPLC was carried out using a Agilent 1200series on Agilent Eclipse XDB-C18 5 μm column (4.6×150 mm) as thestationary phase and eluting with acetonitrile:H₂O with 0.1% TFA.Reverse phase Semi-Prep HPLC was carried out using a Agilent 1100 Serieson a Phenomenex Gemini™ 10 μm C18 column (250×21.20 mm) as thestationary phase and eluting with acetonitrile:H₂O with 0.1% TFA.

Procedure A

A mixture of 2-chloro-quinoline-3-carbaldehyde (1 eq), arylboronic acid(1.1 eq), tetrakis(triphenylphosphine)palladium (5 mol %), and sodiumcarbonate (2M aq. Sol., 5.0 eq) in CH₃CN-water (3:1, 0.1 M) was heatedat 100° C. under N₂ for several hours. The mixture was partitionedbetween EtOAc and H₂O, the organic layer was separated, and the aqueouslayer was extracted with EtOAc. The combined organic layers were driedover Na₂SO₄, filtered, concentrated under reduced pressure, and purifiedby column chromatography on silica gel using 0% to 25% gradient of EtOAcin hexane to provide 2-arylquinoline-3-carbaldehydes.

Procedure B

Solid sodium borohydride (1.5 eq) was added to a solution of2-arylquinoline-3-carbaldehyde (1 eq) in THF (0.5M) at 0° C. and themixture was stirred at 0° C. for 2 h. The reaction was quenched byaddition of water. The aqueous layer was extracted with EtOAc (3 times).The combined organic layers were dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The residue was purified by columnchromatography on silica gel using 50% of EtOAc in hexane to provide(2-arylquinolin-3-yl)methanols.

Procedure C

(2-Arylquinolin-3-yl)methanol (1 eq) in CHCl₃ (0.25M) was treated withSOCl₂ (5 eq) at rt for 2 h. Solvents were removed under reduced pressureand the residue was partitioned between EtOAc and saturated aq. NaHCO₃solution. The organic layer was separated, washed with water and brine,dried over Na₂SO₄, filtered, and concentrated under reduced pressure.The crude product was purified by column chromatography on a Redi-Sep™column using 0 to 100% gradient of EtOAc in hexane to provide3-(chloromethyl)-2-arylquinolines.

Procedure D

To a solution of 3-(chloromethyl)-2-arylquinoline (1 eq) in DMSO (0.25M) was added NaN₃ (3 eq) at rt and the mixture was stirred for 4 h atrt. The mixture was diluted with water, extracted with EtOAc (2 times)and the combined organic layers were washed with water (2 times), driedover Na₂SO₄, filtered, and concentrated under reduced pressure. Theresidue was dissolved in MeOH and treated with 10% Pd—C (5 wt %) and themixture was then stirred under H₂ balloon over night. The mixture wasfiltered through a Celite™ pad followed by removal of solvents to give(2-arylquinolin-3-yl)methanamines.

Procedure E

To a stirring solution of 3-(chloromethyl)-2-arylquinoline (1 eq) in 16mL of DMF was added NaN₃ (2 eq) at rt. The mixture was stirred at rt for1 h. The mixture was partitioned between EtOAc and H₂O. The organiclayer was dried over MgSO₄, filtered, and concentrated under reducedpressure to provide 3-(azidomethyl)-2-arylquinolines. The crude productwas carried on without purification for the next step. To a stirringsolution of 3-(azidomethyl)-2-arylquinoline in THF-H₂O (4:1, 0.21 M) wasadded dropwise PMe₃ (1.0 M solution in THF, 1.2 eq) at rt and themixture was stirred at rt for 1 h. To the mixture was added EtOAc andthe mixture was extracted with 1N HCl(2 times). The combined extractswere neutralized with solid sodium bicarbonate, and extracted with EtOAc(2 times). The combined organic extracts were dried over MgSO₄,filtered, and concentrated under reduced pressure to give dark syrup.The crude product was purified by column chromatography on a Redi-Sep™column using 0 to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂as eluent to provide (2-arylquinolin-3-yl)methanamines.

Procedure F

A mixture of 2-arylquinoline-3-carbaldehyde (1 eq), DCE (0.2 M), andPMBNH₂ (1.5 eq) was stirred at rt. After 1 h, to the mixture was addedNaBH(OAc)₃ (3 eq) and the mixture was stirred at 50° C. for 2 h. To themixture was added saturated aq. NaHCO₃ and the mixture was stirred for15 min. The organic layer was separated and the aqueous layer wasextracted with CH₂Cl₂ (2 times). The combined organic layers were washedwith brine, dried over MgSO₄, filtered, and concentrated under reducedpressure. The residue was purified by column chromatography on aRedi-Sep™ column using 0 to 100% gradient of EtOAc in hexane to provideN-(4-methoxybenzyl)(2-arylquinolin-3-yl)methanamines.

Procedures G

A mixture of N-(4-methoxybenzyl)(2-arylquinolin-3-yl)methanamine (1 eq)and ammonium cerium(iv) nitrate (3.5 eq) in CH₃CN—H₂O (2:1, 0.22M) wasstirred at rt for 24 h. To the mixture wad added 0.5M HCl (12 eq) andthe mixture was washed with CH₂Cl₂ (3 times) to remove4-methoxybenzaldehyde produced. The organic fraction was then extractedwith 0.5M HCl (2 times). The combined acidic aqueous layer was basifiedto pH 9.0 with 2N HaOH. The resulting precipitate was collected byfiltration. The crude product was purified by column chromatography on aRedi-Sep™ column using 0 to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ as eluent to provide (2-arylquinolin-3-yl)methanamines.

Procedures H

A mixture (2-arylquinolin-3-yl)methanamine (1 eq) in EtOH (0.16 M) wastreated with iPr₂NEt (1.2 eq) followed with 6-chloropurine (1 eq) at 80°C. for 8 h. The reaction mixture was concentrated and purified by columnchromatography on a Redi-Sep™ column using 0 to 100% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ as eluent to provideN-((2-arylquinolin-3-yl)methyl)-9H-purin-6-amines.

Procedure K

To a mixture of 2-phenylquinoline-3-carbaldehyde (1.0 eq) in THF (0.28M)at 0° C. was added dropwise a solution of a Grignard reagent (3 M, 2 eq)and the reaction was stirred overnight before being quenched with NH₄Clsaturated solution. The mixture was extracted with EtOAc (2×10 mL) andthe combined organic layers were dried (Na₂SO₄) and concentrated underreduced pressure. The residue was purified by column chromatography onsilica gel (eluent: EtOAc/hexane, 1/1) to provide1-(2-phenylquinolin-3-yl)alcohols.

Procedure L

A mixture of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (2.0 eq) and1,4-diazabicyclo[2.2.2]octane (4.0 eq) in anhydrous DMSO (0.69M) wasstirred at rt for 5 h and then added via cannula to a mixture of1-(2-phenylquinolin-3-yl) alcohol (1 eq) and sodium hydride, 60%dispersion in mineral oil (3 eq) in DMSO (0.5M) that had been stirredfor 30 min at rt and 30 min at 50° C. prior to the addition. The mixturewas stirred at rt for 6 h before addition of water, and the mixture wasextracted with EtOAc (4×). The combined organic layers were washed withwater, brine, dried (MgSO₄) and concentrated under reduced pressure. Theresidue was purified by column chromatography on silica gel (eluent:CH₂Cl₂/MeOH, 50/1) to provide the desired product.

Example 1 Preparation ofN-((8-Methyl-2-o-tolylquinolin-3-yl)methyl)-9H-purin-6-amine8-Methyl-2-o-tolylquinoline-3-carbaldehyde

Prepared according to Procedure A using2-chloro-8-methylquinoline-3-carbaldehyde (2.1 g, 10 mmol),o-tolylboronic acid (1.5 g, 1.1 eq),tetrakis(triphenyl-phosphine)palladium (575 mg, 0.05 eq), and sodiumcarbonate (5.5 g, 5 eq) in MeCN (75 mL) and water (25 mL). Afterpurification, 8-methyl-2-o-tolylquinoline-3-carbaldehyde was obtained aswhite solid. ¹H-NMR (CDCl₃) 9.96 (s, 1H), 8.83 (s, 1H), 7.88 (d, J=7.8Hz, 1H), 7.74 (d, J=6.3 Hz, 1H), 7.55 (t, J=7.8 Hz, 1H), 7.36-7.46 (m,4H), 2.84 (s, 3H), δ 2.30 (s, 3H). Mass Spectrum (ESI) m/e=262 (M+1).

(8-Methyl-2-o-tolylquinolin-3-yl)methanol

Prepared according to Procedure B using8-methyl-2-o-tolylquinoline-3-carb-aldehyde (1.28 g, 4.9 mmol) and solidNaBH₄ (278 mg, 1.5 eq) in THF (10 mL). After purification,(8-methyl-2-o-tolylquinolin-3-yl)methanol was obtained as white solid.

3-(Chloromethyl)-8-methyl-2-o-tolylquinoline

Prepared according to Procedure C using(8-methyl-2-o-tolylquinolin-3-yl)-methanol (670 mg, 2.5 mmol) and SOCl₂(0.91 mL, 5 eq) in CHCl₃ (10 mL). After isolation, the resultant oil wascarried on crude without purification for the next step.

(8-Methyl-2-o-tolylquinolin-3-yl)methanamine

Prepared according to Procedure D using3-(chloromethyl)-8-methyl-2-o-tolyl-quinoline (667 mg, 2.4 mmol) in DMSO(10 mL) was added NaN₃ (500 mg, 3 eq). After purification,(8-methyl-2-o-tolylquinolin-3-yl)methanamine was obtained as pale yellowoil.

Prepared according to procedure H. A mixture of(8-methyl-2-o-tolylquinolin-3-yl)methanamine (80 mg, 0.31 mmol) in EtOH(2 mL) was treated with iPr₂NEt (65 μL, 1.2 eq) followed with6-chloropurine (46.4 mg, 0.3 mmol) at 80° C. for 8 h. The reactionmixture was concentrated and purified by column chromatography on silicagel (eluent: DCM/MeOH, 25/1) to provide a white solid [PI3KδIC₅₀=84 nM].¹H-NMR (DMSO-d⁶) δ 8.24 (s, 1H), 8.19 (s, br, 1H), 8.15 (s, 1H), 7.81(d, J=8.0 Hz, 1H), 7.63 (d, J=7.1 Hz, 1H), 7.50 (t, J=7.4 Hz, 1H),7.39-7.42 (m, 4H), 4.62 (s, br, 2H), 2.66 (s, 3H), 2.16 (s, 3H). MassSpectrum (ESI) m/e=381 (M+1).

Example 2 Preparation ofN-((8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)-methyl)-9H-purin-6-amine2,8-Dichloroquinoline-3-carbaldehyde

A solution of LDA (14.8 mL 1.5M in cyclohexene, 22.2 mmol, 1.1 eq) inTHF (30 mL) was stirred at −78° C. as a solution of2,8-dichloroquinoline (4.0 g, 20.2 mmol) in THF (15 mL) was addeddropwise. The mixture stirred for two hours, at which time a solution ofethylformate (6.5 mL, 80.8 mmol, 4 eq) in THF (10 mL) was added slowly,and the mixture continued to stir at −78° C. for four hours. Wet THF (1mL H₂O in 5 mL THF) was added to quench the reaction and it was warmedto room temperature. After partitioning between Et₂O and water, theaqueous layer was further extracted with Et₂O, and the combined organiclayers were dried over MgSO₄, filtered and condensed under reducedpressure. The residue was chromatographed on a silica column using a0-50% gradient of EtOAc in hexane. 2,3-Dichloroquinoline-3-carbaldehydewas obtained as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.25(1H, s), 8.93 (1H, s), 8.14 (1H, d, J=8.6 Hz), 8.03 (1H, d, J=9.0 Hz),7.55-7.64 (1H, t, J=8.0 Hz) Mass Spectrum (ESI) m/e=226.0 and 227.9(M+1)

8-Chloro-2-(2-chlorophenyl)quinoline-3-carbaldehyde

Prepared according to Procedure A using 2,8-dichloroquinoline3-carbaldehyde (1.70 g, 7.5 mmol), 2-chlorophenyl boronic acid (1.29 g,8.25 mmol, 1.1 eq), tetrakis(triphenylphosphine)palladium (0.430 g,0.375 mmol, 0.05 eq), and sodium carbonate (3.97 g, 37.5 mmol, 5 eq) inacetonitrile (57 mL) and water (19 mL). After purification,8-chloro-2-(2-chlorophenyl)quinoline-3-carbaldehyde was obtained as ayellow solid. 1H NMR (400 MHz, DMSO-d₆) δ ppm 10.25 (1H, s), 8.93 (1H,s), 8.14 (1H, d, J=8.6 Hz), 8.03 (1H, d, J=9.0 Hz), 7.55-7.64 (1 H, t,J=8.0 Hz) Mass Spectrum (ESI) m/e=302.0 and 304.0 (M+1)

(8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methanol

Prepared according to Procedure B using2-(2-chlorophenyl)-8-chloroquinoline-3-carbaldehyde (1.18 g, 3.9 mmol),and sodium borohydride (0.222 g, 5.86 mmol, 1.5 eq) in THF (20 mL).(2-(2-chlorophenyl)-8-chloroquinolin-3-yl)methanol was obtained as ayellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.56 (1H, s), 8.10 (1H,dd, J=8.2, 1.2 Hz), 7.94 (1H, dd, J=7.6, 1.4 Hz), 7.63 (2H, t, J=7.8Hz), 7.44-7.59 (3H, m), 5.54 (1H, t, J=5.3 Hz) Mass Spectrum (ESI)m/e=304.0 and 306.1 (M+1)

8-Chloro-3-(chloromethyl)-2-(2-chlorophenyl)quinoline

Prepared according to Procedure C using(2-(2-chlorophenyl)-8-chloroquinolin-3-yl)methanol (0.675 g, 2.22 mmol)and SOCl₂ (0.81 mL).8-Chloro-3-(chloro-methyl)-2-(2-chlorophenyl)quinoline was obtained as ayellow foam. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.53 (1H, s), 7.88 (1H, dd,J=8.2, 1.2 Hz), 7.81 (1 H, dd, J=7.4, 1.2 Hz), 7.48 (1H, d, J=7.4 Hz),7.42-7.46 (1H, m), 7.27-7.41 (3 H, m), 4.63 (1H, d, J=9.8 Hz), 4.33-4.45(1H, m) Mass Spectrum (ESI) m/e=322.0 and 324.0 (M+1)

(8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methanamine

Prepared according to Procedure E using8-chloro-3-(chloromethyl)-2-(2-chloro-phenyl)quinoline (0.685 g, 2.12mmol) and sodium azide (1.10 g, 17 mmol, 8 eq) in DMF (10 mL). Theresulting intermediate was submitted to trimethyl phosphine (1.0M) inTHF (2.5 mL, 2.5 mmol, 1.2 eq) in THF (8 mL) and water (2 mL).(8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methanamine was obtained as alight yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.62 (1H, s), 8.05(1 H, dd, J=8.6, 1.2 Hz), 8.00 (1H, dd, J=7.4, 1.2 Hz), 7.63-7.73 (2H,m), 7.47-7.62 (3H, m), 3.90 (1H, s), 3.75 (1H, s) Mass Spectrum (ESI)m/e=303.1 and 305.0 (M+1)

N-((8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(8-chloro-2-(2-chlorophenyl)quinolin-3-yl)methanamine (0.100 g, 0.33mmol), 6-chloropurine (0.051 g, 0.33 mmol, 1 eq) and DIEA (0.07 mL, 0.4mmol, 1.2 eq) in ethanol (3 mL).N-((8-chloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine[PI3K δ IC₅₀=68 nM] was obtained after purification as a white solid. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 8.37 (1H, s), 8.11 (1H, s), 8.08 (1H, s),8.00 (1H, dd, J=8.2, 1.2 Hz), 7.93 (1H, dd, J=7.4, 1.2 Hz), 7.42-7.67(5H, m) Mass Spectrum (ESI) m/e=421.0 and 423.1 (M+1)

Example 3 Preparation of2-Chloro-N-((8-chloro-2-(2-chlorophenyl)-quinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(8-chloro-2-(2-chlorophenyl)quinolin-3-yl)methanamine (0.100 g, 0.33mmol), 2,6-dichloropurine (0.062 g, 0.33 mmol, 1 eq) and DIEA (0.07 mL,0.4 mmol, 1.2 eq) in ethanol (5 mL).2-Chloro-N-((8-chloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=615 nM] was obtained after purification as a white solid. ¹HNMR (500 MHz, DMSO-d₆) δ ppm 8.44 (1H, s), 8.15 (1H, s), 8.04 (1H, dd,J=8.5, 1.2 Hz), 7.96 (1H, d, J=6.7 Hz), 7.60 (1H, d, J=7.3 Hz), 7.61(1H, t, J=7.9 Hz), 7.54 (1H, d, J=6.7 Hz), 7.50 (1H, t, J=6.7 Hz), 7.44(1H, t, J=7.3 Hz), 4.62 (2H, d, J=26.9 Hz) Mass Spectrum (ESI) m/e=455.0and 457.0 (M+1)

Example 4 Preparation ofN-((8-chloro-2-(2-chlorophenyl)quinolin-3-yl)-methyl)-2-methoxy-7H-pyrrolo[2,3-d]pyrimidin-4-amine

Prepared according to Procedure H using(8-chloro-2-(2-chlorophenyl)quinolin-3-yl)methanamine (0.100 g, 0.33mmol), 4-chloro-2-methoxy-pyrrolo[2,3-d]pyrimidine (0.061 g, 0.33 mmol,1 eq) and DIEA (0.07 mL, 0.4 mmol, 1.2 eq) in ethanol (3 mL).N-((8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-2-meth-oxy-7H-pyrrolo[2,3-d]pyrimidin-4-amine[PI3Kδ IC₅₀=5420 nM] was obtained after purification as a tan solid. 1HNMR (400 MHz, DMSO-d₆) δ ppm 11.28 (1H, s), 8.37 (1H, s), 8.03 (1H, dd,J=8.4, 1.0 Hz), 7.94-7.99 (1H, m), 7.94 (1H, dd, J=7.6, 1.4 Hz),7.40-7.65 (5H, m), 6.88 (1H, dd, J=3.3, 2.2 Hz), 6.47 (1H, s), 4.59 (2H,s), 3.67 (3H, s) Mass Spectrum (ESI) m/e=450.1 and 452.0 (M+1)

Example 5 Preparation of 3-(1-(9H-Purin-6-yloxy)ethyl)-8-methyl-2-O—tolylquinoline 1-(8-Methyl-2-o-tolylquinolin-3-yl)ethanol

Prepared according to Procedure K. To a mixture of8-methyl-2-o-tolylquinoline-3-carbaldehyde (434 mg, 1.7 mmol) in THF (6mL) at 0° C. was added dropwise a solution of MeMgCl (3M, 2 eq, 1.1 mL)and the reaction was stirred over night before quenched with NH₄Clsaturated solution. The mixture was extracted with EtOAc (2×10 mL) andthe combined organic layers were dried (Na₂SO₄) and concentrated underreduced pressure. The residue was purified by column chromatography onsilica gel (eluent: EtOAc/hexane, 1/1) to provide1-(8-methyl-2-o-tolylquinolin-3-yl)ethanol as a white solid. ¹H-NMR(CDCl₃) δ 8.34 (s, 1H), 7.66 (d, J=8.2 Hz, 1H), 7.48 (d, J=6.7 Hz, 1H),7.39 (t, J=7.8 Hz, 1H), 7.19-7.27 (m, 4H), 2.69 (s, 3H), 2.08 (s, 3H),1.30 (m, 3H). Mass Spectrum (ESI) m/e=278 (M+1).

3-(1-(9H-Purin-6-yloxy)ethyl)-8-methyl-2-o-tolylquinoline

Prepared according to procedure K using1-(8-methyl-2-o-tolylquinolin-3-yl)-ethanol,3-(1-(9H-purin-6-yloxy)ethyl)-8-methyl-2-o-tolylquinoline [PI3Kδ IC₅₀=12nM] was prepared. ¹H-NMR (DMSO-d⁶) δ 13.3 (s, 1H), 8.60 (s, br, 1H),8.36 (s, br, 1H), 7.88 (d, J=7.9 Hz, 1H), 7.62 (d, J=6.6 Hz, 1H), 7.50(t, J=7.2 Hz, 1H), 7.02-7.21 (m, 4H), 6.28-6.41 (m, 1H), 2.65 (s, 3H),2.10 (s, 3H), 1.74 (s, br, 3H, major), 1.62 (s, br, 3H, minor). MassSpectrum (ESI) m/e=396 (M+1).

Example 6 Preparation ofN-(1-(2-(2-chlorophenyl)-8-methylquinolin-3-yl)-ethyl)-9H-purin-6-amine

Prepared by procedure K, C and E:1-(2-(2-Chlorophenyl)-8-methylquinolin-3-yl)ethanamine. ¹H-NMR (CDCl₃) δ8.47 (s, major, 1H), 8.38 (s, minor, 1H), 7.40-7.74 (m, 7H), 4.19-4.21(m, 1H), 2.78 (s, 3H), 1.49 (d, J=6.3 Hz, minor, 3H), 1.22 (d, J=6.7 Hz,major, 3H). Mass Spectrum (ESI) m/e=297 (M+1).

N-(1-(2-(2-Chlorophenyl)-8-methylquinolin-3-yl)ethyl)-9H-purin-6-amine

Prepared according to procedure H [PI3Kδ IC₅₀=31 nM]. ¹H-NMR (DMSO-d⁶) δ10.21-10.32 (m, 1H), 8.40-8.78 (m, 2H), 7.88 (d, J=7.4 Hz, 1H), 7.65 (d,J=6.6 Hz, 1H), 7.19-7.56 (m, 6H), 5.46-5.58 (m, 1H), 2.63 (s, 3H), 1.66(d, J=6.6 Hz, 3H). Mass Spectrum (ESI) m/e=415 (M+1).

Example 7 Preparation of3-((9H-Purin-6-yloxy)methyl)-2-(2-methoxy-phenyl)-8-methylquinoline2-(2-Methoxyphenyl)-8-methylquinoline-3-carbaldehyde

Prepared according to Procedure A using 2-chloro-8-methylquinoline3-carbaldehyde (0.206 g, 1 mmol), 2-methoxyphenyl boronic acid (0.167 g,1.1 mmol, 1.1 eq), tetrakis(triphenylphosphine)palladium (0.058 g, 0.05mmol, 0.05 eq), and sodium carbonate (0.530 g, 5 mmol, 5 eq) inacetonitrile (7.5 mL) and water (2.5 mL). After purification,2-(2-methoxyphenyl)-8-methylquinoline-3-carbaldehyde (0.250 g, 90%) wasobtained as a white solid. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 9.86 (1H, s),8.88 (1H, s), 8.13 (1H, d, J=8.1 Hz), 7.85 (1H, d, J=7.1 Hz), 7.56-7.74(3H, m), 7.22-7.30 (2H, m), 3.78 (3H, s), 2.80 (3H, s) Mass Spectrum(ESI) ink=278.0 (M+1)

(2-(2-Methoxyphenyl)-8-methylquinolin-3-yl)methanol

Prepared according to Procedure B using2-(2-methoxyphenyl)-8-methylquinoline-3-carbaldehyde (0.250 g, 0.9mmol), and sodium borohydride (0.0378 g, 1.35 mmol, 1.5 eq), in THF (5mL). (2-(2-Methoxyphenyl)-8-methylquinolin-3-yl)-methanol was obtainedas a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.41 (1H, s), 7.92(1H, d, J=7.8 Hz), 7.64 (1H, d, J=7.0 Hz), 7.50-7.59 (2H, m), 7.33 (1H,dd, J=7.4, 1.6 Hz), 7.22 (1H, d, J=7.8 Hz), 7.16 (1H, t, J=7.2 Hz), 5.37(1H, t, J=5.5 Hz), 3.79 (3H, s), 2.72 (3H, s) Mass Spectrum (ESI)ink=280.1 (M+1)

3-((9H-Purin-6-yloxy)methyl)-2-(2-methoxyphenyl)-8-methylquinoline

Prepared according to modified Procedure L. 6-Chloropurine (0.077 g, 0.5mmol, 2 eq) and DABCO (0.112 g, 1 mmol, 4 eq) were stirred in DMSO (0.7mL) at room temperature for 5 h. In a separate flask, sodium hydride(0.040 g, 1 mmol, 4 eq) was added portion-wise to a stirring solution of(2-(2-methoxyphenyl)-8-methyl-quinolin-3-yl)methanol (0.070 g, 0.25mmol) in DMSO (0.5 mL), and after 30 minutes, the purine-DABCO salt wasadded to this mixture. The reaction stirred at room temperature 18 h.3-((9H-purin-6-yloxy)methyl)-2-(2-methoxyphenyl)-8-methylquinoline[PI3Kδ IC₅₀=38 nM] was isolated as a white solid after purification on asilica column. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 13.41 (1 H, s), 8.51 (1H,s), 8.39 (1H, s), 7.87 (1H, d, J=7.8 Hz), 7.65 (1H, d, J=7.0 Hz),7.49-7.56 (1H, m), 7.34-7.46 (2H, m), 7.12 (1H, d, J=8.2 Hz), 7.03 (1H,t, J=7.2 Hz), 5.58 (2H, s), 3.72 (3H, s), 2.69 (3H, s) Mass Spectrum(ESI) m/e=398.2 (M+1)

Example 8 Preparation of3-((9H-Purin-6-yloxy)methyl)-2-(biphenyl)-8-methylquinoline2-(Biphenyl)-8-methylquinoline-3-carbaldehyde

Prepared according to Procedure A using 2-chloro-8-methylquinoline3-carb-aldehyde (0.206 g, 1 mmol), 2-phenylbenzene boronic acid (0.218g, 1.1 mmol, 1.1 eq), tetrakis(triphenylphosphine)palladium (0.058 g,0.05 mmol, 0.05 eq), and sodium carbonate (0.530 g, 5 mmol, 5 eq) inacetonitrile (7.5 mL) and water (2.5 mL). After purification,2-(2-biphenyl)-8-methylquinoline-3-carbaldehyde (0.312 g, 97%) wasobtained as a white solid. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 9.71 (1H, s),8.66 (1H, s), 8.01 (1H, d, J=8.1 Hz), 7.79 (1H, d, J=6.8 Hz), 7.65-7.72(2H, m), 7.53-7.65 (3H, m), 7.11-7.19 (3H, m), 7.00-7.09 (2H, m), 2.66(3H, s) Mass Spectrum (ESI) m/e=324.1 (M+1)

(2-(Biphenyl)-8-methylquinolin-3-yl)methanol

Prepared according to Procedure B using2-(biphenyl)-8-methylquinoline-3-carb-aldehyde (0.312 g, 0.96 mmol), andsodium borohydride (0.055 g, 1.44 mmol, 1.5 eq) in THF (5 mL).(2-(Biphenyl)-8-methylquinolin-3-yl)methanol was obtained as a whitesolid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.19 (1H, s), 7.77 (1H, d, J=7.8Hz), 7.55-7.62 (1H, m), 7.48-7.55 (3H, m), 7.44 (2H, d, J=8.2 Hz), 7.11(5H, s), 5.24 (1H, t, J=5.3 Hz), 2.57 (3H, s) Mass Spectrum (ESI)m/e=326.2 (M+1)

3-((9H-Purin-6-yloxy)methyl)-2-(biphenyl)-8-methylquinoline

Prepared according to modified Procedure L: 6-Chloropurine (0.077 g, 0.5mmol, 2 eq) and DABCO (0.112 g, 1 mmol, 4 eq) were stirred in DMSO (0.7mL) at room temperature for 5 h. In a separate flask, sodium hydride(0.040 g, 1 mmol, 4 eq) was added portion-wise to a stirring solution of(2-(biphenyl)-8-methylquinolin-3-yl)methanol (0.081 g, 0.25 mmol) inDMSO (0.5 mL), and after 30 minutes, the purine-DABCO salt was added tothis mixture. The reaction stirred at room temperature 18 h.3-((9H-Purin-6-yloxy)methyl)-2-(biphenyl)-8-methylquinoline [PI3KδIC₅₀=22 nM] was isolated as a white solid after purification on a silicacolumn. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 13.39 (1H, s), 8.37 (2H, d,J=9.8 Hz), 7.77 (1H, d, J=7.8 Hz), 7.54-7.63 (2H, m), 7.37-7.54 (4H, m),7.14-7.21 (2H, m), 7.07-7.14 (3H, m), 5.51 (1H, d, J=12.5 Hz), 5.29 (1H,d, J=9.4 Hz), 2.54 (3H, s) Mass Spectrum (ESI) m/e=444.2 (M+1)

Example 9 Preparation of3-(1-(7H-Pyrrolo[2,3-d]pyrimidin-4-yloxy)but-3-enyl)-2-(2-chlorophenyl)-8-methylquinoline1-(2-(2-Chlorophenyl)-8-methylquinolin-3-yl)but-3-en-1-ol

Prepared according to procedure K: To a solution of2-(2-chlorophenyl)-8-methylquinoline-3-carbaldehyde (1.4 g, 5 mmol) inTHY (20 mL) at 0° C. under N₂ was added dropwise a solution ofallylmagenisiumbromide (1M, 1.1 eq, 5.5 mL) in TI-IF and the mixture wasstirred at 0° C. for 2 h. The mixture was partitioned between EtOAc (50mL) and H₂O (30 mL), the layers were separated, and the aqueous layerwas extracted with EtOAc (2×30 mL). The combined organic layers weredried (Na₂SO₄), concentrated and purified by flash chromatography (0% to25% EtOAc/hexane) to provide1-(2-(2-chlorophenyl)-8-methyl-quinolin-3-yl)but-3-en-1-ol as acolorless oil. ¹H-NMR (CDCl₃) δ 8.45 (s, major, 1H), 8.40 (s, minor,1H), 7.77 (d, J=7.9 Hz, 1H), 7.43-7.60 (m, 6H), 5.56-5.73 (m, 1H),4.96-5.17 (m, 2H), 4.80-4.84 (m, 1H), 2.80 (s, 3H), 2.34-2.59 (m, 2H).Mass Spectrum (ESI) m/e=324 (M+1).

3-(1-(7H-Pyrrolo[2,3-d]pyrimidin-4-yloxy)but-3-enyl)-2-(2-chlorophenyl)-8-methylquinoline

Prepared according to procedure L. A mixture of4-chloro-7H-pyrrolo[2,3-d]pyrimidine (474 mg, 3.1 mmol) and1,4-diazabicyclo[2.2.2]octane (694 mg, 6.2 mmol) in anhydrous DMSO (4.5mL) was stirred at it for 5 h and then added via cannula to a mixture of1-(2-(2-chlorophenyl)-8-methylquinolin-3-yl)but-3-en-1-ol (500 mg, 1.5mmol) and sodium hydride, 60% dispersion in mineral oil (180 mg, 4.5mmol) in DMSO (3 mL) that had been stirred for 30 min at rt and 30 minat 50° C. prior to the addition. The mixture was stirred at rt for 6 hbefore addition of water (10 mL), and the mixture was extracted withEtOAc (4×20 mL). The combined organic layers were washed with water,brine, dried (MgSO₄) and concentrated under reduced pressure. Theresidue was purified by column chromatography on silica gel (eluent:DCM/MeOH, 50/1) to provide3-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)but-3-enyl)-2-(2-chlorophenyl)-8-methyl-quinoline[PI3Kδ IC₅₀=28 nM] as a white solid. ¹H-NMR (CDCl₃) δ 10.20 (s, br, 1H),8.22 (d, J=7.5 Hz, 1H), 7.15-7.64 (m, 8H), 6.59-6.62 (m, 1H), 6.34-6.37(m, 1H), 5.64-5.79 (m, 1H), 4.93-5.01 (m, 2H), 2.74 (t, J=8.7 Hz, 2H),2.70 (s, 3H). Mass Spectrum (ESI) m/e=441 (M+1).

Example 103-((9H-Purin-6-yloxy)methyl)-2-(2-chlorophenyl)-8-methylquinoline

Prepared according to procedure L A mixture of 6-chloropurine (75 mg,0.49 mmol) and 1,4-diazabicyclo[2.2.2]octane (109 mg, 0.97 mmol) in DMSO(0.5 mL) was stirred at rt for 5 h and was then added via cannula to amixture of (2-(2-chlorophenyl)-8-methylquinolin-3-yl)methanol (69 mg,0.24 mmol) and sodium hydride, 60% dispersion in mineral oil (39 mg,0.97 mmol) in DMSO (0.5 mL) that had been stirred at rt for 15 min priorto the addition. The mixture was stirred at rt for 3.5 h, cooled to 0°C., and H₂O (5 mL) was added carefully. The mixture was extracted withEtOAc (3×10 mL), and the combined organic layers were dried (MgSO₄) andconcentrated under reduced pressure. The resulting yellow oil wasdissolved in CH₂Cl₂, evaporated onto silica gel (deactivated with 2M NH₃in MeOH), and purified by flash chromatography (Biotage® Si 25+M)eluting with 2M NH₃ in MeOH/CH₂Cl₂ (5%) to provide a white solid [PI3KδIC₅₀=25 nM]. MS (ESI+) m/z=402.0 (M+1).

Example 11 3-((9H-Purin-6-yloxy)methyl)-8-methyl-2-o-tolylquinoline

Prepared according to procedure L A mixture of 6-chloropurine (110 mg,0.71 mmol) and 1,4-diazabicyclo[2.2.2]octane (160 mg, 1.43 mmol) in DMSO(0.7 mL) was stirred at rt for 4 h and was then added via cannula to amixture of (8-methyl-2-o-tolylquinolin-3-yl)methanol (94 mg, 0.36 mmol)and sodium hydride, 60% dispersion in mineral oil (57 mg, 1.43 mmol) inDMSO (1 mL) that had been stirred at rt for 15 min prior to theaddition. The mixture was stirred at rt for 3.5 h, neutralized by theaddition of glacial acetic acid, diluted with brine (15 mL), andextracted with EtOAc (3×15 mL). The combined organic layers were dried(MgSO₄) and concentrated under reduced pressure. The resulting yellowoil was dissolved in CH₂Cl₂, evaporated onto silica gel (deactivatedwith 2M NH₃ in MeOH), and purified by flash chromatography (Biotage® Si25+M) eluting with 2 M NH₃ in MeOH/CH₂Cl₂ (5%) to provide a white solid[PI3Kδ IC₅₀=27 nM]. MS (APCI+) m/z=282.3 (M+1).

Example 12 3-((9H-Purin-6-ylthio)methyl)-8-methyl-2-o-tolylquinoline

Solid carbontetrabromide (429 mg, 1.29 mmol) was added to a mixture of(8-methyl-2-o-tolylquinolin-3-yl)methanol (227 mg, 0.86 mmol) andtriphenyl-phosphine (339 mg, 1.29 mmol) in CH₂Cl₂ (5 mL) at 0° C., andthe mixture was stirred at 0° C. for 0.5 h. The crude mixture wasconcentrated under reduced pressure, evaporated onto silica gel, andpurified by flash chromatography (Biotage® Si 25+M) eluting withEtOAc/hexane (0% to 10%) to provide an off-white solid; used withoutfurther purification, MS (ESI+) m/z=326.0 (M). A 2.0M aqueous solutionof sodium hydroxide (0.86 mL, 1.72 mmol) was added to a mixture of3-(bromomethyl)-8-methyl-2-o-tolylquinoline (140 mg, 0.43 mmol) and6-mercaptopurine monohydrate (146 mg, 0.86 mmol) in THF (1.6 mL), andthe biphasic mixture was heated under reflux for 5 h. The reactionmixture was cooled to 0° C., neutralized by the addition of 1N aqueousHCl, diluted with brine (10 mL), and extracted with THF (3×15 mL). Thecombined organic layers were dried (MgSO₄) and concentrated underreduced pressure. The resulting yellow solid was dissolved inTI-IF/DMSO, evaporated onto silica gel, and purified by flashchromatography (Biotage® Si 25+M) eluting with acetone/hexane (20% to50%). The resulting off-white solid was recrystallized from THF/MeOH toprovide a white solid [PI3Kδ C₅₀=889 nM]. MS (ESI+) m/z=398.1 (M+1).

Example 13N6-((8-Methyl-2-o-tolylquinolin-3-yl)methyl)-9H-purine-2,6-diamine

A mixture of (8-methyl-2-o-tolylquinolin-3-yl)methanamine (40 mg, 0.15mmol), 2-amino-6-chloropurine (52 mg, 0.30 mmol), and triethylamine (42μL, 0.30 mmol) in i-PrOH (0.8 mL) was heated in a microwave reactor at150° C. four times for 20 min. The mixture was partitioned betweensaturated aqueous NaHCO₃ (15 mL) and EtOAc (15 mL), the layers wereseparated, and the aqueous layer was extracted with EtOAc (2×15 mL). Thecombined organic layers were dried (MgSO₄) and concentrated underreduced pressure. The resulting yellow oil was dissolved in CH₂Cl₂,evaporated onto silica gel, and purified by flash chromatography(Biotage® Si 25+M) eluting with MeOH/CH₂Cl₂ (5% to 10%) to provide awhite solid. The compound was further purified by reversed-phase HPLC(Gilson) eluting with H₂O/MeCN/TFA to provide a white solid [PI3KδIC₅₀=82 nM]. MS (ESI+) m/z=396.2 (M+1).

Example 14 Preparation of3-(1-(7H-Pyrrolo[2,3-d]pyrimidin-4-yloxy)but-3-enyl)-2-(2-chlorophenyl)-8-methylquinoline

Prepared according to procedure L [PI3Kδ IC₅₀=56 nM]. ¹H-NMR (DMSO-d⁶) δ12.0 (s, 1H), 8.60 (s, 1H), 8.26 (s, 1H), 7.90 (d, J=7.9 Hz, 1H), 7.66(d, J=7.0 Hz, 1H), 7.54 (t, J=7.4 Hz, 1H), 7.22-7.37 (m, 5H), 6.50 (d,J=2.1 Hz, 1H), 5.45 (s, 2H), 2.68 (s, 3H), 2.11 (s, 3H). Mass Spectrum(ESI) m/e=381 (M+1).

Example 15 Preparation of3-((7H-Pyrrolo[2,3-d]pyrimidin-4-yloxy)methyl)-8-methyl-2-phenylquinoline(8-Methyl-2-phenylquinolin-3-yl)methanol

Prepared according to procedures A and B. ¹H-NMR (DMSO-d6) δ 8.45 (s,1H), 7.86-7.88 (d, 1H), 7.71-7.72 (m, 2H), 7.61-7.62 (d, 1H), 7.49-7.53(m, 4H), 5.47-5.48 (t, 1H), 4.64-4.65 (d, J=5 Hz, 2H), 2.72 (s, 3H).Mass Spectrum (ESI) m/e=250 (M+1).

3-((7H-Pyrrolo[2,3-d]pyrimidin-4-yloxy)methyl)-8-methyl-2-phenylquinoline

Prepared according to procedure L [PI3Kδ IC₅₀=68 nM]. ¹H-NMR (DMSO-d⁶)-δ8.65 (s, 1H), 8.32 (s, 1H), 7.89-7.01 (d, 1H), 7.74-7.75 (m, 2H),7.67-7.68 (d, 1H), 7.47-7.55 (m, 5H), 7.37-7.38 (d, J=5 Hz, 1H),6.53-6.54 (d, J=5 Hz, 1H), 5.70 (s, 2H), 2.74 (s, 3H). Mass Spectrum(ESI) m/e=367 (M+1).

Example 16 Preparation ofN-((8-Methyl-2-(2-(trifluoromethyl)phenyl)-quinolin-3-yl)methyl)-9H-purin-6-amine8-Methyl-2-(2-(trifluoromethyl)phenyl)quinoline-3-carbaldehyde

Prepared according to Procedure A using2-chloro-8-methylquinoline-3-carbaldehyde (2.0 g, 9.73 mmol),2-(trifluoromethyl)phenylboronic acid (2.032 g, 10.7 mmol, 1.1 eq),tetrakis(triphenylphosphine)palladium (562 mg, 5% mmol), and sodiumcarbonate (5.15 g, 48.6 mol, 5 eq) in MeCN (75 mL) and water (25 mL).After purification,8-methyl-2-(2-(trifluoromethyl)phenyl)quinoline-3-carb-aldehyde wasobtained as a white solid. ¹H NMR (DMSO-d₆) δ ppm 9.93 (1H, s), 9.04(1H, s), 8.13 (1H, d, J=8.1 Hz), 7.93 (1H, d, J=7.3 Hz), 7.85 (1H, d,J=7.1 Hz), 7.72-7.82 (2H, m), 7.64-7.71 (1H, m), 7.59 (1H, d, J=7.3 Hz),2.67 (3H, s). Mass Spectrum (ESD m/e=316.1 (M+1).

N-(4-Methoxybenzyl)(8-methyl-2-(2-(trifluoromethyl)phenyl)quinolin-3-yl)-methanamine

Prepared according to Procedure F using8-methyl-2-(2-(trifluoromethyl)phenyl)-quinoline-3-carbaldehyde (1 g,3.17 mmol), DCE (16 mL), PMBNH₂ (0.62 mL, 4.75 mmol, 1.5 eq), andNaBH(OAc)₃ (2.0166 g, 9.52 mmol, 3 eq). After purification,N-(4-methoxybenzyl)(8-methyl-2-(2-(trifluoromethyl)phenyl)-quinolin-3-yl)methanaminewas obtained as light yellow syrup. ¹H NMR (DMSO-d₆) δ ppm 8.48 (1H, s),7.87 (2H, t, J=7.2 Hz), 7.64-7.77 (2H, m), 7.48-7.62 (3H, m), 7.14 (2H,d, J=8.6 Hz), 6.81 (2H, d, J=8.6 Hz), 3.71 (3H, s), 3.44-3.62 (4H, m),2.61 (3H, s), 2.54 (1H, s). Mass Spectrum (ESI) m/e=437.2 (M+1).

(8-Methyl-2-(2-(trifluoromethyl)phenyl)quinolin-3-yl)methanamine

Prepared according to Procedure G usingN-(4-methoxybenzyl)(8-methyl-2-(2-(trifluoromethyl)phenyl)quinolin-3-yl)methanamine(1.1427 g, 2.62 mmol, 1 eq) and ammonium cerium(iv) nitrate (3.59 g,6.55 mmol, 2.5 eq) in CH₃CN—H₂O (2:1, 12 mL). After purification,(8-methyl-2-(2-(trifluoromethyl)phenyl)quino-lin-3-yl)methanamine wasobtained as brown syrup. ¹H NMR (DMSO-d₆) δ ppm 8.47 (1H, s), 7.91 (1H,d, J=7.4 Hz), 7.84 (1H, d, J=7.4 Hz), 7.67-7.81 (2H, m), 7.47-7.62 (3H,m), 3.46-3.70 (2H, m), 2.61 (3H, s), 1.86 (2H, br. s.). Mass Spectrum(ESI) m/e=317.0 (M+1).

N-((8-Methyl-2-(2-(trifluoromethyl)phenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(8-methyl-2-(2-(trifluoromethyl)-phenyl)quinolin-3-yl)methanamine (0.1g, 0.316 mmol, 1 eq) in EtOH (2 mL) was treated with ^(i)Pr₂NEt (0.07mL, 0.4 mmol, 1.2 eq) followed by 6-chloropurine (0.049 g, 0.317 mmol, 1eq). After purification,N-((8-methyl-2-(2-(trifluoro-methyl)phenyl)quinolin-3-yl)methyl)-9H-purin-6-amineas yellow syrup. The yellow syrup was triturated with CH₂Cl₂ andfiltered to provideN-((8-methyl-2-(2-(trifluoromethyl)phenyl)quinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=91nM] as yellow syrup. ¹H NMR (DMSO-d₆) δ ppm 12.93 (1H, s),7.98-8.31 (4H, m), 7.90 (1H, d, J=7.8 Hz), 7.74-7.82 (2H, m), 7.69 (2H,t, J=6.5 Hz), 7.59 (1H, d, J=7.0 Hz), 7.42-7.52 (1H, m), 4.42-4.77 (2H,m), 2.62 (3H, s). Mass Spectrum (ESI) m/e=435.1 (M+1).

Example 17 Preparation ofN-((2-(2-Fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)methyl)-9H-purin-6-amine2-(2-Fluoro-6-methoxyphenyl)-8-methylquinoline-3-carbaldehyde

Prepared according to Procedure A using2-chloro-8-methylquinoline-3-carb-aldehyde (1.07 g, 5.21 mmol),2-fluoro-6-methoxyphenylboronic acid (0.9738 g, 5.73 mmol, 1.1 eq),tetrakis(triphenylphosphine)palladium (0.3011 g, 5% mmol), and sodiumcarbonate (2.76 g, 26.1 mol, 5 eq) in MeCN (37.5 mL) and water (12.5mL). After purification,2-(2-fluoro-6-methoxyphenyl)-8-methylquinoline-3-carbaldehyde wasobtained as white solid. ¹H NMR (DMSO-d₆) δ ppm 9.88 (1H, s), 8.95 (1H,s), 8.10 (1H, d, J=8.1 Hz), 7.82 (1H, d, J=7.1 Hz), 7.62-7.69 (1 H, m),7.49-7.59 (1H, m), 6.96-7.10 (2H, m), 3.71 (3H, s), 2.70 (3H, s). MassSpectrum (ESI) m/e=296.0 (M+1).

N-(4-Methoxybenzyl)(2-(2-fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)-methanamine

Prepared according to Procedure F using2-(2-fluoro-6-methoxyphenyl)-8-methylquinoline-3-carbaldehyde (1.086 g,3.68 mmol), DCE (18 mL), PMBNH₂ (0.95 mL, 7.36 mmol, 2.0 eq), andNaBH(OAc)₃ (2.3387 g, 11.03 mmol, 3 eq) After purification,N-(4-methoxybenzyl)(2-(2-fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)methanaminewas obtained as yellow syrup. ¹H NMR (DMSO-d₆) δ ppm 8.42 (1H, s), 7.84(1H, d, J=7.4 Hz), 7.55-7.62 (1H, m), 7.43-7.54 (2H, m), 7.13 (2H, d,J=8.6 Hz), 6.90-7.01 (2H, m), 6.77-6.85 (2 H, m), 3.71 (3H, s), 3.65(3H, s), 3.47-3.62 (4H, m), 2.64 (3H, s), 2.43 (1H, s). Mass Spectrum(ESI) m/e=417.3 (M+1).

(2-(2-Fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)methanamine

Prepared according to Procedure G usingN-(4-methoxybenzyl)(2-(2-fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)methanamine(1.1795 g, 2.8320 mmol, 1 eq) and ammonium cerium(iv) nitrate (5.434 g,9.912 mmol, 3.5 eq) in CH₃CN—H₂O (2:1, 13 mL). After purification,(2-(2-fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)methanamine wasobtained as yellow sticky solid. NMR (DMSO-d₆) δ ppm 8.41 (1H, s), 7.82(1H, d, J=7.4 Hz), 7.55-7.60 (1H, m), 7.45-7.54 (2H, m), 7.03 (1H, d,J=8.2 Hz), 6.92-7.00 (1H, m), 3.71 (3H, s), 3.59 (2H, q, J=16.6 Hz),2.64 (3H, s), 1.88 (2H, br. s.). Mass Spectrum (ESI) m/e=297.1 (M+1).

N-((2-(2-Fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(2-(2-fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)methanamine (0.1000g, 0.337 mmol, 1 eq) in EtOH (2 mL) was treated with ^(i)Pr₂NEt (0.0764mL, 0.439 mmol, 1.3 eq) followed by 6-chloro-purine (0.0522 g, 0.337mmol, 1 eq). After purification,N-((8-methyl-2-(2-(trifluoromethyl)phenyl)quinolin-3-yl)methyl)-9H-purin-6-aminewas obtained as as yellow syrup. The yellow syrup was triturated withCH₂Cl₂ and filtered to provideN-((2-(2-fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)methyl)-9H-purin-6-amineas yellow syrup. The yellow syrup was triturated with CH₂Cl₂ and theresulting solid was filtered to provideN-((2-(2-fluoro-6-methoxyphenyl)-8-methylquinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=651 nM] as white solid. NMR (DMSO-d₆) δ ppm 12.87 (1H, s),8.19 (1H, s), 8.11 (1H, s), 8.07 (1H, s), 8.00 (1H, s), 7.77 (1H, d,J=7.8 Hz), 7.58 (1H, d, J=7.0 Hz), 7.40-7.51 (2H, m), 6.87-7.02 (2H, m),4.64 (2H, br. s.), 3.74 (3H, s), 2.64 (3H, s). Mass Spectrum (ESI)m/e=415.1 (M+1).

Examples 18 and 19N-((3-(2-Chlorophenyl)-8-methylquinoxalin-2-yl)-methyl)-9H-purin-6-amineandN-((3-(2-Chlorophenyl)-5-methylquinoxalin-2-yl)methyl)-9H-purin-6-amine1-(2-Chlorophenyl)propane-1,2-dione

To a solution of 2-chlorophenylacetone (7.14 g, 42 mmol) in CH₂Cl₂ (184mL), PCC (27 g, 127 mmol, 3 eq) and pyidine (10 mL, 127 mmol, 3 eq) inthree portions were added over five hours at reflux under vigorousstirring. After the addition was complete, the mixture was furtherrefluxed under vigorous stirring for 21.5 h. The mixture was filteredthrough a pad of silica gel, washed the pad with CH₂Cl₂, andconcentrated under reduced pressure to provide a dark red syrup. Theresidue was purified by column chromatography on a 120 g of Redi-Sep™column using 0-15% gradient of EtOAc in hexane over 40 min as eluent toprovide 1-(2-chlorophenyl)propane-1,2-dione as yellow liquid. ¹H NMR(choroform-d) δ ppm 7.66 (1H, dd, J=7.6, 1.8 Hz), 7.48-7.54 (1H, m),7.37-7.46 (2H, m), 2.58 (3H, s). Mass Spectrum (ESI) m/e=182.9 (M+1).

3-Bromo-1-(2-chlorophenyl)propane-1,2-dione

A mixture of 1-(2-chlorophenyl)propane-1,2-dione (1.2592 g, 6.9 mmol),glacial acetic acid (0.20 mL, 3.4 mmol, 0.5 eq), and bromine (0.35 mL,6.8 mmol, 1 eq) in CHCl₃ (17 mL) was heated at 60° C. for 12 h. Themixture was concentrated under reduced pressure to provide3-bromo-1-(2-chlorophenyl)propane-1,2-dione as yellow liquid. The yellowliquid was carried on crude without purification for the next step. ¹HNMR (CDCl₃) δ ppm 7.71 (1H, dd, J=7.8, 1.6 Hz), 7.53-7.59 (1H, m),7.40-7.49 (2H, m), 4.52 (2H, s). Mass Spectrum (ESI) m/e=261.0 [M+1(⁷⁹Br)] and 262.9 [M+1 (⁸¹Br)].

3-(Bromomethyl)-2-(2-chlorophenyl)-5-methylquinoxaline and2-(Bromomethyl)-3-(2-chlorophenyl)-5-methylquinoxaline

To a solution of 3-bromo-1-(2-chlorophenyl)propane-1,2-dione (1.8030 g,6.895 mmol) in EtOAc (46 mL) was added 2,3-diaminotoluene (0.8423 g,6.895 mmol, 1.0 eq) as solid and the mixture was at rt for 62 h. Themixture was concentrated under reduced pressure to provide a mixture of3-(bromomethyl)-2-(2-chloro-phenyl)-5-methylquinoxaline and2-(bromomethyl)-3-(2-chlorophenyl)-5-methyl-quinoxaline as red syrup(2.3845 g, 99.48%). The red syrup was carried on crude withoutpurification for the next step. Mass Spectrum (ESI) m/e=347.0 [M+1(⁷⁹Br)] and 349.0 [M+1 (⁸¹ Br)].

(3-(2-Chlorophenyl)-8-methylquinoxalin-2-yl)methanamine and(3-(2-Chlorophenyl)-5-methylquinoxalin-2-yl) methanamine

To a stirring solution of3-(bromomethyl)-2-(2-chlorophenyl)-5-methyl-quinoxaline and2-(bromomethyl)-3-(2-chlorophenyl)-5-methylquinoxaline (1.1204 g, 3.223mmol) in DMF (16 mL) was added sodium azide (0.4190 g, 6.446 mmol, 2 eq)and the mixture was stirred at rt for 1 h. The mixture was partitionedbetween EtOAc (100 mL) and H₂O (100 mL). The organic layer was driedover MgSO₄, filtered, and concentrated under reduced pressure to providea mixture of 3-(azidomethyl)-2-(2-chlorophenyl)-5-methylquinoxaline and2-(azidomethyl)-3-(2-chlorophenyl)-5-methylquinoxaline. The crudemixture was carried on crude without purification for the next step.Mass Spectrum (ESI) m/e=310.0 (M+1).

To a stirring solution of3-(azidomethyl)-2-(2-chlorophenyl)-5-methylquinoxaline and2-(azidomethyl)-3-(2-chlorophenyl)-5-methylquinoxaline (0.9983 g, 3.22mmol) in THF-H₂O (4: 1, 15 mL) was added dropwise trimethylphosphine,1.0M solution in THF (3.8700 mL, 3.87 mmol, 1.2 eq) and the mixture wasstirred at rt for 1 h. To the mixture was added EtOAc (100 mL) was addedand the mixture was extracted with 1N HCl (2×50 mL). The combinedextracts were neutralized with solid sodium bicarbonate, and extractedwith EtOAc (2×50 mL). The combined organic extracts were dried overMgSO₄, filtered, and concentrated under reduced pressure to provide darksyrup. The crude product was purified by column chromatography on a 40 gof Redi-Sep™ column using 0 to 100% gradient of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ over 14 min as eluent to provide a mixture of(3-(2-chlorophenyl)-8-methylquinoxalin-2-yl)methanamine and(3-(2-chlorophenyl)-5-methylquinoxalin-2-yl)methanamine. Mass Spectrum(ESI) m/e=284.0 (M+1).

N-((3-(2-Chlorophenyl)-8-methylquinoxalin-2-yl)methyl)-9H-purin-6-amineand N-((3-(2-Chlorophenyl)-5-methylquinoxalin-2-methyl)-9H-purin-6-amine

A mixture of the 6-chloropurine (0.126 g, 0.813 mmol, 1 eq),(3-(2-chlorophenyl)-5-methylquinoxalin-2-yl)methanamine (0.2308 g, 0.813mmol, 1 eq), and N,N-diisopropylethylamine (0.184 mL, 1.06 mmol, 1.3 eq)in EtOH (5 mL) was stirred at 75° C. for 15 h. The mixture wasconcentrated under reduced pressure to provide green syrup. The greensyrup was purified by column chromatography on a 40 g of Redi-Sep™column using 0 to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂over 14 min as eluent to provide a mixture ofN-((3-(2-chlorophenyl)-8-methylquinoxalin-2-yl)methyl)-9H-purin-6-amineandN-((3-(2-chlorophenyl)-5-methylquinoxalin-2-yl)methyl)-9H-purin-6-amineas orange solid. The orange solid was suspended in CH₂Cl₂ and filteredto provide a mixture ofN-((3-(2-chlorophenyl)-8-methylquinoxalin-2-yl)methyl)-9H-purin-6-amineandN-((3-(2-chlorophenyl)-5-methylquinoxalin-2-yl)methyl)-9H-purin-6-amineas off-white solid. The white solid was dissolved in DMSO (3 mL) andpurified by semi-prep-HPLC on C18 column using 20-70% gradient of CH₃CN(0.1% of TFA) in water (0.1% of TFA) over 40 min as eluent to provideN-((3-(2-chlorophenyl)-8-methylquinoxalin-2-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=325 nM] as off-white solid as a TFA salt andN-((3-(2-chlorophenyl)-5-methylquinoxalin-2-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=66 nM] as off-white solid as a TFA salt. Example 18: ¹H NMR(DMSO-d₆) δ ppm 8.50 (1H, s), 8.27 (2H, s), 7.95 (1H, d, J=7.9 Hz),7.75-7.80 (1H, m), 7.72-7.75 (1H, m), 7.61-7.66 (2H, m), 7.53-7.58 (1H,m), 7.47-7.53 (1H, m), 4.89 (2H, s), 3.17 (1H, s), 2.61 (3H, s); MassSpectrum (ESI) m/e=402.1 (M+1); HPLC: a peak at 6.439 min. Example 19:¹H NMR (DMSO-d₆) δ ppm 8.42 (1H, br. s.), 8.18-8.31 (2H, m), 7.94 (1H,d, J=7.9 Hz), 7.76-7.82 (1H, m), 7.71-7.75 (1 H, m), 7.67 (1H, dd,J=7.3, 1.8 Hz), 7.63 (1H, d, J=7.9 Hz), 7.52-7.57 (1H, m), 7.48-7.52(1H, m), 4.87 (2H, br. s.), 2.70 (3H, s); Mass Spectrum (ESI) m/e=402.1(M+1); HPLC: a peak at 6.758 min.

Example 204-((8-Methyl-2-o-tolylquinolin-3-yl)methoxy)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one

To a solution of34(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)methyl)-8-methyl-2-O—tolylquinoline (120 mg, 0.316 mmol) in AcOH (4 mL) and t-BuOH (2.43 mL)under N₂ was added pyridinium bromide perbromide (303 mg, 0.947 mmol) inone portion. After stirring at room temperature for 5 h the solvents wasremoved, and the remaining solids suspended in H₂O and extracted withethyl acetate, after drying with brine and MgSO₄ the crude dry solid wasdissolved in THF (8 mL) followed by 5 mL of a saturated NH₄Cl solution,this was followed in turn by Zn powder (528 mg, 26 mmol) and stirred atroom temperature for 24 h. The mixture was then extracted with ethylacetate and chromatographed {gradient elutionDCM/89:9:1(DCM/MeOH/NH₄OH)}. The solid was recrystallized from DCM toprovide the pure product [PI3Kι IC₅₀=349 nM]. ¹H NMR (400 MHz, DMSO-d₆)δ ppm 11.29 (1H, s), 8.52 (1H, s), 8.30 (1H, s), 7.89 (1H, d, J=7.8 Hz),7.65 (1 H, d, J=7.0 Hz), 7.51-7.57 (1H, m), 7.30-7.35 (3H, m), 7.22-7.29(1H, m), 3.47 (2H, s), 2.67 (3H, s), 2.09 (3H, s) Mass Spectrum (ESI)m/e=397.1 [M+1].

Example 21 2,5-Dichloroquinoline-3-carbaldehyde (1)

To a cold solution of diisopropylamine (6.6 mL, 1.1 eq) in THF (100 mL)was added dropwise a solution of Bu^(n)Li (1.1 eq, 2.5 M, 18.7 mL) inhexane at −20° C. The resulted LDA solution was kept in 0° C. for 30 minand cooled to −78° C. before addition of a solution of 1 (8.4 g, 42.4mmol) in THF (44 mL) dropwise. The temperature was controlled below −72°C. by adjusting of adding rate (15 min). The reaction was a clearsolution at beginning but turned into a suspension after 25 min. Afteranother 5 min, DMF (5.0 mL) was added dropwise. After 30 min, thereaction was quenched with NH₄Cl and partitioned between EtOAc (150 mL)and water (100 mL). The combined organics were washed with water, brine,dried over Na₂SO₄. Removal of solvent gave a white solid which waswashed with hexane (3×50 mL). A white solid was obtained (7.47 g). Thecombined hexane washings were concentrated and purified by columnchromatography on silica gel (DCM/Hexane, 3/2) to give additional 500mg. Overall, 7.97 g, 83%. ¹H NMR (400 MHz, CDCl₃) δ ppm 10.60 (1H, s),9.17 (1H, s), 8.02 (1H, d, J=8.0 Hz), 7.82 (1H, t, J=8.0 Hz), 7.73 (1H,d, J=8.0 Hz) Mass Spectrum (ESI) m/e=226.0 and 228 (M+1).

N-((5-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine(2)

Compound 2 was prepared from 1 according to Procedures A, B, C, D, E,and H. ¹H-NMR (400 Hz, DMSO-d⁶) δ 9.68 (s, br, 1H), 8.74 (s, 1H), 8.53(s, br, 1H), 8.42 (s, 1H), 8.05 (d, J=8.0 Hz, 1H), 7.87 (d, J=8.0 Hz,1H), 7.81 (t, J=8.0 Hz, 1H), 7.51-7.28 (m, 5H), 4.91 (s, 2H). MassSpectrum (ESI) m/e=422 (M+1).

3-(Azidomethyl)-8-chloro-2-(piperidin-1-yl)quinoline

A solution of (2,8-dichloroquinolin-3-yl)methanol (228 mg, 1 mmol) inCHCl₃ (4 mL) was treated with SOCl₂ (0.36 mL, 5 eq) dropwise, and thereaction was stirred at rt for 2 h before removal of solvents and theresidue was partitioned between EtOAc and NaHCO₃. The organic wasseparated and dried over Na₂SO₄. Solvents were removed under reducedpressure and the residue was dried under vacuum. The residue wasdissolved in DMSO (2 mL) and treated with NaN₃ (72 mg, 1.1 eq) at rt.LCMS showed completion after 4 h. The reaction mixture was partitionedbetween EtOAc (2 mL) and water (1 mL), and the water layer was extractedwith EtOAc (5 mL) once and combined organics were washed with water,brine, dried over Na₂SO₄ and concentrated to give a pale yellow solid as3-(azidomethyl)-2,8-dichloroquinoline (215 mg, 85%, 2 steps). This solid(50 mg, 0.2 mmol) in DCM (2 mL) was treated with piperidine (143 μL, 7.3eq) in EtOH (2 mL) at reflux over night. The reaction was worked up andthe residue was purified by column chromatography on silica gel (eluent:EtOAc/hexane, 1/5) to give a yellow solid (30 mg, 50%). ¹H NMR (400 MHz,CDCl₃) δ ppm 8.01 (1H, s), 7.62 (1H, t, J=8.0 Hz), 7.53 (1H, d, J=8.0Hz), 7.49 (1H, d, J=8.0 Hz), 4.02 (2H, s), 3.26-3.23 (m, 4H), 1.74-1.58(m, 6H). Mass Spectrum (ESI) m/e=302 (M+1).

N-((8-Chloro-2-(piperidin-1-yl)quinolin-3-yl)methyl)-9H-purin-6-amine

3-(Azidomethyl)-8-chloro-2-(piperidin-1-yl)quinoline (30 mg, 0.1 mmol)was dissolved in MeOH (1 mL) and treated with 10% Pd—C (5 wt %) and themixture was then stirred under H₂ balloon over night. The mixture wasfiltered through a Celite™ pad followed by removal of solvents to give(8-chloro-2-(piperidin-1-yl)-quinolin-3-yl)methanamine as a colorlessoil.N-((8-chloro-2-(piperidin-1-yl)-quinolin-3-yl)methyl)-9H-purin-6-aminewas prepared according to Procedure H. ¹H NMR (400 MHz, CDCl₃) δ ppm8.29 (s, 1H), 7.79 (m, 3H), 7.45 (m, 2H), 5.43 (2H, s), 3.90 (m, 4H),2.23 (m, 4H), 1.84 (m, 2H). Mass Spectrum (ESI) m/e=394 (M+1).

N-((8-Bromo-2-(3-fluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

8-Bromo-2-chloroquinoline-3-carbaldehyde was prepared in the similarmanner as 1 from 8-bromo-2-chloroquinoline.N-((8-bromo-2-(3-fluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine wasprepared according to Procedures A, B, C, D, E, and H. ¹H-NMR (400 Hz,DMSO-d⁶) δ 8.43 (s, 1H), 8.27 (s, br, 2H), 8.13 (d, J=8.0 Hz, 1H), 8.02(d, J=8.0 Hz, 1H), 7.59-7.56 (m, 3H), 7.51 (t, J=8.0 Hz, 1H), 7.37-7.32(m, 1H), 4.95 (s, 2H). Mass Spectrum (ESI) m/e=449, 451 (M+1).

Example 222-((8-Bromo-2-(3-fluorophenyl)quinolin-3-yl)methyl)isoindoline-1,3-dione

8-Bromo-3-(chloromethyl)-2-(3-fluorophenyl)quinoline was preparedaccording to Procedures A, B, and C. A solution of8-bromo-3-(chloromethyl)-2-(3-fluoro-phenyl)-quinoline (1.15 g, 3.3mmol) in DMF (10 mL) was treated with phthalimide potassium salt (1.52g, 2.5 eq) at rt. After over night, the reaction was diluted with water.Filtration gave a solid which was washed with water and hot MeOH anddried to give a white solid. ¹H-NMR (400 Hz, DMSO-d⁶) δ 8.43 (s, 1H),8.15-7.84 (m, 7H), 7.62-7.49 (m, 3H), 7.39-735 (m, 1H), 4.98 (s, 2H).Mass Spectrum (ESI) m/e=461, 463 (M+1).

N-((2-(3-Fluorophenyl)-8-morpholinoquinolin-3-yl)methyl)-9H-purin-6-amine

A mixture of2-((8-bromo-2-(3-fluorophenyl)quinolin-3-yl)methyl)isoindoline-1,3-dione(100 mg, 0.22 mmol), racemic BINAP (16.2 mg, 0.12 eq), Pd₂(dba)₃ (10 mg,0.05 eq), NaOBu^(t) (29.2 mg, 1.4 eq) and morpholine (38 mg, 2 eq) indioxane (2 mL) was heated to 120° C. under N₂ for 8 h. LCMS showed amixture of starting material and product. To the reaction was added thereactants again. The reaction was further heated for 2 h beforepartitioned between water and EtOAc. The water layer was extracted oncewith EtOAc and acidified to pH 2 by 3 N HCl and extracted with DCM (5mL×3). Removal of solvent gave a foam, which was treated with NH₂NH₂(0.5 mL) in EtOH (2 mL) at reflux. Solvents were removed and the residuewas worked up and purified by CombiFlash® (DCM/MeOH/Et₃N, 20/1/0.1). Awhite solid was obtained as(2-(3-fluorophenyl)-8-morpholinoquinolin-3-yl)methanamine.N-((2-(3-fluorophenyl)-8-morpholinoquinolin-3-yl)methyl)-9H-purin-6-aminewas prepared according to Procedures H. ¹H-NMR (400 Hz, CD₃OD) δ 8.77(s, 1H), 8.54 (s, 1H), 8.50 (s, 1H), 8.25 (d, J=8.0 Hz, 2H), 7.85 (t,J=8.0 Hz, 1H), 7.61-7.54 (m, 3H), 7.24 (t, J=8.0 Hz, 1H), 5.24 (s, 2H),4.20 (s, 4H), 4.02 (s, 4H). Mass Spectrum (ESI) m/e=456 (M+1).

Example 23 tert-Butyl(2-(3-fluorophenyl)-8-(methylsulfonyl)quinolin-3-yl)methyl-carbamate

2-((8-Bromo-2-(3-fluorophenyl)quinolin-3-yl)methyl)isoindoline-1,3-dione(1.1 g, 2.4 mmol) in EtOH (10 mL) was treated with NH₂NH₂ (0.75 mL, 10eq) at reflux for 30 min. After cool to rt, the by product was filteredand washed with MeOH. The filtrate was concentrated and purified byCombiFlash® (DCM/MeOH, 20/1) to give an off white solid as amine (720mg, 91%). A mixture of amine (500 mg, 1.5 mmol), Boc₂O (362 mg, 1.1 eq)and Et₃N (0.25 mL, 1.2 eq) in THF (10 mL) was heated to 80° C. for 2 hbefore cool to rt and separated by CombiFlash® (EtOAc/Hexane, 1/4). Awhite solid was obtained as tert-butyl(8-bromo-2-(3-fluorophenyl)quinolin-3-yl)methylcarbamate (640 mg, 98%).A mixture tert-butyl(8-bromo-2-(3-fluorophenyl)quinolin-3-yl)methyl-carbamate (184 mg, 0.43mmol), MeSNa (29 mg, 1 eq) and Pd(PPh₃)₄ (25 mg, 5% mmol) in BuOH (3 mL)was purged with N₂ for 5 min before heating to 110° C. After over night,the reaction mixture was purified by CombiFlash® to give an impuresulfide (65 mg) was treated with oxone (200 mg, 2 eq) in THY (1 mL) andwater (1 mL) at rt for 8 h. Work up, the residue was purified by column(EtOAc/Hexane, 1/9 to 9/1) to give tert-butyl(2-(3-fluorophenyl)-8-(methylsulfonyl)quinolin-3-yl)methylcarbamate as awhite solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.54 (d, J=4.0 Hz, 1H), 8.26(d, J=4.0 Hz, 1H), 8.05 (d, J=8.0 Hz, 1H), 7.62 (t, J=8.0 Hz, 1H),7.43-7.36 (m, 2H), 7.30 (d, J=8.0 Hz, 1H), 7.13 (t, J=8.0 Hz, 1H),4.53-4.47 (m, 2H), 4.01 (t, J=8.0 Hz, 1H), 3.49 (s, 3H). Mass Spectrum(ESI) m/e=431 (M+1).

N-((2-(3-Fluorophenyl)-8-(methylsulfonyl)quinolin-3-yl)methyl)-9H-purin-6-amine

tert-Butyl(2-(3-fluorophenyl)-8-(methylsulfonyflquinolin-3-yl)methylcarbamate (18mg, 0.042 mmol) was treated with 50% TFA in DCM (1 mL) for 30 min at rtand the reaction mixture was concentrated to driness. The resulted solidwas treated with 6-chloropurine (7.1 mg, 1.1 eq) and hunig's base (0.04mL, 4 eq) in Bu^(n)OH (1 mL) at 90° C. HPLC on reverse phase gave awhite solid. ¹H-NMR (400 Hz, CD₃OD) δ 8.47 (s, 1H), 8.38 (dd, J=8.0, 4.0Hz, 1H), 8.24 (s, 1H), 8.18 (dd, J=8.0, 4.0 Hz, 1H), 7.68 (t, J=8.0 Hz,1H), 7.50-7.39 (m, 3H), 7.11 (t, J=8.0 Hz, 1H), 5.24 (s, 2H), 3.45 (s,3H). Mass Spectrum (ESI) m/e=449 (M+1).

Example 24 (8-Chloro-2-(pyridin-2-yl)quinolin-3-yl)methanamine

2-((2,8-Dichloroquinolin-3-yl)methyl)isoindoline-1,3-dione was preparedin the similar manner as24(8-bromo-2-(3-fluorophenyl)quinolin-3-yl)methyl)-isoindoline-1,3-dionefrom 2,8-dichloroquinoline-3-carbaldehyde. A mixture of2-((2,8-dichloroquinolin-3-yl)methyl)isoindoline-1,3-dione (71 mg, 0.2mmol), 2-pyridylzine bromide (0.5 M, 0.8 mL, 2.0 eq) andtetrakis(triphenylphosphine) palladium (11 mg, 5%) in dioxane (3 mL) waspurged with N₂ and heated to 65° C. After 12 h, the reaction was cooledto it and quenched with NH₄Cl solution. After work up, The residuecontaining a mixture of2-((8-chloro-2-(pyridin-2-yl)-quinolin-3-yl)methyl)isoindoline-1,3-dioneand 2-((8-chloro-2-(pyridin-2-yl)-quinolin-3-yl)methyl)carbamoyl)benzoicacid was treated with NH₂NH₂ (31 μL) in EtOH (1 mL) at reflux. Afterusual work up, the residue was purified on column chromatography onsilica gel (DCM/MeOH/Et₃N, 20/1/0.1) to give a pale yellow solid as(8-chloro-2-(pyridin-2-yl)quinolin-3-yl)methanamine. ¹H NMR (400 MHz,CDCl₃) δ ppm 8.60 (d, J=8.0 Hz, 1H), 8.31 (d, J=8.0 Hz, 1H), 8.17 (s,1H), 7.84 (t, J=8.0 Hz, 1H), 7.74 (d, J=8.0 Hz, 1H), 7.66 (d, J=8.0 Hz,1H), 7.38 (t, J=8.0 Hz, 1H), 7.30 (t, J=8.0 Hz, 1H), 4.13 (s, 3H). MassSpectrum (ESI) m/e=270 (M+1).

2-((8-Chloro-2-(pyridin-2-yl)quinolin-3-yl)methyl)isoindoline-1,3-dione

(8-Chloro-2-(pyridin-2-yl)quinolin-3-yl)methanamine (20 mg, 0.074 mmol)was treated with 6-chloropurine (13 mg, 1.1 eq) and hunig's base (0.053mL, 4 eq) in Bu^(n)OH (1 mL) at 120° C. (modification of procedureH)HPLC on reverse phase gave a white solid. ¹H-NMR (400 Hz, CD₃OD) δ8.72 (d, J=8.0 Hz, 1H), 8.54-8.28 (m, 4H), 8.04 (t, J=8.0 Hz, 1H), 7.82(t, J=8.0 Hz, 1H), 7.53-7.44 (m, 2H), 5.27 (s, br, 2H). Mass Spectrum(ESI) m/e=388 (M+1).

Example 25 1-(2,8-Dichloroquinolin-3-yl)ethanol

To a cold solution of diisopropylamine (6.6 mL, 1.1 eq) in THF (100 mL)was added dropwise a solution of Bu^(n)Li (1.1 eq, 2.5 M, 18.7 mL) inhexane at −20° C. The resulted LDA solution was kept in 0° C. for 30 minand cooled to −78° C. before addition of a solution of2,8-dichloroquinoline (8.4 g, 42.4 mmol) in THF (44 mL) dropwise. Thetemperature was controlled below −72° C. by adjusting of adding rate (15min). After 45 min, MeCHO (3.6 mL, 1.5 eq) was added dropwise. After 30min, the reaction was quenched with NH₄Cl and partitioned between EtOAc(150 mL) and water (100 mL). The combined organics were washed withwater, brine, dried over Na₂SO₄ Removal of solvent gave colorless oilwhich was purified by column chromatography on silica gel (DCM/Hexane,3/2) to give an oil. Hexane was added (80 mL) and the mixture was leftover night. Filtration gave a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm8.43 (s, 1H), 7.84 (d, J=8.0 Hz, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.50 (t,J=8.0 Hz, 1H), 5.40 (q, J=8.0 Hz, 1H), 1.63 (d, J=8.0 Hz, 31-1). MassSpectrum (ESI) m/e=242 (M+¹).

(R)-1-(2,8-Dichloroquinolin-3-yl)ethanol

A mixture of 1-(2,8-dichloroquinolin-3-yl)ethanol (5.0 g, 21 mmol) andMnO₂ (18 g, 10 eq) in toluene (200 mL) were heated to reflux for 2 h.Filtration followed with removal of solvent gave a white solid as1-(2,8-dichloroquinolin-3-yl)-ethanone (4.5 g, 91%). A solution of thissolid (5.0 g, 21 mmol) in THF (50 mL) was added to a solution of(+)-DIP-Cl (14.7 g, 2.2 eq) in THF (150 mL) at −78° C. dropwise. Thereaction was slowly warmed up to rt over night. The reaction was thenquenched with acetone (23 mL) and stirred at 0° C. for 1 h beforeaddition of EtOAc. The reaction was warmed up to rt and washed with 10%Na₂CO₃ and water. Chiral HPLC on IA column (isopropanol in hexane, 10%)showed a ratio of 19:1 for two enantiomers. The combined crude productswere concentrated under high vacuum and purified by columnchromatography on silica gel (EtOAc/hexane, 1/3) to give a white solidwhich is recrystallized from a mixture of EtOAc (30 mL) and Hexane (210mL). A white needle was obtained. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.43 (s,1H), 7.84 (d, J=8.0 Hz, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.50 (t, J=8.0 Hz,1H), 5.40 (q, J=8.0 Hz, 1H), 1.63 (d, J=8.0 Hz, 3H). Mass Spectrum (ESI)m/e=242 (M+1).

(S)-2-(1-(2,8-Dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione

To a solution of (R)-1-(2,8-dichloroquinolin-3-yl)ethanol (22.00 g, 91mmol) in THF (500 mL) were added PPh₃ (28.60 g, 1.2 eq), phthalimide(16.04 g, 1.2 eq), and DIAD (21.47 mL, 1.2 eq) dropwise. The reactionmixture was stirred at it for 6 h and TLC (EtOAc/Hexane, 1/4) showedsmall amount of 1. To the reaction mixture were added PPh₃ (2.86 g, 0.12eq), phthalimide (1.60 g, 0.12 eq), and DIAD (2.15 mL, 0.12 eq) and themixture was stirred over night. The reaction mixture was concentratedand purified by column chromatography on silica gel (EtOAc/hexane, 1/4)to give a semi solid ˜50 g To the semi solid was added hexane and EtoAc(10/1, 200 mL), the resulted solid was washed with hexane. The filtratewas concentrated and purified by column chromatography on silica gel(DCM/hexane, 2/1) to give a white foam. ¹H NMR (400 MHz, CDCl₃) δ ppm8.49 (s, 1H), 7.77-7.73 (m, 4H), 7.66-7.63 (m, 2H), 7.43 (t, J=8.0 Hz,1H), 5.89 (q, J=8.0 Hz, 1H), 1.91 (d, J=8.0 Hz, 3H). Mass Spectrum (ESI)m/e=372 (M+1).

2-((S)-1-(8-Chloro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione

A mixture of(S)-2-(1-(2,8-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (22.7 g,61 mmol), Pd(PPh₃)₄ (3.53 g, 0.05 eq) and 2-(tributylstannyl)pyridine(33.8 g, 80%, 1.2 eq) in dioxane (840 mL) was heated to 100° C. underN₂. After over night, LCSM showed around 50% starting material left. Thereaction mixture was heated to 110° C. for additional 2 days. LCMSshowed less than 10% starting material left. The reaction was heated to120° C. for 5 h before cool to rt. Removal of solvent followed withcolumn chromatography on silica gel (EtOAc/hexane, 0/1 to 1/3) gave anoff white foam 14.2 g and the impure portions were combined and purifiedin the similar manner to give a white foam. ¹H NMR (400 MHz, CDCl₃) δppm 8.69 (s, 1H), 8.66 (d, J=4.0 Hz, 1H), 7.94 (d, J=4.0 Hz, 1H), 7.85(t, J=8.0 Hz, 1H), 7.75 (t, J=8.0 Hz, 1H), 7.70-7.65 (m, 4H), 7.50 (t,J=8.0 Hz, 1H), 7.33-7.29 (m, 1H), 6.58 (q, J=8.0 Hz, 1H), 2.02 (d, J=8.0Hz, 3H). Mass Spectrum (ESI) m/e=414 (M+1).

N—((S)-1-(8-Chloro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

A solution of2-((S)-1-(8-chloro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione(16.8 g, 41 mmol) in EtOH (350 mL) was treated with NH₂NH₂ (29 mL)dropwise at rt (formation of a white solid upon addition) before heatingat 90° C. for 30 min (the reaction became homogenous for 5 min and a newwhite solid formed) and cool to rt. The reaction mixture was filtered.The filter cake was washed with EtOAc. The combined organics wereconcentrated and partitioned between EtOAc (200 mL) and water (100 mL).The water layer was extracted with EtOAc (100 mL×2). The organics werewashed with water, brine, dried over Na₂SO₄ and concentrated to give ayellow oil (16 g). The crude material was heated to 90° C./2 mmHg toremove a colorless liquid by product to give a heavy tan oil. A mixtureof this oil (11 g, 38.8 mmol), 6-chloro-9H-purine (6.6 g, 1.1 eq) andhunig's base (8.2 mL, 1.2 eq) in n-BuOH (200 mL) was heated to 130° C.After over night, the concentrated reaction mixture was partitionedbetween EtOAc (500 mL) and water (300 mL). Water layer was extractedwith EtOAc (200 mL×2). The combined organics were washed with water,brine, dried, concentrated and purified by column (DCM/MeOH, 15/1) togive a yellow foam (15.7 g, 96%) with 96% purity. The foam was furtherpurified by careful column chromatography on silica gel (DCM/MeOH, 1/0to 20/1) and the front fractions were checked by reverse HPLC (15 min,MeCN/water). The later fractions were combined and concentrated to givea white foam, which was treated with hot hexane to give a fine powder.¹H-NMR (400 Hz, DMSO-d⁶) δ 12.66 (s, br, 1H), 8.54 (s, 1H), 8.50 (s,1H), 8.12 (s, 1H), 7.92-7.84 (m, 2H), 7.77-7.74 (m, 3H), 7.39 (t, J=8.0Hz, 1H), 7.34 (t, J=8.0 Hz, 1H), 5.91 (s, 1H), 1.48 (d, J=4.0 Hz, 3H).Mass Spectrum (ESI) m/e=402 (M+1).

Example 263-((S)-1-(9H-Purin-6-ylamino)ethyl)-2-(pyridin-2-yl)quinoline-8-carbonitrile

A mixture ofN—((S)-1-(8-chloro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine(80 mg, 0.2 mmol), Pd(PPh₃)₄ (23 mg, 0.1 eq) and Zn(CN)₂ (117 mg, 5.0eq) in DMF (5 mL) was purged with N₂ for 5 min before heating to 130° C.After 3 h, LCMS showed formation of trace amount of 2. The reaction wasthen heated to 165° C. over night. After cool to rt, the reaction wasfiltered through Celite™ and purified by reverse HPLC (MeCN/H₂O, 0.1%TFA) to give a white solid. ¹H-NMR (400 Hz, DMSO-d⁶) δ 8.83 (s, 1H),8.72 (s, 1H), 8.52 (s, 1H), 8.42-8.37 (m, 3H), 8.14 (d, J=8.0 Hz, 1H),8.08 (t, J=8.0 Hz, 1H), 7.79 (t, J=8.0 Hz, 1H), 7.55 (t, J=8.0 Hz, 1H),6.24 (s, 1H), 1.72 (d, J=8.0 Hz, 3H). Mass Spectrum (ESD m/e=393 (M+1).

Example 27N—((S)-1-(2-(Pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

A mixture of 1 (53 mg, 0.13 mmol) in EtOH (1 mL) was treated with Pd/C(10%, 10 mg) and NH₂NH₂ (21 μl, 5.0 eq) for 2 h at refluxing. After coolto rt, the reaction mixture was partitioned between water and EtOAc. Theorganic layer was separated, washed with water, brine, dried andconcentrated to give a white solid. ¹H-NMR (400 Hz, CD₃OD) δ 9.25 (s,1H), 9.06 (d, J=4.0 Hz, 1H), 8.55-8.47 (m, 4H), 8.27 (d, J=8.0 Hz, 2H),8.07-8.02 (m, 2H), 7.88 (t, J=8.0 Hz, 1), 5.56-5.55 (m, 1H), 1.93 (d,J=8.0 Hz, 3H). MS (ESI) m/e=368 (M+1).

Example 28 1-(2-Chloro-7-fluoroquinolin-3-yl)ethanol

To a suspension of 2-chloro-7-fluoroquinoline-3-carbaldehyde (44.7 g,213 mmol) in THF (600 mL) was treated with MeMgBr (78 mL, 1.1 eq)dropwise at −20° C. After overnight, the reaction was quenched withNH₄Cl solution and extracted with Ether (300 mL and 100 mL). Theorganics were washed with water, brine, dried over Na₂SO₄, concentratedand recrystallized from EtOAc (100 mL) and hexane (1 L). A pale yellowsolid was obtained (41 g, 85%). ¹H NMR (400 MHz, CDCl₃) δ ppm 8.41 (s,1H), 7.87 (dd, J=8.0, 4.0 Hz, 1H), 7.67 (dd, J=8.0, 2.0 Hz, 1H), 7.38(td, J=8.0, 2.0 Hz, 1H), 5.38 (q, J=4.0 Hz, 1H), 1.63 (d, J=4.0 Hz,31-1). Mass Spectrum (ESI) m/e=226 (M+1).

(S)-2-(1-(2-Chloro-7-fluoroquinolin-3-yl)ethyl)isoindoline-1,3-dione

(S)-2-(1-(2-Chloro-7-fluoroquinolin-3-yl)ethyl)isoindoline-1,3-dione wasprepared according to corresponding 8-Cl analog. ¹H NMR (400 MHz, CDCl₃)δ ppm 8.48 (s, 1H), 7.85 (dd, J=8.0, 4.0 Hz, 1H), 7.75-7.73 (m, 2H),7.65-7.63 (m, 2H), 7.55 (dd, J=8.0 Hz, 1H), 7.30 (td, J=8.0, 4.0 Hz,1H), 5.88 (q, J=8.0 Hz, 1H), 1.90 (d, J=8.0 Hz, 3H). Mass Spectrum (ESI)m/e=355 (M+1).

N—((S)-1-(7-Fluoro-2-(2-(methylsulfonyl)phenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine

A mixture of(R)—N—((S)-1-(2-chloro-7-fluoroquinolin-3-yl)ethyl)-2-methylpropane-2-sulfinamide(164 mg, 0.4 mmol), 2-(methylthio)phenylboronic acid (92 mg, 1.1 eq),Na₂CO₃ (214 mg, 5.0 eq), Pd(PPh₃)₄(31 mg, 5%), MeCN (3 mL) and water (1mL) was heated to 85° C. under N₂ over night. After cool to rt, thereaction was partitioned between EtOAc (10 mL) and water (5 mL). Theorganic layer was separated, washed, dried and concentrated. The residuewas purified by column chromatography on silica gel to give a whitesolid. A solution of this solid (140 mg, 0.34 mmol) in MeOH (2 mL) wastreated with 4 N HCl in dioxane (1 mL) for 2 h at rt before removal ofsolvents. The residue was dissolved in THF (3 mL) and treated with Et₃N(2 eq, 93 μL) followed with Boc₂O (1.1 eq, 81 mg) at 70° C. After overnight, the reaction mixture was worked up and purified on columnchromatography on silica gel (EtOAc/hexane, 1/9) to give a white foam(100 mg, 72%) as tert-butyl(S)-1-(7-fluoro-2-(2-(methylsulfonyl)-phenyl)-quinolin-3-yl)ethylcarbamate.This material (100 mg, 0.24 mmol) in CHCl₃ (3 mL) was treated with mCPBA(174 mg, 72%, 3.0 eq) at rt for 2 h. LCMS showed the desired MW+16. Workup. The residue was purified by column chromatography on silica gel(EtOAc/hexane, 1/1) to give two fractions, 1st (50 mg) and 2nd (20 mg)with the same M+1=461 on LCMS. The compounds were dissolved in MeOH (2mL) and water (1 mL) and treated with TiCl₃ in water (30%, 10 drops) atrt for 2 h. The reaction mixture was partitioned between EtOAc andwater. The organic layer was separated and washed with water, brine,dried and concentrated to give a white solid (83 mg), which was treatedwith TFA (1 mL) in DCM (1 mL) at rt for 2 h. The residue after removalof solvents was treated with 6-chloro-9H-purine (32 mg, 1.1 eq) andhunig's base (104 μl, 1.2 eq) in BuOH (2 mL) at 130° C. over night.After cool to rt, the reaction mixture was purified by reverse HPLC(MeCN/water/0.1 TFA, 10% to 60%) to give a white solid. ¹H-NMR (400 Hz,CD₃OD) δ 9.35 (s, 1H), 8.53-8.47 (m, 2H), 8.25 (s, 1H), 7.98-7.76 (m,6H), 5.85 (s, br, 0.4H), 5.58-5.56 (m, 0.6H), 3.19 (s, 3H), 1.88-1.81(m, 3H). Mass Spectrum (ESI)=463 (M+1).

Example 29(S)—N-(1-(7-Fluoro-1-[O]-2-phenylquinolin-3-yl)ethyl)-9H-purin-6-amine

A mixture of(S)-2-(1-(7-fluoro-2-phenylquinolin-3-yl)ethyl)isoindoline-1,3-dione (33mg, 83 μmol) and mCPBA (19 mg, 1.3 eq) in CHCl₃ (1 mL) was stirred at rtfor 2 h. The reaction was partitioned between CHCl₃ and NaHCO₃. Theorganic was isolated and purified by column chromatography on silica gel(EtOAc/hexane, 3/1) to give a white solid, which was treated withhydrazine (0.1 mL) in EtOH (1 mL) at 35° C. for 2 h. Usual work up gavea colorless oil (25 mg). This oil was treated with 6-chloro-9H-purine(15 mg, 1.1 eq) and hunig's base (49 μl, 1.2 eq) in BuOH (1 mL) at 130°C. over night. After cool to rt, the reaction mixture was purified byreverse HPLC (MeCN/water/0.1 TFA, 10% to 60%) to give a white solid.¹H-NMR (400 Hz, CD₃OD) δ 8.67 (s, 1H), 8.48 (s, 2H), 8.30-8.28 (m, 2H),7.75-7.41 (m, 7H), 5.42 (q, J=4.0 Hz, 1H), 1.71 (d, J=4.0 Hz, 3H). MassSpectrum (ESI) m/e=401 (M+1).

Example 30 Preparation ofN-((8-chloro-2-phenoxyquinolin-3-yl)methyl)-9H-purin-6-amine8-chloro-2-phenoxyquinoline-3-carbaldehyde

To a solution of 2,8-dichloroquinoline-3-carbaldehyde (1 eq) in DMF(0.25 M) was added phenol (1.5 eq) and K₂CO₃ (2.0 eq) at rt and themixture was stirred for 3 h at rt. The mixture was diluted with water,extracted with EtOAc (2 times) and the combined organic layers werewashed with water (2 times), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The crude product was purified bycolumn chromatography on a Redi-Sep™ column using 0 to 40% gradient ofEtOAc in hexane to provide 8-chloro-2-phenoxyquinoline-3-carbaldehyde.

(8-Chloro-2-phenoxyquinolin-3-yl)methanol

Prepared according to Procedure B using8-chloro-2-phenoxyquinoline-3-carbaldehyde (1.0 eq) and solid sodiumborohydride (1.5 eq) in THF (0.5 M) at 0° C.(8-chloro-2-phenoxyquinolin-3-yl)methanol was obtained afterpurification as a yellow solid.

8-Chloro-3-(chloromethyl)-2-phenoxyquinoline

Prepared according to Procedure C using(8-chloro-2-phenoxyquinolin-3-yl)-methanol (1.0 eq) and SOCl₂ (5 eq) inCHCl₃ (0.25M) at rt. 8-chloro-3-(chloromethyl)-2-phenoxyquinoline wasobtained after purification as a yellow oil.

(8-Chloro-2-phenoxyquinolin-3-yl)methanamine

To a solution of 8-chloro-3-(chloromethyl)-2-phenoxyquinoline (1 eq) inDMSO (0.25 M) was added NaN₃ (3 eq) at rt and the mixture was stirredfor 4 h at it. The mixture was diluted with water, extracted with EtOAc(2 times) and the combined organic layers were washed with water (2times), dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The residue was dissolved in MeOH and treated with 10% Pd—C (5wt %) and the mixture was then stirred under H₂ balloon over night. Themixture was filtered through a Celite™ pad followed by removal ofsolvents to give (8-chloro-2-phenoxyquinolin-3-yl)methanamine.

N-((8-Chloro-2-phenoxyquinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(8-chloro-2-phenoxyquinolin-3-yl)-methanamine (0.110 g, 0.360 mmol),6-chloropurine (0.072 g, 0.46 mmol, 1.2 eq) and DIEA (0.72 mmol, 2.0 eq)in n-butanol (3 mL).N-((8-chloro-2-phenoxyquinolin-3-yl)methyl)-9H-purin-6-amine [PI3KδIC₅₀=125 nM] was obtained after purification as a white solid. ¹H-NMR(MeOD) δ ppm 8.18-8.24 (s, 1H), 8.14-8.20 (s, 1H), 7.85-7.91 (d, J=7.58,1H), 7.72-7.79 (d, J=7.34, 1H), 7.47-7.55 (m, 3H), 7.42-7.47 (m, 3H),7.35-7.42 (m, 1H), 4.01-4.14 (m, 2H), Mass Spectrum (ESI) m/e=403 (M+1)

Example 31N-((8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(8-chloro-2-(3-fluorophenyl)quinolin-3-yl)methanamine (0.030 g, 0.11mmol), 6-Chloropurine (0.019 g, 0.13 mmol, 1.2 eq) and DIEA in n-butanol(3 mL).N-((8-chloro-2-(3-fluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=74 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 8.41 (s, 1H), 8.13 (s, 1H), 7.88-8.02 (m, 4H), 7.59(dd, J=4.40, 2.20 Hz, 4H), 4.80-4.98 (m, 2H), Mass Spectrum (ESI)m/e=405 (M+1).

Example 32N-((8-Chloro-2-phenylquinolin-3-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4

Prepared according to Procedure H using(8-chloro-2-phenylquinolin-3-yl)meth-anamine (0.050 g, 0.186 mmol),4-chloro-7H-pyrrolo[2,3-d]pyrimidine (0.034 g, 0.22 mmol, 1.2 eq) andDIEA (0.38 mmol, 2.0 eq) in n-butanol (3 mL).N-((8-chloro-2-phenylquinolin-3-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine[PI3Kδ IC₅₀=270 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 8.65-8.76 (m, 1H), 8.53 (s, 1H), 8.11-8.20 (m, 4H),8.07 (d, J=1.96 Hz, 1H), 7.91-8.00 (m, 2H), 7.86 (s, 1H), 7.51-7.58 (m,2H), 4.73-4.85 (m, 2H), Mass Spectrum (ESI) m/e=386 (M+1).

Example 33N-((8-Chloro-2-(3,5-difluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(8-chloro-2-(3,5-difluorophenyl)-quinolin-3-yl)methanamine (0.105 g,0.345 mmol), 6-chloropurine (0.064 g, 0.41 mmol, 1.2 eq) and DIEA (0.70mmol, 2.0 eq) in n-butanol (3 mL).N-((8-chloro-2-(3,5-difluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=76 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 8.48 (s, 1H), 8.35 (s, 1H), 8.24 (s, 1H), 7.86-7.94(m, 2H), 7.52-7.61 (m, 1 H), 7.27-7.35 (m, 2H), 6.96-7.06 (m, 1H), 4.73(d, J=5.71, 2 H), Mass Spectrum (ESI) m/e=423 (M+1).

Example 34N-((8-Chloro-2-(2-chloro-5-fluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(8-chloro-2-(2-chloro-5-fluorophenyl)-quinolin-3-yl)methanamine (0.050g, 0.156 mmol), 6-chloropurine (0.027 g, 0.17 mmol, 1.2 eq) and DIEA(0.70 mmol, 2.0 eq) in n-butanol (3 mL).N-((8-chloro-2-(2-chloro-5-fluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=71 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 8.30 (s, 1H), 8.20 (s, 1H), 7.80 (dd, J=7.58, 0.49Hz, 2H), 7.69-7.75 (m, 1 H), 7.42-7.47 (m, 1H), 7.31-7.37 (m, 1H),7.11-7.16 (m, 1H), 6.99-7.06 (m, 1H), 4.90-497. (m, 2H), Mass Spectrum(ESI) m/e=440 (M+1)

Example 35N-((8-chloro-2-(2-(methylsulfonyl)phenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(8-chloro-2-(2-(methylsulfonyl)phenyl) quinolin-3-yl)methanamine (0.060g, 0.173 mmol), 6-chloropurine (0.032 g, 0.21 mmol, 1.2 eq) and DIEA(0.34 mmol, 2.0 eq) in n-butanol (3 mL).N-((8-chloro-2-(2-(methylsulfonyl)phenyl)quinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=222 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) 8 ppm 8.29 (s, 1H), 8.13 (s, 1H), 8.01-8.09 (m, 2H),7.78-7.81 (m, 1H), 7.66-7.76 (m, 1H), 7.57-7.65 (m, 1H), 7.46 (d, J=7.83Hz, 2H), 4.87-4.98 (m, 2H), 3.28 (s, 3H), Mass Spectrum (ESI) m/e=465(M+1).

Example 36N-((2-(2-Chlorophenyl)-7-fluoroquinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(2-(2-chlorophenyl)-7-fluoroquinolin-3-yl)methanamine (0.080 g, 0.279mmol), 6-chloropurine (0.065 g, 0.42 mmol, 1.5 eq) and DIEA (0.56 mmol,2.0 eq) in n-butanol (3 mL).N-((2-(2-chlorophenyl)-7-fluoroquinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=225 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 8.49 (s, 1 H), 8.14 (s, 1H), 8.03-8.10 (m, 2H),7.66-7.73 (m, 2H), 7.47-7.56 (m, 2H), 7.43-7.44 (m, 1H), 7.33-7.40 (m,1H), 4.10-4.18 (m, 2H), Mass Spectrum (ESI) m/e=405 (M+1).

Example 37N-((2-(2-Chlorophenyl)-6-fluoroquinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(2-(2-chlorophenyl)-6-fluoroquinolin-3-yl)methanamine (0.080 g, 0.279mmol), 6-chloropurine (0.065 g, 0.42 mmol, 1.5 eq) and DIEA (0.56 mmol,2.0 eq) in n-butanol (3 mL).N-((2-(2-chlorophenyl)-6-fluoroquinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=1683 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 8.44 (s, 1H), 8.14 (s, 1H), 8.07-8.11 (m, 2H),7.66-7.71 (m, 1H), 7.59-7.66 (m, 1H), 7.49-7.55 (m, 2H), 7.40-7.46 (m,1H), 7.34-7.40 (m, 1H), 4.05-4.17 (m, 2 H), Mass Spectrum (ESI) m/e=405(M+1).

Example 38N-((2-(2-Chlorophenyl)-6,7-difluoroquinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(2-(2-chlorophenyl)-6,7-difluoro-quinolin-3-yl)methanamine (0.080 g,0.279 mmol), 6-chloropurine (0.065 g, 0.42 mmol, 1.5 eq) and DIEA (0.56mmol, 2.0 eq) in n-butanol (3 mL).N-((2-(2-chlorophenyl)-6,7-difluoroquinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=551 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 8.46 (s, 1H), 8.13 (s, 1H), 8.09 (s, 1H), 7.83-7.94(m, 3H), 7.49-7.55 (m, 2 H), 7.41-7.48 (m, 1H), 7.35-7.41 (m, 1H),4.89-4.85 (m, 2H), Mass Spectrum (ESI) m/e=423 (M+1).

Example 39N-((2-(2-(Benzyloxy)-5-fluorophenyl)-8-chloroquinolin-3-yl)methyl)-9H-purin-6-amine

Prepared according to Procedure H using(2-(2-(benzyloxy)-5-fluorophenyl)-8-chloroquinolin-3-yl)methanamine(0.021 g, 0.053 mmol), 6-chloropurine (0.012 g, 0.06 mmol, 1.5 eq) andDIEA (0.1 mmol, 2.0 eq) in n-butanol (3 mL).N-((2-(2-(benzyloxy)-5-fluorophenyl)-8-chloroquinolin-3-yl)methyl)-9H-purin-6-amine[PI3Kδ IC₅₀=31 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 8.38 (s, 1H), 8.12 (s, 1H), 8.07 (s, 1H), 7.90 (s,1H), 7.88 (s, 1 H), 7.52-7.59 (t, 1H), 7.21-7.25 (m, 2H), 7.19 (m, 4H),7.06-7.12 (m, 2H), 5.05-5.10 (m, 2H), 4.90-4.96 (s, 2H), Mass Spectrum(ESI) m/e=511 (M+1).

Example 40N-((8)-1-(8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amineandN4R)-1-(8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine

A mixture of(2-(2-(benzyloxy)-5-fluorophenyl)-8-chloroquinolin-3-yl)-methanamine(0.120 g, 0.40 mmol) in n-butanol (5 mL) was treated with DIEA (0.80mmol, 2.0 eq) followed with 6-chloropurine (0.075 g, 0.48 mmol, 1.2 eq)at 100° C. for 8 h. The reaction mixture was concentrated and purifiedby column chromatography on a Redi-Sep™ column using 0 to 100% gradientof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ as eluent to provide the mixtureofN—((S)-1-(8-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amineandN-aR)-1-(8-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine.Further separation by chiral HPLC with IA column at IPA/Hexane (10%)providesN—((S)-1-(8-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine[PI3Kδ IC₅₀=6 nM] as a white solid. ¹H-NMR (MeOD) δ ppm 8.43 (s, 1 H),8.05 (s, 1H), 7.98 (s, 1H), 7.73-7.80 (m, 2H), 7.48-7.53 (m, 1H),7.44-7.49 (m, 1H), 7.35-7.44 (m, 2H), 7.04-7.11 (m, 1H), 1.44-1.47 (d,3H), Mass Spectrum (ESI) ink=419 (M+1), andN4R)-1-(8-chloro-2-(3-fluorophenyl)-quinolin-3-yl)ethyl)-9H-purin-6-amine[PI3Kδ IC₅₀=424 nM] as a white solid. ¹H-NMR (MeOD) δ ppm, 8.56 (s, 1H),8.17 (s, 1H), 8.10 (s, 1H), 7.84-7.93 (m, 2H), 7.45-7.66 (m, 4H),7.14-7.23 (m, 1H), 3.89-3.98 (m, 1H), 1.57-1.60 (d, 3H) Mass Spectrum(ESI) mile=419 (M+1).

Example 41N—((S)-1-(8-Chloro-2-(2-chloro-5-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine

Prepared according to Procedure H using(1S)-1-(8-chloro-2-(2-chloro-5-fluoro-phenyl)quinolin-3-yl)ethanamine(0.072 g, 0.215 mmol), 6-chloropurine (0.040 g, 0.26 mmol, 1.2 eq) andDIEA (0.42 mmol, 2.0 eq) in n-butanol (3 mL).N—((S)-1-(8-chloro-2-(2-chloro-5-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine[PI3Kδ IC₅₀=8 nM] was obtained after purification as a white solid.^(I)H-NMR (MeOD) 8 ppm 8.68 (s, 1H), 8.60 (s, 1H), 8.02-8.10 (m, 2H),7.92-7.99 (m, 1 H), 7.85-7.93 (m, 1H), 7.54-7.63 (m, 1H), 7.50 (dd,J=8.80, 4.89 Hz, 1H), 7.07 (td, J=8.61, 3.13 Hz, 1H), 5.48-5.65 (m, 1H),1.71 (d, J=7.04 Hz, 3H), Mass Spectrum (ESI) Ink=454 (M+1).

Example 42N—((S)-1-(8-Chloro-2-(3-fluorophenyl)quinolin-3-yl)propyl)-9H-purin-6-amine

A mixture of 1-(8-chloro-2-(3-fluorophenyl)quinolin-3-yl)propan-1-amine(0.060 g, 0.19 mmol) in n-butanol (5 mL) was treated with DIEA (0.38mmol, 2.0 eq) followed with 6-chloropurine (0.029 g, 0.19 mmol, 1.0 eq)at 100° C. for 8 h. The reaction mixture was concentrated and purifiedby column chromatography on a Redi-Sep™ column using 0 to 100% gradientof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ as eluent to provide the mixtureofN—((S)-1-(8-chloro-2-(3-fluoro-phenyl)quinolin-3-yl)propyl)-9H-purin-6-amineandN—((R)-1-(8-chloro-2-(3-fluorophenyl)quinolin-3-yl)propyl)-9H-purin-6-amine.Further separation by chiral HPLC with IA column at IPA/Hexane (10%)providesN—((S)-1-(8-chloro-2-(3-fluorophenyl)quinolin-3-yl)propyl)-9H-purin-6-amine[PI3Kδ IC₅₀=13 nM] as a white solid. ¹H-NMR (MeOD) 8 ppm 8.39 (s, 1H),8.08 (s, 1H), 8.01 (s, 1 H), 7.72-7.78 (m, 2H), 7.51-7.60 (m, 2H),7.38-7.47 (m, 2H), 7.10-7.16 (m, 1H), 3.82 (m, 1H), 1.74-1.84 (m, 2H),1.03-1.11 (t, 3H), Mass Spectrum (ESI) m/e=433 (M+1)

Example 43N—((S)-1-(5-Chloro-3-(3-fluorophenyl)quinolin-2-yl)ethyl)-9H-purin-6-amine

Prepared according to Procedure H using(1S)-1-(5-chloro-3-(3-fluorophenyl)-quinolin-2-yl)ethanamine (0.050 g,0.166 mmol), 6-chloropurine (0.031 g, 0.20 mmol, 1.2 eq) and DIEA (0.33mmol, 2.0 eq) in n-butanol (3 mL).N—((S)-1-(5-chloro-3-(3-fluorophenyl)quinolin-2-yl)ethyl)-9H-purin-6-amine[PI3Kδ C₅₀=5 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 9.22 (s, 1H), 8.63 (s, 1H), 8.44-8.47 (m, 3H), 8.42(s, 1H), 8.34 (s, 1H), 7.87-7.94 (m, 2H), 7.56 (t, 1H), 1.79 (d, 3H),Mass Spectrum (ESI) m/e=419 (M+1).

Example 44N—((S)-1-(8-Chloro-2-(thiazol-4-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

Prepared according to Procedure H using(1S)-1-(8-chloro-2-(thiazol-4-yl)-quinolin-3-yl)ethanamine (0.045 g,0.155 mmol), 6-chloropurine (0.029 g, 0.19 mmol, 1.2 eq) and DIEA (0.33mmol, 2.0 eq) in n-butanol (3 mL).N—((S)-1-(8-chloro-2-(thiazol-4-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine[PI3Kδ IC₅₀=16 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 9.22 (s, 1H), 8.63 (s, 1H), 8.44-8.46 (m, 1H), 8.42(s, 1H), 8.34 (s, 1H), 7.88-7.93 (m, 2H), 7.56 (t, 1H), 1.77 (d, 3H),Mass Spectrum (ESI) m/e=408 (M+1).

Example 45N—((S)-1-(7-Fluoro-2-(pyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

Prepared according to Procedure H using(1S)-1-(7-fluoro-2-(pyridin-3-yl)-quinolin-3-yl)ethanamine (0.067 g,0.236 mmol), 6-chloropurine (0.044 g, 0.283 mmol, 1.2 eq) and DIEA (0.48mmol, 2.0 eq) in n-butanol (3 mL).N—((S)-1-(7-fluoro-2-(pyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine[PI3Kδ IC₅₀=23 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) 8 ppm 8.99 (s, 1H), 8.57-8.65 (m, 2H), 8.33 (d, J=7.83 Hz,1H), 8.16 (s, 1H), 8.08 (s, 1H), 7.85-7.96 (m, 2H), 1.62 (d, 3H), MassSpectrum (ESI) m/e=402 (M+1).

Example 46N—((S)-1-(7-Fluoro-2-(thiophen-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

Prepared according to Procedure H using(1S)-1-(7-fluoro-2-(thiophen-2-yl)-quinolin-3-yl)ethanamine (0.078 g,0.286 mmol), 6-chloropurine (0.053 g, 0.344 mmol, 1.2 eq) and DIEA (0.58mmol, 2.0 eq) in n-butanol (3 mL).N—((S)-1-(7-fluoro-2-(thiophen-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine[PI3Kδ IC₅₀=8 nM] was obtained after purification as a white solid.¹H-NMR (MeOD) δ ppm 8.62 (s, 1H), 8.43 (s, 1H), 8.37 (s, 1H), 8.00-8.07(m, 1H), 7.62-7.73 (m, 3 H), 7.43-7.51 (m, 1H), 7.18 (m 1H), 1.78 (d,J=7.04 Hz, 3H), 1H), Mass Spectrum (ESD ink=391 (M+1).

Example 47 1-(2,5-Dichloroquinolin-3-yl)ethanol

Dissolved 2,5-dichloroquinoline-3-carbaldehyde (2.46 g, 11 mmol) in THF(70 mL) and submerged in an ice-bath. Added methylmagnesium bromide (5.4mL, 16 mmol) and removed the ice-bath. After 10 min. the reactionmixture was poured into 1.0 N HCl and extracted with EtOAc. The organiclayer was dried with sodium sulfate, filtered, and concentrated. Theresidue was chromatographed on 80 g silica gel column with 0-40%EtOAc:Hex. The desired fractions were combined and concentrated to yieldan off white, crystalline solid. ¹H NMR (400 MHz, DCM-d₂) δ ppm 1.60 (d,J=6.26 Hz, 3H) 2.35 (br. s., 1H) 5.36 (q, J=6.39 Hz, 1H) 7.61-7.67 (m,2H) 7.87-7.94 (m, 1H) 8.75 (s, 1H). LC-MS (+esi, M+H⁺=242.1).

2-(1-(2,5-Dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione

Added DCM (2 mL) to 1-(2,5-dichloroquinolin-3-yl)ethanol (200 mg, 826μmol). Added thionyl chloride (301 μl, 4131 μmol). Obtained a clearcolorless solution within minutes. Concentrated reaction mixture todryness on the rotavap to obtain an oil, which was used without furtherpurification. LC-MS (+esi, M+H⁺=260.0). Dissolved2,5-dichloro-3-(1-chloroethyl)quinoline (215 mg, 825 μmol) in DMF (2 mL)and added phthalimide (127 mg, 866 μmol) and K₂CO₃ (228 mg, 1650 μmol).Submerged in oil bath and began heating to 55° C. After 10 min thetemperature of the oil bath was raised to 80° C. After 30 more minutesthe reaction mixture was partitioned between EtOAc:H₂O. The organiclayer was washed with water (3×), dried with sodium sulfate, filtered,and concentrated. The crude was solid was chromatographed on 12 g silicagel column with 0-20% EtOAc:Hex. The desired fractions were combined andconcentrated to yield a white crystalline solid. ¹H NMR (400 MHz,DICHLOROMETHANE-d₂) δ ppm 1.99 (d, J=7.04 Hz, 3H) 5.93 (q, J=7.17 Hz,1H) 7.64-7.70 (m, 2H) 7.71-7.76 (m, 2H) 7.77-7.83 (m, 2H) 7.88-7.93 (m,1H) 8.95 (s, 1H). LC-MS (+esi, M+H⁺=371.0)

-   2-(1-(5-Chloro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione

Transferred 2-(1-(2,5-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione(197 mg, 531 μmol) from 100 mL flask to 10 mL flask bydissolving/slurrying in toluene and concentrating. Added Pd(Ph₃P)₄ (61mg, 53 μmol) and 2-tri-n-butylstannylpyridine (955 μl, 2653 μmmol).Bubbled argon through mixture for 30 sec. Equipped with condenser andnitrogen inlet. Heated at 110° C. for ˜16 h. The reaction mixture wasconcentrated and chromatographed on 12 g silica gel column with 0-60%EtOAc. The desired fractions were combined and concentrated to yield anoil. NMR indicates residual EtOAc. LC. ¹H NMR (400 MHz,DICHLOROMETHANE-d₂) δ ppm 1.98 (d, J=7.04 Hz, 3H) 6.38 (q, J=7.04 Hz,1H) 7.24-7.37 (m, 1H) 7.62-7.76 (m, 8H) 8.01 (dd, J=8.61, 1.96 Hz, 1H)8.56-8.66 (m, 1H) 9.02 (s, 1H). −MS (+esi, M+H+=414.1)

1-(5-Chloro-2-(pyridin-2-yl)quinolin-3-yl)ethanamine

2-(1-(5-Chloro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione(220 mg, 532 μmol) was added to EtOH. To the resulting slurry was addedhydrazine hydrate (133 μl, 2658 μmol) and the mixture was heated in anoil bath at 80° C. for 3 h. The reaction mixture was cooled to roomtemperature, filtered, and rinsed with EtOH (˜10 mL). The filtrate wasacidified with 1.0 N HCl (˜5 mL) and concentrated on the rotavap toremove ethanol. A minor amount of solid precipitated and was removed byfiltration. The filtrate was neutralized with solid sodium carbonate andextracted (2×) with DCM:IPA (4:1). The organic extracts were dried withsodium sulfate, filtered and concentrated to obtain 103 mg (68%) of asolid/film. LC-MS (+esi, M+H⁺=284.0). 1H NMR (400 MHz,DICHLOROMETHANE-d₂) δ ppm 1.42 (d, J=6.65 Hz, 3H) 4.71 (q, J=6.65 Hz,1H) 7.38-7.42 (m, 1H) 7.60-7.68 (m, 2H) 7.88-7.97 (m, 2H) 8.02 (dq,J=7.78, 0.80 Hz, 1H) 8.68-8.71 (m, 1H) 8.82 (t, J=0.78 Hz, 1H). LC-MS(+esi, M+H⁺=284.0).

N-(1-(5-Chloro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

Added 1-(5-chloro-2-(pyridin-2-yl)quinolin-3-yl)ethanamine (103 mg, 363μmol), 6-bromopurine (72 mg, 363 μmol), n-butanol (2 mL) and DIPEA (190μl, 1089 μmol) to a 10 mL flask. Submerged in an oil bath and heated at110° C. for 40 h. The reaction mixture was concentrated on the rotavapto ˜0.5 mL of solvent, diluted with DCM, and chromatographed with 0-15%MeOH:DCM on 12 g silica gel column. The desired fractions were combinedand concentrated to an oil which was dissolved in ACN:H₂O andlyophilized to obtained 100 mg (69%) of a light tan solid. LC-MS (+esi,M+H⁴=402.1).

N-(1-(8-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)quinolin-3-3-yl)ethyl)-9H-purin-6-amine

Hydrazine hydrate (1.37 g, 27.4 mmol, 10 eq) was added to a slurry of2-(1-(2,8-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (1.02 g,2.74 mmol) in ethanol (30 mL) at 70 C to form a clear solution. In ashort time, a precipitate begins to form. Additional ethanol (20 mL) wasadded to facilitate stirring. The temperature was increased to refluxand continued overnight. Solids were removed by filtration. The filtratewas concentrated to minimize ethanol and redissolved in DCM. The organiclayer was washed with water, then dried over MgSO₄, and concentrated toafford the arylhydrazine as a yellow solid. mp 133 C., ¹H NMR (500 MHz,DMSO-d6) δ ppm 9.2 (1H, br s), 7.854 (1H, s), 7.635 (1H, dd, J=8, 1.5Hz), 7.620 (1H, dd, J=8, 1.5 Hz), 7.139 (1H, t, J=8 Hz), 4.635 (2H, brs), 4.164 (1H, q, J=6.5 Hz), 2.167 (2H, br s), 1.359 (3H, d, J=6.5 Hz)LCMS-ESI (POS), M/Z, M+1. Found 237.1

The intermediate arylhydrazine (0.067 g, 0.66 mmol) was treated with2,4-pentanedione (0.046 ml, 2 eq) in ethanol at 75 C bath temperatureovernight. Residual solvent was removed under vacuum to give an orangeoil (˜0.1 g). 6-bromopurine (66 mg, 1.5 eq) was added along with ethanol(3 mL) and triethylamine (3 eq). The suspension was heated at 80covernight. The reaction was incomplete so the solvent was replaced withn-pentanol and triethylamine (3 eq) and heated at 130 C. for 4 h. Thesolvent was removed under vacuum and the residue purified by flashchromatography on silica gel with DCM and increasing amounts of methanolto 5%. Fractions containing desired product were combined to affordN-(1-(8-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine. ¹H NMR @ 125 C (500 MHz,DMSO-d6), 8 ppm 12.5 (1H, br s), 8.721 (1H, s), 8.046 (1H, s), 7.975(1H, br s), 7.935 (1H, d, J=7.5 Hz), 7.892 (1H, d, J=7.5 Hz), 7.62 (1H,br s), 7.561 (1H, t, J=7.5 Hz), 6.124 (1H, s), 5.860 (1H, br m), 2.453(3H, s), 2.264 (3H, s), 1.619 (3H, d, J=7 Hz) LCMS-ESI (POS), M/Z, M+1.Found 419.1

Example 48 N-(2-Fluorophenyl)cinnamamide

To a solution of 2-fluoroaniline (25.0 g, 225 mmol) and potassiumcarbonate (47 g, 337 mmol) in water (112 mL) and acetone (45 mL) at 0°C. was added cinnamoyl chloride (37 g, 225 mmol, 1 eq) in acetone (45mL) over 2 h. The reaction was stirred for 1 h @ 0° C., then quenchedinto 200 mL of ice-water. The white crystalline solid was filtered andwashed with water. The solid was air dried for 2 h, then washed with 400mL of hexanes. The solid was dried under vacuum overnight to affordproduct. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.49 (br t, J=7.8 Hz, 1H), 7.80(d, J=15.3 Hz, 1H), 7.57 (m, 3H), 7.41 (m, 3H), 7.17 (m, 3H), 6.61 (d,J=15.6 Hz, 1H). Mass Spectrum (ESI) m/e=242.1 (M+1).

2-Chloro-8-fluoroquinoline

N-(2-Fluorophenyl)cinnamamide (10.5 g, 44 mmol) was dissolved inchlorobenzene (60 mL) and aluminum trichloride (29 g, 218 mmol, 5 eq)was added. The reaction was heated to 125 C for 3 h and then cooled tort over 45 minutes. The reaction was poured onto 300 g of ice withstirring, producing a tan solid. The solid was filtered and washed with100 mL of water and 3×100 mL of hexanes and dried under high vacuum. Thesolid was extracted with 1 L of DCM and filtered to remove insolublebyproducts. The solvent was removed in vacuo to afford8-fluoroquinolin-2(1H)-one. ¹H NMR (400 MHz, CDCl₃) δ ppm 10.95 (br s,1H), 7.77 (dd, J=9.8, 1.6 Hz), 7.35 (d, J=7.8 Hz, 1H), 7.27 (ddd,J=10.2, 7.8, 1.2 Hz, 1H), 7.14 (td, J=8.0, 5.1 Hz, 1H), 6.76 (d, J=9.4Hz, 1H).

8-Fluoroquinolin-2(1H)-one (26 g, 159 mmol) was slurried phosphoryltrichloride (163 mL, 1753 mmol, 11 eq) and heated to 125 for 2 h. Thereaction was cooled to rt and poured onto 1.2 L of ice water withvigorous stirring. When mixture had cooled to rt, the orange solid wasfiltered and washed with water and dried under vacuum overnight toafford 27 g of crude material. The crude material was recrystallizedfrom hexanes by dissolving in ˜700 mL of hexanes at reflux and decantingaway from residual tar. The hexane solution was cooled to 0° C. and theprecipitate 2-chloro-8-fluoroquinoline was filtered. The mother liquorwas concentrated in vacuo and recrystallized from hexanes to obtain asecond crop of 2-chloro-8-fluoroquinoline. ¹H NMR (400 MHz, CDCl₃) δ ppm8.14 (dd, J=8.6, 1.2 Hz, 1H), 7.62 (br d, 1H), 7.52 (td, J=7.8, 4.7 Hz,1H), 7.45 (m, 2H).

1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol

2-Chloro-8-fluoroquinoline (182 mg, 1.0 mmol) was dissolved in THF (2mL) and cooled to −78° C. To this solution was added Lithiumdiisopropylamide (1M solution in TIM, 1.1 mL, 1.1 mmol, 1.1 eq). Thereaction was allowed to stir at −78° C. for 20 min, after which timeacetaldehyde (113 μl, 2.0 mmol, 2 eq.) was added via syringe. After 30minutes, the reaction was quenched with water and diluted with ethylacetate. The layers were separated and washed with brine. The crudereaction mixture was purified by column chromatography (8:2hexanes:ethyl acetate) to afford1-(2-chloro-8-fluoroquinolin-3-yl)ethanol. ¹H NMR (400 MHz, CDCl₃) δ ppm8.43 (br s, 1H), 7.64 (td, J=7.8, 5.1 Hz, 1H), 7.41 (ddd, J=10.2, 7.4,1.2 Hz, 1H), 5.39 (qdd, J=6.3, 3.9, 0.8 Hz, 1H), 2.22 (d, J=3.9 Hz, 1H),1.62 (d, J=6.3 Hz, 3H).

1-(2-Chloro-8-fluoroquinolin-3-yl)ethanone

To a round-bottomed flask containing toluene (183 mL) was added1-(2-chloro-8-fluoroquinolin-3-yl)ethanol (6.2 g, 27.5 mmol) andmanganese dioxide (19.1 g, 219.8 mmol, 8 eq). The reaction was heated toreflux for 2 h, cooled to rt, filtered concentrated. The product wasdiluted with hexanes and filtered to give as a white solid1-(2-chloro-8-fluoroquinolin-3-yl)ethanone. ¹H NMR (400 MHz, CDCl₃) δppm 8.40 (d, J=1.6 Hz, 1H), 7.71 (br d, J=8.2 Hz, 1H), 7.56 (td, J=7.8,5.1 Hz, 1H), 7.54 (ddd, J=9.8, 7.8, 1.6 Hz, 1H). Mass Spectrum (ESI)m/e=223.9 (M+1).

(R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol

In a round bottomed flask was dissolved (+)-dip-chloride(tm) (4418 mg,13773 μmol) in anhydrous THF (50 mL) and the solution was cooled to −55°C. (using a dry ice/MeCN bath). To this solution was added1-(2-chloro-8-fluoroquinolin-3-yl)ethanone (1.4 g, 6.3 mmol) as asolution in THF (10 mL). The reaction was allowed to warm to +10° C.over 5 h. The reaction was quenched with 10 mL acetone and 20 mL of 10%Na₂CO₃ and allowed to stir for 1 h at rt. Ethyl acetate (200 mL) wasadded and the layers were separated. The organic phase was washed withthree times with a 50% saturated sodium bicarbonate solution and oncewith brine. The organic layer was dried over MgSO₄, filtered, andconcentrated to provide 5 g of crude material. The crude material waspurified using 7:3 hexanes:ethyl acetate on 120 g silica gel column toafford (R)-1-(2-chloro-8-fluoroquinolin-3-yl)ethanol. Chiral HPLC (10%IPA in hexanes, chiralcel AD) shows product to be 96.0% ee. ¹H NMR (400MHz, CDCl₃) δ ppm 8.43 (br s), 7.64 (br d, J=8.2 Hz, 1H), 7.50 (td,J=7.8, 4.7 Hz, 1H), 7.41 (ddd, J=10.2, 7.8, 1.2 Hz, 1H), 5.40 (qd,J=5.9, 0.8 Hz, 1H), 2.22 (br s, 1H), 1.62 (d, J=6.3 Hz, 3H). MassSpectrum (ESI) m/e=226.0 (M+1).

(S)-3-(1-Azidoethyl)-2-chloro-8-fluoroquinoline

Triphenylphosphine (1.81 g, 6.9 mmol, 1.2 eq) was dissolved in anhydrousTHF (30 mL) and cooled to 0° C. To this solution was addeddiispropylazodicarboxylate (1.36 mL, 6.9 mmol, 1.2 eq). The reaction wasstirred for 30 minutes at 0° C. and(R)-1-(2-chloro-8-fluoroquinolin-3-yl)ethanol (1.3 g, 5.7 mmol) in 30 mLof THF was added, followed by diphenylphosphoryl azide (1.37 mL, 6.3mmol, 1.1 eq). The reaction was allowed to warm to rt and stir at rtovernight. The reaction was deposited on silica gel and concentrated.Purification by column chromato-graphy (3% etoac in hexanes) afforded(S)-3-(1-azidoethyl)-2-chloro-8-fluoro-quinoline. ¹H NMR (400 MHz,CDCl₃) δ ppm 8.30 (d, J=1.2 Hz, 1H), 7.67 (br d, J=8.22 Hz, 1H), 7.54(td, J=7.8, 4.7 Hz, 1H), 7.45 (ddd, J=10.2, 7.8, 1.2 Hz) 5.22 (q, J=6.7Hz, 1H), 1.68 (d, J=6.7 Hz, 3H). Mass Spectrum (ESI) m/e=250.9 (M+1).

General procedures for 8-fluoroquinoline Analogues:

Procedure BSL-1

To a round bottomed flask was added(S)-3-(1-azidoethyl)-2-chloro-8-fluoro-quinoline (1 eq),tetrakistriphenylphosphine palladium (0) (0.04 eq), sodium carbonate (5eq), and an aryl boronic acid (1.5 eq). The flask was purged withnitrogen and a 3:1 mixture of MeCN:H₂O was added to give a concentrationof 0.1 M with respect to the starting azide. The reaction was heated to80° C. until judged to be complete. The solvent was removed and theresidue was redissolved in of ethyl acetate and water. The layers wereseparated and the organic layer was washed with brine, dried over MgSO₄,filtered, and concentrated. The crude reaction was purified columnchromatography (ethyl acetate in hexanes, gradient) to afford(S)-3-(1-azidoethyl)-8-fluoro-2-arylquinoline.

Procedure BSL-2

(S)-3-(1-azidoethyl)-8-fluoro-2-arylquinoline was dissolved in THF (toyield a 0.1 M solution) and triphenylphosphine (1.1 eq) and water (20eq) were added. The reaction was heated to 60° C. overnight. Aftercooling to rt, the solvent was removed in vacuo and the residue wasredissolved in ethyl ether. The ether layer was extracted three timeswith 1 N HCl. The aqueous layer was brought to a pH of 10-12 by additionof 15% NaOH and the basic aqueous layer was extracted twice with ethylether. The ether layers were washed with brine, dried over MgSO₄,filtered, and concentrated to afford(S)-1-(8-fluoro-2-aryllquinolin-3-yl)-ethanamine.

Procedure BSL-3

To a round bottomed flask was added(S)-1-(8-fluoro-2-aryllquinolin-3-yl)-ethanamine (1 eq), 6-bromopurine(1.2 eq), and diisopropylethylamine (3 eq). Enough n-butanol was addedto make a 0.1 M solution with respect to the(S)-1-(8-fluoro-2-aryllquinolin-3-yl)ethanamine. The mixture was heatedto 100-115° C. for 24 h, cooled to rt, and the solvent was removed invacuo. Purification by reverse phase HPLC afforded(S)—N-(1-(8-fluoro-2-arylquinolin-3-yl)ethyl)-9H-purin-6-amine. Theproducts were dissolved in DCM/NaHCO₃ and the organic layer wasseparated, dried over MgSO₄, filtered, and concentrated to provide(S)—N-(1-(8-fluoro-2-phenylquinolin-3-yl)ethyl)-9H-purin-6-amine asfreebases.

Example 49 3-((S)-1-Azidoethyl)-8-fluoro-2-(3-fluorophenyl)quinoline

3-((S)-1-Azidoethyl)-8-fluoro-2-(3-fluorophenyl)quinoline was madeaccording to Procedure BSL-1 using(S)-3-(1-azidoethyl)-2-chloro-8-fluoroquinoline (50 mg, 0.199 mmol),tetrakis triphenylphosphine palladium (0) (9 mg, 0.008 μmol, 0.04 eq),sodium carbonate (106 mg, 0.997 mmol, 5 eq), and 3-fluoro-phenylboronicacid (42 mg, 0.299 mmol, 1.5 eq).34(S)-1-azidoethyl)-8-fluoro-2-(3-fluorophenyl)quinoline was obtainedafter purification. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.39 (d, J=1.6 Hz,1H), 7.71 (br d, J=8.2 Hz, 1H), 7.54 (td, J=7.8, 4.7 Hz, 1H), 7.52-7.42(series of m, 2H), 7.35 (dt, J=7.8, 1.2 Hz), 7.31 (ddd, J=9.0, 2.4, 1.6Hz, 1H), 7.20 (tdd, J=8.6, 2.7, 1.2 Hz, 1H), 4.94 (q, J=6.7 Hz, 1H),1.56 (d, J=6.7 Hz, 31-1). Mass Spectrum (ESI) m/e=310.9 (M+1).

(1S)-1-(8-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine

(1S)-1-(8-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine was madeaccording to procedure BSL-2 using3-((S)-1-azidoethyl)-8-fluoro-2-(3-fluoro-phenyl)quinoline (54 mg, 0.174mmol, triphenylphosphine (50 mg, 0.191 mmol), and water (63 μl, 3.480mmol). Obtained(1S)-1-(8-fluoro-2-(3-fluorophenyl)-quinolin-3-yl)ethanamine. ¹H NMR(400 MHz, CDCl₃) δ ppm 8.51 (d, J=1.6 Hz, 1H), 7.65 (br d, J=8.21 Hz,1H), 7.52-7.42 (series of m, 2H), 7.39 (ddd, J=10.5, 7.4, 1.2 Hz, 1H),7.34 (dt, J=7.5, 1.2 Hz, 1H), 7.30 (ddd, J=9.4, 2.7, 1.6 Hz, 1H), 7.16(tdd, J=8.6, 2.4, 0.8 Hz, 1H), 4.48 (q, J=6.2 Hz, 1H), 1.37 (d, J=6.7Hz, 3H). Mass Spectrum (ESI) m/e=285.0 (M+1).

N—((S)-1-(8-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine

N—((S)-1-(8-Fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-aminewas made according to procedure BSL-3 usingN-ethyl-N-isopropylpropan-2-amine (27 μl, 155 μmol), 6-bromo-7H-purine(18 mg, 93 μmol), and(1S)-1-(8-fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine (22 mg, 77μmol). IsolatedN—((S)-1-(8-fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-7H-purin-6-amine.¹H NMR (400 MHz, CDCl₃) δ ppm 8.33 (s, 2H), 7.97 (s, 1H), 7.65-7.61 (m,2H), 7.52 (d, J=8.2 Hz, 1H), 7.47-7.39 (series of m, 2H), 7.35 (ddd,J=10.6, 7.8, 1.6 Hz, 1H), 6.76 (br s, 1H), 5.80 (br s, 1H), 1.51 (d,J=7.0 Hz, 3H). Mass Spectrum (ESI) m/e=403.0 (M+1).

The following compounds were made according to the sequence(BSL-1→BSL-2→BSL-3) described above. Data for these compounds is listedbelow:

Example 50(S)—N-(1-(8-Fluoro-2-phenylquinolin-3-yl)ethyl)-9H-purin-6-amine

Data for(S)—N-(1-(8-fluoro-2-phenylquinolin-3-yl)ethyl)-9H-purin-6-amine: ¹H NMR(400 MHz, CDCl₃) δ ppm 8.32 (s, 2H), 7.95 (s, 1H), 7.84 (d, J=7.0 Hz,2H), 7.51 (d, J=6.6 Hz, 1H), 6.41 (br s, 1H), 5.83 (br s, 1H), 1.50 (d,J=6.7 Hz, 3H). Mass Spectrum (ESI) m/e=385.0 (M+1).

Example 51N—((S)-1-(2-(2-Chlorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine

Data forN—((S)-1-(2-(2-chlorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine:¹H NMR (400 MHz, CDCl₃) δ ppm (rotomers present at room temperature)8.42-8.35 (s, 1H), 8.23 (s, 1H), 7.92 (s, 1H), 7.71-7.23 (series of m,5H), 6.27 (br s, 1H), 5.60 (br m, 1H), 1.66 (m, 3H). Mass Spectrum (ESI)m/e=418.9 (M+1).

Example 52(S)—N-(1-(2-(3,5-Difluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6

Data for(S)—N-(1-(2-(3,5-difluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine:¹H NMR (400 MHz, CDCl₃) δ ppm 8.35 (s, 2H), 8.00 (s, 1H), 7.56 (d, J=8.6Hz, 1H), 7.46 (m, 3H), 7.38 (ddd, J=10.6, 7.8, 1.6 Hz, 1H), 6.90 (tt,J=9.0, 2.4 Hz, 1H), 6.50 (br s, 1H), 5.80 (br s, 1H), 1.53 (d, J=6.4 Hz,3H). Mass Spectrum (ESI) m/e=420.9 (M+1).

Example 53N—((S)-1-(8-Fluoro-2-(pyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

Data forN—((S)-1-(8-fluoro-2-(pyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine:¹H NMR (400 MHz, CDCl₃) δ ppm 9.15 (s, 1H), 8.71 (dd, J=4.7, 1.6 Hz,1H), 8.36 (s, 1H), 8.28 (s, 1H), 8.22 (d, J=7.8 Hz, 1H), 7.97 (s, 1H),7.54 (d J=7.4 Hz, 1H), 7.46-7.41 (m, 2H), 7.36 (ddd J=10.2, 7.4, 1.2 Hz,1H), 6.67 (br s, 1H), 5.74 (br s, 1H), 1.53 (d, J=6.7 Hz, 3H). MassSpectrum (ESI) m/e=385.9 (M+1).

Example 54N—((S)-1-(2-(2-Chloro-5-fluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine

Data forN—((S)-1-(2-(2-chloro-5-fluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine:¹H NMR (400 MHz, CDCl₃) δ ppm (rotomers present at room temperature)8.43-8.37 (s, 1H), 8.25 (s, 1H), 7.95 (s, 1H), 7.69-7.39 (m, 3H),7.16-7.01 (m, 2H), 6.39 (br s, 1H), 5.60 (br m, 1H), 1.68 (d, J=5.9 Hz,3H). Mass Spectrum (ESI) m/e=436.9 (M+1).

Example 55N4(S)-1-(2-(2,5-Difluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine

Data forN—((S)-1-(2-(2,5-difluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine:¹H NMR (400 MHz, CDCl₃) δ ppm 8.37 (s, 1H), 8.24 (s, 1H), 7.94 (s, 1H),7.60 (d, J=8.2 Hz, 1H), 7.49 (td, J=7.8, 4.7 Hz, 1H), 7.40 (ddd, J=10.6,7.8, 1.6 Hz, 1H), 7.08 (m, 2H), 6.40 (br s, 1H), 5.55 (br s, 1H), 1.67(d, J=7.0 Hz, 31-1). Mass Spectrum (ESI) m/e=420.9 (M+1).

Example 56N—((S)-1-(2-(3-chloro-5-fluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine

Data forN—((S)-1-(2-(3-chloro-5-fluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine:¹H NMR (400 MHz, CD₃OD) δ ppm 8.60 (s, 1H), 8.15 (s, 1H), 8.08 (s, 1H),7.78 (d, J=8.2 Hz, 1H), 7.59 (m, 2H), 7.21 (dt, J=8.6, 2.0 Hz, 1H), 5.70(br s, 1H), 1.62 (d, J=31-1). Mass Spectrum (ESI) m/e=436.9 (M+1).

Example 57N—((S)-1-(2-(5-Chloro-2-fluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine

Data forN—((S)-1-(2-(5-chloro-2-fluorophenyl)-8-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine:¹H NMR (400 MHz, CDCl₃) δ ppm 8.36 (s, 1H), 8.24 (s, 1H), 7.97 (s, 1H),7.73 (br s, 1H), 7.60 (d, J=7.8 Hz, 1H), 7.48 (td, J=7.8, 4.7 Hz, 1H),7.38 (ddd, J=10.6, 7.8, 1.2 Hz, 1H), 7.31 (m, 1H), 7.08 (br s, 1H), 6.61(br s, 1H), 5.55 (br s, 1H) 1.69 (d, J=7.0 Hz, 3H). Mass Spectrum (ESI)m/e=436.9 (M+1).

Example 58(S)—N-(1-(8-Fluoro-2-(4-(trifluoromethyl)phenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine

Data for(S)—N-(1-(8-fluoro-2-(4-(trifluoromethyl)phenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine:¹H NMR (400 MHz, CDCl₃) δ ppm 8.37 (S, 1H), 8.30 (s, 1H), 7.97 (m, 3H),7.73 (d, J=7.8 Hz, 2H), 7.60 (d, J=7.8 Hz, 1H), 7.48 (td, J=7.8, 5.1 Hz,1H), 7.39 (ddd, J=10.6, 7.8, 1.6 Hz, 1H), 6.49 (br s, 1H), 5.77 (br s,1H), 1.56 (d, J=7.0 Hz, 3H). Mass Spectrum (ESI) m/e=453.0 (M+1).

Example 59 (E)-N-Benzylidene-2-fluorobenzenamine

Dissolved 2-fluoroaniline (2.0 mL, 20.8 mmol, 1.05 eq) in 40 mL ofanhydrous ether. Added Magnesium Sulfate (7146 mg, 59.3 mmol, 4 eq), 7 gof powdered mol sieves, and benzaldehyde (2.0 mL, 19.8 mmol). To thismixture was added pTsOH (18.8 mg, 98.9 μmol, 0.005 eq) and heated toreflux overnight. The reaction was cooled, filtered and concentrated toyield (E)-N-benzylidene-2-fluorobenzenamine. ¹H NMR (400 MHz, CDCl₃) δppm 8.55 (s, 1H), 7.95 (m, 2H), 7.52 (m, 5H), 7.18 (m, 4H).

N-((8-Fluoro-2-phenylquinolin-3-yl)methyl)acetamide

Dissolved 1-(azet-1(2H)-yl)ethanone (22 mg, 227 μmol, eq),(E)-N-benzylidene-2-fluorobenzenamine (45 mg, 227 μmol, 1 eq),2-fluorobenzenamine (22 μl, 227 μmol, 1 eq), and yttriumtrifluoromethanesulfonate (6 mg, 11 μmol, 0.05 eq) in 9 mL ofacetonitrile. The reaction was stirred at rt overnight. The reaction washeated to 90° C. for 5 h. The reaction was cooled to rt and the solventwas removed under vacuum. The residue was dissolved in 20 mL of DCM andwashed with 1×5 mL of NaHCO₃. The organic layer was dried over MgSO₄,filtered and concentrated. Purification by column chromatography (7:3hexanes:ethyl acetate) affordedN-((8-fluoro-2-phenylquinolin-3-yl)methyl)acetamide. ¹H NMR (400 MHz,CDCl₃) δ ppm 8.20 (s, 1H), 7.60 (d, J=7.83, 1H), 7.50 (m, 2H), 7.45 (m,4H), 7.37 (ddd, J=10.6, 7.8, 1.6 Hz, 1H), 5.92 (br t, J=5.9 Hz, 1H),4.55 (d, J=6.3 Hz, 2H), 1.96 (s, 3H). Mass Spectrum (ESI) m/e=295.0(M+1).

(8-Fluoro-2-phenylquinolin-3-yl)methanamine

To N-((8-fluoro-2-phenylquinolin-3-yl)methyl)acetamide (28 mg, 95 μmol)was added added hydrochloric acid (2M solution in water, 2 mL, 4000μmol). The reaction was heated to 80 C for 24 h. The reaction was cooledto it and quenched with 15% NaOH. The product was extracted into ether(2×10 mL) and the combined organics were washed with brine, dried overMgSO₄, filtered, and concentrated to afford(8-fluoro-2-phenylquinolin-3-yl)methanamine. ¹H NMR (400 MHz, CDCl₃) δppm 8.34 (s, 1H), 7.65 (d, J=8.2 Hz, 1H), 7.61 (m, 2H), 7.48 (m, 4H),7.39 (ddd, J=10.6, 7.8, 1.6 Hz, 1H), 4.05 (s, 2H), 2.03 (br s, 2H). MassSpectrum (ESI) m/e=253.0 (M+1).

N-((8-Fluoro-2-phenylquinolin-3-yl)methyl)-9H-purin-6-amine

To a reaction flask was added 6-bromopurine (19 mg, 95 μmol, 1.2 eq),diisopropylethylamine (42 μl, 238 μmol, 3 eq),(8-fluoro-2-phenylquinolin-3-yl)-methanamine (20 mg, 79 μmol, 1 eq), andn-butanol (0.75 mL). The reaction was heated to 110° C. for 8 h. Thereaction was cooled to rt and the solvent was removed in vacuo. Thecompound was purified by reverse phase HPLC. The fractions wereconcentrated and freebased with sat. NaHCO₃. The organic layer wasextracted into DCM, dried over MgSO₄, filtered, and concentrated toafford a white solid,

N-((8-fluoro-2-phenylquinolin-3-yl)methyl)-7H-purin-6-amine. ¹H NMR (400MHz, CDCl₃) δ ppm 8.35 (s, 1H), 8.31 (s, 1H), 7.90 (s, 1H), 7.68 (m,2H), 7.45 (m, 6H), 6.78 (br s, 1H), 5.07 (br s, 2H). Mass Spectrum (ESI)m/e=370.9 (M+1).

Example 60(S)-2-(1-(8-Chloro-2-vinylquinolin-3-yl)ethyl)isoindoline-1,3-dione

To a stirred solution of(S)-2-(1-(2,8-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (1 g,2.7 mmol) in dioxane (25 mL) under a nitrogen atmosphere was added vinyltributyltin (1.28 mL, 4.04 mmol) andtetrakis(triphenylphosphine)palladium (156 mg, 0.13 mmol). The reactionwas heated at 100° C. for 3 hours and then the solvent was evaporated invacuo. The resulting black residue was purified by column chromatography(40 g SiO₂, Hexanes:Ethyl acetate, 1:0 to 3:1) to give(S)-2-(1-(8-chloro-2-vinylquinolin-3-yl)ethyl)isoindoline-1,3-dione as awhite solid. ¹H-NMR (400 MHz, CDCl₃) δ ppm 8.53 (1H, s), 7.76-7.81 (4H,m), 7.68-7.72 (2H, m), 7.41 (1H, dd, J=7.8, 7.8 Hz), 7.26-7.33 (1H, m),6.71 (1H, dd, J=16.4, 2.3 Hz), 6.00 (1H, q, J=7.3 Hz), 5.64 (1H, dd,J=10.6, 2.3 Hz), 2.00 (3H, d, J=7.0 Hz). Mass Spectrum (ESI) m/e=362.8(M+1).

2-((S)-1-(8-Chloro-2-(1,2-dihydroxyethyl)quinolin-3-yl)ethyl)isoindoline-1,3-dione

To a stirred solution of(S)-2-(1-(8-chloro-2-vinylquinolin-3-yl)ethyl)isoindoline-1,3-dione (200mg, 0.55 mmol) in THY (5 mL) and water (1.0 mL) was added potassiumosmate(VI) dihydrate (10.2 mg, 27.6 μmol). The reaction was stirred for5 minutes and then NMO (64.6 mg, 0.55 mmol) was added. The reaction wasstirred for 3 hours and then it was diluted with ethyl acetate (80 mL)and 1.0 M aqueous citric acid (40 mL). The separated aqueous layer wasextracted with ethyl acetate (140 mL) and the combined organic layerswere washed with brine (40 mL), dried (MgSO₄), filtered and evaporatedin vacuo to give2-((S)-1-(8-chloro-2-(1,2-dihydroxyethyl)quinolin-3-yl)ethyl)isoindoline-1,3-dione.The product was used without further purification in the next step. ¹HNMR (400 MHz, CDCl₃) δ ppm 8.77 (1H, d, J=11.7 Hz), 7.61-7.88 (6H, m),7.49 (1H, q, J=8.1 Hz), 5.95-6.17 (1H, m), 5.22-5.32 (1H, m), 4.02-4.26(2H, m), 1.94-1.97 (3H, m). Mass Spectrum (ESI) m/e=396.9 (M+1).

(S)-8-Chloro-3-(1-(1,3-dioxoisoindolin-2-yl)ethyl)quinoline-2-carbaldehyde

To a stirred solution of2-((S)-1-(8-chloro-2-(1,2-dihydroxyethyl)quinolin-3-yl)-ethyl)isoindoline-1,3-dione(170 mg, 0.43 mmol) in THF (4.0 mL) and water (1.0 mL) was added sodiumperiodate (91.6 mg, 0.43 mmol). The reaction was stirred at roomtemperature for 3 hours and then it was diluted with water (50 mL). Theseparated aqueous layer was extracted with DCM (2×50 mL) and thecombined organic layers were washed with brine (50 mL), dried (MgSO₄),filtered and evaporated in vacuo to give(S)-8-chloro-3-(1-(1,3-dioxoisoindolin-2-yl)ethyl)-quinoline-2-carbaldehyde.¹H NMR (400 MHz, CDCl₃) δ ppm 10.36 (1H, s), 8.59 (1H, s), 7.89-7.91(1H, m), 7.82-7.86 (3H, m), 7.71-7.73 (2H, m), 7.57-7.61 (1H, m), 6.67(1H, q, J=7.0 Hz), 2.00 (3H, d, J=7.0 Hz).

(S)-8-Chloro-3-(1-(1,3-dioxoisoindolin-2-yl)ethyl)quinoline-2-carboxylicacid

To a stirred solution of(S)-8-chloro-3-(1-(1,3-dioxoisoindolin-2-yl)ethyl)-quinoline-2-carbaldehyde(110 mg, 0.30 mmol) and potassium phosphate monobasic (41.0 mg, 0.30mmol) in 2-methyl-2-butene (2 mL), tBuOH (2 mL), DCM (1.0 mL) and water(2.0 mL) was added sodium chlorite (27.3 mg, 0.30 mmol) in water (2.0mL). The reaction was stirred at room temperature. for 2 hours and thenit was treated with additional potassium phosphate monobasic (41.0 mg,0.30 mmol) and sodium chlorite (27.3 mg, 0.30 mmol) in water (2.0 mL).The reaction was stirred for 2 hours and then it was diluted with 1.0 Mcitric acid (40 mL) and ethyl acetate (60 mL). The separated aqueouslayer was extracted with ethyl acetate (2×60 mL) and the combinedorganic layers were washed with brine (40 mL), dried (MgSO₄), filteredand evaporated in vacuo to give(S)-8-chloro-3-(1-(1,3-dioxoisoindolin-2-yl)ethyl)quinoline-2-carboxylicacid. 1H NMR (400 MHz, CDCl₃) δ ppm 8.62 (1H, s), 7.72-7.84 (6H, m),7.65 (1H, dd, J=5.3, 2.9 Hz), 6.80 (1H, q, J=7.0 Hz), 1.96 (3H, d, J=7.0Hz). Mass Spectrum (ESI) m/e=381.0 (M+1).

(S)—N′-Acetyl-8-chloro-3-(1-(1,3-dioxoisoindolin-2-yl)ethyl)quinoline-2-carbohydrazide

To a stirred solution of(S)-8-chloro-3-(1-(1,3-dioxoisoindolin-2-yl)ethyl)-quinoline-2-carboxylicacid (100 mg, 0.26 mmol) in DMF (3.0 mL) was added sodium bicarbonate(66 mg, 0.79 mmol), hoat (54 mg, 0/39 mmol), acetic hydrazide (23 mg,0.31 mmol) and edc (76 mg, 0.39 mmol). The reaction was stirred at r.t.for 2 hours and then it was diluted with ethyl acetate (60 mL) and water(20 mL). The separated aqueous layer was extracted with ethyl acetate(30 mL) and the combined organic layers were washed with LiCl (1.0 Maqueous solution, 30 mL), brine (30 mL) and then dried (MgSO₄), filteredand evaporated in vacuo to give(S)—N′-acetyl-8-chloro-3-(1-(1,3-dioxoisoindolin-2-yl)ethyl)-quinoline-2-carbohydrazide.1H NMR (400 MHz, CDCl₃) δ ppm 10.45 (1H, s), 8.88 (1H, s), 8.64 (1H, s),7.70-7.84 (4H, m), 7.64-7.66 (2H, m), 7.52 (1H, dd, J=5.3, 2.9 Hz), 6.87(1H, q, J=7.0 Hz), 2.13 (3H, s), 1.98 (3H, d, J=7.0 Hz). Mass Spectrum(ESI) m/e=437.0 (M+1).

2-((S)-1-(8-Chloro-2-(5-methyl-1,3,4-thiadiazol-2-yl)quinolin-3-yl)ethyl)-isoindoline-1,3-dione

To a stirred solution of(S)—N′-acetyl-8-chloro-3-(1-(1,3-dioxoisoindolin-2-yl)-ethyl)quinoline-2-carbohydrazide(85 mg, 0.19 mmol) in THF (1.5 mL) and toluene (3.0 mL) was addedLawesson's reagent (118 mg, 0.29 mmol). The reaction was heated in themicrowave at 120° C. for 20 minutes and then cooled to room temperatureand purified by column chromatography (SiO₂, 12 g, hexanes:ethylacetate, 1:0 to 1:1) to give2-((S)-1-(8-chloro-2-(5-methyl-1,3,4-thiadiazol-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione.¹H NMR (400 MHz, CDCl₃) δ ppm 8.63 (1H, s), 7.77-7.84 (4H, m), 7.70 (2H,dd, J=5.3, 2.9 Hz), 7.46-7.51 (1H, m), 7.06 (1H, q, J=7.0 Hz), 2.85 (3H,s), 2.11 (3H, d, J=7.0 Hz).(1S)-1-(8-Chloro-2-(5-methyl-1,3,4-thiadiazol-2-yl)quinolin-3-yl)ethanamine

To a stirred solution of2-((S)-1-(8-chloro-2-(5-methyl-1,3,4-thiadiazol-2-yl)-quinolin-3-yl)ethyl)isoindoline-1,3-dione(30 mg, 69 μmol) in THF (1.0 mL) and ethanol (3.0 mL) was addedhydrazine monohydrate (69 μl, 1380 μmol). The reaction was heated to 90°C. for 40 minutes and then cooled to room temperature evaporated invacuo. The resulting residue was diluted with ethyl acetate (60 mL) andwater (40 mL) and the aqueous layer was extracted with ethyl acetate (30mL). The combined organic layers were washed with brine and then dried(MgSO₄), filtered and evaporated in vacuo to give(1S)-1-(8-chloro-2-(5-methyl-1,3,4-thiadiazol-2-yl)quinolin-3-yl)ethanamine.¹H NMR (500 MHz, choroform-d) δ ppm 8.62 (1H, s), 7.79-7.84 (2H, m),7.49-7.52 (1H, m), 5.61 (1H, d, J=6.4 Hz), 2.86 (3H, s), 1.57 (3H, d,J=6.6 Hz). Mass Spectrum (ESI) m/e=305.0 (M+1).

N—((S)-1-(8-Chloro-2-(5-methyl-1,3,4-thiadiazol-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

To a stirred solution of(1S)-1-(8-chloro-2-(5-methyl-1,3,4-thiadiazol-2-yl)-quinolin-3-yl)ethanamine(9 mg, 30 μmol) in 1-butanol (1.5 mL) was added huenig's base (6 μl, 35mol) and 6-chloropurine (5 mg, 30 μmol). The reaction was heated to 130°C. for 16 hours and then cooled to room temperature. The crude reactionmixture was purified by reverse phase HPLC (gradient: 20% water inacetonitrile to 85% water in acetonitrile) to giveN—((S)-1-(8-chloro-2-(5-methyl-1,3,4-thiadiazol-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine.¹H NMR (400 MHz, MeOH-d₄) δ ppm 8.62 (1H, s), 8.05 (1H, s), 7.83-7.89(2H, m), 7.53-7.57 (1H, m), 2.89 (3H, s), 1.83 (3H, d, J=6.6 Hz). MassSpectrum (ESI) m/e=423.1 (M+1).

Example 61 8-Chloro-2-(5-fluoro-2-methoxyphenylquinoline-3-carbaldehyde

To a stirred degassed solution of 2,8-dichloroquinoline-3-carbaldehyde(305.8 mg, 1.353 mmol) in 12 mL of 3:1 MeCN/H₂O was added5-fluoro-2-methoxyphenylboronic acid (252.9 mg, 1.488 mmol) and sodiumcarbonate (716.8 mg) and then Pd tetrakis (78.16 mg). The mixture washeated at 100° C. for 4 hour, poured into water and extracted withEtOAc. Chromatography: gradient Hex/EtOAc, ¹H NMR (400 MHz, choroform-d)δ ppm 9.90 (1H, s), 8.78 (1H, s), 7.91-8.00 (2H, m), 7.52-7.61 (2H, m),7.22 (1H, td, J=8.4, 3.1 Hz), 6.96 (1 H, dd, J=9.0, 4.3 Hz), 3.74 (3H,s) Mass Spectrum (ESI) m/e=343.1 (M+1).

3-(Azidomethyl)-8-chloro-2-(5-fluoro-2-methoxyphenyl)quinoline

To a stirred solution of8-chloro-2-(5-fluoro-2-methoxyphenyl)quinoline-3-carb-aldehyde (385.4mg, 1.221 mmol) in THF (6.0 mL) was added sodium borohydride (1.831mmol) at rt. The solution was stirred 1 hour then diluted with water,and extracted with EtOAc to provide a crude solid after solvent removal,which was used without further purification. To the crude alcohol inCHCl₃ (6 mL) was added thionyl chloride (0.445 mL, 6.103 mmol) at r.t.and stirred overnight. After 14 h the solvents were removed (TLCindicates complete.) The solid was dissolved in DMF (6 mL) then sodiumazide (2.441 mmol) was added at once, and stirred 1 hour, poured intowater and extracted EtOAc to give a crude material: 373.3 mgChromatography, gradient 89/9/1.

1H NMR (400 MHz, choroform-d) δ ppm 8.28 (1H, s), 7.86 (1H, dd, J=7.4,1.4 Hz), 7.83 (1H, dd, J=8.2, 1.4 Hz), 7.51 (1H, dd, 7.5 Hz), 7.22 (1H,dd, J=8.2, 3.1 Hz), 7.13-7.19 (1H, m), 6.95 (1H, dd, J=9.0, 4.3 Hz),4.48 (2H, s), 3.76 (3H, s) Mass Spectrum (ESI) m/e=343.1 (M+1).

(8-Chloro-2-(5-fluoro-2-methoxyphenyl)quinoline-3-yl)methanamine

To a stirred solution of3-(azidomethyl)-8-chloro-2-(5-fluoro-2-methoxyphenyl)-quinoline (210.7mg, 615 μmol) in THF 5 mL and MeOH 12 mL was added palladium, 10 wt. %on activated carbon (0.329 mmol) and placed under a medium ballooncontaining H₂. The reaction was complete after 2 h, it was filtered(Celite™) and solvents removed.

Chromatography:Gradient 89:9:1. ¹H NMR (400 MHz, choroform-d) δ ppm 8.30(1H, s), 7.80 (2H, ddd, J=7.9, 6.5, 1.3 Hz), 7.49-7.50 (1H, m), 7.47(1H, dd), 7.09-7.18 (2H, m), 6.93 (1H, dd, J=8.9, 4.2 Hz), 3.89 (2H, br.s.), 3.74 (3 H, s) Mass Spectrum (ESI) m/e=317.0 (M+1).

N-((8-Chloro-2-(5-fluoro-2-methoxyphenyl)quinoline-3-yl)methyl)-9H-purin-6-amine

To a stirred mixture of (8-chloro-2-(5-fluoro-2-methoxyphenyl)quinolin-3yl)-methanamine (190.4 mg, 0.601 mmol) and 6-bromopurine (126 mg, 0.631mmol) in 1-butanol (3.300 mL, 36.1 mmol) was addedN,N-ethyldiisopropylamine (0.209 mL, 1.20 mmol). The mixture was heatedto 100° C. overnight. The solvents were removed and the residuesubjected to chromatography: gradient/isocratic ¹H NMR (500 MHz,DMSO-d₆) δ ppm 12.93 (1H, br. s.), 8.28 (1H, br. s.), 8.09 (2 H, s),7.96 (1H, d, J=8.1 Hz), 7.91 (1H, d, J=7.3 Hz), 7.55 (1H, t, J=7.8 Hz),7.26-7.33 (1H, m), 7.21 (1H, dd, J=8.6, 3.2 Hz), 7.15 (1H, br. s.), 3.77(3H, s), 3.32 (2H, s) Mass Spectrum (ESI) m/e=335.1 (M+1).

Example 62N⁶-((8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-9H-purine-2,6-diamine

A mixture of (8-chloro-2-(2-chlorophenyl)quinolin-3-yl)methanamine(144.8 mg, 0.478 mmol), 2-amino-6-chloropurine (89.1 mg, 0.525 mmol) andN,N-diiso-propylethylamine, redestilled, 99.5% (0.166 mL, 0.955 mmol) in1-butanol, anhydrous, 99.8% (5.24 mL) was heated to reflux and stirredovernight. The reaction was cooled solvents removed and subjected tochromatography, 89:9:1(DCM/MeOH, NH4OH)gradient,

1H NMR (400 MHz, DMSO-d₆) δ ppm 12.08 (1H, br. s.), 8.36 (1H, s), 8.01(1 H, d, J=8.2 Hz), 7.92 (1H, d, J=6.3 Hz), 7.47-7.71 (8H, m), 5.56 (2H,br. s.), 4.59 (2H, br. s.) Mass Spectrum (ESI) m/e=436.1 (M+1).

Example 63N-((8-Chloro-2-(3-isopropylphenyl)quinolin-3-yl)methyl)-9H-Purine-6-diamine

To a stirred solution of(8-chloro-2-(3-isopropylphenyl)quinolin-3-yl)-methanamine (181.7 mg, 585μmol) in 1-butanol (3210 μl, 35075 μmol) was addedN,N-diisopropylethylamine (204 μl, 1169 μmol) andN,N-diisopropylethylamine (204 μl, 1169 μmol) and slowly heated to 100°C., heated 24 h removed from heat and the solvents removed.chromatographed gradient 89:9:1 (DCM/MeOH, NH4OH): 0-20% grad (15 min)isocratic 20%, (10 min) 20-50 grad, (10 min) then isocratic 50% 10 minto give pure desired product, ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.97 (1H,br. s.), 8.34 (1H, s), 8.12 (2H, s), 7.94 (1H, dd, J=8.3, 1.1 Hz), 7.91(1H, dd, J=7.5, 1.3 Hz), 7.62 (1 H, s), 7.46-7.55 (3H, m), 7.39 (1H, d,J=7.2 Hz), 4.84 (1H, br. s.), 2.95-3.03 (1H, m), 1.25 (6H, d, J=7.0 Hz)Mass Spectrum (ESI)=429.2 (M+1).

Example 642-((S)-1-(8-Chloro-2-(6-methylpyridin-2-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione

A stirred mixture of(S)-2-(1-(2,8-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (254.3mg, 0.685 mmol) and tetrakis(triphenylphosphine)palladium (79.16 mg,68.50 μmol), 2-methyl-6-(tributylstannyl)pyridine (523.6 mg, 1.37 mmol)in dioxane (degassed) was heated at 100° C. for 28 h, complete by LC-MSsolvent removed and chromatographed: 89:9:1(DCM/MeOH, NH₄OH)gradient. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 8.78 (1H, s), 8.15 (1H, dd, J=8.3, 1.3 Hz),7.98 (1 H, dd, J=7.5, 1.3 Hz), 7.73-7.78 (2H, m), 7.58-7.69 (4H, m),7.36 (1H, d, J=7.6 Hz), 7.16 (1H, d, J=7.6 Hz), 6.11-6.19 (1H, m), 2.33(3H, s), 1.82 (3H, d, J=7.0 Hz)

Mass Spectrum (ESI) m/e=427.9 (M+1).

(1S)-1-(8-Chloro-2-(6-methylpyridin-2-yl)quinolin-3-yl)ethyl)ethanamine

To a flask was charged2-((S)-1-(8-chloro-2-(6-methylpyridin-2-yl)quinolin-3-yl)-ethyl)isoindoline-1,3-dione(260.0 mg, 0.608 mmol) in ethanol 95% (12.2 mL) and hydrazine hydrate(0.189 mL, 6.076 mmol) was added, followed by refluxing.

After

2 h added an additional 10 eq hydrazine, reflux continued for 3 h. Allsolvents were removed and the residue chromatographed, 89:9:1 (DCM/MeOH,NH₄OH). 1H NMR (400 MHz, choroform-d) δ ppm 8.37 (1H, s), 7.90 (1H, d,J=7.4 Hz), 7.68-7.75 (3H, m), 7.38 (1H, dd, J=8.2, 7.4 Hz), 7.17 (1H, d,J=7.4 Hz), 4.69 (1H, q, J=6.7 Hz), 2.58 (3H, s), 1.43 (3H, d, J=6.8 Hz)Mass Spectrum (ESI) m/e=298.0 (M+1).

N—((S)-1-(8-Chloro-2-(6-methylpyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

To a stirred solution of(1S)-1-(8-chloro-2-(6-methylpyridin-2-yl)quinolin-3-yl)-ethanamine (146mg, 0.49 mmol) in 1-butanol (5.4 mL, 59 mmol) was added 6-bromopurine(0.107 g, 0.54 mmol) and N,N-diisopropylethylamine (0.17 mL, 0.98 mmol)with heating (110° C.) overnight. solvents were removed and the residuesubjected to chromatography, gradient, 89:9:1(DCM:MeOH:NH₄OH).

¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.84 (1H, br. s.), 8.67 (1H, s), 8.38(1 H, br. s.), 8.03-8.10 (1H, m), 7.84-7.98 (5H, m), 7.56 (1H, t, J=7.8Hz), 7.36 (1H, d, J=5.5 Hz), 6.03 (1H, br. s.), 2.58 (3H, br. s.), 1.66(3H, d, J=6.3 Hz) Mass Spectrum (ESI) m/e=415.9 (M+1).

Example 65

Mcpba (8.7 g, 50 mmol) was added at room temperature to3H-imidazo[4,5-b]pyridine (5.0 g, 42 mmol) in acetic acid (84 mL, 1469mmol). The mixture was stirred for 3 hours. The resulting precipitatewas filtered and rinsed with Et₂O, it gave 4-azabenzimidazole-N-oxide.To 4-azabenzimidazole-N-oxide (2.00 g, 14.8 mmol) phosphorousoxychloride (25.00 mL, 266 mmol) was added at room temperature. Thesolution was heated to 90° C. for 18 h. The solution was cooled and therest POCl₃ was distilled off in vacuo. The residue was dissolved inCH₃CN and quenched with slow addition of ice-water. The mixture wasbasified to PH 9 with 50% NaOH solution. At room temperature theresulting precipitates were filtered. The collected solid was dissolvedin MeOH and insoluble residue was removed by filtration. The filtrateswere concentrated and the residue was purified by flash chromatographyover silica gel, using 3:7 EtOAc-hexane, gave7-chloro-3H-imidazo[4,5-b]pyridine (1.20 g, 52.8%). To the mixture ofdi-tert-butylpyrocarbonate (1193 mg, 5465 μmol),7-chloro-3H-imidazo[4,5-b]pyridine (0.763 g, 4968 mop in acetonitrile(15 mL), 4-(dimethylamino)pyridine (61 mg, 497 μmol) was added. Themixture was stirred at room temperature overnight. Evaporation of thesolvent, flash chromatography of the residue over silica gel, using 0%to 25% EtOAc/hexane, gave tert-butyl7-chloro-3H-imidazo[4,5-b]pyridine-3-carboxylate, Mass Spectrum (ESI)m/e=253.0 (M+1).

A sealed flask was charged with(8-chloro-2-(2-chlorophenyl)quinolin-3-yl)-methanamine, made inprocedure E in A-1216 US PSP, tert-butyl7-chloro-3H-imidazo[4,5-b]pyridine-3-carboxylate (109 mg, 429 μmol),diisopropylethylamine (0.075 mL, 429 μmol) and 1-butanol (2.0 mL, 21856μmol). The mixture was subjected to microwave at 180° C. for 120 min.After cooled to room temperature, the mixture was concentrated, and theresidue was diluted with MeOH. The solution was purified by HPLC,25%-45% of B in 35 min. The collected fractions were dissolved in CH₂Cl₂and neutralized by washing with aq. NaHCO₃, the CH₂Cl₂ layer was dried,concentrated and gaveN-((8-chloro-2-(2-chlorophenyl)-quinolin-3-yl)methyl)-3H-imidazo[4,5-b]pyridin-7-amine(20.2 mg, 15%), ¹H NMR (DMSO-d₆) δ ppm 12.72 (1H, s), 8.43 (1H, s), 8.15(1H, s), 8.09 (1H, d, J=8.0 Hz), 8.05 (1H, d, J=8.0 Hz), 7.73-7.80 (2H,m), 7.63-7.70 (4H, m), 7.45 (1 H, s), 6.13 (1H, d, J=8.0 Hz), 4.60 (2H,br). Mass Spectrum (ESI) m/e=420.0 (M+1).

Example 66

Using the above or other analogous synthetic techniques and substitutingwith appropriate reagents the following compound was prepared:

N-((8-chloro-3-(2-(trifluoromethyl)phenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amine,NMR (MeOD) δ ppm 8.11 (1H, s), 8.08 (1H, br), 8.03 (1H, d, J=8.5 Hz),7.97 (1H, d, J=8.5 Hz), 7.89 (1H, d, J=8.5 Hz), 7.80 (1H, t, J=8.5 Hz),7.68-7.75 (4H, m), Mass Spectrum (ESI), m/e=456.1 (M+1).

Using the same or analogous synthetic techniques and substituting withappropriate reagents as in procedure H, the following compounds wereprepared:

Example 67

2-(349H-Purin-6-yl)amino)methyl)-8-chloroquinolin-2-yl)-N,N-dimethylbenzamide,¹H NMR (DMSO-d₆) δ ppm 8.39 (1H, s), 8.23 (1H, s), 8.19 (1H, s), 8.01(1H, d, J=8.0 Hz), 7.96 (1H, d, J=8.0 Hz), 7.82 (1H, br), 7.52-7.64 (4H,m). Mass Spectrum (ESI) in/e=458.2 (M+1).

Example 68

N-((8-Chloro-2-(2-isopropylphenyl)quinolin-3-yl)methyl)-9H-purin-6-amine,¹H NMR (DMSO-d₆) δ ppm 8.30 (1H, s), 8.14 (1H, br), 8.09 (1H, s), 7.97(1H, d, J=8.0 Hz), 7.90 (1H, d, J=8.0 Hz), 7.45-7.57 (3H, m), 7.31-7.36(2H, m), 2.62-2.69 (1H, m), 1.15-1.22 (6H, m). Mass Spectrum (ESI)m/e=429.2 (M+1).

Example 69

N-((8-Chloro-2-(2-phenylphenyl)quinolin-3-yl)methyl)-9H-purin-6-amine,¹H NMR (DMSO-d₆) δ ppm 8.13 (1H, s), 8.09 (1H, br), 8.03 (1H, s), 7.86(2H, t, J=8.0 Hz), 7.45-7.57 (4H, m), 7.20-7.25 (2H, m), 7.13-7.18 (2H,m). Mass Spectrum (ESI) m/e=463.1 (M+1).

Example 70

N-((2-(2-(2H-Tetrazol-5-yl)phenyl)-8-chloroquinolin-3-yl)methyl)-9H-purin-6-amine,¹H NMR (DMSO-d₆) δ ppm 8.24 (1H, s), 8.11 (2H, br), 7.07 (2H, t, J=8.0Hz), 7.95 (1H, t, J=8.0 Hz), 7.86 (1H, t, J=8.0 Hz), 7.50-7.63 (4H, m),Mass Spectrum (ESI) m/e=455.2 (M+1).

Example 71

N-((6,7-Dichloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine,¹H NMR (DMSO-d₆) δ ppm 8.29 (1H, s), 8.14 (1H, s), 8.01 (2H, br), 7.97(1H, s), 7.55 (1H, t, J=8.0 Hz), 7.41-7.50 (4H, m), Mass Spectrum (ESI)m/e=457.0 (M+1).

N-((7-Chloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine,NMR (DMSO-d₆) δ ppm 8.35 (1H, s), 8.13 (1H, br), 8.09 (3H, br), 8.07(1H, s), 7.59-7.66 (2H, m), 7.43-7.55 (3H, m), Mass Spectrum (ESDm/e=421.1 (M+1).

Example 73

N-((8-Chloro-2-(1H-pyrazol-4-yl)quinolin-3-yl)methyl)-9H-purin-6-amine,¹H NMR (DMSO-d₆) δ ppm 13.30 (0.5H, s), 13.02 (0.5H, s), 8.47 (0.5H, s),8.10-8.28 (3.5H, m), 7.82-7.92 (2H, m), 7.44 (1H, t, J=8.0 Hz), 5.07(1H, s). Mass Spectrum (ESD m/e=377.0 (M+1).

Example 74

N-((8-chloro-2-(isothiazol-5-yl)quinolin-3-yl)methyl)-9H-purin-6-amine,¹H NMR (DMSO-d₆) δ ppm 8.72 (1H, s), 8.45 (1H, br), 8.17 (2H, br), 8.08(1 H, s), 7.96-8.02 (2H, m), 7.58 (1H, t, J=8.0 Hz), Mass Spectrum (ESI)m/e=394.1 (M+1).

Example 75

N-((8-Chloro-2-(2-chloropyridin-3-yl)quinolin-3-yl)methyl)-9H-purin-6-amine,¹H NMR (DMSO-d₆) δ ppm 8.49 (1H, s), 8.37 (1H, d, J=8.0 Hz), 8.09 (1H,s), 8.08 (1H, br), 7.90-7.98 (3H, m), 7.59 (1H, t, J=8.0 Hz), 7.36 (1H,dd, J=8.0, 8.0 Hz), Mass Spectrum (ESI) m/e=422.0 (M+1).

Example 76

N-((8-Chloro-2-(4-(trifluoromethyl)pyridin-3-yl)quinolin-3-yl)methyl)-9H-purin-6-amine,¹H NMR (MeOD) δ ppm 8.75 (1H, s), 8.69 (1H, d, J=8.0 Hz), 8.41 (1H, s),7.98 (1H, s), 7.95 (1H, br), 7.84 (1H, d, J=8.0 Hz), 7.81 (1H, d, J=8.0Hz), 7.67 (1H, d, J=8.0 Hz), 7.50 (1H, t, J=8.0 Hz), Mass Spectrum (ESI)m/e=456.1 (M+1).

Example 77

N-((8-Chloro-2-(pyrazin-2-yl)quinolin-3-yl)methyl)-9H-purin-6-amine, ¹HNMR (MeOD) δ ppm 9.43 (1H, s), 8.80-8.85 (2H, m), 8.49 (1H, s), 8.08(2H, br), 8.01 (1H, d, J=8.0 Hz), 7.98 (1H, d, J=8.0 Hz), 7.61 (1H, t,J=8.0 Hz), Mass Spectrum (ESI) m/e=389.0 (M+1).

Using the same or analogous synthetic techniques and substituting withappropriate reagents as in example 109, with additional two differentsteps as shown below, following compounds were prepared:

Example 78

N—((S)-1-(8-Chloro-2-(2-ethyl-5-fluoropyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine,¹H NMR (MeOD) 8 ppm 8.71 (1H, s), 8.28-8.57 (3H, m), 7.85-8.07 (3H, m),7.64 (1H, t, J=8.0 Hz), 1.84 (1.5H, br), 1.69 (1.5H, br), 1.28 (1.5H,br), 1.16 (1.5H, br), Mass Spectrum (ESI) m/e=448.1 (M+1).

Example 79

N—((S)-1-(8-Chloro-2-(5-fluoropyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine,¹H NMR (MeOD) 8 ppm 8.80 (1H, s), 8.67 (1H, s), 8.58 (1H, br), 8.48 (1H, br), 8.43 (1H, br), 8.11 (1H, br), 7.97 (1H, d, J=8.0 Hz), 7.94 (1H,d, J=8.0 Hz), 7.61 (1H, t, J=8.0 Hz), 1.76 (3H, d, J=8.0 Hz), MassSpectrum (ESI) m/e=420.1 (M+1).

Example 80

A mixture of(S)-2-(1-(2,8-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (120.0mg, 323 μmol), 2-chloro-5-fluoropyridin-3-ylboronic acid (57 mg, 323μmol), tetrakis(triphenylphosphine)palladium (37 mg, 32 μmol), cesiumfluoride (147 mg, 970 μmol) and copper(I) iodide (12 mg, 65 μmol) in1,2-ethanediol, dimethyl ether (3.0 mL, 323 μmol) was subjected tomicrowave at 100° C. for 1 h, cooled to room temperature. Filtration ofthe resultant mixture and rinsed with EtOAc, the filtrates werecollected and concentrated. Purification of the residue by flashchromatography over silica gel, gradient elution, 0-100% EtOAc inhexane, gave2-((S)-1-(8-chloro-2-(2-chloro-5-fluoropyridin-3-yl)quinolin-3-yl)-ethyl)isoindoline-1,3-dione,Mass Spectrum (ESI)=466.0 (M+1).

A mixture of2-((S)-1-(8-chloro-2-(2-chloro-5-fluoropyridin-3-yl)quinolin-3-yl)-ethyl)isoindoline-1,3-dione(192.7 mg, 413 μmol): dioxan (15 mL, 175989 μmol)-,triethylaluminum (236mg, 2066 μmol) and tetrakis(triphenylphosphine)-palladium (96 mg, 83μmol) was refluxed for 4 hs under N₂, cooled to room temperature. Thereaction mixture was acidified with HCl (2N) and the solvent wasevaporated. The residue was diluted with water, basified with NaOH(20%), and the mixture was extracted with EtOAc. The combined extractswere washed with water, brine, dried and concentrated. Purification ofthe residue by flash chromatography over silica gel, gradient elution,0-100% EtOAc in hexane, gave2-((S)-1-(8-chloro-2-(2-ethyl-5-fluoropyridin-3-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione,Mass Spectrum (ESI) m/e=460.1 (M+1). And2-((S)-1-(8-chloro-2-(5-fluoropyridin-3-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione,Mass Spectrum (ESI) m/e=432.1 (M+1).

Example 81 Preparation ofN-((5-Chloro-3-(2-chlorophenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amine3-Chlorobenzene-1,2-diamine

To solution of 3-chloro-2-nitroaniline (10.00 g, 57.95 mmol), 3 N aq.HCl (96.58 mL, 289.7 mmol), and ethyl alcohol (148.6 mL, 57.95 mmol) wasadded Tin(II) chloride dihydrate (65.96 g, 289.7 mmol) and the mixturewas heated under reflux with stirring. After 3 h, the mixture was cooledto room temperature and concentrated under reduced pressure to give abrown syrup. The mixture was cautiously treated with an excess of 10 MKOH (115.9 mL, 1159 mmol, 20 eqv.). The mixture was diluted with EtOAc(200 mL), filtered through Celite™ pad, and washed the pad well withEtOAc (100 mL×2). The filtrate was extracted with EtOAc (100 mL×2). Thecombined organic layers were washed with water (100 mL ×1), dried overMgSO₄, filtered, and concentrated under reduced pressure to give3-chlorobenzene-1,2-diamine as a red oil: NMR (400 MHz, DMSO-d₆) δ ppm6.43-6.53 (2H, m), 6.38 (1H, t, J=7.8 Hz), 4.80 (2H, s), 4.60 (2H, s);LC-MS (ESI) m/z 142.9 [M+H]⁺. The crude product was carried on crudewithout purification for the next step.

1-(2-Chlorophenyl)propane-1,2-dione

To a solution of 2-chlorophenylacetone (10.800 g, 64.049 mmol) in 279 mLof CH₂Cl₂, pyridinium chlorochromate (41.418 g, 192.15 mmol), andpyidine (16 mL) in three portions were added over 2.5 hours and themixture was refluxed under vigorous stirring. After 22 h, he mixture wasremoved from heat. The mixture was concentrated in vacuo to give a darkred syrup. The crude mixture was purified by column chromatography on a120 g of Redi-Sep™ column using 0-10% gradient of EtOAc in hexane over28 min as eluent to give 1-(2-chlorophenyl)propane-1,2-dione as yellowliquid: ¹H NMR (400 MHz, choroform-d) δ ppm 7.66 (1H, dd, J=7.6, 1.8Hz), 7.49-7.54 (1H, m), 7.38-7.45 (2H, m), 2.58 (3H, s); LC-MS: m/z182.9 [M+H]⁺.

3-Bromo-1-(2-chlorophenyl)propane-1,2-dione

A mixture of 1-(2-chlorophenyl)propane-1,2-dione (4.2379 g, 23.208mmol), bromine (1.1891 mL, 23.208 mmol), and glacial acetic acid(0.67005 mL, 11.604 mmol) in chloroform (58.020 mL, 23.208 mmol) washeated at 60° C. After 17 h of stirring at 60° C., the mixture wasremoved from heat and concentrated under reduced pressure to give3-bromo-1-(2-chlorophenyl)propane-1,2-dione as an orange liquid: LC-MS:a peak of m/z 261.0 [M+H(⁷⁹Br)]⁺and 262.9 [M+H (⁸¹Br)-]⁺. The orangeliquid was carried on crude without purification for the next step.

3-(Bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline and2-(Bromomethyl)-5-chloro-3-(2-chlorophenyl)quinoxaline

To a solution of 3-bromo-1-(2-chlorophenyl)propane-1,2-dione (6.0689 g,23.208 mmol) in 100 mL of EtOAc was added a solution of3-chlorobenzene-1,2-diamine (3.3091 g, 23.208 mmol) in 54.7 mL of EtOAcat room temperature and the resulting red mixture was stirred at roomtemperature. After 6 h of stirring at room temperature, the mixture wasconcentrated under reduced pressure to give a mixture of3-(bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline and2-(bromomethyl)-5-chloro-3-(2-chlorophenyl)quinoxaline as a red syrup:LC-MS (ESI) m/z 369.0 [M+H]⁺. The crude product was carried on crudewithout purification for the next step.

(8-Chloro-3-(2-chlorophenyl)quinoxalin-2-yl)methanamine and(5-Chloro-3-(2-chlorophenyl)quinoxalin-2-yl)methanamine

To a stirring solution of a mixture of3-(bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline and2-(bromomethyl)-5-chloro-3-(2-chlorophenyl)-quinoxaline (8.5418 g, 23.21mmol) in DMF (100.0 mL, 23.21 mmol) was added sodium azide (3.017 g,46.42 mmol) at room temperature and the mixture was stirred at roomtemperature. After 40 min, the mixture was partitioned between EtOAc(200 mL) and H₂O (100 mL). The organic layer was washed with brine (100mL×1), dried over Na₂SO₄, filtered, and concentrated under reducedpressure to give 2-(azidomethyl)-5-chloro-3-(2-chlorophenyl)quinoxalineas a brown liquid: LC-MS (ESD major peak of m/z 330.1 [M+H]⁺. The crudeproduct was carried on crude without purification for the next step.

To a stirring solution of2-(azidomethyl)-5-chloro-3-(2-chlorophenyl)quinoxaline (7.6630 g, 23.21mmol) in 100 mL of THF-H₂O (4:1) was added dropwise trimethylphosphine,1.0 M solution in THF (27.85 mL, 27.85 mmol) at room temperature and themixture was stirred at room temperature. After 1 h, the mixture wasdiluted with ice-cold 1 N NaOH (100 mL) and extracted with EtOAc (100mL×3). The combined organic layers were washed with brine (100 mL×3),dried over Na₂SO₄, and concentrated under the reduced pressure to givegreen syrup. The green syrup was purified by column chromatography on a120 g of Redi-Sep™ column using 3% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ for 42 min, then 3% to 100% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 27 min, and then 100%isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 5 min as eluent togive two separated regiosiomers:(8-chloro-3-(2-chlorophenyl)quinoxalin-2-yl)methanamine as a dark brownsyrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.07-8.15 (2H, m), 7.81-7.90 (1H,m), 7.65-7.71 (1H, m), 7.52-7.66 (3H, m), 3.85 (2H, s), 2.23 (2H, br.s.); LC-MS (ESI) m/z 304.0 and 306.0 [M+H]⁺and(5-chloro-3-(2-chlorophenyl)-quinoxalin-2-yl)methanamine as areddish-brown syrupy solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.15 (1H,dd, J=8.2, 1.2 Hz), 8.05 (1H, dd, J=7.8, 1.2 Hz), 7.85-7.93 (1H, m),7.67-7.72 (1H, m), 7.53-7.66 (3H, m), 3.83 (2H, s), 2.07 (2H, br. s.);LC-MS (ESI) m/z 304.0 and 306.0 [M+H]⁺. The structures of tworegiosiomers were confirmed by NOESY experiment.

N-((5-Chloro-3-(2-chlorophenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.4553 g, 2.288 mmol),(5-chloro-3-(2-chlorophenyl)quinoxalin-2-yl)methanamine (0.6959 g, 2.288mmol), and N,N-diisopropylethylamine (0.7970 mL, 4.576 mmol) in1-butanol (13.46 mL, 2.288 mmol) was stirred at 100° C. After 3.5 h, themixture was removed from the heat and concentrated under reducedpressure. The residue was purified by flash column chromatography on asilica gel column using 50% of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ aseluent to give a light-yellow solid. The light-yellow solid wassuspended in CH₂Cl₂-Hexane (1:1) and filtered to giveN-((5-chloro-3-(2-chlorophenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amineas a light-yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.93 (1H, s),8.02-8.16 (4H, m), 7.95 (1H, br. s.), 7.83-7.90 (1H, m), 7.61-7.72 (2H,m), 7.53-7.59 (1H, m), 7.47-7.53 (1H, m), 4.72-4.98 (2H, m),89676-20-1-1H-NMR; LC-MS (ESI) m/z 422.0 and 424.0 [M+H]⁺.

Example 82 Preparation ofN-((8-Chloro-2-(2-chlorophenyl)quinolin-3-yl)-methyl)morpholin-4-amine

To a mixture of 8-chloro-3-(chloromethyl)-2-(2-chlorophenyl)quinoline(Prepared in Example 2), N,N-diisopropylethylamine (0.584 mL, 3.35mmol), and lithium iodide (0.00566 mL, 0.148 mmol) in 7 mL of DMF wasadded 4-aminomorph-oline (0.0647 mL, 0.670 mmol) and the mixture wasstirred at 50° C. After 19 h, the mixture was concentrated under reducedpressure to give an yellow oil. The crude mixture was purified by columnchromatography on a 40 g of Redi-Sep™ column using 0-100% gradient ofEtOAc in hexane over 14 min and then 100% isocratic of EtOAc for 10 minas eluent to giveN-((8-chloro-2-(2-chlorophenyl)-quinolin-3-yl)methyl)morpholin-4-amineas a light yellow foam (syrup): ¹H NMR (400 MHz, choroform-d) 8 ppm 8.39(1H, s), 7.73-7.88 (2H, m), 7.37-7.53 (5 H, m), 3.78-4.07 (2H, m), 3.64(4H, t, J=4.7 Hz), 2.53 (4H, s); LC-MS (ESI) m/z 388.0 and 390.1 [M+H]⁺.

Example 83 Preparation ofN-((3-(2-Chlorophenyl)-8-methylquinoxalin-2-yl)methyl)thieno[3,2-d]pyrimidin-4-amineas a TFA salt andN-((3-(2-chlorophenyl)-5-methylquinoxalin-2-yl)methyl)thieno[3,2-d]pyrimidin-4-amineas a TFA salt

A mixture of 4-chlorothieno[3,2-d]pyrimidine (0.1200 g, 0.7033 mmol), amixture of (3-(2-chlorophenyl)-8-methylquinoxalin-2-yl)methanamine and(3-(2-chloro-phenyl)-5-methylquinoxalin-2-yl)methanamine (Prepared inExamples 18 and 19, 0.2276 g, 0.8018 mmol), andN,N-diisopropylethylamine (0.2450 mL, 1.407 mmol) in 4 mL of EtOH wasstirred at 75° C. After 20.5 h, the mixture was removed from the heatand concentrated in vacuo to give a brown syrup. The brown syrup waspurified by column chromatography on a 40 g of Redi-Sep™ column using 0to 100% gradient of EtOAc in hexane over 14 min and then 100% isocraticof EtOAc for 5 min as eluent to give a mixture of two regioisomers as abrown foam type syrup. The brown foam type syrup (0.1333 g) was purifiedby semi-prep-HPLC on a Gemini™ 10μ C18 column (250×21.2 mm, 10 μm) using20-50% gradient of CH₃CN (0.1% of TFA) in water (0.1% of TFA) over 40min as eluent to give two separated regiosiomers:N-((3-(2-chlorophenyl)-8-methyl-quinoxalin-2-yl)methyl)thieno[3,2-d]pyrimidin-4-amineas a TFA salt as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.58(1H, s), 8.56 (1H, s), 8.37 (1H, d, J=5.5 Hz), 7.93-7.98 (1H, m),7.76-7.80 (1H, m), 7.72-7.76 (1 H, m), 7.54-7.62 (2H, m), 7.44-7.50 (2H,m), 7.37-7.43 (1H, m), 5.00 (2H, br. s.), 2.59 (3H, s); LC-MS (ESI) m/z418.0 [M+H]⁺andN-((3-(2-chlorophenyl)-5-methylquinoxalin-2-yl)methyl)thieno[3,2-d]pyrimidin-4-amineas a TFA salt as an off-white solid: NMR (400 MHz, DMSO-d₆) δ ppm 9.77(1H, br. s.), 8.55 (1H, s), 8.37 (1H, d, J=5.5 Hz), 7.89-7.95 (1H, m),7.77-7.82 (1H, m), 7.73-7.76 (1H, m), 7.63 (1H, dd, J=7.4, 1.6 Hz),7.54-7.58 (1H, m), 7.43-7.49 (2H, m), 7.37-7.42 (1H, m), 4.99 (2H, br.s.), 2.69 (3 H, s); LC-MS (ESI) m/z 418.0 [M+H]⁺at 1.498 min, (ExactMass of neutral form: 417.081).

Example 84 Preparation ofN-((3-(2-Chlorophenyl)-8-fluoroquinoxalin-2-yl)-methyl)-9H-purin-6-amineas a TFA salt andN-((3-(2-chlorophenyl)-5-fluoroquinoxalin-2-yl)methyl)-9H-purin-6-amineas a TFA salt: 3-(Bromomethyl)-2-(2-chlorophenyl)-5-fluoroquinoxalineand 2-(Bromomethyl)-342-chlorophenyl)-5-fluoroquinoxaline

To a solution of 3-bromo-1-(2-chlorophenyl)propane-1,2-dione (Preparedin Example 81, 2.3832 g, 9.114 mmol) in 61 mL of EtOAc was added asolution of 3-fluorobenzene-1,2-diamine (1.150 g, 9.114 mmol) at roomtemperature and the resulting red mixture was stirred at roomtemperature. After 3 h, the mixture was concentrated in vacuo to give amixture of two regioisomers as a black syrup. The black syrup waspurified by column chromatography on a 80 g of Redi-Sep™ column using 0to 50% gradient of EtOAc in hexane over 25 min and then 100% isocraticof EtOAc for 4 min as eluent to give a mixture of3-(bromomethyl)-2-(2-chlorophenyl)-5-fluoroquinoxaline and2-(bromomethyl)-3-(2-chlorophenyl)-5-fluoroquinoxaline as a red syrup;LC-MS (ESI) two peaks of m/z 351.0 [M+H (⁷⁹Br)]⁺and 352.9 [M+H (⁸¹Br)]⁺.The crude product was used without further purification in the nextstep.

(3-(2-Chlorophenyl)-8-fluoroquinoxalin-2-yl)methanamine and(3-(2-Chlorophenyl)-5-fluoroquinoxalin-2-yl)methanamine)

To a stirring solution of a mixture of3-(bromomethyl)-2-(2-chlorophenyl)-5-fluoroquinoxaline and2-(bromomethyl)-3-(2-chlorophenyl)-5-fluoroquinoxaline (0.7617 g, 2.166mmol) in 11 mL of DMF was added sodium azide (0.2113 g, 3.250 mmol) atroom temperature and the mixture was stirred at room temperature. After50 min, the mixture was partitioned between EtOAc (100 mL) and H₂O (100mL). The organic layer was washed with brine (50 mL×1), dried overMgSO₄, filtered, and concentrated under reduced pressure to give amixture of 3-(azidomethyl)-2-(2-chlorophenyl)-5-fluoroquinoxaline and2-(azidomethyl)-3-(2-chlorophenyl)-5-fluoroquinoxaline as a dark redsyrup: LC-MS (ESI) m/z 314.0 [M+H]⁺. The crude product was carried oncrude without purification for the next step.

To a stirring solution of a mixture of3-(azidomethyl)-2-(2-chlorophenyl)-5-fluoroquinoxaline and2-(azidomethyl)-3-(2-chlorophenyl)-5-fluoroquinoxaline (0.6796 g, 2.166mmol) in 10 mL of THF-H₂O (4:1) was added dropwise trimethylphosphine,1.0m solution in thf (2.600 mL, 2.600 mmol) at room temperature and themixture was stirred at room temperature. After 1 h, to the mixture wasadded EtOAc (100 mL) was added and the mixture was extracted with 1 NHCl (3×60 mL). The combined extracts were neutralized with solid sodiumbicarbonate, and extracted with EtOAc (50 mL×2). The combined organicextracts were washed with brine (50 mL×2), dried over MgSO4, filtered,and concentrated in vacuo to give the crude product as a violet syrup(0.3319 g). The violet syrup was purified by column chromatography on a40 g of Redi-Sep™ column using 0 to 15% gradient of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ over 2 min, 15% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ for 5 min, then 15% to 100% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 3 min, 30% isocratic ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 5 min, and then 30% to 100%gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 9 min, and then100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 3 min as eluent to givea mixture of 3-(2-chlorophenyl)-8-fluoroquinoxalin-2-yl)methanamine and(3-(2-chlorophenyl)-5-fluoroquinoxalin-2-yl)methanamine as a dark greensyrup: LC-MS (ES) m/z 288.1 [M+H]⁺. A mixture of the two regioisomerswas used without further purification for the next step.

N-((3-(2-Chlorophenyl)-8-fluoroquinoxalin-2-yl)methyl)-9H-purin-6-amineas a TFA salt andN-((3-(2-Chlorophenyl)-5-fluoroquinoxalin-2-yl)methyl)-9H-purin-6-amineas a TFA salt

A mixture of 6-chloropurine (0.171 g, 1.11 mmol), a mixture of((3-(2-chlorophenyl)-8-fluoroquinoxalin-2-yl)methanamine and(3-(2-chlorophenyl)-5-fluoroquinoxalin-2-yl)methanamine) (0.3186 g, 1.11mmol), and N,N-diisopropylethylamine (0.386 mL, 2.21 mmol) in 6.5 mL ofEtOH was stirred at 75° C. After 19 h, the mixture was removed from theheat and concentrated under reduced pressure to give an orange syrup.The orange syrup was chromatographed on a 40 g of Redi-Sep™ column using0 to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 minand 100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 5 min as eluent togive a mixture of two regioisomers as a brown solid. The brown solid(0.0635 g) was purified (1.0 mL (˜20 mg)×3 injections) by semi-prep-HPLCon a Gemini™ 10μ C18 column (250×21.2 mm, 10 μm) using 20-50% gradientof CH₃CN (0.1% of TFA) in water (0.1% of TFA) over 40 min as eluent togive two separated regiosiomers:

N-((3-(2-chlorophenyl)-8-fluoroquinoxalin-2-yl)methyl)-9H-purin-6-amineas a TFA salt as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.55(1H, br. s.), 8.25 (2H, d, J=20.7 Hz), 7.99 (1H, d, J=8.2 Hz), 7.84-7.92(1H, m), 7.72-7.80 (1H, m), 7.67 (1H, dd, J=7.2, 1.8 Hz), 7.63 (1H, dd,J=8.0, 1.0 Hz), 7.51-7.57 (1H, m), 7.46-7.51 (1H, m), 4.90 (2H, s);LC-MS (ESI) m/z 406.0 [M+H]⁺(Exact Mass of neutral form: 405.09) andN-((3-(2-chlorophenyl)-5-fluoroquinoxalin-2-yl)methyl)-9H-purin-6-amineas a TFA salt as a off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.44(1H, br. s.), 8.17-8.30 (2H, m), 7.93-7.99 (1H, m), 7.85-7.93 (1H, m),7.71-7.78 (1H, m), 7.68 (1H, dd, J=7.2, 1.8 Hz), 7.62-7.66 (1H, m),7.53-7.59 (1H, m), 7.48-7.53 (1H, m), 4.88 (2H, br. s.); LC-MS (ESI) m/z406.0 [M+H]⁺(Exact Mass of neutral form: 405.09).

Example 85 Preparation ofN-((5-Chloro-3-(2-(trifluoromethyl)phenyl)-quinoxalin-2-yl)methyl)-9H-purin-6-amine

8-Chloro-3-methylquinoxalin-2(1H)-one and5-chloro-3-methylquinoxalin-2(1H)-one

A mixture of ethyl pyruvate (11.523 mL, 103.70 mmol) and3-chlorobenzene-1,2-diamine (Prepared in Example 81, 14.7866 g, 103.70mmol) in polyphosphoric acid (100.00 g) was stirred and heated at 115°C. After 6 h, the mixture was cooled to room temperature, thoroughlymixed with water (500 mL), and neutralized with 10 N NaOH (180 mL). Theresulting precipitate was collected by filtration and the solid waswashed with water (1000 mL) and dried to give a dark brown solid as amixture of chloro-3-methylquinoxalin-2(1H)-one and5-chloro-3-methylquinoxalin-2(1H)-one as a dark brown solid. The darkbrown solid was purified by silica gel column chromatography on a 330 gof Redi-Sep™ column using 100% of Hexane for 5 min, then 0 to 18%gradient of EtOAc in hexane over 9.5 min, then 18% isocratic of EtOAc inhexane for 23.2 min, then 18% to 100% gradient of EtOAc in hexane over48 min, and then 100% isocratic of EtOAc for 10 min as eluent to givetwo separated regiosiomers: 8-chloro-3-methylquinox-alin-2(1H)-one as anorange solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.88 (1H, s), 7.68 (1H,dd, J=7.8, 1.2 Hz), 7.58-7.63 (1H, m), 7.28 (1H, t, J=8.0 Hz), 2.43 (3H,s); LC-MS (ESI) m/z 195.1 [M+H]⁺ and5-chloro-3-methyl-quinoxalin-2(1H)-one as an orange solid: ¹H NMR (400MHz, DMSO-d_(o)) δ ppm 12.48 (1H, s), 7.37-7.47 (2H, m), 7.23 (1H, dd,J=7.8, 1.6 Hz), 2.44 (3H, s); LC-MS (ESI) m/z 195.1 [M+H]⁺.

3,5-Dichloro-2-methylquinoxaline

A mixture of 8-chloro-3-methylquinoxalin-2-ol (1.0765 g, 5.5314 mmol)and phosphorous oxychloride (10.127 mL, 110.63 mmol) was stirred at 100°C. After 3 h, the mixture was cooled to room temperature. The mixturewas poured into ice (˜100 mL) with stirring and neutralized with NH₄OH(30 mL) and ice with stirring. The resulting precipitate was collectedby filtration, rinsed with water (200 mL), and dried to give3,5-dichloro-2-methylquinoxaline as a pink solid: ¹H NMR (400 MHz,DMSO-d₆) δ ppm 7.98-8.07 (2H, m), 7.84 (1H, dd, J=8.3, 7.7 Hz), 2.79(3H, s); LC-MS (ESI) m/z 213.0 [M+H]⁺. The pink solid was carried oncrude without purification for the next step.

5-Chloro-2-methyl-3-(2-(trifluoromethyl)phenyl)quinoxaline

A mixture of 3,5-dichloro-2-methylquinoxaline (1.1209 g, 5.261 mmol),2-(trifluoromethyl)phenylboronic acid (1.099 g, 5.787 mmol),tetrakis(triphenyl-phosphine)palladium (0.3040 g, 0.2630 mmol), andsodium carbonate anhydrous (2.788 g, 26.30 mmol) in 53 mL of CH₃CN—H₂O(3:1) was stirred at 100° C. After 13.5 h, the mixture was cooled toroom temperature and partitioned between EtOAc (100 mL) and water (100mL). The organic layer was washed with brine (50 mL×3), dried overNa₂SO₄, filtered, and concentrated under reduced pressure to give a redsyrup. The red syrup was purified by silica gel column chromatography ona 80 g of Redi-Sep™ column using 0 to 50% gradient of EtOAc in hexaneover 25 min and then 50% isocratic of EtOAc for 20 min as eluent to give5-chloro-2-methyl-3-(2-(trifluoromethyl)phenyl)quinoxaline as a redsolid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.09 (1H, dd, J=8.4, 1.4 Hz),8.02 (1H, dd, J=7.6, 1.2 Hz), 7.98 (1H, d, J=7.8 Hz), 7.73-7.92 (4H, m),2.47 (3H, s); LC-MS (ESI) m/z 323.0 [M+H]⁺.

2-(Bromomethyl)-5-chloro-3-(2-(trifluoromethyl)phenyl)quinoxaline

5-Chloro-2-methyl-3-(2-(trifluoromethyl)phenyl)quinoxaline (1.4455 g,4.479 mmol) and 1,3-dibromo-5,5-dimethylhydantoin (0.6404 g, 2.240 mmol)were suspended in carbon tetrachloride (44.79 mL, 4.479 mmol). To themixture was added benzoyl peroxide (0.1447 g, 0.4479 mmol) and themixture was heated at reflux. After 21.5 h, the mixture was cooled toroom temperature and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography on a 80 g of Redi-Sep™column using 0 to 9% gradient of EtOAc in hexane over 2 min, then 9%isocratic of EtOAc for 13 min, then 9 to 100% gradient of EtOAc inhexane over 23 min, then 100% isocratic of EtOAc for 4 min as eluent togive 2-(bromomethyl)-5-chloro-3-(2-(trifluoromethyl)-phenyl)quinoxalineas a yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.18 (1H, dd, J=8.4,1.4 Hz), 8.13 (1H, dd, J=7.8, 1.2 Hz), 7.81-8.03 (5H, m), 4.69 (2H, dd,J=88.4, 10.2 Hz); LC-MS (ESI) m/z 400.9 and 403.0 [M+H]⁺.

(5-Chloro-3-(2-(trifluoromethyl)phenyl)quinoxalin-2-yl)methanamine

To a stirring solution of2-(bromomethyl)-5-chloro-3-(2-(trifluoromethyl)phenyl)-quinoxaline(0.7173 g, 1.786 mmol) in DMF (8.930 mL, 1.786 mmol) was added sodiumazide (0.2322 g, 3.572 mmol) at room temperature and the mixture wasstirred at room temperature. After 30 min, the mixture was partitionedbetween EtOAc (100 mL) and H₂O (100 mL). The organic layer was washedwith brine (50 mL×1), dried over Na₂SO₄, filtered, and concentratedunder reduced pressure to give bluish-brown syrup. The bluish-brownsyrup was purified by silica gel column chromatography on a 40 g ofRedi-Sep™ column using 0 to 50% gradient of EtOAc in hexane over 14 min,then 50% isocratic of EtOAc for 5 min as eluent to give2-(azidomethyl)-5-chloro-3-(2-(trifluoromethyl)phenyl)quinoxaline: ¹HNMR (400 MHz, DMSO-d₆) δ ppm 8.20 (1H, dd, J=8.6, 1.2 Hz), 8.10-8.14 (1H, m), 7.99 (1H, d, J=7.8 Hz), 7.95 (1H, dd, J=8.4, 7.6 Hz), 7.79-7.91(3H, m), 4.41-4.67 (2H, m); LC-MS (ESI) major peak of m/z 364.0 [M+H]⁺.The crude product was carried on crude without purification for the nextstep.

To a solution of2-(azidomethyl)-5-chloro-3-(2-(trifluoromethyl)phenyl)-quinoxaline(0.5736 g, 1.58 mmol) in methanol (17.500 mL, 1.58 mmol) was addedpalladium, 10 wt. % on activated carbon (0.0839 g, 0.0789 mmol). Afterrepeating three times of evacuation of air in the flask by house vacuumand filling the flask with H₂, the mixture was stirred under H₂. After45 min, the mixture was filtered through a pad of Celite™ and rinsed thepad with MeOH. The filtrate was concentrated under reduced pressure togive blue syrup. The blue syrup was purified by column chromatography ona 80 g of Redi-Sep™ column using 0 to 12% gradient of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ over 3 min, 12% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ for 4 min, 12% to 100% gradient of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ over 22 min as eluent to give(5-chloro-3-(2-(trifluoromethyl)phenyl)quinoxalin-2-yl)methanamine as ablue syrupy solid: ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.15 (1H, dd, J=8.6,1.2 Hz), 8.04 (1H, dd, J=7.6, 1.2 Hz), 7.97 (1H, d, J=7.6 Hz), 7.74-7.92(4H, m), 3.62-3.91 (2H, m), 1.98 (2H, br. s.); LC-MS (ESI) m/z 338.0[M+H]⁺.

N-((5-Chloro-3-(2-(trifluoromethyl)phenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amine

A mixture of 6-chloropurine (0.147 g, 0.954 mmol),(5-chloro-3-(2-(trifluoro-methyl)phenyl)quinoxalin-2-yl)methanamine(0.3223 g, 0.954 mmol), and N,N-diisopropylethylamine (0.332 mL, 1.91mmol) in ethanol (5.61 mL, 0.954 mmol) was stirred at 75° C. After 19 h,the mixture was removed from the heat and concentrated under reducedpressure. The residue was purified by column chromatography on a 40 g ofRedi-Sep™ column using 0 to 100% gradient of EtOAc in hexane over 14min, then 100% isocratic of EtOAc for 10 min, then 0 to 65% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 10 min, then 65% isocratic ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 10 min, then 65% to 100%gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 4 min, and then100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 4 min as eluent to givethe desired product as a brown solid. The brown solid was suspended inCH₂Cl₂ filtered to giveN-((5-chloro-3-(2-(trifluoromethyl)phenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amineas an-off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.94 (1H, s),7.57-8.34 (10H, m), 4.76 (2H, d, J=55.9 Hz); LC-MS (ESI) m/z 456.1[M+H]⁺.

Example 86 Preparation ofN-((8-Chloro-2-(2-(trifluoromethoxy)phenyl)-quinolin-3-yl)methyl)-9H-purin-6-amine8-Chloro-2-(2-(trifluoromethoxy)phenyl)quinoline-3-carbaldehyde

A mixture of 2,8-dichloroquinoline-3-carbaldehyde (Prepared in Example2, 0.5000 g, 2.212 mmol), 2-(trifluoromethoxyphenyl)boronic acid (0.5010g, 2.433 mmol), tetrakis(triphenylphosphine)palladium (0.1278 g, 0.1106mmol), and sodium carbonate anhydrous (1.172 g, 11.06 mmol) in 90 mL ofCH₃CN—H₂O (3:1) was stirred at 100° C. After 15 h, the mixture wascooled to room temperature and partitioned between EtOAc (100 mL) andwater (100 mL). The organic layer was washed with brine (50 mL×2), driedover Na₂SO₄, filtered, and concentrated under reduced pressure andpurified by silica gel column chromatography on a 40 g of Redi-Sep™column using 0 to 50% gradient of EtOAc in hexane over 14 min and then50% isocratic of EtOAc for 5 min as eluent to give8-chloro-2-(2-(trifluoromethoxy)phenyl)quinoline-3-carbaldehyde: ¹H NMR(500 MHz, DMSO-d₆) δ ppm 9.98 (1H, s), 9.14 (1H, s), 8.31 (1H, dd,J=8.1, 1.0 Hz), 8.18 (1H, dd, J=7.5, 1.3 Hz), 7.70-7.82 (3H, m),7.62-7.67 (1 H, m), 7.57 (1H, d, J=8.3 Hz); LC-MS (ESI) m/z 352.0[M+H]⁺.

(8-Chloro-2-(2-(trifluoromethoxy)phenyl)quinolin-3-yl)methanol

To a solution of8-chloro-2-(2-(trifluoromethoxy)phenyl)quinoline-3-carbaldehyde (0.5427g, 1.543 mmol) in tetrahydrofuran (7.715 mL, 1.543 mmol) at 0° C. wasadded SODIUM BOROHYDRIDE (0.08757 g, 2.315 mmol) and the mixture wasstirred at 0° C. and allowed to warm to room temperature over 1 hour.After 1 h of stirring at 0° C., the mixture was partitioned betweenEtOAc (100 mL) and H₂O (100 mL), and the organic layer was washed withbrine (50 mL×2), dried over Na₂SO₄, filtered, and concentrated underreduced pressure to give(8-chloro-2-(2-(trifluoromethoxy)phenyl)quinolin-3-yl)methanol as alight-yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.58 (1H, s), 8.10(1H, dd, J=8.3, 1.3 Hz), 7.95 (1H, dd, J=7.5, 1.3 Hz), 7.51-7.72 (5H,m), 5.54 (1H, s), 4.44 (2 H, s); LC-MS (ESI) m/z 354.0 [M+H]⁺. Theproduct was carried on crude without purification for the next step.

8-Chloro-3-(chloromethyl)-2-(2-(trifluoromethoxy)phenyl)quinolinehydrochloride

A solution of(8-chloro-2-(2-(trifluoromethoxy)phenyl)quinolin-3-yl)methanol (0.5470g, 1.546 mmol) in chloroform (5.155 mL, 1.546 mmol) was treated withthionyl chloride (0.5626 mL, 7.732 mmol) dropwise, and the reactionmixture was stirred at room temperature. After 2.5 h, the mixture wasconcentrated under reduced pressure and co-evaporated three times withCH₂Cl₂ to give8-chloro-3-(chloromethyl)-2-(2-(trifluoromethoxy)phenyl)quinolinehydrochloride as a yellow syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H, s), 8.10 (1H, dd, J=8.2, 1.2 Hz), 8.03 (1H, dd, J=7.5, 1.3 Hz),7.64-7.74 (3H, m), 7.53-7.63 (2 H, m), 4.75 (2H, br. s.),89676-3-1-¹H-NMR; LC-MS (ESI) m/z 372.0 [M+H]⁺ (Exact Mass of neutralform: 371.009). The yellow syrup was carried on crude withoutpurification for the next step.

(8-Chloro-2-(2-(trifluoromethoxy)phenyl)quinolin-3-yl)methanamine

To a stirring solution of8-chloro-3-(chloromethyl)-2-(2-(trifluoromethoxy)-phenyl)quinolinehydrochloride (0.6319 g, 1.546 mmol) in DMF (7.732 mL, 1.546 mmol) wasadded sodium azide (0.2011 g, 3.093 mmol) at room temperature and themixture was stirred at room temperature. After 1 h, the mixture waspartitioned between EtOAc (100 mL) and H₂O (100 mL). The organic layerwas washed with brine (50 mL×1), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography on a 40 g of Redi-Sep™ column using 0 to 50%gradient of EtOAc in hexane over 14 min, then 50% isocratic of EtOAc for5 min as eluent to give3-(azidomethyl)-8-chloro-2-(2-(trifluoromethoxy)phenyl)quinoline as acolorless syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.66 (1H, s), 8.11 (1H,dd, J=8.2, 1.2 Hz), 8.02 (1H, dd, J=7.6, 1.4 Hz), 7.54-7.74 (5H, m),4.52 (2H, br. s.); LC-MS (ESI) m/z 379.0 [M+H]⁺.

To a solution of3-(azidomethyl)-8-chloro-2-(2-(trifluoromethoxy)phenyl)-quinoline(0.5374 g, 1.42 mmol) in methanol (14.2 mL, 1.42 mmol) was addedpalladium, 10 wt. % on activated carbon (0.0755 g, 0.0709 mmol). Afterrepeating three times of evacuation of air in the flask by house vacuumand filling the flask with H₂, the mixture was stirred under H₂. After30 min, the mixture was filtered through a pad of Celite™ and rinsed thepad with MeOH. The filtrate was concentrated under reduced pressure togive dark green syrup. The dark green syrup was purified by columnchromatography on a 40 g of Redi-Sep™ column using 0% to 20% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min, and then 20% isocraticof CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 15 min as eluent to give(8-chloro-2-(2-(trifluoromethoxy)phenyl)quinolin-3-yl)-methanamine: ¹HNMR (400 MHz, DMSO-d₆) δ ppm 8.62 (1H, s), 8.03 (1H, dd, J=8.2, 1.2 Hz),7.93 (1H, dd, J=7.4, 1.2 Hz), 7.50-7.70 (5H, m), 3.66 (2H, s), 1.97 (2H,br. s.); LC-MS (ESI) m/z 353.0 [M+H]⁺.

N-((8-Chloro-2-(2-(trifluoromethoxy)phenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

A mixture of 6-chloropurine (0.1109 g, 0.7175 mmol),(8-chloro-2-(2-(trifluoro-methoxy)phenyl)quinolin-3-yl)methanamine(0.2531 g, 0.7175 mmol), and N,N-diisopropylethylamine (0.2500 mL, 1.435mmol) in ethanol (4.221 mL, 0.7175 mmol) was stirred at 75° C. After 36h, the mixture was removed from the heat and concentrated under reducedpressure. The residue was purified by flash column chromatography on asilica gel column using 50% of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ aseluent to giveN-((8-chloro-2-(2-(trifluoromethoxy)phenyl)quinolin-3-yl)methyl)-9H-purin-6-amineas a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.94 (1H, s), 8.38(1H, s), 8.03-8.32 (3H, m), 7.96-8.02 (1H, m), 7.93 (1H, dd, J=7.5, 0.9Hz), 7.51-7.75 (5 H, m), 4.69 (2H, br. s.); LC-MS (ESI) m/z 471.1[M+H]⁺.

Example 87 Preparation ofN-((8-Chloro-2-(5-fluoro-2-(trifluoromethyl)-phenyl)quinolin-3-yl)methyl)-9H-purin-6-amine8-Chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinoline-3-carbaldehyde

A mixture of 2,8-dichloroquinoline-3-carbaldehyde (Prepared in Example2, 1.0000 g, 4.424 mmol), 5-fluoro-2-(trifluoromethyl)phenylboronic acid(1.012 g, 4.866 mmol), tetrakis(triphenylphosphine)palladium (0.2556 g,0.2212 mmol), and sodium carbonate anhydrous (2.344 g, 22.12 mmol) in 40mL of CH₃CN—H₂O (3:1) was stirred at 100° C. After 14 h, the mixture wascooled to room temperature and partitioned between EtOAc (100 mL) andwater (100 mL). The organic layer was washed with brine (50 mL×2), driedover Na₂SO₄, filtered, and concentrated under reduced pressure to give abrown solid. The brown solid was purified by silica gel columnchromatography on a 80 g of Redi-Sep™ column using 0 to 50% gradient ofEtOAc in hexane over 25 min and then 50% isocratic of EtOAc for 10 minas eluent to give8-chloro-2-(5-fluoro-2-(trifluoromethyl)-phenyl)quinoline-3-carbaldehydeas a yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.00 (1H, s), 9.21(1H, s), 8.32 (1H, dd, J=8.3, 1.1 Hz), 8.20 (1H, dd, J=7.6, 1.4 Hz),8.01 (1H, dd, J=8.7, 5.4 Hz), 7.76-7.84 (1H, m); 7.55-7.66 (2H, m);LC-MS (ESI) m/z 354.0 [M+H]⁺.

(8-Chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinolin-3-yl)methanol

To a solution of8-chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinoline-3-carbaldehyde(0.3036 g, 0.8584 mmol) in tetrahydrofuran (4.292 mL, 0.8584 mmol) at 0°C. was added sodium borohydride (0.04871 g, 1.288 mmol) and the mixturewas stirred at 0° C. After 1 h of stirring at 0° C., the mixture waspartitioned between EtOAc (100 mL) and H₂O (100 mL), and the organiclayer was washed with brine (50 mL×2), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure to give(8-chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)-quinolin-3-yl)methanolas a light-yellow syrupy solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.57(1H, s), 8.10 (1H, dd, J=8.2, 1.2 Hz), 8.01 (1H, dd, J=8.8, 5.3 Hz),7.95 (1H, dd, J=7.6, 1.4 Hz), 7.53-7.69 (3H, m), 5.55 (1H, br. s.),4.25-4.56 (2H, m); LC-MS (ESI) m/z 356.0 [M+H]⁺. The light-yellow syrupysolid was carried on crude without purification for the next step.

8-Chloro-3-(chloromethyl)-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinolinehydrochloride

A solution of(8-chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinolin-3-yl)-methanol(0.3016 g, 0.8479 mmol) in chloroform (2.826 mL, 0.8479 mmol) wastreated with thionyl chloride (0.3085 mL, 4.239 mmol) dropwise, and thereaction mixture was stirred at room temperature. After 3 h, the mixturewas concentrated under reduced pressure and co-evaporated three timeswith CH₂Cl₂ to give8-chloro-3-(chloromethyl)-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinolinehydrochloride as a yellow syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.76 (1H, s), 8.11 (1H, dd, J=8.2, 1.2 Hz), 7.99-8.07 (2H, m), 7.60-7.75 (3H,m), 4.63-4.90 (2H, m); LC-MS (ESI) m/z [M+H]⁺ (Exact Mass of neutralform: 373.005). The yellow syrup was carried on crude withoutpurification for the next step.

(8-Chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl]quinolin-3-yl)methanamine

To a stirring solution of8-chloro-3-(chloromethyl)-2-(5-fluoro-2-(trifluoro-methyl)phenyl)quinolinehydrochloride (0.3482 g, 0.8480 mmol) in DMF (4.240 mL, 0.8480 mmol) wasadded sodium azide (0.1103 g, 1.696 mmol) at room temperature and themixture was stirred at room temperature. After 1.5 h, the mixture waspartitioned between EtOAc (100 mL) and H₂O (100 mL). The organic layerwas washed with brine (50 mL×1), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography on a 40 g of Redi-Sep™ column using 0 to 50%gradient of EtOAc in hexane over 14 min, then 50% isocratic of EtOAc for5 min as eluent to give3-(azidomethyl)-8-chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinolineas a colorless syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.65 (1H, s), 8.12(1 H, dd, J=8.3, 1.3 Hz), 7.99-8.06 (2H, m), 7.69 (1H, dd, J=8.1, 7.5Hz), 7.58-7.66 (2H, m), 4.44-4.59 (2H, m); LC-MS (ESI) m/z 381.1 [M+H]⁺.To a solution of3-(azidomethyl)-8-chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)-quinoline(0.2573 g, 0.676 mmol) in methanol (6.76 mL, 0.676 mmol) was addedpalladium, 10 wt. % on activated carbon (0.0360 g, 0.0338 mmol). Afterrepeating three times of evacuation of air in the flask by house vacuumand filling the flask with H₂, the mixture was stirred under H₂ After 30min, the mixture was filtered through a pad of Celite™ and rinsed thepad with MeOH. The filtrate was concentrated under reduced pressure togive green syrup. The green syrup was purified by column chromatographyon a 40 g of Redi-Sep™ column using 0% to 20% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min, and then 20% isocraticof CH₂Cl₂:MeOH:NR₄OH (89:9:1) for 20 min as eluent to give(8-chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinolin-3-yl)methanamineas a yellow syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.62 (1H, s), 8.04(1H, dd, J=8.4, 1.2 Hz), 8.01 (1H, dd, J=8.5, 5.4 Hz), 7.93 (1H, dd,J=7.4, 1.4 Hz), 7.54-7.67 (3H, m), 3.48-3.74 (2H, m), 1.96 (2H, br. s.);LC-MS (ESI) m/z 355.1 [M+H]⁺.

N-((8-Chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.09706 g, 0.4877 mmol),(8-chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinolin-3-yl)methanamine(0.1730 g, 0.4877 mmol), and N,N-diisopropylethylamine (0.1699 mL,0.9754 mmol) in 2.8 mL of 1-butanol was stirred at 100° C. After 22 h,the mixture was removed from the heat and concentrated under reducedpressure to give a yellow syrupy solid. The yellow syrupy solid waspurified by column chromatography on a 40 g of Redi-Sep™ column using 0to 20% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min,then 20% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 10 min,then 20 to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 10min, and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for10 min as eluent to giveN-((8-chloro-2-(5-fluoro-2-(trifluoromethyl)-phenyl)quinolin-3-yl)methyl)-9H-purin-6-amineas an off-white solid: YS-89676-13-1. The off white solid was suspendedin CH₂Cl₂ and filtered to giveN-((8-chloro-2-(5-fluoro-2-(trifluoromethyl)phenyl)quinolin-3-yl)methyl)-9H-purin-6-amine:¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.93 (1H, s), 8.46 (1H, s), 8.05-8.24(3H, m), 8.02 (1H, d, J=8.0 Hz), 7.90-7.98 (2H, m), 7.56-7.64 (2H, m),7.52 (1H, t, J=8.7 Hz), 4.64 (2H, s); LC-MS (ESD m/z 473.2 [M+H]⁺.

Example 88 Preparation ofN-((2-(3-Fluorophenyl)-8-methoxyquinolin-3-yl)-methyl)-9H-purin-6-amine2-Chloro-8-methoxyquinoline-3-carbaldehyde

To a cooled solution of lithium diisopropylamide mono(tetrahydrofuran),1.5 M sol. in cyclohexane (25.82 mL, 38.73 mmol) in 72 mL of THF at −75°C. was added a solution of 2-chloro-8-methoxyquinoline (5.0000 g, 25.82mmol) in 26 mL of THF dropwise over 35 min (10:00 am˜10:35 am) withstirring and keeping the temperature below −65° C. After 40 min, to thecooled mixture was added DMF (2.999 mL, 38.73 mmol) dropwise and themixture was stirred at −72° C. for 30 min. After 30 min, the reactionwas quenched with NH₄Cl (20 mL) and partitioned between EtOAc (150 mL)and water (100 mL). The combined organic layers were washed with water(100 mL×1), brine (100 mL×2), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure to give a yellow solid. The yellowsolid was purified by flash column chromatography on a silica gel columnusing 20% of EtOAc in hexane as eluent to give2-chloro-8-methoxyquinoline-3-carbaldehyde as a yellow solid: ¹H NMR(400 MHz, DMSO-d_(b)) δ ppm 10.38 (1H, s), 8.92 (1H, s), 7.79 (1H, dd,J=8.4, 1.0 Hz), 7.67 (1H, t, J=8.0 Hz), 7.44 (1H, dd, J=7.8, 1.2 Hz),4.00 (3H, s); LC-MS (ESI) m/z 222.1

2-(3-Fluorophenyl)-8-methoxyquinoline-3-carbaldehyde

A mixture of 2-chloro-8-methoxyquinoline-3-carbaldehyde (1.8583 g, 8.384mmol), 3-fluorobenzeneboronic acid (1.290 g, 9.223 mmol),tetrakis(tri-phenylphosphine)palladium (0.4844 g, 0.4192 mmol), andsodium carbonate anhydrous (4.443 g, 41.92 mmol) in 76 mL of CH₃CN—H₂O(3:1) was stirred at 100° C. After 3 h, the mixture was cooled to roomtemperature and partitioned between EtOAc (200 mL) and water (100 mL).The organic layer was washed with brine (100 mL×2), dried over Na₂SO₄,filtered, and concentrated under reduced pressure to give an orangesolid. The orange solid was purified by silica gel column chromatographyon a 80 g of Redi-Sep™ column using 0 to 50% gradient of EtOAc in hexaneover 25 min and then 50% isocratic of EtOAc for 25 min as eluent to give2-(3-fluorophenyl)-8-methoxyquinoline-3-carbaldehyde as a light-yellowsolid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.09 (1H, s), 8.94 (1 H, s),7.80 (1H, dd, J=8.2, 1.2 Hz), 7.66 (1H, t, J=8.0 Hz), 7.53-7.64 (2H, m),7.47-7.53 (1H, m), 7.36-7.44 (2H, m), 4.00 (3H, s); LC-MS (ESD m/z 282.1[M+H]⁺.

3-(Chloromethyl)-2-(3-fluorophenyl)-8-methoxyquinoline hydrochloride

To a solution of 2-(3-fluorophenyl)-8-methoxyquinoline-3-carbaldehyde(0.2967 g, 8.165 mmol) in tetrahydrofuran (40.83 mL, 8.165 mmol) at 0°C. was added sodium borohydride (0.4634 g, 12.25 mmol) and the mixturewas stirred at 0° C. After 1 h of stirring at 0° C., the mixture waspartitioned between EtOAc (100 mL) and H₂O (100 mL), and the organiclayer was washed with brine (100 mL×2), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure to give(2-(3-fluorophenyl)-8-methoxyquinolin-3-yl)methanol as a brown solid: ¹HNMR (400 MHz, DMSO-d₆) δ ppm 8.43 (1H, s), 7.46-7.60 (5H, m), 7.29-7.36(1H, m), 7.19 (1H, dd, J=7.4, 1.6 Hz), 5.50 (1H, t, J=5.3 Hz), 4.61 (2H,dd, J=5.5, 0.8 Hz), 3.96 (3H, s); LC-MS (ESI) m/z 284.0 [M+H]⁺. Thebrown solid was carried on crude without purification for the next step.

A solution of (2-(3-fluorophenyl)-8-methoxyquinolin-3-yl)methanol(2.2330 g, 7.882 mmol) in chloroform (26.27 mL, 7.882 mmol) was treatedwith thionyl chloride (2.868 mL, 39.41 mmol) dropwise, and the reactionmixture was stirred at room temperature. After 3 h, the mixture wasconcentrated under reduced pressure and co-evaporated three times withCH₂Cl₂ to give 3-(chloromethyl)-2-(3-fluorophenyl)-8-methoxyquinolinehydrochloride as a yellow solid: NMR (400 MHz, DMSO-d₆) δ ppm 8.59 (1H,s), 7.55-7.65 (3H, m), 7.44-7.52 (2H, m), 7.33-7.41 (1H, m), 7.23-7.30(1H, m), 4.91 (2H, s); LC-MS (ESI) m/z 302.0 [M+H]⁺(Exact Mass ofneutral form: 301.067). The yellow solid was carried on crude withoutpurification for the next step.

(2-(3-Fluorophenyl)-8-methoxyquinolin-3-yl)methanamine

To a stirring solution of3-(chloromethyl)-2-(3-fluorophenyl)-8-methoxyquinoline hydrochloride(0.9601 g, 2.839 mmol) in DMF (14.19 mL, 2.839 mmol) was added sodiumazide (0.3691 g, 5.678 mmol) at room temperature and the mixture wasstirred at room temperature After 1 h, the mixture was partitionedbetween EtOAc (100 mL) and H₂O (100 mL). The organic layer was washedwith brine (100 mL×1), dried over Na₂SO₄, filtered, and concentratedunder reduced pressure to give3-(azidomethyl)-2-(3-fluorophenyl)-8-methoxyquinoline as a yellow solid:¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.48 (1H, s), 7.54-7.62 (3 H, m),7.43-7.49 (2H, m), 7.32-7.39 (1H, m), 7.21-7.28 (1H, m), 4.68 (2H, s),3.97 (3H, s); LC-MS (ESI) m/z 309.1 [M+H]⁺. The yellow solid was carriedon crude without purification for the next step.

To a stirring solution of3-(azidomethyl)-2-(3-fluorophenyl)-8-methoxyquinoline (0.8163 g, 2.65mmol) in 12 mL of THF-H₂O (4:1) was added dropwise trimethyl-phosphine,1.0 M solution in THF (3.18 mL, 3.18 mmol) at room temperature and themixture was stirred at room temperature. After 1.5 h, the mixture wasdiluted with ice-cold 1N NaOH (100 mL) and extracted with EtOAc (100mL×2). The combined organic layers were washed with brine (100 mL×3),dried over Na₂SO₄, and concentrated under the reduced pressure of give ayellow solid (0.8054 g). The yellow solid (0.8054 g) was purified bycolumn chromatography on a 80 g of Redi-Sep™ column using 0-100%gradient of EtOAc in hexane over 25 min, then 100% isocratic of EtOAcfor 10 min, then 0% to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) inCH₂Cl₂ over 25 min, and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1)for 10 min as eluent to give(2-(3-fluorophenyl)-8-methoxyquinolin-3-yl)methanamine as a yellowsyrupy solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.45 (1H, s), 7.44-7.59(5H, m), 7.28-7.36 (1H, m), 7.13-7.19 (1H, m), 3.95 (3H, s), 3.83 (2H,d, J=0.8 Hz), 1.98 (2H, br. s.); LC-MS (ESI) m/z 283.1 [M+H]⁺.

N-((2-(3-Fluorophenyl)-8-methoxyquinolin-3-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.1418 g, 0.7125 mmol),(2-(3-fluorophenyl)-8-methoxyquinolin-3-yl)methanamine (0.2213 g, 0.7838mmol), and N,N-diiso-propylethylamine (0.2482 mL, 1.425 mmol) in1-butanol (7.125 mL, 0.7125 mmol) was stirred at 100° C. After 24 h, themixture was removed from the heat and concentrated under reducedpressure. The residue was purified by flash column chromatography on asilica gel column using 50% of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ aseluent to give an off-white solid. The off-white solid was suspended inEtOAc and filtered to giveN-((2-(3-fluoro-phenyl)-8-methoxyquinolin-3-yl)methyl)-9H-purin-6-amineas a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.95 (1H, s),8.18-8.30 (2H, m), 8.11 (2 H, s), 7.42-7.61 (5H, m), 7.28-7.36 (1H, m),7.16 (1H, dd, J=7.1, 1.7 Hz), 4.71-4.95 (2H, m), 3.95 (3H, s); LC-MS(ESI) m/z 401.2 [M+H]⁺.

Example 89 Preparation ofN—((S)-1-(8-Chloro-2-(2-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine2-4(8)-1-(8-Chloro-2-(2-fluorophenyl)quinolin-3-yl)ethyl)carbamoyl)benzoicacid

A mixture of(S)-2-(1-(2,8-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (0.5000g, 1.347 mmol), 2-fluorobenzeneboronic acid (0.2073 g, 1.482 mmol),tetrakis(triphenylphosphine)palladium (0.07782 g, 0.06735 mmol), andsodium carbonate anhydrous (0.7138 g, 6.735 mmol) in acetonitrile-water(3:1) (12.00 mL, 1.346 mmol) was stirred at 85° C. After 28 h, themixture was cooled to room temperature. The mixture was concentratedunder reduced pressure to remove acetonitrile. The mixture waspartitioned between CH₂Cl₂ (50 mL) and water (50 mL). The aqueous layer(pH 10-11) was washed with CH₂Cl₂ (50 mL×2) to remove byproducts. Theaqueous layer was treated with 2 N HCl (50 mL) and extracted with CH₂Cl₂(50 mL×2). The combined organic layers were washed with water (50 mL×1),brine (50 mL×1), dried over Na₂SO₄, filtered, and concentrated underreduced pressure to give2-(((S)-1-(8-chloro-2-(2-fluoro-phenyl)quinolin-3-yl)ethyl)carbamoyl)benzoicacid as a solid: LC-MS (ESI) m/z 448.9 [M+H]⁺. The crude product wascarried on crude without purification for the next step.

(1S)-1-(8-Chloro-2-(2-fluorophenyl)quinolin-3-yl)ethanamine

To a suspension of2-(((S)-1-(8-chloro-2-(2-fluorophenyl)quinolin-3-yl)ethyl)-carbamoyl)benzoicacid (0.6046 g, 1.347 mmol) in ethanol (5.000 mL, 1.347 mmol) was added12 N HCl (1.123 mL, 13.47 mmol), and the mixture was stirred underreflux. After 22 h, the mixture was poured into ice water (100 mL). Themixture was basified with 10 N NaOH (0.4 mL) to pH ˜10 and extractedwith CH₂Cl₂ (50 mL×2). The combined organic layers were washed withwater (50 mL×2) and brine (50 mL×3), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure to give a mixture of2-((S)-1-(8-chloro-2-(2-fluoro-phenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dioneand (1S)-1-(8-chloro-2-(2-fluorophenyl)quinolin-3-yl)ethanamine as ayellow syrup. To a mixture of2-((S)-1-(8-chloro-2-(2-fluorophenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dioneand (1S)-1-(8-chloro-2-(2-fluorophenyl)quinolin-3-yl)ethanamine inethanol (12.50 mL, 1.347 mmol) was added hydrazine monohydrate (0.4183mL, 13.47 mmol), and the mixture was stirred under reflux. After 1 h,the mixture was cooled to room temperature and concentrated underreduced pressure to give a green solid. The green solid was purified bycolumn chromatography on a 80 g of Redi-Sep™ column using 0% to 50%gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 25 min and then50% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 25 min aseluent to give(1S)-1-(8-chloro-2-(2-fluorophenyl)quinolin-3-yl)-ethanamine as a lightyellow syrup: NMR (400 MHz, DMSO-d₆) δ ppm 8.74 (1H, s), 8.03 (1H, dd,J=8.3, 1.3 Hz), 7.93 (1H, dd, J=7.5, 1.3 Hz), 7.50-7.65 (3 H, m),7.33-7.43 (2H, m), 4.03 (1H, q, J=6.3 Hz), 1.98 (2H, s), 1.16 (3H, d,J=5.5 Hz); LC-MS (ESI) m/z 301.0 [M+H]⁺.

N—((S)-1-(8-chloro-2-(2-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine

A mixture of 6-chloropurine (0.1680 g, 1.087 mmol),(1S)-1-(8-chloro-2-(2-fluorophenyl)quinolin-3-yl)ethanamine (0.2972 g,0.9882 mmol), and N,N-diisopropylethylamine (0.5164 mL, 2.965 mmol) in1-butanol (9.882 mL, 0.9882 mmol) was stirred at 110° C. After 26 h, themixture was cooled to room temperature and concentrated under reducedpressure to give a yellow syrup. The yellow syrup was dissolved inCH₂Cl₂(50 mL) and washed with water (30 mL×1). The organic layer wasdried over Na₂SO₄, filtered, and concentrated under reduced pressure.The residue was purified by column chromatography on a 40 g of Redi-Sep™column using 0 to 35% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂over 14 min and then 35% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) inCH₂Cl₂ for 25 min as eluent to give a tan solid. The tan solid wassuspended in CH₂Cl₂ and filtered to giveN—((S)-1-(8-chloro-2-(2-fluorophenyl)-quinolin-3-yl)ethyl)-9H-purin-6-amineas a solid: ¹H NMR (400 MHz, DMSO-d₆) 8 ppm 12.86 (1H, s), 8.67 (1H, s),8.20 (1H, s), 8.09 (1H, s), 7.95-8.03 (2H, m), 7.93 (1H, dd, J=7.6, 1.0Hz), 7.69 (1H, s), 7.58 (1H, t, J=7.8 Hz), 7.46-7.55 (1H, m), 7.25-7.39(2H, m), 5.38 (1H, s), 1.55 (3H, d, J=7.0 Hz); LC-MS (ESI) m/z 418.9[M+H]⁺.

Example 90 Preparation ofN-((6-Chloro-2-(2-chlorophenyl)quinolin-3-yl)-methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.1000 g, 0.5025 mmol),(6-chloro-2-(2-chlorophenyl)quinolin-3-yl)methanamine as a TFA salt(0.2138 g, 0.5125 mmol), and N,N-diisopropylethylamine (0.3501 mL, 2.010mmol) in 1-butanol (1.005 mL, 0.5025 mmol) was stirred at 100° C. After15.5 h, the mixture was cooled to room temperature and concentratedunder reduced pressure. The residue was purified by columnchromatography on a 40 g of Redi-Sep™ column using 0 to 50% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min and then 50% isocraticof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 10 min as eluent to give atan solid (0.0939 g). The tan solid was suspended in EtOAc and filteredto giveN-((6-chloro-2-(2-chlorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine asa tan solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.94 (1H, s), 8.28 (1H,s), 8.06-8.24 (4H, m), 8.03 (1H, d, J=9.0 Hz), 7.75 (1H, dd, J=9.0, 2.3Hz), 7.61 (1H, d, J=7.4 Hz), 7.42-7.57 (3H, m), 4.49-4.77 (2H, m); LC-MS(ESI) m/z 421.0 [M+H]⁺.

Example 91 Preparation ofN-((8-chloro-2-(2-fluorophenyl)quinolin-3-yl)-methyl)-9H-purin-6-amine

8-Chloro-2-(2-fluorophenyl)quinoline-3-carbaldehyde

2,8-Dichloroquinoline-3-carbaldehyde (Prepared in Example 2, 1.000 g,4.42 mmol), 2-fluorophenylboronic acid (0.681 g, 4.87 mmol),tetrakis(triphenyl-phosphine)palladium (0.256 g, 0.221 mmol), and sodiumcarbonate (2.34 g, 22.1 mmol) were stirred in 3:1 acetonitrile-water (48mL) at 100° C. After 1 h, the mixture was partitioned between EtOAc andwater. The organic layer was washed with brine, dried over MgSO₄,filtered, and concentrated under reduced pressure. The crude product waspurified by column chromatography on a 40 g of Redi-Sep™ column using 0%to 100% gradient of EtOAc in hexane as eluent to give8-chloro-2-(2-fluorophenyl)quinoline-3-carbaldehyde: LC-MS (ESI) m/z286.0 [M+H]⁺.

(8-Chloro-2-(2-fluorophenyl)quinolin-3-yl)methanol

Sodium borohydride (0.159 g, 4.20 mmol) was added portion wise to astirring solution of 8-chloro-2-(2-fluorophenyl)quinoline-3-carbaldehyde(0.800 g, 2.80 mmol) in 15 mL of THF. The reaction stirred at roomtemperature. After 1.5 h, the mixture was partitioned between water andEtOAc. The organic layer was dried over MgSO₄, filtered, andconcentrated under reduced pressure: LC-MS (ESI) m/z 288.1 [M+H]⁺. Thecrude product was carried on crude without purification for the nextstep.

8-Chloro-3-(chloromethyl)-2-(2-fluorophenyl)quinoline

Thionyl chloride (0.850 mL, 11.6 mmol) was added to a stirring solutionof (8-chloro-2-(2-fluorophenyl)quinolin-3-yl)methanol (0.670 g, 2.33mmol) in CH₂Cl₂. The reaction mixture was stirred at room temperature.After 2.5 h, the crude product was purified by column chromatography ona 40 g Redi-Sep™ column using 0% to 100% gradient of CH₂Cl₂-MeOH—NH₄OH(89:9:1) in CH₂Cl₂ to give8-chloro-3-(chloromethyl)-2-(2-fluorophenyl)quinoline: LC-MS (ESI) m/z306.0 [M+H]⁺.

3-(Azidomethyl)-8-chloro-2-(2-fluorophenyl)quinoline

To stirring solution of8-chloro-3-(chloromethyl)-2-(2-fluorophenyl)quinoline (0.330 g, 1.08mmol) in DMF was added sodium azide (0.561 g, 8.62 mmol), and themixture stirred at room temperature. After 3 hours, the mixture waspartitioned between CH₂Cl₂ and H₂O. The organic layer was dried overMgSO₄, filtered and concentrated under reduced pressure: LC-MS (ESI) m/z313.0 [M+H]⁺. The crude product was carried on crude withoutpurification for the next step.

(8-Chloro-2-(2-fluorophenyl)quinolin-3-yl)methanamine

To a stirring solution of3-(azidomethyl)-8-chloro-2-(2-fluorophenyl)quinoline (0.3083 g, 0.9858mmol) in THF-H₂O (4:1) (12.000 mL) was added dropwisetrimethylphosphine, 1.0 M solution in THF (1.183 mL, 1.183 mmol) at roomtemperature and the mixture was stirred at room temperature. After 1 h,the mixture was diluted with ice-cold 1 N NaOH (60 mL) and extractedwith EtOAc (50 mL×2). The combined organic layers were washed with brine(50 mL×2), dried over Na₂SO₄, and concentrated under the reducedpressure to give a yellow syrup. The yellow syrup was purified by columnchromatography on a 40 g of Redi-Sep™ column using 0-100% gradient ofEtOAc in hexane over 14 min, then 100% isocratic of EtOAc for 10 min,then 0% to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14min, and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 10 min aseluent to give (8-chloro-2-(2-fluorophenyl)quinolin-3-yl)methanamine. ¹HNMR (500 MHz, DMSO-d₆) δ ppm 8.62 (1H, s), 8.03 (1H, dd, J=8.2, 1.1 Hz),7.93 (1H, dd, J=7.3, 1.2 Hz), 7.55-7.66 (2H, m), 7.49-7.55 (1H, m),7.34-7.43 (2H, m), 3.72 (2H, s), 1.94 (2H, br. s.); LC-MS (ESI) m/z287.2 [M+H]⁺.

N-((8-Chloro-2-(2-fluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.1456 g, 0.7317 mmol),(8-chloro-2-(2-fluoro-phenyl)quinolin-3-yl)methanamine (0.2203 g, 0.7683mmol), and N,N-diisopropylethylamine (0.3824 mL, 2.195 mmol) in1-butanol (2.000 mL, 0.7317 mmol) was stirred at 100° C. After 15 h, themixture was removed from the heat and cooled to room temperature. Theresulting precipitate was collected by filtration and washed with MeOHto give a yellow solid. The yellow solid was purified by columnchromatography on a 40 g of Redi-Sep™ column using 0 to 50% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min and then 50% isocraticof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 10 min as eluent to give anoff-white solid. The off-white solid was suspended in EtOAc-Hexane (1:1)and filtered to giveN-((8-chloro-2-(2-fluorophenyl)quinolin-3-yl)methyl)-9H-purin-6-amine asan off-white solid: ¹H NMR (500 MHz, DMSO-d₆) δ ppm 12.95 (1H, s), 8.35(1H, s), 8.03-8.29 (3H, m), 7.99 (1H, dd, J=8.2, 1.1 Hz), 7.93 (1H, dd,J=7.5, 1.1 Hz), 7.53-7.65 (3H, m), 7.36-7.44 (2H, m), 4.63-4.82 (2H, m);LC-MS (ESI) m/z 405.1 [M+H]⁺.

Example 92 Preparation ofN-((3-(2-Chlorophenyl)-5,6-difluoroquinoxalin-2-yl)methyl)-9H-purin-6-amine3-(Bromomethyl)-2-(2-chlorophenyl)-5,6-difluoroquinoxaline and2-(Bromomethyl)-3-(2-chlorophenyl)-5,6-difluoroquinoxaline

To a solution of 3-bromo-1-(2-chlorophenyl)propane-1,2-dione (Preparedin Example 81, 1.4324 g, 5.4775 mmol) in ethyl acetate (36.517 mL,5.4775 mmol) was added 1,2-diamino-3,4-difluorobenzene (0.78943 g,5.4775 mmol) at room temperature and the resulting red mixture wasstirred at room temperature. After 26 h of stirring at room temperature,the mixture was concentrated under reduced pressure to give a mixture of3-(bromomethyl)-2-(2-chlorophenyl)-5,6-difluoro-quinoxaline and2-(bromomethyl)-3-(2-chlorophenyl)-5,6-difluoroquinoxaline as a brownsyrup: LC-MS (ESI) m/z 369.0 and 370.9 [M+H]⁺. The crude product as abrown syrup was carried on crude without purification for the next step.

(3-(2-Chlorophenyl)-7,8-difluoroquinoxalin-2-yl)methanamine and(3-(2-Chlorophenyl)-5,6-difluoroquinoxalin-2-yl)methanamine

To a stirring solution of a mixture of3-(bromomethyl)-2-(2-chlorophenyl)-5,6-difluoroquinoxaline and2-(bromomethyl)-3-(2-chlorophenyl)-5,6-difluoro-quinoxaline (2.0244 g,5.477 mmol) in DMF (20.00 mL, 5.477 mmol) was added sodium azide (0.7122g, 10.95 mmol) at room temperature and the mixture was stirred at roomtemperature. After 1.5 h, the mixture was partitioned between EtOAc (100mL) and H₂O (100 mL). The organic layer was washed with brine (100mL×1), dried over Na₂SO₄, filtered, and concentrated under reducedpressure to give a mixture of3-(azidomethyl)-2-(2-chlorophenyl)-5,6-difluoro-quinoxaline and2-(azidomethyl)-3-(2-chlorophenyl)-5,6-difluoroquinoxaline as a dark redsyrup: LC-MS (ESI) m/z 332.0 [M+H]⁺. The crude product was carried oncrude without purification for the next step.

To a stirring solution of3-(azidomethyl)-2-(2-chlorophenyl)-5,6-difluoro-quinoxaline and2-(azidomethyl)-3-(2-chlorophenyl)-5,6-difluoroquinoxaline (1.8170 g,5.478 mmol) in 25 mL of THF-H₂O (4:1) was added dropwisetrimethylphosphine, 1.0 M solution in THF (6.573 mL, 6.573 mmol) at roomtemperature and the mixture was stirred at room temperature. After 1 h,the mixture was diluted with ice-cold 1 N NaOH (25 mL) and extractedwith EtOAc (50 mL×3). The combined organic layers were washed with brine(50 mL×3), dried over Na₂SO₄, and concentrated under the reducedpressure to give a green syrup. The green syrup was purified by columnchromatography on a 120 g of Redi-Sep™ column using 0% to 20% gradientof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 15 min, then 20% isocraticof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 15 min, then 20% to 50%gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 5 min, and then50% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 15 min aseluent to give two separated regioisomers:(3-(2-chlorophenyl)-7,8-difluoroquinoxalin-2-yl)methanamine as abrown-green syrupy solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.94-8.10 (2H,m), 7.50-7.73 (4H, m), 3.84 (2H, br. s.), 2.03 (2H, br. s.); LC-MS (ESI)m/z 306.1 [M+H]⁺and(3-(2-chlorophenyl)-5,6-difluoroquinoxalin-2-yl)methanamine as a bluesyrupy solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.97-8.13 (2H, m),7.45-7.74 (4H, m), 3.82 (2H, s), 2.10 (2H, br. s.); LC-MS (ESI) m/z306.1 [M+H]⁺. The structures of two separated isomers were confirmed by¹H-¹⁵N HMBC experiment.

N-((3-(2-Chlorophenyl)-5,6-difluoroquinoxalin-2-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.1978 g, 0.9938 mmol),(3-(2-chlorophenyl)-5,6-difluoroquinoxalin-2-yl)methanamine (0.3342 g,1.093 mmol), and N,N-diiso-propylethylamine (0.5193 mL, 2.981 mmol) in1-butanol (3.000 mL, 0.9938 mmol) was stirred at 100° C. After 3 h, themixture was removed from the heat and concentrated under reducedpressure. The residue was suspended in MeOH and the resultingprecipitate was collected by filtration, and washed with MeOH to give ayellow solid. The yellow solid (0.1232 g) was purified by columnchromatography on a 40 g of Redi-Sep™ column using 0 to 50% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min and then 50% isocraticof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 14 min as eluent to give anoff-white solid (0.1014 g). The off white solid was suspended in CH₂Cl₂and filtered to giveN-((3-(2-chlorophenyl)-5,6-difluoroquinoxalin-2-yl)methyl)-9H-purin-6-amineas an off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.93 (1H, s),7.81-8.16 (5H, m), 7.61-7.72 (2H, m), 7.53-7.58 (1H, m), 7.46-7.52 (1H,m), 4.71-4.97 (2H, m); LC-MS (ESI) m/z 424.0 [M+H]⁺.

Example 93 Preparation ofN-((3-(2-Chlorophenyl)-7,8-difluoroquinoxalin-2-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.1359 g, 0.6828 mmol),(3-(2-chlorophenyl)-7,8-difluoroquinoxalin-2-yl)methanamine (Prepared inExample 92, 0.2296 g, 0.7510 mmol), and N,N-diisopropylethylamine(0.3568 mL, 2.048 mmol) in 1-butanol (3.000 mL, 0.6828 mmol) was stirredat 100° C. After 3 h, the mixture was removed from the heat andconcentrated under reduced pressure. The residue was suspended in MeOHand the insoluble solid was removed by filtration. The filtrate wasconcentrated under reduced pressure and purified by columnchromatography on a 40 g of Redi-Sep™ column using 0 to 50% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min and then 50% isocraticof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 14 min as eluent to give ayellow solid. The yellow solid was suspended in CH₂Cl₂ and filtered togiveN-((3-(2-chlorophenyl)-7,8-difluoroquinoxalin-2-yl)methyl)-9H-purin-6-amineas a yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.92 (1H, br. s.),7.93-8.15 (4H, m), 7.60-7.69 (2H, m), 7.51-7.57 (1H, m), 7.45-7.50 (1H,m), 4.83 (2H, br. s.); LC-MS (ESI) m/z 424.1 [M+H]⁺.

Example 94 Preparation of3-((9H-Purin-6-ylamino)methyl)-2-(3-fluoro-phenyl)quinolin-8-ol

To a solution ofN-((2-(3-fluorophenyl)-8-methoxyquinolin-3-yl)methyl)-9H-purin-6-amine(0.1500 g, 0.3746 mmol) in DCM (3.746 mL, 0.3746 mmol) at 0° C., borontribromide, 1.0 M sol. in DCM (1.498 mL, 1.498 mmol) was added dropwiseand the mixture was cooling bath was removed and stirred at roomtemperature. After 29 h, the mixture was cooled to 0° C. and to thecooled mixture, ice-water (50 mL) was added with stirring. The mixturewas neutralized with 10 N NaOH (˜5 mL) to pH 8 and the resultingprecipitate was collected by filtration to give a yellow solid. yellowsolid (YS-90942-4-1) was purified by column chromatography on a 40 g ofRedi-Sep™ column using 0 to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ over 14 min and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ for 10 min as eluent to give an off-white solid. Theoff-white solid was suspended in CH₂Cl₂ and filtered to give3-((9H-purin-6-ylamino)methyl)-2-(3-fluorophenyl)quinolin-8-ol as anoff-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.95 (1H, s), 9.58(1H, s), 8.18 (4 H, d, J=50.5 Hz), 7.26-7.71 (6H, m), 7.06 (1H, d, J=6.7Hz), 4.88 (2H, br. s.); LC-MS (ESI) m/z 387.1 [M+H]⁺.

Example 95 Preparation ofN-((5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)-methyl)-9H-purin-6-amine5-Chloro-3-(3-fluorophenyl)-2-methylquinoxaline

A mixture of 3,5-dichloro-2-methylquinoxaline (Prepared in Example 85,0.3361 g, 1.577 mmol), 3-fluorobenzeneboronic acid (0.2428 g, 1.735mmol), tetrakis(triphenylphosphine)palladium (0.09114 g, 0.07887 mmol),and sodium carbonate anhydrous (0.8360 g, 7.887 mmol) in CH3CN—H2O (3:1)(16.00 mL) was stirred at 100° C. After 3.5 h, the mixture was cooled toroom temperature and partitioned between EtOAc (100 mL) and water (100mL). The organic layer was washed with brine (50 mL×2), dried overNa₂SO₄, filtered, and concentrated under reduced pressure to give redsyrup. The red syrup was purified by silica gel column chromatography ona 40 g of Redi-Sep™ column using 0 to 50% gradient of EtOAc in hexaneover 14 min and then 50% isocratic of EtOAc for 10 min as eluent to give5-chloro-3-(3-fluorophenyl)-2-methylquinoxaline as a solid: ¹H NMR (400MHz, DMF) δ ppm 8.05 (1H, dd, J=8.4, 1.4 Hz), 8.00 (1H, dd, J=7.6, 1.4Hz), 7.83 (1H, dd, J=8.4, 7.6 Hz), 7.60-7.67 (3H, m), 7.38-7.46 (1H, m),2.74 (3H, s); LC-MS (ESI) m/z 273.1 [M+H]⁺.

2-(Bromomethyl)-5-chloro-3-(3-fluorophenyl)quinoxaline

5-chloro-3-(3-fluorophenyl)-2-methylquinoxaline (0.3907 g, 1.433 mmol)and 1,3-dibromo-5,5-dimethylhydantoin (0.2458 g, 0.8596 mmol) weresuspended in carbon tetrachloride (14.33 mL, 1.433 mmol). To the mixturewas added benzoyl peroxide (0.04627 g, 0.1433 mmol) and the mixture washeated at reflux. After 24 h, the mixture was cooled to room temperatureand concentrated under reduced pressure. The residue was purified bysilica gel column chromatography on a 40 g of Redi-Sep™ column using 0to 9% gradient of EtOAc in hexane over 1.3 min, then 9% isocratic ofEtOAc for 7.6 min, then 9 to 100% gradient of EtOAc in hexane over 12.7min, then 100% isocratic of EtOAc for 10 min as eluent to give2-(bromomethyl)-5-chloro-3-(3-fluorophenyl)quinoxaline as an off-whitesolid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.14 (1H, dd, J=8.4, 1.2 Hz),8.12 (1H, dd, J=7.6, 1.4 Hz), 7.92 (1H, dd, J=8.4, 7.8 Hz), 7.64-7.70(3H, m), 7.43-7.50 (1H, m), 4.91 (2H, s); LC-MS (ESI) m/z 351.0 and352.9 [M+H]⁺.

2-((5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)methyl)isoindoline-1,3-dione

To a heterogeneous mixture of2-(bromomethyl)-5-chloro-3-(3-fluorophenyl)-quinoxaline (0.2401 g,0.6829 mmol) in DMF (5.003 mL, 0.6829 mmol) was added potassiumphthalimide (0.3162 g, 1.707 mmol) and the heterogeneous mixture wasstirred at 100° C. After stirring at 100° C. for 1 h, the mixture wasconcentrated under reduced pressure and triturated with water (30 mL).The precipitate was collected by filtration. The solid was washed withwater (50 mL), then MeOH (100 mL), and dried to give24(5-chloro-3-(3-fluorophenyl)-quinoxalin-2-yl)methyl)isoindoline-1,3-dioneas an off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.04 (1H, dd,J=7.6, 1.4 Hz), 7.84-7.92 (5H, m), 7.60-7.81 (4H, m), 7.38-7.46 (1H, m),5.22 (2H, s); LC-MS (ESI) m/z 418.1 [M+H]⁺. The crude product wascarried on crude without purification for the next step.

(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)methanamine

To a suspension of2-((5-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)methyl)-isoindoline-1,3-dione(0.2061 g, 0.493 mmol) in ethanol (5.00 mL, 0.493 mmol) was addedhydrazine, anhydrous (0.155 mL, 4.93 mmol), and the mixture was stirredunder reflux. After 1 h, the mixture was cooled to room temperature. Theby product was filtered off and washed with MeOH. The filtrate wasconcentrated under reduced pressure to give a yellow solid (0.2012 g).The yellow solid (0.2012 g) was purified by column chromatography on a40 g of Redi-Sep™ column using 0% to 100% gradient of CH₂Cl₂:MeOH:NR₄OH(89:9:1) in CH₂Cl₂ over 14 min, and then 100% isocratic ofCH₂Cl₂:MeOH:NR₄OH (89:9:1) in CH₂Cl₂ for 3 min as eluent to give(5-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)-methanamine as a greensolid: ^(I)H NMR (400 MHz, DMSO-d₆) δ ppm 8.12 (1H, dd, J=8.4, 1.4 Hz),8.03 (1H, dd, J=7.6, 1.4 Hz), 7.86 (1H, dd, J=8.4, 7.6 Hz), 7.59-7.71(3H, m), 7.39-7.47 (1H, m), 4.06 (2H, s); LC-MS (ESI) m/z 288.1 [M+H]⁺.

N-((5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.05568 g, 0.2798 mmol),(5-chloro-3-(3-fluoro-phenyl)quinoxalin-2-yl)methanamine (0.09660 g,0.3357 mmol), and N,N-diisopropylethylamine (0.1462 mL, 0.8394 mmol) in1-butanol (3.000 mL, 0.2798 mmol) was stirred at 100° C. After 5 h, themixture was removed from the heat and concentrated under reducedpressure. The residue was suspended in MeOH and the resultingprecipitate was collected by filtration, and washed with MeOH to give agreen solid. The green solid (0.0542 g) was purified by columnchromatography on a 40 g of Redi-Sep™ column using 0 to 100% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min and then 100% isocraticof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 14 min as eluent to giveN-((5-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amineas a green solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.94 (1H, s),7.93-8.20 (5H, m), 7.83 (1H, t, J=8.0 Hz), 7.57-7.73 (3H, m), 7.34-7.45(1H, m), 5.04 (2H, br. s.); LC-MS (ESI) m/z 406.1 [M+H]⁺.

Example 96 Preparation ofN—((S)-1-(8-Chloro-2-(2-methylpyridin-3-yl)-quinolin-3-yl)ethyl)-9H-purin-6-amineandN—((R)-1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine8-Chloro-2-(2-methylpyridin-3-yl)quinoline-3-carbaldehyde

A mixture of 2,8-dichloroquinoline-3-carbaldehyde (Prepared in Example2, 1.0000 g, 4.424 mmol), tetrakis(triphenylphosphine)palladium (0.2556g, 0.2212 mmol), and sodium carbonate anhydrous (2.344 g, 22.12 mmol) in90 mL of CH₃CN—H₂O (3:1) was stirred at 100° C. After 3 h, the mixturewas cooled to room temperature and partitioned between EtOAc (150 mL)and water (150 mL). The organic layer was washed with brine (100 mL×2),dried over Na₂SO₄, filtered, and concentrated under reduced pressure togive a yellow solid. The yellow solid was purified by silica gel columnchromatography on a 80 g of Redi-Sep™ column using 0 to 100% gradient ofEtOAc in hexane over 25 min and then 100% isocratic of EtOAc for 10 minas eluent to give8-chloro-2-(2-methylpyridin-3-yl)quinoline-3-carbaldehyde as anoff-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.96 (1H, s), 9.16 (1H,s), 8.62 (1H, dd, J=4.9, 1.8 Hz), 8.31 (1H, dd, J=8.2, 1.2 Hz), 8.18(1H, dd, J=7.4, 1.2 Hz), 7.80 (1H, dd, J=7.6, 1.8 Hz), 7.76 (1H, dd,J=8.2, 7.4 Hz), 7.40 (1H, dd, J=7.4, 4.7 Hz), 2.35 (3H, s); LC-MS (ESI)m/z 283.0 [M+H]⁺.

1-(8-Chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl) ethanol

To a stirring heterogeneous mixture of8-chloro-2-(2-methylpyridin-3-yl)-quinoline-3-carbaldehyde (1.0741 g,3.799 mmol) in THF (14.61 mL, 3.799 mmol) was added methylmagnesiumbromide 3 M in diethyl ether (1.900 mL, 5.699 mmol) dropwise at 0° C.,and the mixture was allowed to warm to room temperature over 2 h. Thereaction was quenched with NH₄Cl (50 mL) and extracted with EtOAc (50mL×2). The combined organics were washed with water (50 mL×1), brine (50mL×1), dried over Na₂SO₄, filtered, and concentrated under reducedpressure to give an orange syrup (1.4409 g). The orange syrup (1.4409 g)was purified by silica gel column chromatography on a 80 g of Redi-Sep™column using 0 to 100% gradient of EtOAc in hexane over 25 min and then100% isocratic of EtOAc for 30 min as eluent to give1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethanol as a solid: ¹HNMR (400 MHz, DMSO-d₆) δ ppm 8.68 (1H, s), 8.59 (1H, dd, J=4.9, 1.8 Hz),8.10 (1H, dd, J=8.2, 1.2 Hz), 7.94 (1H, dd, J=7.6, 1.4 Hz), 7.74 (1H,dd, J=7.8, 1.6 Hz), 7.58-7.65 (1H, m), 7.39 (1H, dd, J=7.6, 4.9 Hz),5.47 (1H, d, J=4.3 Hz), 4.64 (1H, br. s.), 2.25 (3H, s), 1.20 (3H, d,J=7.4 Hz); LC-MS (ESI) m/z 299.0 [M+H]⁺.

8-Chloro-3-(1-chloroethyl)-2-(2-methylpyridin-3-yl)quinolinehydrochloride

A solution of 1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethanol(1.1090 g, 3.712 mmol) in chloroform (12.37 mL, 3.712 mmol) was treatedwith thionyl chloride (1.350 mL, 18.56 mmol) dropwise, and the reactionmixture was stirred at room temperature. After 3 h, the mixture wasconcentrated under reduced pressure and co-evaporated three times withCH₂Cl₂ to give8-chloro-3-(1-chloroethyl)-2-(2-methylpyridin-3-yl)quinolinehydrochloride as an off-white syrupy solid: ¹H NMR (400 MHz, DMSO-d₆) δppm 9.04 (1H, s), 8.94 (1H, dd, J=5.7, 1.4 Hz), 8.56 (1H, d, J=7.4 Hz),8.19 (1H, dd, J=8.2, 1.2 Hz), 8.07 (1H, dd, J=7.4, 1.2 Hz), 8.02 (1H,dd, J=7.6, 5.7 Hz), 7.71-7.77 (1H, m), 5.25 (1H, d, J=6.3 Hz), 2.52 (3H,s), 1.92 (3H, d, J=6.7 Hz); LC-MS (ESI) m/z 317.0 [M+H]⁺ (Exact Mass ofneutral form: 316.053). The crude product was carried on crude withoutpurification for the next step.

2-(1-(8-Chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione

To a stirring solution of8-chloro-3-(1-chloroethyl)-2-(2-methylpyridin-3-yl)-quinolinehydrochloride (1.3130 g, 3.712 mmol) in DMF (18.56 mL, 3.712 mmol) at100° C. was added potassium phthalimide (1.719 g, 9.281 mmol) at 100° C.and the mixture was stirred at 100° C. After 1.5 h, the mixture wasconcentrated under reduced pressure and triturated with water (50 mL).The resulting solid was filtered and washed with 2 N NaOH (50 mL) andthen with water (500 mL), and air-dried to give2-(1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-isoindoline-1,3-dioneas a tan solid: LC-MS (ESI) m/z 428.0 [M+H]⁺. The impure product wascarried on crude without purification for the next step.

1-(8-Chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethanamine

To a suspension of2-(1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-isoindoline-1,3-dione(1.5831 g, 3.700 mmol) in ethanol (37.00 mL, 3.700 mmol) was addedhydrazine, anhydrous (1.161 mL, 37.00 mmol), and the mixture was stirredunder reflux. After 1.5 h, the mixture was cooled to room temperature.The by product was filtered off and washed with MeOH (˜100 mL). Thefiltrate was concentrated under reduced pressure to give a yellow solid.The yellow solid was purified by column chromatography on a 80 g ofRedi-Sep™ column using 0% to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ over 25 min, and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ for 10 min as eluent to give1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethanamine as a yellowsyrup: NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H, s), 8.58 (1H, dd, J=4.9,1.8 Hz), 8.04 (1H, dd, J=8.2, 1.2 Hz), 7.92 (1H, dd, J=7.4, 1.2 Hz),7.77 (1H, s), 7.60 (1H, dd, J=8.2, 7.4 Hz), 7.34-7.44 (1H, m), 4.09 (1H,d, J=4.7 Hz), 2.25 (3H, s), 2.05 (2H, br. s.), 1.13 (3H, d, J=6.7 Hz):LC-MS (ESI) m/z 298.1 [M+H]⁺.

N—((S)-1-(8-Chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineandN4R)-1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.4148 g, 2.084 mmol),1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethanamine (0.6827 g,2.293 mmol), and N,N-diisopropylethylamine (1.089 mL, 6.253 mmol) in1-butanol (5.698 mL, 2.084 mmol) was heated under reflux with stirring.After 18 h, the mixture was removed from the heat and concentrated underreduced pressure. The residue was purified by column chromatography on a80 g of Redi-Sep™ column using 0 to 50% gradient of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ over 20 min, then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ for 20 min, then 50 to 100% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 20 min, and then 100%isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 10 min as eluentto give a yellow solid. The yellow solid was suspended in MeOH andfiltered to giveN-(1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineas an off-white solid. The 0.1505 g of racemic mixture was dissolved inMeOH—CH₂Cl₂ (1:4, 5 mL), filtered, and separated on a Chiralpak™ IAcolumn (30×250 mm, 5 μm) using 20% isocratic of isopropanol in hexanefor 40 min as eluent to give two separated isomers:N—((S)-1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.90 (1H, s), 8.59(2H, d, J=61.6 Hz), 7.70-8.37 (6H, m), 7.58 (1H, t, J=7.8 Hz), 7.32 (1H,s), 5.34 (1H, br. s.), 2.32 (3H, s), 1.53 (3H, br. s.); LC-MS (ESI) m/z416.2 [M+H]⁺andN—((R)-1-(8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.90 (1H, s), 8.59(2H, d, J=56.5 Hz), 7.69-8.34 (6H, m), 7.58 (1H, t, J=7.7 Hz), 7.32 (1H,s), 5.32 (1H, s), 2.32 (3 H, d, J=1.8 Hz), 1.54 (3H, br. s.); LC-MS(ESI) m/z 416.2 [M+H]⁺.

Example 97 Preparation ofN-((3-(2-Chlorophenyl)-8-iodoquinoxalin-2-yl)-methyl)-9H-purin-6-amine2-(Bromomethyl)-3-(2-chlorophenyl)-5-nitroquinoxaline and3-(Bromomethyl)-2-(2-chlorophenyl)-5-nitroquinoxaline

To a solution of 3-bromo-1-(2-chlorophenyl)propane-1,2-dione (Preparedin Example 81, 4.2971 g, 16.4325 mmol) in ethyl acetate (109.55 mL,16.433 mmol) was added 3-nitro-1,2-phenylenediamine (2.5165 g, 16.433mmol) at room temperature and the resulting red mixture was stirred atroom temperature. After 26 h of stirring at room temperature, themixture was concentrated under reduced pressure to give2-(bromomethyl)-3-(2-chlorophenyl)-5-nitroquinoxaline including itsregioisomer as a red syrup: LC-MS (ESI) m/z 378.0 and 379.9 [M+H]⁺. Thecrude product as a red syrup was carried on crude without purificationfor the next step.

2-((3-(2-Chlorophenyl)-5-nitroquinoxalin-2-yl)methyl)isoindoline-1,3-dioneand2-((3-(2-Chlorophenyl)-8-nitroquinoxalin-2-yl)methyl)isoindoline-1,3-dione

To a stirring solution of a mixture of2-(bromomethyl)-3-(2-chlorophenyl)-5-nitroquinoxaline and3-(bromomethyl)-2-(2-chlorophenyl)-5-nitroquinoxaline (6.2215 g, 16.43mmol) in DMF (82.16 mL, 16.43 mmol) was added potassium phthalimide(7.609 g, 41.08 mmol) and the mixture was stirred at 100° C. After 2 h,the mixture was concentrated under reduced pressure and triturated withwater (150 mL). The resulting solid was filtered and washed with 2 NNaOH (150 mL) and then with water (500 mL), and dried to give a mixtureof2-((3-(2-chlorophenyl)-5-nitroquinoxalin-2-yl)methyl)isoindoline-1,3-dioneand2-((3-(2-chlorophenyl)-8-nitroquinoxalin-2-yl)methyl)isoindoline-1,3-dioneas a dark brown solid: ¹H NMR (400 MHz, DMSO-d₆); LC-MS (ESI) m/z 445.1[M+H]⁺. The crude product was carried on crude without purification forthe next step.

2-((5-Amino-3-(2-chlorophenyl)quinoxalin-2-yl)methyl)isoindoline-1,3-dioneand2-((8-Amino-3-(2-chlorophenyl)quinoxalin-2-yl)methyl)isoindoline-1,3-dione

To solution of2-((3-(2-chlorophenyl)-5-nitroquinoxalin-2-yl)methyl)-isoindoline-1,3-dioneand24(3-(2-chlorophenyl)-8-nitroquinoxalin-2-yl)methyl)-isoindoline-1,3-dione(5.9271 g, 13.32 mmol) in EtOAc (78.38 mL, 13.32 mmol) was added tin(II)chloride dihydrate (15.17 g, 66.62 mmol) and the mixture was heatedunder reflux. After 5 h, the mixture was concentrated under reducedpressure to remove EtOAc. To the residue was added aqueous saturatedNaHCO₃ (300 mL). The resulting precipitate was collected by filtrationand washed with water (300 mL) to give a brown solid. The brown solidwas suspended in CH₂Cl₂ (200 mL) and filtered off through Celite™ padand washed the solid well with CH₂Cl₂ (100 mL). The filtrate wasconcentrated under reduced pressure to give a dark brown syrup (0.7 g).The dark brown syrup (0.7 g) was purified by silica gel columnchromatography on a 120 g of Redi-Sep™ column using 0 to 26% gradient ofEtOAc in hexane over 7 min, then 26% isocratic of EtOAc in hexane for 10min, then 26 to 100% gradient of EtOAc in hexane over 20 min, and then100% isocratic of EtOAc in hexane for 15 min as eluent to give twoseparated regioisomers:2-((5-amino-3-(2-chlorophenyl)quinoxalin-2-yl)methyl)-isoindoline-1,3-dioneas a solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.83-7.91 (4H, m), 7.62-7.68(2H, m), 7.45-7.59 (3H, m), 6.97 (1H, dd, J=8.4, 1.0 Hz), 6.91 (1H, dd,J=7.6, 1.0 Hz), 6.11 (2H, s), 4.87 (2H, br. s.), 90942-16-2-1H-NMR;LC-MS (ESI) m/z 415.1 [M+H]⁺and24(8-amino-3-(2-chlorophenyl)-quinoxalin-2-yl)methyl)isoindoline-1,3-dioneas a solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.83-7.91 (4H, m), 7.59-7.66(2H, m), 7.46-7.58 (3H, m), 7.21 (1H, dd, J=8.2, 1.2 Hz), 6.92 (1H, dd,J=7.8, 1.2 Hz), 5.74 (2H, s), 4.90 (2 H, d, J=31.7 Hz); LC-MS (ESI) m/z415.1 [M+H]⁺. The structures of two regioisomers were confirmed by¹H-¹⁵N HMBC and 1D NOE experiment.

2-((3-(2-Chlorophenyl)-8-iodoquinoxalin-2-yl)methyl)isoindoline-1,3-dione

2-((8-amino-3-(2-chlorophenyl)quinoxalin-2-yl)methyl)isoindoline-1,3-dione(1.1337 g, 2.733 mmol) was dissolved in acetone (39.04 mL, 2.733 mmol)and cooled to 0° C. While being stirred, the solution was treated firstwith 2 M hydrochloric acid (7.652 mL, 15.30 mmol) and then dropwise with1M aq. sodium nitrite (5.466 mL, 5.466 mmol) while maintaining thetemperature of the mixture at 0° C. After the additions were complete,the mixture was stirred for 15 min and then treated with 5 M aq.potassium iodide (5.411 mL, 27.06 mmol) maintaining the temperaturebelow 5° C. The mixture was then allowed to warm to 15° C. over 3.5 h.The acetone was removed under reduced pressure, and the residue waspartitioned between water (100 mL) and ethyl acetate (100 mL). Theorganic solution was washed with 10% aqueous sodium bisulfite (100 mL×1)and saturated aqueous sodium bicarbonate (100 mL×1), brine (100 mL×1),dried over MgSO₄, filtered, and concentrated under reduced pressure togive a dark violet syrupy solid. The dark violet syrupy solid waspurified by silica gel column chromatography on a 80 g of Redi-Sep™column using 0 to 50% gradient of EtOAc in hexane over 15 min and then50% isocratic of EtOAc in hexane for 25 min as eluent to give24(3-(2-chlorophenyl)-8-iodoquinoxalin-2-yl)methyl)-isoindoline-1,3-dioneas a solid: LC-MS (ESI) m/z 526.0 [M+H]⁺.

(3-(2-Chlorophenyl)-8-iodoquinoxalin-2-yl)methanamine

To a suspension of2-((3-(2-chlorophenyl)-8-iodoquinoxalin-2-yl)methyl)-isoindoline-1,3-dione(0.5530 g, 1.052 mmol) in ethanol (10.00 mL, 1.052 mmol) was addedhydrazine, anhydrous (0.3301 mL, 10.52 mmol), and the mixture wasstirred under reflux. After 20 min, the mixture was cooled to roomtemperature. The mixture was concentrated under reduced pressure. Theresidue was purified by column chromatography on a 80 g of Redi-Sep™column using 0% to 50% gradient of CH₂Cl₂:MeOH:NR₄OH (89:9:1) in CH₂Cl₂over 25 min, and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) inCH₂Cl₂ for 5 min as eluent to give(3-(2-chlorophenyl)-8-iodoquinoxalin-2-yl)methanamine: ¹H NMR (400 MHz,DMSO-d₆) δ ppm 8.50 (1H, dd, J=7.4, 1.2 Hz), 8.14 (1H, dd, J=8.4, 1.4Hz), 7.52-7.71 (5H, m), 3.84 (2H, s), 2.15 (2H, s); LC-MS (ESI) m/z396.0 [M+H]⁺.N-((3-(2-Chlorophenyl)-8-iodoquinoxalin-2-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.1119 g, 0.5622 mmol),(3-(2-chlorophenyl)-8-iodoquinoxalin-2-yl)methanamine (0.2669 g, 0.6746mmol), and N,N-diisopropylethylamine (0.2938 mL, 1.687 mmol) in1-butanol (2.000 mL, 0.5622 mmol) was stirred at 100° C. After 3 h, themixture was removed from the heat and the green precipitate wascollected by filtration and washed the solid with MeOH to give a greensolid. The green solid was purified by column chromatography on a 40 gof Redi-Sep™ column using 0 to 100% gradient of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ over 14 min and then 100% isocratic ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) for 5 min as eluent to give a yellow solid.The yellow solid was suspended in CH₂Cl₂ and filtered to giveN-((3-(2-chloro-phenyl)-8-iodoquinoxal in-2-yl)methyl)-9H-purin-6-amineas a yellow solid: 1H NMR (400 MHz, DMSO-d₆) δ ppm 12.93 (1H, s), 8.48(1H, d, J=7.4 Hz), 8.03-8.20 (3H, m), 7.43-7.88 (6H, m), 4.84 (2H, s);LC-MS (ESI) m/z 514.0 [M+H]⁺.

Example 98 Preparation ofN-((3-(2-Chlorophenyl)-8-(methylsulfonyl)-quinoxalin-2-yl)methyl)-9H-purin-6-amineas a TFA salt

To a Schlenk tube with a stirrer bar was addedN-((3-(2-chlorophenyl)-8-iodoquinoxalin-2-yl)methyl)-9H-purin-6-amine(Prepared in Example 97, 0.1000 g, 0.19 mmol), copper (I)trifluoromethanesulfonate toluene complex (2 to 1) (0.0050 g, 0.0097mmol), and sodium methanesulfinate (0.047 g, 0.39 mmol) under an argonatmosphere. The aperture of the tube was then covered with a rubberseptum and an argon atmosphere was established.N,N′-dimethylethyl-enediamide (0.0021 mL, 0.019 mmol) and DMSO (1.0 mL,0.19 mmol) were added via syringe. The septum was replaced by a tefloncoated screw cap and the reaction vessel was placed in a 110° C. Afterstirring for 20 h, the reaction mixture was cooled to room temperature,diluted with CH₂Cl₂ (50 mL), filtered through a pad of silica gel,washed the pad with CH₂Cl₂ (100 mL). The filtrate was washed with water(50 mL×2) and brine (50 mL×1), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure to give a green syrup. The greensyrup was purified by column chromatography on a 40 g of Redi-Sep™column using 0 to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂over 14 min and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 3min as eluent to give a red syrupy solid (0.0172 g). The dark red syrup(0.0172 g) was purified by semi-prep-HPLC on C18 column using 20-70%gradient of CH₃CN (0.1% of TFA) in water (0.1% of TFA) over 40 min aseluent to giveN-((3-(2-chlorophenyl)-8-(methylsulfonyl)quinoxalin-2-yl)methyl)-9H-purin-6-amineas a TFA salt as a light-yellow solid: LC-MS (ESI) m/z 466.1 [M+H]⁺(Exact Mass of neutral form: 465.077).

Example 99 Preparation ofN-((3-(2-Chlorophenyl)-5-iodoquinoxalin-2-yl)-methyl)-9H-purin-6-amine2-((3-(2-Chlorophenyl)-5-iodoquinoxalin-2-yl)methyl)isoindoline-1,3-dione

2-((5-amino-3-(2-chlorophenyl)quinoxalin-2-yl)methyl)isoindoline-1,3-dione(Prepared in Example 97, 0.8364 g, 2.016 mmol) was dissolved in acetone(28.80 mL, 2.016 mmol) and cooled to 0° C. While being stirred, thesolution was treated first with 2 M hydrochloric acid (5.645 mL, 11.29mmol) and then dropwise with 1 M aq. sodium nitrite (6.049 mL, 6.049mmol) while maintaining the temperature of the mixture at 0° C. Afterthe additions were complete, the mixture was stirred for 15 min and thentreated with 5 M aq. potassium iodide (4.839 mL, 24.19 mmol) maintainingthe temperature below 5° C. The mixture was then allowed to warm to 15°C. over 3 h. The acetone was removed under reduced pressure, and theresidue was partitioned between water (100 mL) and ethyl acetate (100mL). The organic solution was washed with 10% aqueous sodium bisulfite(100 mL×3) and saturated aqueous sodium bicarbonate (100 mL×1), brine(100 mL×1), dried over MgSO₄, filtered, and concentrated under reducedpressure to give a red solid. The red solid was purified by silica gelcolumn chromatography on a 80 g of Redi-Sep™ column using 0 to 50%gradient of EtOAc in hexane over 25 min and then 50% isocratic of EtOAcin hexane for 25 min as eluent to give24(3-(2-chlorophenyl)-5-iodoquinoxalin-2-yl)methyl)-isoindoline-1,3-dioneas a solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.48 (1H, dd, J=7.4, 1.2Hz), 7.97 (1H, dd, J=8.2, 1.2 Hz), 7.83-7.91 (4H, m), 7.51-7.75 (5H, m),4.96 (2H, d, J=21.9 Hz); LC-MS (ESI) m/z 526.0 [M+H]⁺.

(3-(2-Chlorophenyl)-5-iodoquinoxalin-2-yl)methanamine

To a suspension of2-((3-(2-chlorophenyl)-5-iodoquinoxalin-2-yl)methyl)-isoindoline-1,3-dione(0.7028 g, 1.337 mmol) in ethanol (12.00 mL, 1.337 mmol) was addedhydrazine, anhydrous (0.4196 mL, 13.37 mmol), and the mixture wasstirred under reflux. After 30 min, the mixture was cooled to roomtemperature. The mixture was concentrated under reduced pressure. Theresidue was purified by column chromatography on a 80 g of Redi-Sep™column using 0% to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂over 25 min, and then 50% isocratic of CH₂Cl₂:MeOH:NR₄OH (89:9:1) inCH₂Cl₂ for 5 min as eluent to give(3-(2-chlorophenyl)-5-iodoquinoxalin-2-yl)methanamine as a green syrupysolid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.45 (1H, dd, J=7.4, 1.0 Hz),8.17 (1H, dd, J=8.4, 1.2 Hz), 7.52-7.74 (5H, m), 3.83 (2H, br. s.), 1.97(2H, br. s.); LC-MS (ESI) m/z 396.0 [M+H]⁺.

N-((3-(2-Chlorophenyl)-5-iodoquinoxalin-2-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.1859 g, 0.9340 mmol),(3-(2-chlorophenyl)-5-iodoquinoxalin-2-yl)methanamine (0.4434 g, 1.121mmol), and N,N-diisopropyl-ethylamine (0.4880 mL, 2.802 mmol) in1-butanol (5.000 mL, 0.9340 mmol) was stirred at 100° C. After 2 h, themixture was cooled to room temperature and concentrated under reducedpressure. The residue was purified by flash column chromatography on asilica gel column using 50% of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ aseluent to give a yellow solid (0.2120 g). The yellow solid was suspendedin CH₂Cl₂ and filtered to giveN-((3-(2-chlorophenyl)-5-iodoquinoxalin-2-yl)methyl)-9H-purin-6-amine asa light yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.88 (1H, br.s.), 8.46 (1H, dd, J=7.4, 1.2 Hz), 8.12 (2H, d, J=7.2 Hz), 8.06 (1H, s),7.93 (1H, s), 7.69 (1H, dd, J=7.4, 1.8 Hz), 7.64 (2H, t, J=8.0 Hz),7.53-7.59 (1H, m), 7.48-7.53 (1H, m), 4.83 (2H, br. s.); LC-MS (ESI) m/z514.0 [M+H]⁺.

Example 100 Preparation ofN-((5-chloro-3-(2-chloro-5-fluorophenyl)-quinoxalin-2-yl)methyl)-9H-purin-6-amine5-Chloro-3-(2-chloro-5-fluorophenyl)-2-methylquinoxaline

A mixture of 3,5-dichloro-2-methylquinoxaline (Prepared in Example 85,1.0000 g, 4.693 mmol), 2-chloro-5-fluorophenylboronic acid (0.9002 g,5.163 mmol), tetrakis(triphenylphosphine)palladium (0.2712 g, 0.2347mmol), and sodium carbonate anhydrous (2.487 g, 23.47 mmol) inacetonitrile-water (3:1) (47.00 mL) was stirred at 100° C. After 3 hs,the mixture was cooled to room temperature and partitioned between EtOAc(100 mL) and water (100 mL). The organic layer was washed with brine (50mL×2), dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The residue was purified by silica gel column chromatographyon a 80 g of Redi-Sep™ column using 0 to 50% gradient of EtOAc in hexaneover 25 min and then 50% isocratic of EtOAc for 10 min as eluent to give5-chloro-3-(2-chloro-5-fluorophenyl)-2-methylquinoxaline as a red syrupysolid: NMR (400 MHz, DMSO-d₆) δ ppm 8.09 (1H, dd, J=8.4, 1.4 Hz), 8.03(1H, dd, J=7.6, 1.4 Hz), 7.88 (1H, dd, J=8.4, 7.6 Hz), 7.75 (1H, dd,J=9.0, 5.1 Hz), 7.61 (1H, dd, J=8.6, 3.1 Hz), 7.46-7.53 (1H, m), 2.54(3H, s); LC-MS (ESI) m/z 307.0 [M+H]⁺.

2-(Bromomethyl)-5-chloro-3-(2-chloro-5-fluorophenyl)quinoxaline

5-chloro-3-(2-chloro-5-fluorophenyl)-2-methylquinoxaline (0.3013 g,0.981 mmol) and 1,3-dibromo-5,5-dimethylhydantoin (0.280 g, 0.981 mmol)were suspended in carbon tetrachloride (9.81 mL, 0.981 mmol). To themixture was added benzoyl peroxide (0.0317 g, 0.0981 mmol) and themixture was heated at reflux. After 22 h, the mixture was cooled to roomtemperature and concentrated under reduced pressure. The residue waspurified by silica gel column chromatography on a 80 g of Redi-Sep™column using 0 to 5% gradient of EtOAc in hexane over 10 min, then 5%isocratic of EtOAc for 25 min, then 5 to 20% gradient of EtOAc in hexaneover 20 min, then 20% isocratic of EtOAc for 4 min as eluent to give2-(bromomethyl)-5-chloro-3-(2-chloro-5-fluorophenyl)-quinoxaline as alight yellow syrupy solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.12-8.21(2H, m), 7.92-8.00 (1H, m), 7.76 (1H, dd, J=9.0, 5.1 Hz), 7.71 (1 H, dd,J=8.6, 3.1 Hz), 7.49-7.58 (1H, m), 4.74 (2H, br. s.); LC-MS (ESI) m/z387.0 [M+H]⁺.

2-((5-Chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)methyl)isoindoline-1,3-dione

To a heterogeneous mixture of2-(bromomethyl)-5-chloro-3-(2-chloro-5-fluoro-phenyl)quinoxaline (0.1815g, 0.4702 mmol) in DMF (3.444 mL, 0.4702 mmol) was added potassiumphthalimide (0.2177 g, 1.175 mmol) and the heterogeneous mixture wasstirred at 100° C. After stirring at 100° C. for 30 min, the mixture wasconcentrated under reduced pressure and triturated with water (30 mL).The precipitate was collected by filtration. The resulting solid wasfiltered and washed with 2 N NaOH (30 mL) and then with water (100 mL),and air-dried to give2-((5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)methyl)isoindoline-1,3-dioneas an off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.09 (1H, dd,J=7.6, 1.4 Hz), 7.95-8.01 (1H, m), 7.82-7.91 (5H, m), 7.65-7.75 (2H, m),7.43-7.52 (1H, m), 4.99 (2H, br. s.); LC-MS (ESI) m/z 452.0 [M+H]⁺. Thecrude product was carried on crude without purification for the nextstep.

(5-Chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)methanamine

To a suspension of2-((5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)-methyl)isoindoline-1,3-dione(0.1607 g, 0.355 mmol) in ethanol (3.60 mL, 0.355 mmol) was addedhydrazine, anhydrous (0.112 mL, 3.55 mmol), and the mixture was stirredunder reflux. After 30 min, the mixture was cooled to room temperature.The byproduct was filtered off and washed with MeOH. The filtrate wasconcentrated under reduced pressure. The residue was purified by columnchromatography on a 40 g of Redi-Sep™ column using 0% to 100% gradientof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min, and then 100%isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 10 min as eluent to give(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)methanamine as agreen syrupy solid: 1H NMR (400 MHz, DMSO-d₆) δ ppm 8.16 (1H, dd, J=8.4,1.4 Hz), 8.06 (1H, dd, J=7.8, 1.2 Hz), 7.87-7.95 (1H, m), 7.74 (1H, dd,J=9.0, 5.1 Hz), 7.61 (1H, dd, J=8.6, 3.1 Hz), 7.46-7.54 (1H, m), 3.85(2H, s), 2.11 (2H, br. s.); LC-MS (ESI) m/z 322.0 [M+H]⁺.

N-((5-Chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.07531 g, 0.3784 mmol),(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)methanamine (0.1016g, 0.3154 mmol), and N,N-diisopropylethylamine (0.1648 mL, 0.9461 mmol)in 1-butanol (3.000 mL, 0.3154 mmol) was stirred at 100° C. After 2 h,the mixture was removed from the heat and concentrated under reducedpressure. The residue was purified by column chromatography on a 40 g ofRedi-Sep™ column using 0 to 20% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ over 14 min, then 20% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ for 14 min, then 20 to 50% gradient of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ over 10 min and then 50% isocratic ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 10 min as eluent to give alight yellow solid (0.0622 g). The yellow solid (0.0622 g) was suspendedin MeOH and filtered to giveN-((5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)methyl)-9H-purin-6-amineas a light yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.92 (1H, s),8.03-8.19 (4H, m), 7.82-8.01 (2H, m), 7.63 (1H, dd, J=9.0, 5.1 Hz), 7.55(1H, dd, J=8.6, 3.1 Hz), 7.29-7.44 (1H, m), 4.89 (2H, s); LC-MS (ESI)m/z 440.0 [M+H]⁺.

Example 101 Preparation ofN—((S)-1-(5-chloro-3-(2-chloro-5-fluorophenyl)-quinoxalin-2-yl)ethyl)-9H-purin-6-amineandN—((R)-1-(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amine

-   5-Chloro-3-(2-chloro-5-fluorophenyl)quinoxaline-2-carbaldehyde

A mixture of2-(bromomethyl)-5-chloro-3-(2-chloro-5-fluorophenyl)quinoxaline(Prepared in Example 100, 0.5625 g, 1.457 mmol) and sodium metaperiodate(0.1613 mL, 2.914 mmol) in DMF (9.714 mL, 1.457 mmol) was heated at 150°C. with stirring. After 3 h, the mixture was cooled to room temperature,diluted with EtOAc (100 mL), washed with brine (50 mL×2), dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography on a 80 g ofRedi-Sep^(livi) column using 0 to 10% gradient of EtOAc in hexane over10 min, then 10% isocratic of EtOAc for 20 min, then 10 to 20% gradientof EtOAc in hexane over 20 min, then 20% isocratic of EtOAc for 3 min aseluent to give5-chloro-3-(2-chloro-5-fluorophenyl)quinoxaline-2-carbaldehyde as anoff-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.16 (1H, s),8.35-8.41 (1H, m), 8.29-8.34 (1H, m), 8.07 (1H, dd, J=8.4, 7.6 Hz), 7.68(1H, dd, J=8.8, 4.9 Hz), 7.44-7.58 (2H, m); LC-MS (ESI) m/z 321.0[M+H]⁺.

1-(5-Chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethanol

To a stirring heterogeneous mixture of5-chloro-3-(2-chloro-5-fluorophenyl)-quinoxaline-2-carbaldehyde (0.1650g, 0.514 mmol) in THF (5.00 mL, 0.514 mmol) was added methylmagnesiumbromide 3 M in diethyl ether (0.257 mL, 0.771 mmol) dropwise at 0° C.,and the mixture was then allowed to warm to room temperature and stirredat room temperature. After 5.5 h, the reaction was quenched with NH₄Cl(50 mL) and extracted with EtOAc (50 mL×2). The combined organic layerswere washed with water (50 mL×1), brine (50 mL×1), dried over Na₂SO₄,filtered, and concentrated under reduced pressure. The residue waspurified by silica gel column chromatography on a 40 g of Redi-Sep™column using 0 to 50% gradient of EtOAc in hexane over 14 min and then50% isocratic of EtOAc for 10 min as eluent to give1-(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethanol as asolid: NMR (400 MHz, DMSO-d₆) δ ppm 8.17 (1H, dd, J=8.4, 1.4 Hz), 8.09(1H, dd, J=7.8, 1.2 Hz), 7.88-7.96 (1 H, m), 7.72 (1H, dd, J=9.0, 5.1Hz), 7.61 (1H, br. s.), 7.44-7.53 (1H, m), 5.36 (1H, d, J=6.3 Hz), 4.83(1H, br. s.), 1.49 (3H, br. s.); LC-MS (ESI) m/z 337.0 [M+]⁺.

2-(1-(5-Chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethyl)isoindoline-1,3-dione

To a solution of1-(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethanol (0.08320g, 0.2468 mmol) in tetrahydrofuran (2.468 mL, 0.2468 mmol) were addedtriphenylphosphine (0.07766 g, 0.2961 mmol), phthalimide (0.04357 g,0.2961 mmol), and diisopropyl azodicarboxylate (0.05735 mL, 0.2961mmol). The reaction mixture was stirred at room temperature. After 6 h,the mixture was concentrated under reduced pressure and partitionedbetween EtOAc (100 mL) and brine (100 mL). The combined organic layerswere dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The residue was purified by silica gel column chromatographyon a 40 g of Redi-Sep™ column using 0 to 10% gradient of EtOAc in hexaneover 10 min, then 10% isocratic of EtOAc for 20 min, then 10 to 50%gradient of EtOAc in hexane over 20 min, then 50% isocratic of EtOAc for3 min as eluent to give2-(1-(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethyl)isoindoline-1,3-dione as a tan solid: LC-MS (ESD m/z 466.0 [M+H]⁺.

1-(5-Chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethanamine

To a suspension of2-(1-(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)-ethyl)isoindoline-1,3-dione(0.0802 g, 0.172 mmol) in ethanol (3.44 mL, 0.172 mmol) was addedhydrazine, anhydrous (0.0540 mL, 1.72 mmol), and the mixture was stirredunder reflux. After 30 min, the mixture was cooled to room temperature.The mixture was concentrated under reduced pressure. The residue waspurified by column chromatography on a 40 g of Redi-Sep™ column using 0%to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min,and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 5 min aseluent to give1-(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethanamine as alight yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.11-8.17 (1H, m),8.06 (1H, dd, J=7.6, 1.4 Hz), 7.87-7.94 (1H, m), 7.74 (1H, dd, J=9.0,5.1 Hz), 7.67 (1H, dd, J=8.8, 2.9 Hz), 7.46-7.55 (1H, m), 3.99 (1H, q,J=6.7 Hz), 2.24 (2H, br. s.), 1.12-1.43 (3H, m); LC-MS (ESI) m/z 336.1[M+H]⁺.N—((S)-1-(5-Chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineandN—((R)-1-(5-Chloro-3-(2-chloro-5-fluorophenyl)-quinoxalin-2-yl)ethyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.0309 g, 0.155 mmol),1-(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethanamine(0.0522 g, 0.155 mmol), and N,N-diiso-propylethylamine (0.0811 mL, 0.466mmol) in 1-butanol (2.00 mL, 0.155 mmol) was stirred at 100° C. After 50h, the mixture was removed from the heat and concentrated under reducedpressure. The residue was purified by column chromatography on a 40 g ofRedi-Sep™ column using 0% to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ over 14 min and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) for 20 min as eluent to give a racemic mixture as a yellowsolid (0.0601 g, 85.2%). The racemic mixture (0.0601 g) was dissolved inMeOH—CH₂Cl₂ (1:3, 4 mL), filtered, and separated on a Chiralpak™ IAcolumn (30×250 mm, 5 μm) using 10% isocratic of isopropanol in hexanefor 40 min as eluent to give two separated isomers:N—((S)-1-(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineas an off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.87 (1H, s),7.12-8.29 (9H, m), 5.59 (1H, br. s.), 1.63 (3H, d, J=5.9 Hz); LC-MS(ESI) m/z 454.1 [M+H]⁺ andN—((R)-1-(5-chloro-3-(2-chloro-5-fluorophenyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineas an off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.89 (1H, s),7.04-8.40 (9H, m), 5.56 (1H, br. s.), 1.63 (3H, d, J=6.8 Hz); LC-MS(ESI) m/z 454.1 [M+H]⁺.

Example 102 Preparation ofN-((8-chloro-2-(1-methyl-1H-imidazol-5-yl)-quinolin-3-yl)methyl)-9H-purin-6-aminedihydrochloride:24(8-Chloro-2-(1-methyl-1H-imidazol-5-yl)quinolin-3-yl)methyl)isoindoline-1,3-dione

A solution of 2((2,8-dichloroquinolin-3-yl)methyl)isoindoline-1,3-dione(0.5000 g, 1.400 mmol), 1-methyl-5-(tributylstannyl)-1H-imidazole(crude) (1.039 g, 2.800 mmol), andtetrakis(triphenylphosphine)palladium(0) (0.1618 g, 0.1400 mmol) in1,4-Dioxane (11.67 mL, 1.400 mmol) was stirred at 100° C. After 22 h,the mixture was cooled to room temperature and concentrated underreduced pressure. The residue was mixed with Et₂O (20 mL) and sonicated,and filtered. The solid was washed with Et₂O (20 mL) and then hexane (40mL) to give an off-white solid. The off-white solid was purified bycolumn chromatography on a 40 g of Redi-Sep™ column using 0 to 100%gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min and then100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 5 min as eluent to give2-((8-chloro-2-(1-methyl-1H-imidazol-5-yl)quinolin-3-yl)methyl)isoindoline-1,3-dioneas an off-white solid: NMR (400 MHz, DMSO-d₆) δ ppm 8.36 (1H, s),7.86-7.97 (7H, m), 7.62 (1H, d, J=1.2 Hz), 7.53 (1H, t, J=8.0 Hz), 5.13(2H, s), 4.00 (3H, s); LC-MS (ESI) m/z 403.1 [M+H]⁺.

(8-Chloro-2-(1-methyl-1H-imidazol-5-yl)quinolin-3-yl)methanamine

To a suspension of24(8-chloro-2-(1-methyl-1H-imidazol-5-yl)quinolin-3-yl)-methyl)isoindoline-1,3-dione(0.1841 g, 0.457 mmol) in ethanol (10.0 mL, 0.457 mmol) was addedhydrazine, anhydrous (0.143 mL, 4.57 mmol), and the mixture was stirredunder reflux for 30 min. After 30 min, the mixture was cooled to roomtemperature. The mixture was concentrated under reduced pressure. Theresidue was purified by column chromatography on a 40 g of Redi-Sep™column using 0% to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂over 14 min, and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for20 min as eluent to give(8-chloro-2-(1-methyl-1H-imidazol-5-yl)quinolin-3-yl)-methanamine as awhite solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.60 (1H, s), 7.96 (1H, dd,J=8.2, 1.2 Hz), 7.91 (1H, dd, J=7.4, 1.2 Hz), 7.87 (1H, s), 7.52-7.61(2H, m), 4.05 (2H, d, J=0.8 Hz), 3.97 (3H, s), 2.06 (2H, br. s.); LC-MS(ESI) m/z 273.1 [M+H]⁺.

N-((8-Chloro-2-(1-methyl-1H-imidazol-5-yl)quinolin-3-yl)methyl)-9H-purin-6-aminedihydrochloride

A mixture of 6-bromopurine (0.07844 g, 0.3942 mmol),(8-chloro-2-(1-methyl-1-imidazol-5-yl)quinolin-3-yl)methanamine (0.1075g, 0.3942 mmol), and N,N-diisopropylethylamine (0.2060 mL, 1.182 mmol)in 1-butanol (3.942 mL, 0.3942 mmol) was stirred at 100° C. After 16 h,the mixture was removed from the heat. The precipitate was filtered andthe solid was washed with MeOH to give an off-white solid and filtrate.The off-white solid was purified by column chromatography on a 40 g ofRedi-Sep™ column using 0 to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ over 14 min and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) for 20 min as eluent to give an off-white solid. The off-whitesolid was suspended in MeOH and filtered to giveN-((8-chloro-2-(1-methyl-1H-imidazol-5-yl)quinolin-3-ypmethyl)-9H-purin-6-amineas a white solid. A suspension of inN-((8-chloro-2-(1-methyl-1H-imidazol-5-yl)quinolin-3-yl)methyl)-9H-purin-6-amine(0.10596 g) in ethanol absolute (7 mL) was treated with hydrochloricacid volumetric standard, 0.5004 N solution in water (1.084 mL, 0.54322mmol, 2 eqv.). The mixture was stirred at 95° C. oil bath for 5 min.After 5 min, the mixture became clear solution and cooled to roomtemperature. The cooed mixture was concentrated under reduced pressureto give a light yellow solid. The light yellow solid was dissolved in 3mL of water, frozen, and dried on lyophilizer to giveN-((8-chloro-2-(1-methyl-1H-imidazol-5-yl)quinolin-3-yl)-methyl)-9H-purin-6-aminedihydrochloride as an off-white solid: NMR (400 MHz, DMSO-d₆) δ ppm 9.99(1H, br. s.), 9.34 (1H, s), 8.66 (1H, s), 8.42-8.62 (2H, m), 8.37 (1H,s), 7.99-8.07 (2H, m), 7.67 (1H, t, J=8.0 Hz), 5.19 (2H, br. s.), 4.08(3H, s); LC-MS (ESI) m/z 391.1 [M+H]⁺(Exact Mass of neutral form:390.111).

Example 103 Preparation ofN-(2-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)propan-2-yl)-9H-purin-6-amine5-Chloro-3-isopropylquinoxalin-2(1H)-one and8-Chloro-3-isopropyl-quinoxalin-2(1H)-one

A mixture of 3-chlorobenzene-1,2-diamine (Prepared in Example 81, 10.000g, 70.13 mmol) and ethyl 3-methyl-2-oxobutyrate (10.22 mL, 70.13 mmol)in polyphosphoric acid (100.00 g) was stirred and heated at 115° C.After 5 h, the mixture was cooled to room temperature, thoroughly mixedwith water (300 mL), and neutralized with 10 N NaOH (100 mL). Theresulting precipitate was collected by filtration, washed with water (1L), and dried to give a mixture of two resiosiomers as a brown solid.The brown solid was suspended in MeOH (100 mL), filtered, and washedwith MeOH (150 mL) to give a mixture of5-chloro-3-isopropylquinoxalin-2(1H)-one and8-chloro-3-isopropylquinoxalin-2(1H)-one as a tan solid: LC-MS (ESI) m/z223.1 [M+H]⁺. The crude product was carried on crude withoutpurification for the next step.

2,5-Dichloro-3-isopropylquinoxaline and3,5-Dichloro-2-isopropylquinoxaline

A mixture of 5-chloro-3-isopropylquinoxalin-2(1H)-one and8-chloro-3-isopropylquinoxalin-2(1H)-one (3.3933 g, 15.239 mmol) andphosphoryl trichloride (27.900 mL, 304.78 mmol) was stirred at 100° C.After 1 h, the mixture was cooled to room temperature. The mixture waspoured into ice (˜200 mL) with stirring and neutralized with NH₄OH (100mL) and ice (˜400 mL) with stirring. The resulting precipitate wascollected by filtration, rinsed with water (200 mL), and dried to give amixture of 2,5-dichloro-3-isopropylquinoxaline and3,5-dichloro-2-isopropylquinoxaline as a red solid: LC-MS (ESI) m/z241.0 [M+H]⁺. The crude product was carried on crude withoutpurification for the next step.

5-Chloro-3-(3-fluorophenyl)-2-isopropylquinoxaline and5-Chloro-2-(3-fluorophenyl)-3-isopropylquinoxaline

A mixture of 2,5-dichloro-3-isopropylquinoxaline and3,5-dichloro-2-isopropyl-quinoxaline (2.7397 g, 11.36 mmol),3-fluorophenylboronic acid (1.749 g, 12.50 mmol),tetrakis(triphenylphosphine)palladium (0.6565 g, 0.5681 mmol), andsodium carbonate anhydrous (6.021 g, 56.81 mmol) in acetonitrile-water(3:1) (120.00 mL) was stirred at 100° C. After 2.5 h, the mixture wascooled to room temperature and partitioned between EtOAc (100 mL) andwater (100 mL). The organic layer was washed with brine (50 mL×2), driedover Na₂SO₄, filtered, and concentrated under reduced pressure. Theresidue was purified by silica gel column chromatography on a 80 g ofRedi-Sep™ column using 0 to 20% gradient of EtOAc in hexane over 25 minand then 20% isocratic of EtOAc for 10 min as eluent to give a mixtureof 5-chloro-3-(3-fluorophenyl)-2-isopropylquinoxaline and5-chloro-2-(3-fluorophenyl)-3-isopropylquinoxaline as a light yellowsyrupy solid: LC-MS (ESI) m/z 301.1 [M+H]⁺. The mixture of tworegioisomers was carried as a mixture without further purification forthe next step.

3-(2-Bromopropan-2-yl)-5-chloro-2-(3-fluorophenyl)quinoxaline and2-(2-bromopropan-2-yl)-5-chloro-3-(3-fluorophenyl)quinoxaline

A mixture of 5-chloro-2-(3-fluorophenyl)-3-isopropylquinoxaline and5-chloro-3-(3-fluorophenyl)-2-isopropylquinoxaline (3.3042 g, 10.99mmol) and 1,3-dibromo-5,5-dimethylhydantoin (4.712 g, 16.48 mmol) weresuspended in carbon tetrachloride (109.9 mL, 10.99 mmol). To the mixturewas added benzoyl peroxide (0.3548 g, 1.099 mmol) and the mixture washeated at reflux. After 20 h, the mixture was cooled to room temperatureand concentrated under reduced pressure. The residue was purified bysilica gel column chromatography on a 120 g of Redi-Sep™ column using 0to 10% gradient of EtOAc in hexane over 15 min and then 10% isocratic ofEtOAc for 30 min as eluent to give3-(2-bromopropan-2-yl)-5-chloro-2-(3-fluorophenyl)quinoxaline and2-(2-bromopropan-2-yl)-5-chloro-3-(3-fluorophenyl)quinoxaline as ayellow solid: LC-MS (ESI) m/z 379.0 and 381.0 [M+H]⁺. The mixture of tworegioisomers was carried as a mixture without further purification forthe next step.

2-(2-Azidopropan-2-yl)-5-chloro-3-(3-fluorophenyl)quinoxaline and3-(2-Azidopropan-2-yl)-5-chloro-2-(3-fluorophenyl)quinoxaline

To a solution of3-(2-bromopropan-2-yl)-5-chloro-2-(3-fluorophenyl)quinoxaline and2-(2-bromopropan-2-yl)-5-chloro-3-(3-fluorophenyl)quinoxaline (1.0000 g,2.634 mmol) in methyl sulfoxide (17.56 mL, 2.634 mmol) was added sodiumazide (0.3425 g, 5.268 mmol), and the mixture was stirred at roomtemperature. After 40 min, the mixture was partitioned between EtOAc(100 mL) and H₂O (100 mL). The organic layer was washed with brine (100mL×1), dried over Na₂SO₄, filtered, and concentrated under reducedpressure to give a mixture of2-(2-azidopropan-2-yl)-5-chloro-3-(3-fluorophenyl)quinoxaline and3-(2-azidopropan-2-yl)-5-chloro-2-(3-fluorophenyl)quinoxaline as ayellow solid: LC-MS (ESI) m/z 342.1 [M+H]⁺. The crude product wascarried on crude without purification for the next step.

2-(8-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)propan-2-amine and2-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)propan-2-amine

To a stirring solution of a mixture of2-(2-azidopropan-2-yl)-5-chloro-3-(3-fluoro-phenyl)quinoxaline and3-(2-azidopropan-2-yl)-5-chloro-2-(3-fluorophenyl)-quinoxaline (0.9002g, 2.634 mmol) in THF-H₂O (4:1) (15.00 mL, 2.634 mmol) was addeddropwise trimethylphosphine, 1.0 M solution in THF (5.268 mL, 5.268mmol) at room temperature and the mixture was stirred at roomtemperature. After 40 min, the mixture was diluted with ice-cold 2 NNaOH (25 mL) and extracted with EtOAc (50 mL×3). The combined organiclayers were washed with brine (50 mL×3), dried over MgSO₄, andconcentrated under the reduced pressure to give a green syrup. The greensyrup was purified by column chromatography on a 120 g of Redi-Sep™column using 0% to 20% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂over 15 min, then 20% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂for 15 min, then 20% to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) inCH₂Cl₂ over 15 min, and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ for 20 min as eluent to give two separated regiosiomers:2-(8-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)propan-2-amine: ¹H NMR(400 MHz, DMSO-d₆) δ ppm 8.01-8.08 (2H, m), 7.79-7.85 (1H, m), 7.47-7.58(2H, m), 7.31-7.46 (2H, m), 1.99 (2H, br. s.), 1.41 (6H, s); LC-MS (ESI)m/z 316.1 [M+H]⁺ and2-(5-chloro-3-(3-fluoro-phenyl)quinoxalin-2-yl)propan-2-amine: ¹H NMR(400 MHz, DMSO-d₆) δ ppm 8.08 (1H, dd, J=8.4, 1.4 Hz), 8.02 (1H, dd,J=7.6, 1.4 Hz), 7.85 (1H, dd, J=8.4, 7.6 Hz), 7.48-7.59 (2H, m),7.40-7.44 (1H, m), 7.33-7.39 (1H, m), 1.93 (2H, s), 1.39 (6H, s); LC-MS(ESI) m/z 316.1 [M+H]⁺at 1.100 min.

N-(2-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)propan-2-yl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.2423 g, 1.218 mmol),2-(5-chloro-3-(3-fluoro-phenyl)quinoxalin-2-yl)propan-2-amine (0.3845 g,1.218 mmol), and N,N-diisopropylethylamine (0.6363 mL, 3.653 mmol) in1-butanol (7.000 mL, 1.218 mmol) was stirred at 100° C. After 62 h, themixture was removed from the heat and concentrated under reducedpressure. The residue was purified by flash chromatography on a silicagel column using 30% of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ as eluentto giveN-(2-(5-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)propan-2-yl)-9H-purin-6-amineas a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.84 (1H, s), 8.12(1H, dd, J=8.4, 1.0 Hz), 8.00 (2H, dd, J=7.5, 1.1 Hz), 7.80-7:91 (1H,m), 7.78 (1H, s), 6.88-7.19 (3H, m), 6.75 (1H, s), 6.41 (1H, s), 1.94(6H, s); LC-MS (ESD m/z 434.2 [M+H]⁺.

Example 104 Preparation ofN-(2-(8-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)propan-2-yl)-9H-purin-6-amineas a TFA salt

A mixture of 6-bromopurine (0.0195 g, 0.0982 mmol),2-(8-chloro-3-(3-fluoro-phenyl)quinoxalin-2-yl)propan-2-amine (Preparedin Example 103, 0.0310 g, 0.0982 mmol), and N,N-diisopropylethylamine(0.0513 mL, 0.295 mmol) in 1-butanol (1.00 mL, 0.0982 mmol) was stirredat 100° C. for 62 h and then the mixture was irradiated at 300 W at 140°C. in a microwave reactor. The mixture was removed from the heat andconcentrated under reduced pressure. The mixture was dissolved in DMSO(1.5 mL) and purified by semi-prep-HPLC on a Gemini™ 10 μC18 column(250×21.2 mm, 10 μm) using 20-70% gradient of CH₃CN (0.1% of TFA) inwater (0.1% of TFA) over 40 min as eluent to giveN-(2-(8-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)propan-2-yl)-9H-purin-6-amineas a TFA salt as a yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.26(1H, s), 7.99-8.12 (3H, m), 7.76-7.96 (2H, m), 6.94-7.08 (2H, m), 6.76(1H, d, J=7.0 Hz), 6.64 (1H, d, J=9.0 Hz), 2.01 (6H, s); LC-MS (ESI) m/z434.2 [M+H]⁺(Exact Mass of neutral form: 433.122).

Example 105 Preparation ofN—((S)-1-(8-Chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a TFA salt:2-((S)-1-(8-Chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)quinolin-3-yl)-ethyl)isoindoline-1,3-dione

A mixture of(S)-2-(1-(2,8-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (0.2000g, 0.539 mmol), 3-(trifluoromethyl)pyrazole (0.0733 g, 0.539 mmol),cesium carbonate (0.351 g, 1.08 mmol) and in DMF (1.80 mL, 0.539 mmol)was stirred at 100° C. After 2 h, The mixture was cooled to roomtemperature. To the cooled mixture was added water (30 mL). The mixturewas extracted with EtOAc (50 mL×2). The combined organic layers werewashed with brine (50 mL×1), dried over MgSO₄, filtered, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography on a 40 g of Redi-Sep™ column using 0 to 10%gradient of EtOAc in hexane over 10 min, then 10% isocratic of EtOAc for10 min, then 10 to 50% gradient of EtOAc in hexane over 20 min, then 50%isocratic of EtOAc for 10 min as eluent to give2-((S)-1-(8-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dioneas a yellow syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.05 (1H, s), 8.51(1H, d, J=2.2 Hz), 8.25 (1H, dd, J=8.4, 1.0 Hz), 8.08 (1H, dd, J=7.7,0.9 Hz), 7.63-7.85 (5H, m), 6.92 (1H, d, J=2.7 Hz), 5.94-6.05 (1H, m),1.83 (3H, d, J=7.0 Hz); LC-MS (ESI) m/z 471.1 [M+H]⁺.

(1S)-1-(8-Chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)quinolin-3-yl)-ethanamine

To a suspension of2-((S)-1-(8-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)-quinolin-3-yl)ethyl)isoindoline-1,3-dione(0.0435 g, 0.0924 mmol) in ethanol (1.85 mL, 0.0924 mmol) was addedhydrazine, anhydrous (0.0290 mL, 0.924 mmol), and the mixture wasstirred under reflux. After 30 min, the mixture was cooled to roomtemperature. The mixture was concentrated under reduced pressure. Theresidue was purified by column chromatography on a 40 g of Redi-Sep™column using 0% to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂over 14 min, and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 5min as eluent to give(1S)-1-(8-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)quinolin-3-yl)ethanamineas a yellow syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.98 (1H, s),8.65-8.70 (1H, m), 8.11 (1H, dd, J=8.2, 1.2 Hz), 8.02 (1H, dd, J=7.4,1.2 Hz), 7.65-7.72 (1H, m), 7.12 (1H, d, J=2.7 Hz), 4.53 (1H, q, J=6.8Hz), 2.26 (2H, br. s.), 1.24 (3H, d, J=6.7 Hz); LC-MS (ESI) m/z 341.0[M+H]⁺

N—((S)-1-(8-Chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)quinolin-3-yl)-ethyl)-9H-purin-6-amineas a TFA salt

A mixture of 6-bromopurine (0.0107 g, 0.0540 mmol),(1S)-1-(8-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)quinolin-3-yl)ethanamine(0.0184 g, 0.0540 mmol), and N,N-diisopropylethylamine (0:0282 mL, 0.162mmol) in 1-butanol (1.00 mL, 0.0540 mmol) was stirred at 100° C. After13 h at 100° C. and then 6 h at 140° C. in microwave reactor, themixture was removed from the heat and concentrated under reducedpressure. The crude mixture was dissolved in DMSO (1.5 mL) and purified(1.5 mL (30.9 mg)×1 injection) by semi-prep-HPLC on a Gemini™ 10 μC18column (250×21.2 mm, 10 μm) using 20-70% gradient of CH₃CN (0.1% of TFA)in water (0.1% of TFA) over 40 min as eluent, and dried on thelyophilizer to giveN—((S)-1-(8-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a TFA salt as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm8.73-8.93 (3H, m), 8.15-8.41 (2H, m), 7.98-8.09 (2H, m), 7.60-7.71 (1H,m), 7.11 (1H, d, J=2.3 Hz), 5.85 (1H, br. s.), 1.71 (3H, br. s.); LC-MS(ESD m/z 459.1 [M+H]⁺ (Exact Mass of neutral form: 458.098).

Example 106 Preparation ofN—((S)-1-(5-Chloro-3-(3-fluorophenyl)-quinoxalin-2-yl)ethyl)-9H-purin-6-amineandN—((R)-1-(5-Chloro-3-(3-fluoro-phenyl)quinoxalin-2-yl)ethyl)-91H-purin-6-amine5-Chloro-3-(3-fluorophenyl)quinoxaline-2-carbaldehyde

A mixture of 2-(bromomethyl)-5-chloro-3-(3-fluorophenyl)quinoxaline(Prepared in Example 95, 0.8089 g, 2.301 mmol) and sodium metaperiodate(0.9842 g, 4.601 mmol) in DMF (15.34 mL, 2.301 mmol) was heated at 150°C. with stirring. After 5 h, the mixture was cooled to room temperature,diluted with EtOAc (100 mL), washed with sat'd Na₂S₂O₃ (50 mL×1) andbrine (50 mL×2), dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was purified by silica gel columnchromatography on a 80 g of Redi-Sep™ column using 0 to 10% gradient ofEtOAc in hexane over 10 min, then 10% isocratic of EtOAc for 20 min,then 10 to 20% gradient of EtOAc in hexane over 20 min, then 20%isocratic of EtOAc for 20 min as eluent to give5-chloro-3-(3-fluorophenyl)quinoxaline-2-carbaldehyde as a solid: ¹H NMR(400 MHz, DMSO-d₆) δ ppm 10.18 (1H, s), 8.31 (1H, dd, J=8.2, 1.2 Hz),8.25 (1H, dd, J=7.4, 1.2 Hz), 7.99 (1H, dd, J=8.4, 7.6 Hz), 7.56-7.70(3H, m), 7.38-7.46 (1 H, m); LC-MS (ESI) m/z 287.0 [M+H]⁺.

1-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethanol

To a stirring heterogeneous mixture of5-chloro-3-(3-fluorophenyl)quinoxaline-2-carbaldehyde (0.4405 g, 1.537mmol) in THF (14.95 mL, 1.537 mmol) was added methylmagnesium bromide 3M in diethyl ether (1.024 mL, 3.073 mmol) dropwise at 0° C. and themixture was then allowed to warm to room temperature. After 3 h, thereaction was quenched with saturated aq. NH₄Cl (50 mL) and extractedwith EtOAc (50 mL×2). The combined orgainc layers were washed with water(50 mL×1), brine (50 mL×1), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography on a 40 g of Redi-Sep™ column using 0 to 50%gradient of EtOAc in hexane over 14 min and then 50% isocratic of EtOAcfor 10 min as eluent to give1-(5-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethanol as a solid: ¹H NMR(400 MHz, DMSO-d₆) δ ppm 8.14 (1H, dd, J=8.4, 1.2 Hz), 8.06 (1H, dd,J=7.6, 1.4 Hz), 7.87 (1H, dd, J=8.4, 7.6 Hz), 7.56-7.71 (3H, m),7.37-7.46 (1H, m), 5.50 (1H, d, J=6.1 Hz), 5.04-5.13 (1H, m), 1.48 (3H,d, J=6.3 Hz); LC-MS (ESI) m/z 303.1 [M+H]⁺.

2-(1-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethyl)isoindoline-1,3-dione

To a solution of 1-(5-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethanol(0.2875 g, 0.9497 mmol) in tetrahydrofuran (9.497 mL, 0.9497 mmol) wereadded triphenyl-phosphine (0.7473 g, 2.849 mmol), phthalimide (0.4192 g,2.849 mmol), and diisopropyl azodicarboxylate (0.5518 mL, 2.849 mmol).The reaction mixture was stirred at room temperature. After 1 h, themixture was concentrated under reduced pressure and partitioned betweenEtOAc (100 mL) and brine (100 mL). The organic layer was dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography on a 40 g of Redi-Sep™column using 0 to 50% gradient of EtOAc in hexane over 20 min and 50%isocratic of EtOAc for 5 min as eluent to give2-(1-(5-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethyl)isoindoline-1,3-dioneas a yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.19 (1H, dd, J=8.4,1.4 Hz), 8.09 (1H, dd, J=7.6, 1.4 Hz), 7.91 (1H, dd, J=8.4, 7.6 Hz),7.73-7.80 (2H, m), 7.60-7.68 (2 H, m), 7.31-7.38 (1H, m), 7.14-7.24 (2H,m), 7.00-7.09 (1H, m), 6.04-6.13 (1H, m), 1.77 (3H, d, J=6.7 Hz); LC-MS(ESI) m/z 432.1 [M+H]⁺.

1-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethanamine

To a suspension of2-(1-(5-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethyl)-isoindoline-1,3-dione(0.2272 g, 0.526 mmol) in ethanol (10.5 mL, 0.526 mmol) was addedhydrazine, anhydrous (0.165 mL, 5.26 mmol), and the mixture was stirredunder reflux. After 30 min, the mixture was cooled to room temperature.The mixture was concentrated under reduced pressure. The residue waspurified by column chromatography on a 40 g of Redi-Sep™ column using 0%to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14 min,and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 3 min aseluent to give 1-(5-chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethanamineas a yellow syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.11 (1H, dd, J=8.4,1.4 Hz), 8.00-8.05 (1 H, m), 7.86 (1H, dd, J=8.4, 7.6 Hz), 7.57-7.69(3H, m), 7.38-7.47 (1H, m), 4.32 (1H, q, J=6.7 Hz), 2.12 (2H, br. s.),1.31 (3H, d, J=6.7 Hz); LC-MS (ESI) m/z 302.0 [M+H]⁺.

N—((S)-1-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amine andN—((R)-1-(5-Chloro-3-(3-fluorophenyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.09794 g, 0.4921 mmol),1-(5-chloro-3-(3-fluoro-phenyl)quinoxalin-2-yl)ethanamine (0.1485 g,0.4921 mmol), and N,N-diiso-propylethylamine (0.2572 mL, 1.476 mmol) in1-butanol (6.340 mL, 0.4921 mmol) was stirred at 100° C. After 22 h, themixture was removed from the heat and concentrated under reducedpressure. The residue was purified by column chromatography on a 40 g ofRedi-Sep™ column using 0% to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ over 14 min and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) for 10 min as eluent to give the desired product as a racemicmixture as a yellow solid (0.2806 g). The yellow solid was suspended inCH₂Cl₂-MeOH (2:1) and filtered to giveN-(1-(5-chloro-3-(3-fluoro-phenyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineas a white solid. The racemic mixture was separated (5 injections of 40mg in 1 mL) on a Chiralpak™ IA column (30×250 mm, 5 μm) using 10%isocratic of isopropanol in hexane for 40 min as eluent to give twoseparated isomers:N—OS)-1-(5-chloro-3-(3-fluoro-phenyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineas a yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.90 (1H, s),7.92-8.28 (5H, m), 7.78-7.88 (1 H, m), 7.61-7.75 (2H, m), 7.55 (1H, s),7.32 (1H, s), 5.72 (1H, s), 1.55 (3H, d, J=6.3 Hz); LC-MS (ESI) m/z420.1 [M+H]⁺andN4(R)-1-(5-chloro-3-(3-fluoro-phenyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineas a yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.91 (1H, s),7.96-8.30 (5H, m), 7.82 (1H, t, J=8.0 Hz), 7.62-7.75 (2H, m), 7.54 (1H,s), 7.32 (1H, s), 5.72 (1H, s), 1.55 (3 H, d, J=5.1 Hz); LC-MS (ESI) m/z420.1 [M+H]⁺.

Example 107 Preparation ofN—((S)-1-(8-Chloro-2-(thiazol-5-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a TFA salt2-((S)-1-(8-Chloro-2-(thiazol-5-yl)quinolin-3-yl)ethyl)isoindoline-1,3-dione

A solution of(S)-2-(1-(2,8-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (0.2000g, 0.5388 mmol), 5-(tributylstannyl)thiazole (0.4032 g, 1.078 mmol), andtetrakis(triphenylphosphine)palladium(0) (0.06226 g, 0.05388 mmol) in1,4-dioxane (4.490 mL, 0.5388 mmol) was stirred at 100° C. After 94 h,the mixture was cooled to room temperature and concentrated underreduced pressure. The residue was purified by column chromatography on a40 g of Redi-Sep™ column using 0 to 100% gradient of EtOAc in hexaneover 14 min and then 100% isocratic of EtOAc for 7 min as eluent to give2-((S)-1-(8-chloro-2-(thiazol-5-yl)-quinolin-3-yl)ethyl)isoindoline-1,3-dioneas a light yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.10 (1H, s),8.83 (1H, s), 8.30 (1H, d, J=0.8 Hz), 8.13 (1H, dd, J=8.2, 1.2 Hz), 7.99(1H, dd, J=7.6, 1.4 Hz), 7.71-7.82 (4H, m), 7.60-7.69 (1H, m), 6.03 (1H,q, J=7.2 Hz), 1.88 (3H, d, J=7.0 Hz); LC-MS (ESI) m/z 420.1 [M+H]⁺.

(1S)-1-(8-Chloro-2-(thiazol-5-yl)quinolin-3-yl)ethanamine

To a suspension of2-((S)-1-(8-chloro-2-(thiazol-5-yl)quinolin-3-yl)ethyl)-isoindoline-1,3-dione(0.1280 g, 0.3048 mmol) in ethanol (6.097 mL, 0.3048 mmol) was addedhydrazine, anhydrous (0.09568 mL, 3.048 mmol), and the mixture wasstirred under reflux. After 30 min, the mixture was cooled to roomtemperature. The mixture was concentrated under reduced pressure. Theresidue was purified by column chromatography on a 40 g of Redi-Sep™column using 0% to 100% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂over 14 min and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) inCH₂Cl₂ for 5 min as eluent to give(1S)-1-(8-chloro-2-(thiazol-5-yl)quinolin-3-yl)ethanamine as a solid: ¹HNMR (400 MHz, DMSO-d₆) δ ppm 9.26 (1H, s), 8.77 (1H, s), 8.49 (1 H, s),8.00 (1H, dd, J=8.2, 1.2 Hz), 7.93 (1H, dd, J=7.4, 1.2 Hz), 7.58 (1H,dd, J=8.2, 7.4 Hz), 4.63 (1H, q, J=6.4 Hz), 1.42 (3H, d, J=6.7 Hz);LC-MS (ESI) m/z 290.0 [M+H]⁺.

N—((S)-1-(8-Chloro-2-(thiazol-5-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a TFA salt

A mixture of 6-bromopurine (0.01634 g, 0.08213 mmol),(1S)-1-(8-chloro-2-(thiazol-5-yl)quinolin-3-yl)ethanamine (0.02380 g,0.08213 mmol), and N,N-diisopropylethylamine (0.04292 mL, 0.2464 mmol)in 1-butanol (1.521 mL, 0.08213 mmol) was stirred at 100° C. After 68 h,the mixture was removed from the heat and concentrated under reducedpressure. The crude mixture was purified (1.5 mL (42.86 mg)×1 injection)by semi-prep-HPLC on a Gemini™ 10μ C18 column (250×21.2 mm, 10 μm) using20-70% gradient of CH₃CN (0.1% of TFA) in water (0.1% of TFA) over 40min as eluent, and dried on the lyophilizer to giveN—((S)-1-(8-chloro-2-(thiazol-5-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a TFA salt as a light yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm9.27 (1H, s), 8.92 (1H, s), 8.67 (1H, s), 8.54 (1H, s), 8.25-8.40 (2H,m), 7.95 (2H, d, J=7.8 Hz), 7.53-7.62 (1H, m), 5.97 (1H, s), 1.70 (3H,d, J=5.5 Hz); LC-MS (ESI) m/z 408.1 [M+H]⁺ (Exact Mass of neutral form:407.072).

Example 108 Preparation ofN—((S)-1-(5-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amineandN—((R)-1-(5-Chloro-2-(3-fluorophenyl)-quinolin-3-yl)ethyl)-9H-purin-6-amine5-Chloro-2-(3-fluorophenyl)quinoline-3-carbaldehyde

A mixture of 2,5-dichloroquinoline-3-carbaldehyde (1.0000 g, 4.424mmol), 3-fluorophenylboronic acid (0.6808 g, 4.866 mmol),tetrakis(triphenylphosphine)-palladium (0.2556 g, 0.2212 mmol), andsodium carbonate anhydrous (2.344 g, 22.12 mmol) in acetonitrile-water(3:1) (0.04000 mL) was stirred at 100° C. After 3 h, the mixture wascooled to room temperature and partitioned between EtOAc (100 mL) andwater (100 mL). The organic layer was washed with brine (50 mL×2), driedover Na₂SO₄, filtered, and concentrated under reduced pressure. Theresidue was purified by silica gel column chromatography on a 80 g ofRedi-Sep™ column using 0 to 50% gradient of EtOAc in hexane over 25 minand then 50% isocratic of EtOAc for 10 min as eluent to give5-chloro-2-(3-fluorophenyl)-quinoline-3-carbaldehyde as a yellow solid:¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.14 (1H, s), 9.06 (1H, d, J=0.8 Hz),8.13-8.18 (1H, m), 7.92-8.00 (2H, m), 7.59-7.67 (2H, m), 7.53-7.58 (1H,m), 7.39-7.47 (1H, m); LC-MS (ESI) m/z 286.0 [M+H]⁺.

1-(5-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanol

To a stirring heterogeneous mixture of5-chloro-2-(3-fluorophenyl)quinoline-3-carbaldehyde (1.0120 g, 3.542mmol) in tetrahydrofuran (35.42 mL, 3.542 mmol) was addedmethylmagnesium bromide 3 M in diethyl ether (3.542 mL, 10.63 mmol)dropwise at 0° C. (started at 11:10 am), and the mixture was thenstirred at room temperature. After 3 h, the reaction was quenched withsaturated aq. NH₄Cl (50 mL) and extracted with EtOAc (50 mL×2). Thecombined organic layers were washed with water (50 mL×1), brine (50mL×1), dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The residue was purified by silica gel column chromatographyon a 80 g of Redi-Sep™ column using 0 to 50% gradient of EtOAc in hexaneover 25 min and then 50% isocratic of EtOAc for 10 min as eluent to give1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanol as a yellow solid:¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.79 (1H, s), 8.00-8.05 (1H, m),7.73-7.85 (2H, m), 7.54-7.63 (1H, m), 7.41-7.47 (2H, m), 7.33-7.40 (1H,m), 5.56 (1H, d, J=4.3 Hz), 4.98-5.06 (1H, m), 1.27 (3H, d, J=6.7 Hz);LC-MS (ESI) m/z 302.0 [M+H]⁺.

2-(1-(5-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dione

To a solution of 1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanol(0.9927 g, 3.290 mmol) in tetrahydrofuran (32.90 mL, 3.290 mmol) wereadded triphenylphosphine (2.589 g, 9.870 mmol), phthalimide (1.452 g,9.870 mmol), and diisopropyl azodicarboxylate (1.943 mL, 9.870 mmol).The reaction mixture was stirred at room temperature. After 1.5 h, themixture was concentrated under reduced pressure and partitioned betweenEtOAc (100 mL) and brine (100 mL). The organic layer was dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography on a 80 g of Redi-Sep™column using 0 to 50% gradient of EtOAc in hexane over 25 min and 50%isocratic of EtOAc for 10 min as eluent to give2-(1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dioneas a light yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.84 (1H, s),7.98-8.04 (1H, m), 7.85-7.90 (1H, m), 7.82 (1H, s), 7.74-7.81 (2H, m),7.65-7.71 (2H, m), 7.21-7.33 (2H, m), 7.12-7.19 (2H, m), 5.76-5.82 (1H,m), 1.83 (3H, d, J=6.7 Hz); LC-MS (ESI) m/z 431.0 [M+H]⁺.

1-(5-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine

To a suspension of2-(1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-isoindoline-1,3-dione(1.1115 g, 2.580 mmol) in ethanol (51.59 mL, 2.580 mmol) was addedhydrazine, anhydrous (0.8097 mL, 25.80 mmol), and the mixture wasstirred under reflux. After 1 h, the mixture was cooled to roomtemperature. The mixture was diluted with CH₂Cl₂(50 mL), filtered toremoved the precipitated byproduct, and washed the filtered solid withCH₂Cl₂(50 mL). The filtrate containing the desired product wasconcentrated under reduced pressure. The residue was purified by columnchromatography on a 80 g of Redi-Sep™ column using 0% to 100% gradientof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 25 min, and then 100%isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 4 min as eluent to give1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine as a yellowsyrup: NMR (400 MHz, DMSO-d₆) δ ppm 8.87 (1H, s), 7.97-8.02 (1H, m),7.78-7.82 (1H, m), 7.73 (1H, dd, J=8.4, 7.6 Hz), 7.52-7.61 (1H, m),7.41-7.50 (2H, m), 7.31-7.39 (1H, m), 4.29 (1H, q, J=6.7 Hz), 2.10 (2H,br. s.), 1.19 (3H, d, J=6.7 Hz); LC-MS (ESD m/z 301.1 [M+H]⁺.

N—((S)-1-(5-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amineandN—((R)-1-(5-Chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.4753 g, 2.388 mmol),1-(5-chloro-2-(3-fluoro-phenyl)quinolin-3-yl)ethanamine (0.7183 g, 2.388mmol), and N,N-diisopropylethylamine (1.248 mL, 7.165 mmol) in 1-butanol(20.00 mL, 2.388 mmol) was stirred at 110° C. After 59 h, the mixturewas removed from the heat and concentrated under reduced pressure. Theresidue was purified by column chromatography on a 80 g of Redi-Sep™column using 0% to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂over 20 min and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) inCH₂Cl₂ for 20 min as eluent to give the desired product as a racemicmixture as a tan solid (0.7361 g,). The tan solid was suspended in MeOH,sonicated, and filtered to giveN-(1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a racemic mixture as a white solid. The racemic mixture (0.1486 g)was separated (3 injections of—50 mg in 1.5 mL) on a Chiralpak™ IAcolumn (30×250 mm, 5 μm) using 10% isocratic of isopropanol in hexanefor 40 min as eluent to give two separated isomers:N—((S)-1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a light yellow solid: ¹H NMR (400 MHz, DMF) 8 ppm 12.92 (1H, br. s.),8.83 (1H, br. s.), 8.63 (1H, br. s.), 8.11 (2H, d, J=18.4 Hz), 8.00 (1H,d, J=8.2 Hz), 7.53-7.81 (5H, m), 7.29-7.39 (1H, m), 5.61 (1H, br. s.),1.47 (3H, br. s.); LC-MS (ESI) m/z 419.2 [M+H]⁺ andN—((R)-1-(5-chloro-2-(3-fluoro-phenyl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a light yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.93 (1H, s),8.84 (1H, s), 8.63 (1H, s), 8.10 (2 H, d, J=18.0 Hz), 8.00 (1H, d, J=8.2Hz), 7.52-7.81 (5H, m), 7.28-7.39 (1H, m), 5.62 (1H, br. s.), 1.47 (3H,br. s.); LC-MS (ESI) m/z 419.2 [M+H]⁺.

Example 109 Preparation ofN—((S)-1-(8-Chloro-2-(2,3-difluorophenyl)-quinolin-3-yl)ethyl)-9H-purin-6-amine2-(((S)-1-(8-Chloro-2-(2,3-difluorophenyl)quinolin-3-yl)ethyl)carbamoyl)-benzoicacid

A mixture of(S)-2-(1-(2,8-dichloroquinolin-3-yl)ethyl)isoindoline-1,3-dione (0.2000g, 0.5388 mmol), 2,3-difluorobenzeneboronic acid (0.09358 g, 0.5926mmol), tetrakis(triphenylphosphine)palladium (0.03113 g, 0.02694 mmol),and sodium carbonate anhydrous (0.2855 g, 2.694 mmol) inacetonitrile-water (3:1) (5.200 mL, 0.5387 mmol) was stirred at 85° C.After 19 h, the mixture was cooled to room temperature and partitionedbetween CH₂Cl₂ (30 mL) and 2 N HCl (30 mL). The organic layer was washedwith brine (50 mL×2), dried over Na₂SO₄, filtered, and concentratedunder reduced pressure to give2-(((S)-1-(8-chloro-2-(2,3-difluorophenyl)quinolin-3-yl)ethyl)carbamoyl)benzoicacid as a yellow foam type solid: LC-MS (ESI) m/z 467.0 [M+H]⁺.

(1S)-1-(8-Chloro-2-(2,3-difluorophenyl)quinolin-3-yl)ethanamine

To a suspension of2-(((S)-1-(8-chloro-2-(2,3-difluorophenyl)quinolin-3-yl)ethyl)-carbamoyl)benzoicacid (0.2515 g, 0.5387 mmol) in ethanol (3.000 mL, 0.5387 mmol) wasadded 12 N HCl (1.500 mL, 18.00 mmol), and the mixture was stirred underreflux. After 12 h, the mixture was poured into ice water (50 mL). Themixture was neutralized with NaHCO₃ and extracted with CH₂Cl₂ (50 mL×3).The combined organic layers were washed with brine (50 mL×3), dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The residuewas purified by column chromatography on a 40 g of Redi-Sep™ columnusing 0% to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 14min and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 5min as eluent to give(1S)-1-(8-chloro-2-(2,3-difluorophenyl)quinolin-3-yl)ethanamine as alight green syrup: LC-MS (ESI) m/z 319.1 [M4-1-1]⁺.

N—((S)-1-(8-Chloro-2-(2,3-difluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.07479 g, 0.3758 mmol),(1S)-1-(8-chloro-2-(2,3-difluorophenyl)quinolin-3-yl)ethanamine (0.1089g, 0.3416 mmol), and N,N-diisopropylethylamine (0.1785 mL, 1.025 mmol)in 1-butanol (3.416 mL, 0.3416 mmol) was stirred at 110° C. After 14.5h, the mixture was removed from the heat and concentrated under reducedpressure. The residue was purified by column chromatography on a 40 g ofRedi-Sep™ column using 0 to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ over 14 min and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ for 20 min as eluent to giveN—((S)-1-(8-chloro-2-(2,3-difluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amineas a light yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.86 (1H, s),8.71 (1 H, s), 7.91-8.28 (5H, m), 7.61 (1H, t, J=7.8 Hz), 7.47 (2H, br.s.), 7.29 (1H, br. s.), 5.42 (1H, br. s.), 1.58 (3H, d, J=7.0 Hz); LC-MS(ESI) m/z 437.2 [M+H]⁺.

Example 110 Preparation ofN—((S)-1-(3-(2-chlorophenyl)-5-(trifluoro-methyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineandN4(R)-1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amine3-Methyl-8-(trifluoromethyl)quinoxalin-2-ol and3-Methyl-5-(trifluoro-methyl)quinoxalin-2-ol

A mixture of ethyl pyruvate (1.262 mL, 11.35 mmol) and3-(trifluoromethyl)-benzene-1,2-diamine (2.0000 g, 11.35 mmol) inpolyphosphoric acid (16.000 g) was stirred and heated at 115° C. After 5h, the mixture was cooled to room temperature, thoroughly mixed withwater (100 mL), and neutralized with 2 N NaOH (160 mL). The resultingprecipitate was collected by filtration and the solid was washed withwater (250 mL) and dried to give a dark brown solid as a mixture of tworegioisomers. The dark brown solid was purified by flash columnchromatography on a silica gel column (˜400 mL volume of SiO₂) using 30%of EtOAc in hexane and then 50% of EtOAc in hexane to give two separatedregioisomers: 3-methyl-8-(trifluoromethyl)quinoxalin-2-ol as an orangesolid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.73 (1H, s), 8.00 (1H, s), 7.86(1H, s), 7.45 (1H, s), 2.45 (3H, s); LC-MS (ESI) m/z 229.0 [M+H]⁺ and3-methyl-5-(trifluoromethyl)quinoxalin-2-ol as an orange solid: NMR (400MHz, DMSO-d₆) δ ppm 12.58 (1H, s), 7.58-7.64 (2H, m), 7.51-7.57 (1H, m),2.44 (3H, s); LC-MS (ESI) m/z 229.0 [M+H]⁺.

3-Chloro-2-methyl-5-(trifluoromethyl)quinoxaline

A mixture of 3-methyl-8-(trifluoromethyl)quinoxalin-2-ol (0.8292 g,3.634 mmol) and phosphorous oxychloride (6.653 mL, 72.68 mmol) wasstirred at 100° C. After 1.5 h, the mixture was cooled to roomtemperature. The mixture was poured into ice (˜50 mL) with stirring andneutralized with NH₄OH (30 mL) and ice with stirring. The resultingprecipitate was collected by filtration, rinsed with water (100 mL), anddried to give 3-chloro-2-methyl-5-(trifluoromethyl)-quinoxaline as apink solid: ¹H NMR (400 MHz, DMF) 8 ppm 8.35 (1H, d, J=8.4 Hz), 8.25(1H, d, J=7.4 Hz), 7.94-8.02 (1H, m), 2.80 (3H, s); LC-MS (ESI) m/z247.0 [M+H]⁺. The pink solid was carried on crude without purificationfor the next step.

3-(2-Chlorophenyl)-2-methyl-5-(trifluoromethyl)quinoxaline

A mixture of 3-chloro-2-methyl-5-(trifluoromethyl)quinoxaline (0.7939 g,3.219 mmol), [Reactants], tetrakis(triphenylphosphine)palladium (0.1860g, 0.1610 mmol), and sodium carbonate anhydrous (1.706 g, 16.10 mmol) inCH₃CN—H₂O (3:1) (32.00 mL) was stirred at 100° C. After 4 h, the mixturewas cooled to room temperature and partitioned between EtOAc (100 mL)and water (100 mL). The organic layer was washed with brine (50 mL×2),dried over Na₂SO₄, filtered, and concentrated under reduced pressure.The residue was purified by silica gel column chromatography on a 80 gof Redi-Sep™ column using 0 to 50% gradient of EtOAc in hexane over 15min and then 50% isocratic of EtOAc for 4 min as eluent to give3-(2-chlorophenyl)-2-methyl-5-(trifluoromethyl)quinoxaline as an orangesyrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.36-8.41 (1H, m), 8.25 (1 H, d,J=7.4 Hz), 8.01 (1H, t, J=7.8 Hz), 7.66-7.71 (1H, m), 7.54-7.65 (3H, m),2.54 (3H, s); LC-MS (ESI) m/z 323.0 [M+1-1]⁺.

2-(Bromomethyl)-3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxaline

3-(2-Chlorophenyl)-2-methyl-5-(trifluoromethyl)quinoxaline (0.9969 g,3.089 mmol) and 1,3-dibromo-5,5-dimethylhydantoin (0.5299 g, 1.853 mmol)were suspended in carbon tetrachloride (30.89 mL, 3.089 mmol). To themixture was added benzoyl peroxide (0.09977 g, 0.3089 mmol) and themixture was heated at reflux. After 20 h, the mixture was cooled to roomtemperature and concentrated under reduced pressure. The residue waspurified by silica gel column chromatography on a 80 g of Redi-Sep™column using 0 to 5% gradient of EtOAc in hexane over 10 min, then 5%isocratic of EtOAc for 30 min, then 5 to 20% gradient of EtOAc in hexaneover 20 min, then 20% isocratic of EtOAc for 4 min as eluent to give2-(bromomethyl)-3-(2-chlorophenyl)-5-(trifluoromethyl)-quinoxaline as anoff-white syrupy solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.48 (1H, dd,J=8.6, 0.8 Hz), 8.37 (1H, d, J=6.7 Hz), 8.09 (1H, t, J=7.8 Hz),7.55-7.77 (4H, m), 4.73 (2H, d, J=61.8 Hz); LC-MS (ESI) m/z 403.0[M+11]⁺.

3-(2-Chlorophenyl)-5-(trifluoromethyl)quinoxaline-2-carbaldehyde

A mixture of2-(bromomethyl)-3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxaline(0.5137 g, 1.279 mmol) and sodium metaperiodate (0.1416 mL, 2.558 mmol)in DMF (8.527 mL, 1.279 mmol) was heated at 150° C. with stirring. After3 h, the mixture was cooled to room temperature, diluted with EtOAc (100mL), washed with brine (50 mL×2), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography on a 80 g of Redi-Sep™ column using 0 to 10%gradient of EtOAc in hexane over 10 min, then 10% isocratic of EtOAc for20 min, then 10 to 40% gradient of EtOAc in hexane over 20 min, then 40%isocratic of EtOAc for 5 min as eluent to give3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxaline-2-carbaldehyde as ayellow syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.15 (1H, s), 8.66 (1H,dd, J=8.6, 1.2 Hz), 8.52 (1H, d, J=7.0 Hz), 8.18 (1H, t, J=8.0 Hz),7.53-7.67 (4H, m); LC-MS (ESI) m/z 337.0 [M+H]⁺.

1-(3-(2-Chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethanol

To a stirring heterogeneous mixture of3-(2-chlorophenyl)-5-(trifluoromethyl)-quinoxaline-2-carbaldehyde(0.2129 g, 0.632 mmol) in tetrahydrofuran (6.32 mL, 0.632 mmol) wasadded methylmagnesium bromide 3 M in diethyl ether (0.632 mL, 1.90 mmol)dropwise at 0° C. (started at 11:20 am), and the mixture was thenstirred at room temperature. After 3 h, the reaction was quenched withsaturated aq. NH₄Cl (50 mL) and extracted with EtOAc (50 mL×2). Thecombined organic layers were washed with water (50 mL×1), brine (50mL×1), dried over Na₂SO₄, filtered, and concentrated under reducedpressure to give a brown syrup. The brown syrup was purified by silicagel column chromatography on a 80 g of Redi-Sep™ column using 0 to 50%gradient of EtOAc in hexane over 25 min and then 50% isocratic of EtOAcfor 10 min as eluent to give1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethanol as asolid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.47 (1H, d, J=8.6 Hz), 8.31 (1H,d, J=7.0 Hz), 8.05 (1H, t, J=8.0 Hz), 7.48-7.71 (4H, m), 5.33 (1H, br.s.), 4.84 (1H, br. s.), 1.28-1.55 (3H, m); LC-MS (ESI) m/z 353.0 [M+H]⁺.

2-(1-(3-(2-Chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethyl)-isoindoline-1,3-dione

To a solution of1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethanol(0.08980 g, 0.2546 mmol) in tetrahydrofuran (2.546 mL, 0.2546 mmol) wereadded triphenylphosphine (0.2003 g, 0.7637 mmol), phthalimide (0.1124 g,0.7637 mmol), and diisopropyl azodicarboxylate (0.1504 mL, 0.7637 mmol).The reaction mixture was stirred at room temperature. After 1 h, themixture was concentrated under reduced pressure and partitioned betweenEtOAc (100 mL) and brine (100 mL). The organic layer was dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography on a 40 g of Redi-Sep™column using 0 to 50% gradient of EtOAc in hexane over 20 min and 50%isocratic of EtOAc for 10 min as eluent to give2-(1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethyl)-isoindoline-1,3-dioneas a yellow solid: LC-MS (ESI) m/z 482.0 [M+H]⁺.

1-(3-(2-Chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethanamine

To a suspension of2-(1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)-ethyl)isoindoline-1,3-dione(0.07720 g, 0.160 mmol) in ethanol (3.20 mL, 0.160 mmol) was addedhydrazine hydrate (0.0499 mL, 1.60 mmol), and the mixture was stirredunder reflux. After 30 min, the mixture was cooled to room temperature.The mixture was concentrated under reduced pressure. The residue waspurified by column chromatography on a 40 g of Redi-Sep™ column using 0%to 100% gradient of CH₂Cl₂:MeOH:NR_(I)OH (89:9:1) in CH₂Cl₂ over 14 min,and then 100% isocratic of CH₂Cl₂:MeOH:NH₄OH (89:9:1) for 3 min aseluent to give1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethanamine as ayellow syrup: LC-MS (ESI) m/z 352.1 [M+H]⁺.

N—((S)-1-(3-(2-Chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineandN—((R)-1-(3-(2-Chlorophenyl)-5-(trifluoromethyl)-quinoxalin-2-yl)ethyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.0383 g, 0.192 mmol),1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethanamine(0.0564 g, 0.160 mmol), and N,N-diisopropylethylamine (0.0838 mL, 0.481mmol) in 1-butanol (1.60 mL, 0.160 mmol) was stirred at 110° C. After 19h, the mixture was removed from the heat and concentrated under reducedpressure. The residue was purified by column chromatography on a 40 g ofRedi-Sep™ column using 0 to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ over 14 min and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ for 20 min as eluent to giveN-(1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineas a light yellow solid. The racemic mixture (0.0372 g) was separated ona Chiralpak™ IA column (30×250 mm, 5 μm) using 15% isocratic ofisopropanol in hexane for 40 min as eluent to give two separatedisomers:N—((S)-1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineas an off-white solid: ¹H NMR (400 MHz, choroform-d) 8 ppm 8.23-8.51(2H, m), 8.06-8.19 (1H, m), 7.78-8.04 (2H, m), 7.32-7.67 (4H, m), 5.87(1H, br. s.), 1.57 (3H, dd, J=67.4, 6.4 Hz); LC-MS (ESD m/z 470.2[M+H]⁺andN—((R)-1-(3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxalin-2-yl)ethyl)-9H-purin-6-amineas an off-white solid: ¹H NMR (400 MHz, choroform-d) 8 ppm 8.23-8.49(2H, m), 8.13 (1H, t, J=8.6 Hz), 7.78-8.04 (2H, m), 7.35-7.69 (4H, m),5.86 (1H, br. s.), 1.44-1.70 (3H, m); LC-MS (ESI) m/z 470.2 [M+H]⁺.

Example 111 Preparation ofN—((S)-1-(2-(2-Chlorophenyl)-7-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amineandN—((R)-1-(2-(2-Chlorophenyl)-7-fluoro-quinolin-3-yl)ethyl)-9H-purin-6-amine2-(2-Chlorophenyl)-7-fluoroquinoline-3-carbaldehyde

To a solution of 2-(2-chlorophenyl)-7-fluoroquinoline-3-carbonitrile(1.000 g, 3.537 mmol) in toluene (3.537 mL, 3.537 mmol) at −78° C. wasadded with stirring, DIBAL-H, 1 M sol. in Toluene (3.891 mL, 3.891 mmol)and the mixture was allowed to warm to −15° C. with stirring over 13 h.The mixture was cooled in ice water bath, quenched by addition of 1 Naq. HCl (14.15 mL, 14.15 mmol), and stirred for 2 h. To the mixture wasadded potassium acetate (3 g, 30.56 mmol, 8.6 eqv) and the mixtureextracted with ethyl acetate (50 mL×2). The combined organic layers werewashed saturated NaHCO₃ (50 mL×1), brine (50 mL x), filtered, andconcentrated at reduced pressure to give a yellow solid. The yellowsolid was purified by silica gel column chromatography on a 80 g ofRedi-Sep™ column using 0 to 50% gradient of EtOAc in hexane over 25 minand then 50% isocratic of EtOAc for 10 min as eluent to give2-(2-chlorophenyl)-7-fluoro-quinoline-3-carbaldehyde as a light yellowsolid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.88 (1H, s), 9.11 (1H, s), 8.44(1H, dd, J=9.1, 6.4 Hz), 7.92 (1H, dd, J=10.3, 2.6 Hz), 7.72-7.78 (1H,m), 7.50-7.66 (4H, m); LC-MS (ESI) m/z 286.1 [M+H]⁺.

1-(2-(2-Chlorophenyl)-7-fluoroquinolin-3-yl)ethanol

To a stirring mixture of2-(2-chlorophenyl)-7-fluoroquinoline-3-carbaldehyde (0.7588 g, 2.656mmol) in tetrahydrofuran (26.56 mL, 2.656 mmol) was addedmethylmagnesium bromide 3 M in diethyl ether (1.328 mL, 3.984 mmol)dropwise at 0° C. (started at 4:00 pm), and the mixture was allowed towarm to room temperature with stirring over 19 h. The reaction wasquenched with saturated aq. NH₄Cl (50 mL) and extracted with EtOAc (50mL×1). The combined organic layers were washed with water (50 mL×1),brine (50 mL×1), dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was purified by silica gel columnchromatography on a 80 g of Redi-Sep™ column using 0 to 50% gradient ofEtOAc in hexane over 25 min and then 50% isocratic of EtOAc for 10 minas eluent to give 1-(2-(2-chlorophenyl)-7-fluoroquinolin-3-yl)ethanol asa yellow syrup: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.63 (1H, d, J=11.0 Hz),8.20 (1H, dd, J=8.6, 6.7 Hz), 7.75 (1H, dd, J=10.6, 2.7 Hz), 7.42-7.66(5H, m), 5.39 (1H, dd, J=57.5, 3.9 Hz), 4.59-4.69 (1H, m), 1.20 (3H, dd,J=58.7, 6.3 Hz); LC-MS (ESI) m/z 302.0 [M+H]⁺.

2-(1-(2-(2-Chlorophenyl)-7-fluoroquinolin-3-yl)ethyl)isoindoline-1,3-dione

To a solution of 1-(2-(2-chlorophenyl)-7-fluoroquinolin-3-yl)ethanol(0.7018 g, 2.326 mmol) in tetrahydrofuran (23.26 mL, 2.326 mmol) wereadded triphenylphosphine (1.220 g, 4.652 mmol), phthalimide (0.6844 g,4.652 mmol), and diisopropyl azodicarboxylate (0.9159 mL, 4.652 mmol).The reaction mixture was stirred at room temperature. After 2 h, themixture was concentrated under reduced pressure and partitioned betweenEtOAc (100 mL) and brine (100 mL). The organic layer was dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography on a 80 g of Redi-Sep™column using 0 to 50% gradient of EtOAc in hexane over 25 min and 50%isocratic of EtOAc in hexane for 10 min as eluent to2414242-chlorophenyl)-7-fluoroquinolin-3-yl)ethyl)isoindoline-1,3-dioneas an off-white solid: LC-MS (ESI) m/z 431.0 [M+H]⁺.

1-(2-(2-Chlorophenyl)-7-fluoroquinolin-3-yl)ethanamine

To a suspension of2-(1-(2-(2-chlorophenyl)-7-fluoroquinolin-3-yl)ethyl)-isoindoline-1,3-dione(impure) (0.9331 g, 2.166 mmol) in ethanol (43.31 mL, 2.166 mmol) wasadded hydrazine hydrate (1.349 mL, 43.31 mmol), and the mixture wasstirred under reflux. After 2.5 h, the mixture was cooled to roomtemperature. The mixture was diluted with CH₂Cl₂ (50 mL), filtered toremoved the precipitated byproduct, and washed the filtered solid withCH₂Cl₂ (50 mL). The filtrate containing the desired product wasconcentrated under reduced pressure. The residue was purified by columnchromatography on a 80 g of Redi-Sep™ column using 0% to 50% gradient ofCH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ over 25 min, and then 50% isocraticof CH₂Cl₂:MeOH:NH₄OH (89:9:1) in CH₂Cl₂ for 5 min as eluent to give1-(2-(2-chlorophenyl)-7-fluoroquinolin-3-yl)-ethanamine as a yellowsyrup: LC-MS (ESI) m/z 301.1 [M+H]⁺.

N—((S)-1-(2-(2-Chlorophenyl)-7-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amineandN—((R)-1-(2-(2-Chlorophenyl)-7-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amine

A mixture of 6-bromopurine (0.3221 g, 1.618 mmol),1-(2-(2-chlorophenyl)-7-fluoroquinolin-3-yl)ethanamine (0.4056 g, 1.349mmol), and N,N-diisopropyl-ethylamine (0.7047 mL, 4.046 mmol) in1-butanol (4.495 mL, 1.349 mmol) was stirred at 110° C. After 37 h, themixture was removed from the heat and concentrated under reducedpressure. The residue was purified by column chromatography on a 80 g ofRedi-Sep™ column using 0% to 50% gradient of CH₂Cl₂:MeOH:NH₄OH (89:9:1)in CH₂Cl₂ over 20 min and then 50% isocratic of CH₂Cl₂:MeOH:NH₄OH(89:9:1) in CH₂Cl₂ for 20 min as eluent to give the desired product as aracemic mixture as a solid. The solid was suspended in MeOH, sonicated,and filtered to giveN-(1-(2-(2-chlorophenyl)-7-fluoroquinolin-3-yl)ethyl)-9H-purin-6-amineas a yellow syrupy solid. The racemic mixture was dissolved in CH₂Cl₂(7.5 mL), filtered, and separated on a Chiralpak™ IA column (30×250 mm,5 μm) using 30% isocratic of isopropanol in hexane for 40 min as eluentto give two separated isomers:N—((S)-1-(2-(2-chlorophenyl)-7-fluoro-quinolin-3-yl)ethyl)-9H-purin-6-amineas an off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.86 (1H, s),8.52-8.80 (1H, m), 7.91-8.26 (4H, m), 7.26-7.82 (6H, m), 5.28 (1H, d,J=47.7 Hz), 1.52 (3H, d, J=6.7 Hz) LC-MS (ESI) m/z 419.2 [M+H]⁺andN—((R)-1-(2-(2-chlorophenyl)-7-fluoro-quinolin-3-yl)ethyl)-9H-purin-6-amineas an off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.86 (1H, s),8.56-8.81 (1H, m), 7.91-8.28 (4H, m), 7.25-7.82 (6H, m), 5.15-5.44 (1H,m), 1.52 (3H, d, J=6.8 Hz); LC-MS (ESI) m/z 419.2 [M+H]⁺.

Biological Assays

Recombinant expression of PI3Ks

Full length p110 subunits of PI3kα, β, and δ, N-terminally labeled withpolyHis tag, were coexpressed with p85 with Baculo virus expressionvectors in sf9 insect cells. P110/p85 heterodimers were purified bysequential Ni-NTA, Q-HP, Superdex-100 chromatography. Purified α, β andδ isozymes were stored at −20° C. in 20 mM Tris, pH 8, 0.2M NaCl, 50%glycerol, 5 mM DTT, 2 mM Na cholate. Truncated PI3Kγ, residues 114-1102,N-terminally labeled with polyHis tag, was expressed with Baculo virusin Hi5 insect cells. The γ isozyme was purified by sequential Ni-NTA,Superdex-200, Q-HP chromatography. The y isozyme was stored frozen at−80° C. in NaH₂PO₄, pH 8, 0.2M NaCl, 1% ethylene glycol, 2 mMβ-mercaptoethanol.

Alpha Beta Delta gamma 50 mM Tris pH 8 pH 7.5 pH 7.5 pH 8 MgCl2 15 mM 10mM 10 mM 15 mM Na cholate 2 mM 1 mM 0.5 mM 2 mM DTT 2 mM 1 mM 1 mM 2 mMATP 1 uM 0.5 uM 0.5 uM 1 uM PIP2 none 2.5 uM 2.5 uM none time 1 h 2 h 2h 1 h [Enzyme] 15 nM 40 nM 15 nM 50 nMIn vitro enzyme assays.

Assays were performed in 25 μL with the above final concentrations ofcomponents in white polypropylene plates (Costar 3355). Phospatidylinositol phosphoacceptor, Ptdlns(4,5)P2 P4508, was from EchelonBiosciences. The ATPase activity of the alpha and gamma isozymes was notgreatly stimulated by PtdIns(4,5)P2 under these conditions and wastherefore omitted from the assay of these isozymes. Test compounds weredissolved in dimethyl sulfoxide and diluted with three-fold serialdilutions. The compound in DMSO (1 μL) was added per test well, and theinhibition relative to reactions containing no compound, with andwithout enzyme was determined. After assay incubation at roomtemperature, the reaction was stopped and residual ATP determined byaddition of an equal volume of a commercial ATP bioluminescence kit(Perkin Elmer EasyLite) according to the manufacturer's instructions,and detected using a AnalystGT luminometer.

Human B Cells Proliferation Stimulate by anti-IgMIsolate human B Cells:

Isolate PBMCs from Leukopac or from human fresh blood. Isolate human Bcells by using Miltenyi protocol and B cell isolation kit II.—human Bcells were Purified by using autoMACS® column.

Activation of Human B Cells

Use 96 well Flat bottom plate, plate 50000/well purified B cells in Bcell prolifer-ation medium (DMEM+5% FCS, 10 mM Hepes, 50 μM2-mercaptoethanol); 150 μL medium contain 250 ng/mL CD40L-LZ recombinantprotein (Amgen) and 2 μg/mL anti-Human IgM antibody (JacksonImmunoReseach Lab. #109-006-129), mixed with 50 μL B cell mediumcontaining PI3K inhibitors and incubate 72 h at 37° C. incubator. After72 h, pulse labeling B cells with 0.5-1 uCi/well ³H thymidine forovernight ˜18 h, and harvest cell using TOM harvester.

Compound IC50(3S)-3-(8-chloro-2-(2-chlorophenyl)-3-quinolinyl)-3-(9H-purin-6-ylamino)-1-propanol0.0131381-(8-chloro-3-((9H-purin-6-ylamino)methyl)-2-quinolinyl)-3-piperidinol0.0988452-(3-fluorophenyl)-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-8-quinolinecarbonitrile0.0033832-(3-fluorophenyl)-3-((9H-purin-6-ylamino)methyl)-8-quinolinecarbonitrile0.3000152-(8-chloro-3-((9H-purin-6-ylamino)methyl)-2-quinolinyl)-4-fluorophenol0.8186042-(8-chloro-3-((9H-purin-6-ylamino)methyl)-2-quinolinyl)benzonitrile0.0550873-((1S)-1-(9H-purin-6-ylamino)ethyl)-2-(2-pyridinyl)-8-quinolinecarbonitrile0.0466943-(8-chloro-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-2-quinolinyl)-4-pyridinecarboxamide4.6358-chloro-2-phenyl-3-((1S)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)ethyl)quinoline0.003035 8-chloro-2-phenyl-3-((9H-purin-6-yloxy)methyl)quinoline0.081441N-((1R)-1-(3-(2-chlorophenyl)-5-(trifluoromethyl)-2-quinoxalinyl)ethyl)-9H-purin-6-amine0.053372N-((1R)-1-(5-chloro-2-(3-fluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.03363N-((1R)-1-(5-chloro-3-(3-fluorophenyl)-2-quinolinyl)ethyl)-9H-purin-6-amine0.02103N-((1R)-1-(5-chloro-3-(3-fluorophenyl)-2-quinoxalinyl)ethyl)-9H-purin-6-amine0.013869N-((1R)-1-(8-chloro-2-(1,3-thiazol-2-yl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.181889N-((1R)-1-(8-chloro-2-(3-fluorophenyl)-3-quinolinyl)propyl)-9H-purin-6-amine0.003757N-((1R)-1-(8-chloro-2-(3-fluorophenyl)-3-quinolinyl)propyl)-9H-purin-6-amine1.243545N-((1S)-1-(2-(2-(benzyloxy)-5-fluorophenyl)-8-chloro-3-quinolinyl)ethyl)-9H-purin-6-amine0.016795N-((1S)-1-(2-(2,5-difluorophenyl)-8-fluoro-3-quinolinyl)ethyl)-7H-purin-6-amine0.012659N-((1S)-1-(2-(2-chloro-5-fluorophenyl)-7-fluoro-3-quinolinyl)ethyl)-9H-purin-6-amine0.019962N-((1S)-1-(2-(2-chloro-5-fluorophenyl)-8-fluoro-3-quinolinyl)ethyl)-7H-purin-6-amine0.03373N-((1S)-1-(2-(2-chlorophenyl)-7-fluoro-3-quinolinyl)ethyl)-9H-purin-6-amine0.028993N-((1S)-1-(2-(2-chlorophenyl)-7-fluoro-3-quinolinyl)ethyl)-9H-purin-6-amine0.028993N-((1S)-1-(2-(2-chlorophenyl)-8-fluoro-3-quinolinyl)ethyl)-7H-purin-6-amine0.01137 N-((1S)-1-(2-(2-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.005602N-((1S)-1-(2-(3,5-difluorophenyl)-7-fluoro-3-quinolinyl)ethyl)-9H-purin-6-amine0.005149N-((1S)-1-(2-(3,5-difluorophenyl)-8-fluoro-3-quinolinyl)ethyl)-7H-purin-6-amine0.00707N-((1S)-1-(2-(3-chloro-5-fluorophenyl)-8-fluoro-3-quinolinyl)ethyl)-7H-purin-6-amine0.008089N-((1S)-1-(2,8-bis(3-fluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.001062N-((1S)-1-(2,8-di-2-pyridinyl-3-quinolinyl)ethyl)-9H-purin-6-amine0.067391 N-((1S)-1-(2,8-diphenyl-3-quinolinyl)ethyl)-9H-purin-6-amine0.018823N-((1S)-1-(3-(2-chlorophenyl)-5-(trifluoromethyl)-2-quinoxalinyl)ethyl)-9H-purin-6-amine0.010401N-((1S)-1-(5-chloro-2-(3-fluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.014192N-((1S)-1-(5-chloro-3-(2-chloro-5-fluorophenyl)-2-quinoxalinyl)ethyl)-9H-purin-6-amine0.089326N-((1S)-1-(5-chloro-3-(3-fluorophenyl)-2-quinolinyl)ethyl)-9H-purin-6-amine0.008779N-((1S)-1-(5-chloro-3-(3-fluorophenyl)-2-quinoxalinyl)ethyl)-9H-purin-6-amine0.008554N-((1S)-1-(7-fluoro-1-oxido-2-phenyl-3-quinolinyl)ethyl)-9H-purin-6-amine0.004638N-((1S)-1-(7-fluoro-2-(2-(methylsulfonyl)phenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.006821N-((1S)-1-(7-fluoro-2-(2-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.009416N-((1S)-1-(7-fluoro-2-(3-(methylsulfonyl)phenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.148274N-((1S)-1-(7-fluoro-2-(3-fluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.011491N-((1S)-1-(7-fluoro-2-(3-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.01221N-((1S)-1-(7-fluoro-2-(6-fluoro-2-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.00372N-((1S)-1-(7-fluoro-2-phenyl-3-quinolinyl)ethyl)-9H-purin-6-amine0.005114N-((1S)-1-(8-chloro-2-(1,3-thiazol-2-yl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.001636N-((1S)-1-(8-chloro-2-(1,3-thiazol-4-yl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.000537N-((1S)-1-(8-chloro-2-(1,3-thiazol-5-yl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.0219N-((1S)-1-(8-chloro-2-(2,3-difluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.007589N-((1S)-1-(8-chloro-2-(2,4-difluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.014034N-((1S)-1-(8-chloro-2-(2-chloro-5-fluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.046566N-((1S)-1-(8-chloro-2-(2-chlorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.003602N-((1S)-1-(8-chloro-2-(2-ethyl-3-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.003312N-((1S)-1-(8-chloro-2-(2-ethyl-5-fluoro-3-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.00384N-((1S)-1-(8-chloro-2-(2-fluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.003557N-((1S)-1-(8-chloro-2-(2-fluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.003557N-((1S)-1-(8-chloro-2-(2-methoxy-1,3-thiazol-4-yl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.017526N-((1S)-1-(8-chloro-2-(2-methyl-3-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.004344N-((1S)-1-(8-chloro-2-(2-pyridinyl)-3-quinolinyl)ethyl)-2-fluoro-9H-purin-6-amine0.013972N-((1S)-1-(8-chloro-2-(2-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.003236N-((1S)-1-(8-chloro-2-(2-pyrimidinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.090413N-((1S)-1-(8-chloro-2-(3-(methylsulfonyl)phenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.05577N-((1S)-1-(8-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.449196N-((1S)-1-(8-chloro-2-(3,5-difluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.005039N-((1S)-1-(8-chloro-2-(3,5-difluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.005039N-((1S)-1-(8-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.00263N-((1S)-1-(8-chloro-2-(3-chlorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.005516N-((1S)-1-(8-chloro-2-(3-fluorophenyl)-3-quinolinyl)butyl)-9H-purin-6-amine0.006521N-((1S)-1-(8-chloro-2-(3-fluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.002416N-((1S)-1-(8-chloro-2-(3-fluorophenyl)-3-quinolinyl)propyl)-9H-purin-6-amine0.0053N-((1S)-1-(8-chloro-2-(3-methyl-2-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.033221N-((1S)-1-(8-chloro-2-(3-pyridazinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.018032N-((1S)-1-(8-chloro-2-(3-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.003444N-((1S)-1-(8-chloro-2-(4-fluorophenyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.010478N-((1S)-1-(8-chloro-2-(5-fluoro-2-(2-methylpropyl)-3-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.015529N-((1S)-1-(8-chloro-2-(5-fluoro-2-methyl-3-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.016946N-((1S)-1-(8-chloro-2-(5-fluoro-3-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.003571N-((1S)-1-(8-chloro-2-(6-fluoro-2-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.003099N-((1S)-1-(8-chloro-2-(6-methyl-2-pyridinyl)-3-quinolinyl)ethyl)-9H-purin-6-amine0.10543N-((1S)-1-(8-chloro-2-phenoxy-3-quinolinyl)ethyl)-9H-purin-6-amine0.029313N-((1S)-1-(8-chloro-2-phenyl-3-quinolinyl)ethyl)-9H-purin-6-amine0.002654N-((1S)-1-(8-fluoro-2-(3-fluorophenyl)-3-quinolinyl)ethyl)-7H-purin-6-amine0.005152N-((1S)-1-(8-fluoro-2-(3-pyridinyl)-3-quinolinyl)ethyl)-7H-purin-6-amine0.015402N-((1S)-1-(8-fluoro-2-phenyl-3-quinolinyl)ethyl)-7H-purin-6-amine0.00142N-((2-(2-biphenylyl)-8-chloro-3-quinolinyl)methyl)-9H-purin-6-amine0.164542N-((2-(2-chlorophenyl)-7-fluoro-3-quinolinyl)methyl)-9H-purin-6-amine0.088655N-((3-(2-chlorophenyl)-5-fluoro-2-quinoxalinyl)methyl)-9H-purin-6-amine0.299212N-((3-(2-chlorophenyl)-5-iodo-2-quinoxalinyl)methyl)-9H-purin-6-amine0.088387N-((3-(2-chlorophenyl)-5-methyl-2-quinoxalinyl)methyl)thieno[3,2-d]pyrimidin-4-amine0.194243N-((3-(2-chlorophenyl)-8-(methylsulfonyl)-2-quinoxalinyl)methyl)-9H-purin-6-amine2.407455N-((3-(2-chlorophenyl)-8-fluoro-2-quinoxalinyl)methyl)-9H-purin-6-amine0.176806N-((5-chloro-3-(2-(trifluoromethyl)phenyl)-2-quinoxalinyl)methyl)-9H-purin-6-amine0.041805N-((5-chloro-3-(2-chloro-5-fluorophenyl)-2-quinoxalinyl)methyl)-9H-purin-6-amine0.165211N-((5-chloro-3-(2-chlorophenyl)-2-quinoxalinyl)methyl)-9H-purin-6-amine0.082543N-((5-chloro-3-(3-fluorophenyl)-2-quinolinyl)methyl)-9H-purin-6-amine0.130021N-((5-chloro-3-(3-fluorophenyl)-2-quinoxalinyl)methyl)-9H-purin-6-amine0.07192N-((8-bromo-2-(3-fluorophenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.068766N-((8-chloro-2-(1,3-thiazol-2-yl)-3-quinolinyl)methyl)-9H-purin-6-amine0.208949N-((8-chloro-2-(1H-pyrazol-4-yl)-3-quinolinyl)methyl)-9H-purin-6-amine0.157905N-((8-chloro-2-(2-(1-methylethyl)-3-pyridinyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.030614N-((8-chloro-2-(2-(1-methylethyl)phenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.017602N-((8-chloro-2-(2-(2H-tetrazol-5-yl)phenyl)-3-quinolinyl)methyl)-9H-purin-6-amine9.706546N-((8-chloro-2-(2-(methylsulfonyl)phenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.150914N-((8-chloro-2-(2,5-difluorophenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.038235N-((8-chloro-2-(2-chloro-5-fluorophenyl)-3-quinolinyl)methyl)-9H-purin-6-0.03835N-((8-chloro-2-(2-chlorophenyl)-3-quinolinyl)methyl)-3H-imidazo[4,5-b]pyridin-7-amine0.36145N-((8-chloro-2-(2-methyl-3-pyridinyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.013398N-((8-chloro-2-(2-pyridinyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.034112N-((8-chloro-2-(2-thiophenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.103629N-((8-chloro-2-(3-(1-methylethyl)phenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.305301N-((8-chloro-2-(3,5-difluorophenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.055993N-((8-chloro-2-(3-chlorophenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.411098N-((8-chloro-2-(3-fluoro-l-piperidinyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.09547N-((8-chloro-2-(3-fluorophenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.027542N-((8-chloro-2-(3-methyl-2-pyridinyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.07904N-((8-chloro-2-(4-(1-methylethyl)-3-pyridinyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.025841N-((8-chloro-2-(4-(1-methylethyl)-5-pyrimidinyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.078872N-((8-chloro-2-(4-(trifluoromethyl)-3-pyridinyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.069518N-((8-chloro-2-(4-fluorophenyl)-3-quinolinyl)methyl)-7H-purin-6-amine0.265255N-((8-chloro-2-(5-fluoro-2-(1-phenylethoxy)phenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.564971N-((8-chloro-2-(5-fluoro-2-(3-pyridinylmethoxy)phenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.17832N-((8-chloro-2-(5-fluoro-2-methoxyphenyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.027381N-((8-chloro-2-(5-isothiazolyl)-3-quinolinyl)methyl)-9H-purin-6-amine0.06556 N-((8-chloro-2-phenoxy-3-quinolinyl)methyl)-9H-purin-6-amine0.026211 N-((8-chloro-2-phenyl-3-quinolinyl)methyl)-9H-purin-6-amine0.219179 N-((8-fluoro-2-phenyl-3-quinolinyl)methyl)-7H-purin-6-amine0.239808N6-((8-chloro-2-(2-chlorophenyl)-3-quinolinyl)methyl)-9H-purine-2,6-diamine0.008899

Human B Cells Proliferation Stimulate by IL-4 Isolate Human B Cells:

Isolate human PBMCs from Leukopac or from human fresh blood. Isolatehuman B cells using Miltenyi protocol—B cell isolation kit. Human Bcells were Purified by autoMACS® column.Activation of Human B cells

Use 96-well flat bottom plate, plate 50000/well purified B cells in Bcell proliferation medium (DMEM+5% FCS, 50 μM 2-mercaptoethanol, 10 mMHepes). The medium (150 μL) contain 250 ng/mL CD40L-LZ recombinantprotein (Amgen) and 10 ng/mL IL-4 (R&D system #204-IL-025), mixed with50 150 μL B cell medium containing compounds and incubate 72 h at 37° C.incubator. After 72 h, pulse labeling B cells with 0.5-1 uCi/well 3Hthymidine for overnight ˜18 h, and harvest cell using TOM harvester.

Specific T Antigen (Tetanus Toxoid) Induced Human PBMC ProliferationAssays

Human PBMC are prepared from frozen stocks or they are purified fromfresh human blood using a Ficoll® gradient. Use 96 well round-bottomplate and plate 2×10⁵ PBMC/well with culture medium (RPMI1640+10% FCS,50 uM 2-Mercaptoethanol, 10 mM Hepes). For IC₅₀ determinations, PI3Kinhibitors was tested from 10 μM to 0.001 μM, in half log increments andin triplicate. Tetanus toxoid, T cell specific antigen (University ofMassachusetts Lab) was added at 1 μg/mL and incubated 6 days at 37° C.incubator. Supernatants are collected after 6 days for IL2 ELISA assay,then cells are pulsed with ³H-thymidine for ˜18 h to measureproliferation.

GFP Assays for Detecting Inhibition of Class Ia and Class III PI3K

AKT1 (PKBa) is regulated by Class Ia PI3K activated by mitogenic factors(IGF-1, PDGF, insulin, thrombin, NGF, etc.). In response to mitogenicstimuli, AKT1 translocates from the cytosol to the plasma membrane

Forkhead (FKHRL1) is a substrate for AKT1. It is cytoplasmic whenphosphorylated by AKT (survival/growth). Inhibition of AKT(stasis/apoptosis)-forkhead translocation to the nucleus

FYVE domains bind to PI(3)P. the majority is generated by constitutiveaction of PI3K Class III

AKT Membrane Ruffling Assay (CHO-1R-AKT1-EGFP Cells/GE Healthcare)

Wash cells with assay buffer. Treat with compounds in assay buffer 1 h.Add 10 ng/mL insulin. Fix after 10 min at room temp and image

Forkhead Translocation Assay (MDA MB468 Forkhead-DiversaGFP cells)

Treat cells with compound in growth medium 1 h. Fix and image.

Class III PI(3)P assay (U2OS EGFP-2×FYVE cells/GE Healthcare)

Wash cells with assay buffer. Treat with compounds in assay buffer 1 h.Fix and image.

Control for all 3 assays is 10 uM Wortmannin:AKT is cytoplasmicForkhead is nuclearPI(3)P depleted from endosomes

Biomarker Assay: B-cell Receptor Stimulation of CD69 or B7.2 (CD86)Expression

Heparinized human whole blood was stimulated with 10 μg/mL anti-IgD(Southern Biotech, #9030-01). 90 μL of the stimulated blood was thenaliquoted per well of a 96-well plate and treated with 10 μL of variousconcentrations of blocking compound (from 10-0.0003 μM) diluted inIMDM+10% FBS (Gibe®). Samples were incubated together for 4 h (for CD69expression) to 6 h (for B7.2 expression) at 37° C. Treated blood (50 μL)was transferred to a 96-well, deep well plate (Nunc) for antibodystaining with 10 μL each of CD45-PerCP (BD™ Biosciences, #347464),CD19-FITC (BD™ Biosciences, #340719), and CD69-PE (BD™ Biosciences,#341652). The second 50 μL of the treated blood was transferred to asecond 96-well, deep well plate for antibody staining with 10 μL each ofCD19-FITC (BD™ Biosciences, #340719) and CD86-PeCy5 (BD™ Biosciences,#555666). All stains were performed for 15-30 minutes in the dark atroom temperature. The blood was then lysed and fixed using 450 μL ofFACS lysing solution (BD™ Biosciences, #349202) for 15 minutes at roomtemperature. Samples were then washed 2× in PBS+2% FBS before FACSanalysis. Samples were gated on either CD45/CD19 double positive cellsfor CD69 staining, or CD19 positive cells for CD86 staining.

Gamma Counterscreen Stimulation of Human Monocytes for Phospho-AKTExpression

A human monocyte cell line, THP-1, was maintained in RPMI+10% FBS(Gibco®). One day before stimulation, cells were counted using trypanblue exclusion on a hemocytometer and suspended at a concentration of1×10⁶ cells per mL of media. 100 μL of cells plus media (1×10⁵ cells)was then aliquoted per well of 4-96-well, deep well dishes (Nunc) totest eight different compounds. Cells were rested overnight beforetreatment with various concentrations (from 10-0.0003 μM) of blockingcompound. The compound diluted in media (12 μL) was added to the cellsfor 10 minutes at 37° C. Human MCP-1 (12 μL, R&D Diagnostics, #279-MC)was diluted in media and added to each well at a final concentration of50 ng/mL. Stimulation lasted for 2 minutes at room temperature.Pre-warmed FACS Phosflow™ Lyse/Fix buffer (1 mL of 37° C.) (BD™Biosciences, #558049) was added to each well. Plates were then incubatedat 37° C. for an additional 10-15 minutes. Plates were spun at 1500 rpmfor 10 minutes, supernatant was aspirated off, and 1 mL of ice cold 90%MeOH was added to each well with vigorous shaking. Plates were thenincubated either overnight at −70° C. or on ice for 30 minutes beforeantibody staining. Plates were spun and washed 2× in PBS+2% FBS (Gibe®).Wash was aspirated and cells were suspended in remaining buffer. RabbitpAKT (50 μL, Cell Signaling, #4058 L) at 1:100, was added to each samplefor 1 h at rt with shaking. Cells were washed and spun at 1500 rpm for10 minutes. Supernatant was aspirated and cells were suspended inremaining buffer. Secondary antibody, goat anti-rabbit Alexa Fluor® 647(50 μL, Invitrogen™, #A21245) at 1:500, was added for 30 minutes at rtwith shaking. Cells were then washed 1× in buffer and suspended in 150μL of buffer for FACS analysis. Cells need to be dispersed very well bypipetting before running on flow cytometer. Cells were run on an LSR II(Becton Dickinson) and gated on forward and side scatter to determineexpression levels of pAKT in the monocyte population.

Gamma Counterscreen Stimulation of Monocytes for Phospho-AKT Expressionin Mouse Bone Marrow

Mouse femurs were dissected from five female BALB/c mice (Charles RiverLabs.) and collected into RPMI+10% FBS media (Gibco®). Mouse bone marrowwas removed by cutting the ends of the femur and by flushing with 1 mLof media using a 25 gauge needle. Bone marrow was then dispersed inmedia using a 21 gauge needle. Media volume was increased to 20 mL andcells were counted using trypan blue exclusion on a hemocytometer. Thecell suspension was then increased to 7.5×10⁶ cells per 1 mL of mediaand 100 μl, (7.5×10⁵ cells) was aliquoted per well into 4-96-well, deepwell dishes (Nunc) to test eight different compounds. Cells were restedat 37° C. for 2 h before treatment with various concentrations (from10-0.0003 μM) of blocking compound. Compound diluted in media (12 μL)was added to bone marrow cells for 10 minutes at 37° C. Mouse MCP-1 (12μL, R&D Diagnostics, #479-JE) was diluted in media and added to eachwell at a final concentration of 50 ng/mL. Stimulation lasted for 2minutes at room temperature. 1 mL of 37° C. pre-warmed FACS Phosflow™Lyse/Fix buffer (BD™ Biosciences, #558049) was added to each well.Plates were then incubated at 37° C. for an additional 10-15 minutes.Plates were spun at 1500 rpm for 10 minutes. Supernatant was aspiratedoff and 1 mL of ice cold 90% MeOH was added to each well with vigorousshaking. Plates were then incubated either overnight at −70° C. or onice for 30 minutes before antibody staining. Plates were spun and washed2× in PBS+2% FBS (Gibco®). Wash was aspirated and cells were suspendedin remaining buffer. Fc Block™ (2 μL, BD™ Pharmingen, #553140) was thenadded per well for 10 minutes at room temperature. After block, 50 μL ofprimary antibodies diluted in buffer; CD11b-Alexa Fluor®488 (BD™Biosciences, #557672) at 1:50, CD64-PE (BD™ Biosciences, #558455) at1:50, and rabbit pAKT (Cell Signaling, #4058 L) at 1:100, were added toeach sample for 1 h at RT with shaking. Wash buffer was added to cellsand spun at 1500 rpm for 10 minutes. Supernatant was aspirated and cellswere suspended in remaining buffer. Secondary antibody; goat anti-rabbitAlexa Fluor® 647 (50 μL, Invitrogen™, #A21245) at 1:500, was added for30 minutes at rt with shaking. Cells were then washed 1× in buffer andsuspended in 100 μL of buffer for FACS analysis. Cells were run on anLSR II (Becton Dickinson) and gated on CD11b/CD64 double positive cellsto determine expression levels of pAKT in the monocyte population.

pAKT in vivo Assay

Vehicle and compounds are administered p.o. (0.2 mL) by gavage (OralGavage Needles Popper & Sons, New Hyde Park, N.Y.) to mice (TransgenicLine 3751, female, 10-12 wks Amgen Inc, Thousand Oaks, Calif.) 15 minprior to the injection i.v (0.2 mLs) of anti-IgM FITC (50 ug/mouse)(Jackson Immuno Research, West Grove, Pa.). After 45 min the mice aresacrificed within a CO₂ chamber. Blood is drawn via cardiac puncture(0.3 mL) (ice 25 g Syringes, Sherwood, St. Louis, Mo.) and transferredinto a 15 mL conical vial (Nalge/Nunc International, Denmark). Blood isimmediately fixed with 6.0 mL of BD™ Phosflow™ Lyse/Fix Buffer (BD™Bioscience, San Jose, Calif.), inverted 3X's and placed in 37° C. waterbath. Half of the spleen is removed and transferred to an eppendorf tubecontaining 0.5 mL of PBS (Invitrogen™ Corp, Grand Island, N.Y.). Thespleen is crushed using a tissue grinder (Pellet Pestle®, Kimble/Kontes,Vineland, N.J.) and immediately fixed with 6.0 mL of BD™ Phosflow™Lyse/Fix buffer, inverted 3X's and placed in 37° C. water bath. Oncetissues have been collected the mouse is cervically-dislocated andcarcass to disposed. After 15 min, the 15 mL conical vials are removedfrom the 37° C. water bath and placed on ice until tissues are furtherprocessed. Crushed spleens are filtered through a 70 μm cell strainer(BD™ Bioscience, Bedford, Mass.) into another 15 mL conical vial andwashed with 9 mL of PBS. Splenocytes and blood are spun @ 2,000 rpms for10 min (cold) and buffer is aspirated. Cells are resuspended in 2.0 mLof cold (−20° C.) 90% methyl alcohol (Mallinckrodt Chemicals,Phillipsburg, N.J.). Methanol is slowly added while conical vial israpidly vortexed. Tissues are then stored at −20° C. until cells can bestained for FACS analysis.

Multi-dose TNP Immunization

Blood was collected by retro-orbital eye bleeds from 7-8 week old BALB/cfemale mice (Charles River Labs.) at day 0 before immunization. Bloodwas allowed to clot for 30 minutes and spun at 10,000 rpm in serummicrotainer tubes (Becton Dickinson) for 10 minutes. Sera werecollected, aliquoted in Matrix tubes (Matrix Tech. Corp.) and stored at−70° C. until ELISA was performed. Mice were given compound orallybefore immunization and at subsequent time periods based on the life ofthe molecule. Mice were then immunized with either 50 μg of TNP-LPS(Biosearch Tech., #T-5065), 50 μg of TNP-Ficoll® (Biosearch Tech.,#F-1300), or 100 μg of TNP-KLH (Biosearch Tech., #T-5060) plus 1% alum(Brenntag, #3501) in PBS. TNP-KLH plus alum solution was prepared bygently inverting the mixture 3-5 times every 10 minutes for 1 hourbefore immunization. On day 5, post-last treatment, mice were CO₂sacrificed and cardiac punctured. Blood was allowed to clot for 30minutes and spun at 10,000 rpm in serum microtainer tubes for 10minutes. Sera were collected, aliquoted in Matrix tubes, and stored at−70° C. until further analysis was performed. TNP-specific IgG1, IgG2a,IgG3 and IgM levels in the sera were then measured via ELISA. TNP-BSA(Biosearch Tech., #T-5050) was used to capture the TNP-specificantibodies. TNP-BSA (10 μg/mL) was used to coat 384-well ELISA plates(Corning Costar) overnight. Plates were then washed and blocked for 1 husing 10% BSA ELISA Block solution (KPL). After blocking, ELISA plateswere washed and sera samples/standards were serially diluted and allowedto bind to the plates for 1 h. Plates were washed and Ig-HRP conjugatedsecondary antibodies (goat anti-mouse IgG1, Southern Biotech #1070-05,goat anti-mouse IgG2a, Southern Biotech #1080-05, goat anti-mouse IgM,Southern Biotech #1020-05, goat anti-mouse IgG3, Southern Biotech#1100-05) were diluted at 1:5000 and incubated on the plates for 1 h.TMB peroxidase solution (SureBlue Reserve TMB from KPL) was used tovisualize the antibodies. Plates were washed and samples were allowed todevelop in the TMB solution approximately 5-20 minutes depending on theIg analyzed. The reaction was stopped with 2M sulfuric acid and plateswere read at an OD of 450 nm.

For the treatment of PI3Kδ-mediated-diseases, such as rheumatoidarthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis,psoriasis, inflammatory diseases, and autoimmune diseases, the compoundsof the present invention may be administered orally, parentally, byinhalation spray, rectally, or topically in dosage unit formulationscontaining conventional pharmaceutically acceptable carriers, adjuvants,and vehicles. The term parenteral as used herein includes, subcutaneous,intravenous, intramuscular, intrasternal, infusion techniques orintraperitoneally.

Treatment of diseases and disorders herein is intended to also includethe prophylactic administration of a compound of the invention, apharmaceutical salt thereof, or a pharmaceutical composition of eitherto a subject (i.e., an animal, preferably a mammal, most preferably ahuman) believed to be in need of preventative treatment, such as, forexample, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis,psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmunediseases and the like.

The dosage regimen for treating PI3Kδ-mediated diseases, cancer, and/orhyperglycemia with the compounds of this invention and/or compositionsof this invention is based on a variety of factors, including the typeof disease, the age, weight, sex, medical condition of the patient, theseverity of the condition, the route of administration, and theparticular compound employed. Thus, the dosage regimen may vary widely,but can be determined routinely using standard methods. Dosage levels ofthe order from about 0.01 mg to 30 mg per kilogram of body weight perday, preferably from about 0.1 mg to 10 mg/kg, more preferably fromabout 0.25 mg to 1 mg/kg are useful for all methods of use disclosedherein.

The pharmaceutically active compounds of this invention can be processedin accordance with conventional methods of pharmacy to produce medicinalagents for administration to patients, including humans and othermammals.

For oral administration, the pharmaceutical composition may be in theform of, for example, a capsule, a tablet, a suspension, or liquid. Thepharmaceutical composition is preferably made in the form of a dosageunit containing a given amount of the active ingredient. For example,these may contain an amount of active ingredient from about 1 to 2000mg, preferably from about 1 to 500 mg, more preferably from about 5 to150 mg. A suitable daily dose for a human or other mammal may varywidely depending on the condition of the patient and other factors, but,once again, can be determined using routine methods.

The active ingredient may also be administered by injection as acomposition with suitable carriers including saline, dextrose, or water.The daily parenteral dosage regimen will be from about 0.1 to about 30mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg,and more preferably from about 0.25 mg to 1 mg/kg.

Injectable preparations, such as sterile injectable aqueous oroleaginous suspensions, may be formulated according to the known areusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation may also be a sterile injectable solutionor suspension in a non-toxic parenterally acceptable diluent or solvent,for example as a solution in 1,3-butanediol. Among the acceptablevehicles and solvents that may be employed are water, Ringer's solution,and isotonic sodium chloride solution. In addition, sterile, fixed oilsare conventionally employed as a solvent or suspending medium. For thispurpose any bland fixed oil may be employed, including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use inthe preparation of injectables.

Suppositories for rectal administration of the drug can be prepared bymixing the drug with a suitable non-irritating excipient such as cocoabutter and polyethylene glycols that are solid at ordinary temperaturesbut liquid at the rectal temperature and will therefore melt in therectum and release the drug.

A suitable topical dose of active ingredient of a compound of theinvention is 0.1 mg to 150 mg administered one to four, preferably oneor two times daily. For topical administration, the active ingredientmay comprise from 0.001% to 10% w/w, e.g., from 1% to 2% by weight ofthe formulation, although it may comprise as much as 10% w/w, butpreferably not more than 5% w/w, and more preferably from 0.1% to 1% ofthe formulation.

Formulations suitable for topical administration include liquid orsemi-liquid preparations suitable for penetration through the skin(e.g., liniments, lotions, ointments, creams, or pastes) and dropssuitable for administration to the eye, ear, or nose.

For administration, the compounds of this invention are ordinarilycombined with one or more adjuvants appropriate for the indicated routeof administration. The compounds may be admixed with lactose, sucrose,starch powder, cellulose esters of alkanoic acids, stearic acid, talc,magnesium stearate, magnesium oxide, sodium and calcium salts ofphosphoric and sulfuric acids, acacia, gelatin, sodium alginate,polyvinyl-pyrrolidine, and/or polyvinyl alcohol, and tableted orencapsulated for conventional administration. Alternatively, thecompounds of this invention may be dissolved in saline, water,polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil,cottonseed oil, sesame oil, tragacanth gum, and/or various buffers.Other adjuvants and modes of administration are well known in thepharmaceutical art. The carrier or diluent may include time delaymaterial, such as glyceryl monostearate or glyceryl distearate alone orwith a wax, or other materials well known in the art.

The pharmaceutical compositions may be made up in a solid form(including granules, powders or suppositories) or in a liquid form(e.g., solutions, suspensions, or emulsions). The pharmaceuticalcompositions may be subjected to conventional pharmaceutical operationssuch as sterilization and/or may contain conventional adjuvants, such aspreservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

Solid dosage forms for oral administration may include capsules,tablets, pills, powders, and granules. In such solid dosage forms, theactive compound may be admixed with at least one inert diluent such assucrose, lactose, or starch. Such dosage forms may also comprise, as innormal practice, additional substances other than inert diluents, e.g.,lubricating agents such as magnesium stearate. In the case of capsules,tablets, and pills, the dosage forms may also comprise buffering agents.Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups, and elixirscontaining inert diluents commonly used in the art, such as water. Suchcompositions may also comprise adjuvants, such as wetting, sweetening,flavoring, and perfuming agents.

Compounds of the present invention can possess one or more asymmetriccarbon atoms and are thus capable of existing in the form of opticalisomers as well as in the form of racemic or non-racemic mixturesthereof. The optical isomers can be obtained by resolution of theracemic mixtures according to conventional processes, e.g., by formationof diastereoisomeric salts, by treatment with an optically active acidor base. Examples of appropriate acids are tartaric, diacetyltartaric,dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and thenseparation of the mixture of diastereoisomers by crystallizationfollowed by liberation of the optically active bases from these salts. Adifferent process for separation of optical isomers involves the use ofa chiral chromatography column optimally chosen to maximize theseparation of the enantiomers. Still another available method involvessynthesis of covalent diastereoisomeric molecules by reacting compoundsof the invention with an optically pure acid in an activated form or anoptically pure isocyanate. The synthesized diastereoisomers can beseparated by conventional means such as chromatography, distillation,crystallization or sublimation, and then hydrolyzed to deliver theenantiomerically pure compound. The optically active compounds of theinvention can likewise be obtained by using active starting materials.These isomers may be in the form of a free acid, a free base, an esteror a salt.

Likewise, the compounds of this invention may exist as isomers, that iscompounds of the same molecular formula but in which the atoms, relativeto one another, are arranged differently. In particular, the alkylenesubstituents of the compounds of this invention, are normally andpreferably arranged and inserted into the molecules as indicated in thedefinitions for each of these groups, being read from left to right.However, in certain cases, one skilled in the art will appreciate thatit is possible to prepare compounds of this invention in which thesesubstituents are reversed in orientation relative to the other atoms inthe molecule. That is, the substituent to be inserted may be the same asthat noted above except that it is inserted into the molecule in thereverse orientation. One skilled in the art will appreciate that theseisomeric forms of the compounds of this invention are to be construed asencompassed within the scope of the present invention.

The compounds of the present invention can be used in the form of saltsderived from inorganic or organic acids. The salts include, but are notlimited to, the following: acetate, adipate, alginate, citrate,aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate,camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate,ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate,heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide,hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate,pectinate, persulfate, 2-phenylpropionate, picrate, pivalate,propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, andundecanoate. Also, the basic nitrogen-containing groups can bequaternized with such agents as lower alkyl halides, such as methyl,ethyl, propyl, and butyl chloride, bromides and iodides; dialkylsulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, longchain halides such as decyl, lauryl, myristyl and stearyl chlorides,bromides and iodides, aralkyl halides like benzyl and phenethylbromides, and others. Water or oil-soluble or dispersible products arethereby obtained.

Examples of acids that may be employed to from pharmaceuticallyacceptable acid addition salts include such inorganic acids ashydrochloric acid, sulfuric acid and phosphoric acid and such organicacids as oxalic acid, maleic acid, succinic acid and citric acid. Otherexamples include salts with alkali metals or alkaline earth metals, suchas sodium, potassium, calcium or magnesium or with organic bases.

Also encompassed in the scope of the present invention arepharmaceutically acceptable esters of a carboxylic acid or hydroxylcontaining group, including a metabolically labile ester or a prodrugform of a compound of this invention. A metabolically labile ester isone which may produce, for example, an increase in blood levels andprolong the efficacy of the corresponding non-esterified form of thecompound. A prodrug form is one which is not in an active form of themolecule as administered but which becomes therapeutically active aftersome in vivo activity or biotransformation, such as metabolism, forexample, enzymatic or hydrolytic cleavage. For a general discussion ofprodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examplesof a masked carboxylate anion include a variety of esters, such as alkyl(for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl),aralkyl (for example, benzyl, p-methoxybenzyl), andalkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have beenmasked as arylcarbonyloxymethyl substituted derivatives which arecleaved by esterases in vivo releasing the free drug and formaldehyde(Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidicNH group, such as imidazole, imide, indole and the like, have beenmasked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs,Elsevier (1985)). Hydroxy groups have been masked as esters and ethers.EP 039,051 (Sloan and Little, Apr. 11, 1981) discloses Mannich-basehydroxamic acid prodrugs, their preparation and use. Esters of acompound of this invention, may include, for example, the methyl, ethyl,propyl, and butyl esters, as well as other suitable esters formedbetween an acidic moiety and a hydroxyl containing moiety. Metabolicallylabile esters, may include, for example, methoxymethyl, ethoxymethyl,iso-propoxymethyl, α-methoxyethyl, groups such asα-((C₁-C₄)-alkyloxy)ethyl, for example, methoxyethyl, ethoxyethyl,propoxyethyl, iso-propoxyethyl, etc.; 2-oxo-1,3-dioxolen-4-ylmethylgroups, such as 5-methyl-2-oxo-1,3,dioxolen-4-ylmethyl, etc.; C₁-C₃alkylthiomethyl groups, for example, methylthiomethyl, ethylthiomethyl,isopropylthiomethyl, etc.; acyloxymethyl groups, for example,pivaloyloxymethyl, α-acetoxymethyl, etc.; ethoxycarbonyl-1-methyl; orα-acyloxy-α-substituted methyl groups, for example α-acetoxyethyl.

Further, the compounds of the invention may exist as crystalline solidswhich can be crystallized from common solvents such as ethanol,N,N-dimethyl-formamide, water, or the like. Thus, crystalline forms ofthe compounds of the invention may exist as polymorphs, solvates and/orhydrates of the parent compounds or their pharmaceutically acceptablesalts. All of such forms likewise are to be construed as falling withinthe scope of the invention.

While the compounds of the invention can be administered as the soleactive pharmaceutical agent, they can also be used in combination withone or more compounds of the invention or other agents. Whenadministered as a combination, the therapeutic agents can be formulatedas separate compositions that are given at the same time or differenttimes, or the therapeutic agents can be given as a single composition.

The foregoing is merely illustrative of the invention and is notintended to limit the invention to the disclosed compounds. Variationsand changes which are obvious to one skilled in the art are intended tobe within the scope and nature of the invention which are defined in theappended claims.

From the foregoing description, one skilled in the art can easilyascertain the essential characteristics of this invention, and withoutdeparting from the spirit and scope thereof, can make various changesand modifications of the invention to adapt it to various usages andconditions.

1. A compound having the structure:

or any pharmaceutically-acceptable salt thereof, wherein: X¹ is C(R⁹) orN; Y is N(R¹¹), O or S; n is 0, 1, 2 or 3; R¹ is a direct bonded oroxygen-linked saturated, partially-saturated or unsaturated 5-, 6- or7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selectedfrom N, O and S, but containing no more than one O or S, wherein theavailable carbon atoms of the ring are substituted by 0, 1 or 2 oxo orthioxo groups, wherein the ring is substituted by 0 or 1 R²substituents, and the ring is additionally substituted by 0, 1, 2 or 3substituents independently selected from halo, nitro, cyano, C₁₋₄alkyl,OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl, N(C₁₋₄alkyl)C₁₋₄alkyl andC₁₋₄haloalkyl; R² is selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂W,—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a); or R² isselected from C₁₋₆alkyl, phenyl, benzyl, heteroaryl, heterocycle,—(C₁₋₃alkyl)hetero aryl, —(C₁₋₃alkyl)hetero cycle,—O(C₁₋₃alkyl)heteroaryl, —O(C₁₋₃alkyl)hetero cycle,—NR^(a)(C₁₋₃alkyl)hetero aryl, —NR^(a)(C₁₋₃alkyl)hetero cycle, —(C₁₋₃alkyl)phenyl, —O(C₁₋₃alkyl)phenyl and —NR^(a)(C₁₋₃alkyl)phenyl all ofwhich are substituted by 0, 1, 2 or 3 substituents selected fromC₁₋₄haloalkyl, OC₁₋₄alkyl, Br, Cl, F, I and C₁₋₄alkyl; R³ is selectedfrom H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a), —C(═O)OR^(a),—C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a), —OC(═O)R^(a),—OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a), —OC₂₋₆alkylNR^(a)R^(a),—OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a), —S(═O)₂R^(a),—S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from C₁₋₆haloalkyl, OC₁₋₆alkyl, Br, Cl, F,I and C₁₋₆alkyl; R⁴ is, independently, in each instance, halo, nitro,cyano, C₁₋₄alkyl, OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl or C₁₋₄haloalkyl; R⁵ is, independently, in eachinstance, H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, or C₁₋₆alkyl substituted by1, 2 or 3 substituents selected from halo, cyano, OH, OC₁₋₄alkyl,C₁₋₄alkyl, C₁₋₃haloalkyl, OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl; or both R⁵ groups together form a C₃₋₆spiroalkylsubstituted by 0, 1, 2 or 3 substituents selected from halo, cyano, OH,OC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₃haloalkyl, OC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl; R⁶ is selected from H, halo, C₁₋₆alkyl,C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a), —C(═O)OR^(a),—C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —S(═O)R^(a), —S(═O)₂R^(a),—S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a); R⁷ isselected from H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—S(═O)R^(a), —S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a),—S(═O)₂N(R^(a))C(═O)R^(a), —S(═O)₂N(R^(a))C(═O)OR^(a),—S(═O)₂N(R^(a))C(═O)NR^(a)R^(a); R⁸ is selected from H, C₁₋₆haloalkyl,Br, Cl, F, I, OR^(a), NR^(a)R^(a), C₁₋₆alkyl, phenyl, benzyl, heteroaryland heterocycle, wherein the C₁₋₆alkyl, phenyl, benzyl, heteroaryl andheterocycle are additionally substituted by 0, 1, 2 or 3 substituentsselected from C₁₋₆haloalkyl, OC₁₋₆alkyl, Br, Cl, F, I and C₁₋₆alkyl; R⁹is selected from H, halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a),—OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a), C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle, wherein the C₁₋₆alkyl, phenyl,benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1,2 or 3 substituents selected from halo, C₁₋₄haloalkyl, cyano, nitro,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a),—OR^(a), —OC(═O)R^(a), —OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a),—OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a),—S(═O)₂R^(a), —S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a), —NR^(a)C₂₋₆alkylOR^(a); or R⁹ is asaturated, partially-saturated or unsaturated 5-, 6- or 7-memberedmonocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O andS, but containing no more than one O or S, wherein the available carbonatoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups,wherein the ring is substituted by 0, 1, 2, 3 or 4 substituents selectedfrom halo, C₁₋₄haloalkyl, cyano, nitro, —C(═O)R^(a), —C(═O)OR^(a),—C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —OR^(a), —OC(═O)R^(a),—OC(═O)NR^(a)R^(a), —OC(═O)N(R^(a))S(═O)₂R^(a), —OC₂₋₆alkylNR^(a)R^(a),—OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(a), —S(═O)₂R^(a),—S(═O)₂NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a),—NR^(a)R^(a), —N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a),—N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a),—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂NR^(a)R^(a),—NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a); R¹⁰ is H,C₁₋₃alkyl, C₁₋₃haloalkyl, cyano, nitro, CO₂R^(a), C(═O)NR^(a)R^(a),—C(═NR^(a))NR^(a)R^(a), —S(═O)₂N(R^(a))C(═O)R^(a),—S(═O)₂N(R^(a))C(═O)OR^(a), —S(═O)₂N(R^(a))C(═O)NR^(a)R^(a), S(═O)R^(b),S(═O)₂R^(b) or S(═O)₂NR^(a)R^(a); R¹¹ is H or C₁₋₄alkyl; R^(a) isindependently, at each instance, H or R^(b); and R^(b) is independently,at each instance, phenyl, benzyl or C₁₋₆alkyl, the phenyl, benzyl andC₁₋₆alkyl being substituted by 0, 1, 2 or 3 substituents selected fromhalo, C₁₋₄alkyl, C₁₋₃halo alkyl, —OC₁₋₄alkyl, —NH₂, —NHC₁₋₄alkyl,—N(C₁₋₄alkyl)C₁₋₄ alkyl.
 2. A compound according to claim 1, having thestructure:


3. A compound according to claim 1, having the structure:


4. A compound according to claim 1, having the structure:


5. A compound according to claim 1, wherein R³ is F, Cl or Br; and n is0.
 6. A compound according to claim 1, wherein R¹ is phenyl substitutedby 0 or 1 R² substituents, and the phenyl is additionally substituted by0, 1, 2 or 3 substituents independently selected from halo, nitro,cyano, C₁₋₄alkyl, OC₁₋₄alkyl, OC₁₋₄halo alkyl, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl and C₁₋₄halo alkyl.
 7. A compound according toclaim 1, wherein R¹ is a direct-bonded or oxygen-linked saturated,partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ringcontaining 1, 2, 3 or 4 atoms selected from N, O and S, but containingno more than one O or S, wherein the available carbon atoms of the ringare substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring issubstituted by 0 or 1 R² substituents, and the ring is additionallysubstituted by 0, 1, 2 or 3 substituents independently selected fromhalo, nitro, cyano, C₁₋₄alkyl, OC₁₋₄alkyl, OC₁₋₄haloalkyl, NHC₁₋₄alkyl,N(C₁₋₄alkyl)C₁₋₄alkyl and C₁₋₄haloalkyl.
 8. A method of treatingrheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriaticarthritis, psoriasis, inflammatory diseases and autoimmune diseases,inflammatory bowel disorders, inflammatory eye disorders, inflammatoryor unstable bladder disorders, skin complaints with inflammatorycomponents, chronic inflammatory conditions, autoimmune diseases,systemic lupus erythematosis (SLE), myestenia gravis, rheumatoidarthritis, acute disseminated encephalomyelitis, idiopathicthrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome andautoimmune hemolytic anemia, allergic conditions and hypersensitivity,comprising the step of administering a compound according to claim
 1. 9.A method of treating cancers, which are mediated, dependent on orassociated with p110δ activity, comprising the step of administering acompound according to claim
 1. 10. A pharmaceutical compositioncomprising a compound according to claim 1 and apharmaceutically-acceptable diluent or carrier.